Landscape
Who trial criteria leave out
How often each exclusion category appears in the eligibility criteria of recruiting Massachusetts cancer trials.
1011 trials
Headline metric
34.3%
of recruiting MA cancer trials set rules for people with HIV. 16.8% still exclude them outright, against FDA guidance.
347 of 1011 Massachusetts-linked trials.
The other 17.5% set conditions, most often an undetectable viral load on treatment, which FDA's 2020 guidance recommends. Sources: ClinicalTrials.gov; FDA 2020 guidance on HIV, HBV and HCV in cancer trials.
Trials restricting each category
Share of 1011 trials. Bars are scaled to the largest category.
- Performance status
- Pregnancy
- Prior malignancy
- Cardiac
- Brain metastases
- HIV
- Hepatic
- Renal
- Age
- Language
- Diabetes
- BMI
- Smoking
Exclusion criteria in trials
Quoted criteria text, filterable by category, phase and sponsor.
Showing 3839 of 3839 rows
| Trial | Category | Phase | Sponsor | Source text |
|---|---|---|---|---|
| NCT00756665 | Performance status | Not given | University of Washington | ECOG Performance Status 0 or 1. |
| NCT00756665 | Prior malignancy | Not given | University of Washington | History of other malignancies, except: adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > 5 years. |
| NCT00843375 | HIV | Not given | University of Michigan Rogel Cancer Center | Known HIV or chronic active viral hepatitis |
| NCT00843375 | Pregnancy | Not given | University of Michigan Rogel Cancer Center | Women who are pregnant |
| NCT00843375 | Prior malignancy | Not given | University of Michigan Rogel Cancer Center | Other active malignancy within 3 years of enrollment except any of the following: |
| NCT01120353 | Language | Not given | St. Jude Children's Research Hospital | English- or Spanish-speaking and living in the U.S. or Canada at the time of diagnosis. |
| NCT01238250 | Language | Not given | Simons Searchlight | Must be fluent in English or a supported language. |
| NCT01521741 | Cardiac | Not given | Massachusetts General Hospital | congestive heart failure |
| NCT01521741 | Pregnancy | Not given | Massachusetts General Hospital | Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS) |
| NCT01521741 | Renal | Not given | Massachusetts General Hospital | renal insufficiency |
| NCT01696721 | Age | Not given | Massachusetts General Hospital | Age < 22 at time of treatment start. |
| NCT01790152 | Age | Not given | Children's Oncology Group | < 31 years of age at time of initial osteosarcoma diagnosis |
| NCT01790152 | Cardiac | Not given | Children's Oncology Group | No evidence of poor or low cardiac function at time of initial osteosarcoma diagnosis; if reports from the time are available: shortening fraction >= 28% by echocardiogram and within the institutional normative range for age, or radionuclide angiogram ejection fraction >= 50% |
| NCT01790152 | Prior malignancy | Not given | Children's Oncology Group | Must not have been diagnosed with any subsequent malignancy that required additional cardiotoxic therapies (i.e., radiotherapy to the chest [also includes fields directed towards the neck, upper abdomen, or spine], or additional anthracyclines or anthraquinones); patients with history of subsequent malignancy that did not require such therapies remain eligible |
| NCT01873131 | Cardiac | Not given | Massachusetts General Hospital | cardiovascular disease, including sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, and cardiogenic shock |
| NCT01961713 | Prior malignancy | Not given | Massachusetts General Hospital | No prior or current diagnosis of epithelial malignancy, except for skin cancer (squamous cell carcinoma or basal cell carcinoma) |
| NCT02000089 | Performance status | Phase 3 | Johns Hopkins University | Poor performance status |
| NCT02000089 | Pregnancy | Phase 3 | Johns Hopkins University | Pregnancy. |
| NCT02012699 | Language | Not given | University of Nebraska | English or Spanish speaking individuals |
| NCT02172651 | Cardiac | Early phase 1 | Dana-Farber Cancer Institute | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT02172651 | Hepatic | Early phase 1 | Dana-Farber Cancer Institute | Total bilirubin ≤1.5× institutional upper limit of normal (ULN) |
| NCT02172651 | HIV | Early phase 1 | Dana-Farber Cancer Institute | Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection. |
| NCT02172651 | Performance status | Early phase 1 | Dana-Farber Cancer Institute | ECOG performance status ≤ 1 (see Appendix A) |
| NCT02172651 | Pregnancy | Early phase 1 | Dana-Farber Cancer Institute | Non-pregnant and not nursing |
| NCT02172651 | Prior malignancy | Early phase 1 | Dana-Farber Cancer Institute | History of prior or synchronous malignancy except: |
| NCT02172651 | Renal | Early phase 1 | Dana-Farber Cancer Institute | Serum creatinine within normal institutional limits or creatinine clearance ≥60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal. |
| NCT02290834 | Brain metastases | Not given | Massachusetts General Hospital | Participants with clinical or radiographic evidence of metastatic CNS disease |
| NCT02290834 | Performance status | Not given | Massachusetts General Hospital | Karnofsky Performance Score (KPS) ≥ 80 |
| NCT02290834 | Pregnancy | Not given | Massachusetts General Hospital | Serum Pregnancy Testing: STAT quantitative serum hCG pregnancy testing for all women of childbearing potential. Imaging will not start until and unless the test result returns negative. |
| NCT02332668 | Age | Phase 1/2 | Merck Sharp & Dohme LLC | Between 6 months and <18 years of age on day of signing informed consent is documented. |
| NCT02332668 | Brain metastases | Phase 1/2 | Merck Sharp & Dohme LLC | Known active central nervous system (CNS) metastases and/or carcinomatous meningitis |
| NCT02332668 | HIV | Phase 1/2 | Merck Sharp & Dohme LLC | Human immunodeficiency virus (HIV) |
| NCT02332668 | Performance status | Phase 1/2 | Merck Sharp & Dohme LLC | Lansky Play Scale ≥50 for participants from 6 months up to and including 16 years of age; or Karnofsky score ≥50 for participants >16 years of age |
| NCT02332668 | Pregnancy | Phase 1/2 | Merck Sharp & Dohme LLC | Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of study medication |
| NCT02332668 | Prior malignancy | Phase 1/2 | Merck Sharp & Dohme LLC | Known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (eg, breast carcinoma, cervical carcinoma in situ) with potentially curative therapy, or in situ cervical cancer |
| NCT02343042 | Cardiac | Phase 1/2 | Karyopharm Therapeutics Inc | Congestive heart failure (CHF) of New York Heart Association (NYHA) Class ≥ 3, or |
| NCT02343042 | Hepatic | Phase 1/2 | Karyopharm Therapeutics Inc | Total bilirubin < 2* upper limit of normal (ULN) (except patients with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3* ULN) and both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5* ULN |
| NCT02343042 | HIV | Phase 1/2 | Karyopharm Therapeutics Inc | Known human immunodeficiency virus (HIV) infection or HIV seropositivity. |
| NCT02343042 | Performance status | Phase 1/2 | Karyopharm Therapeutics Inc | Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2. |
| NCT02343042 | Pregnancy | Phase 1/2 | Karyopharm Therapeutics Inc | Currently pregnant or breastfeeding. |
| NCT02343042 | Prior malignancy | Phase 1/2 | Karyopharm Therapeutics Inc | Active concomitant malignancies or history of another malignancy within 3 years prior to C1D1 except for adequately treated early-stage basal cell or squamous cell carcinoma of skin, adequately treated carcinoma in situ of breast or cervix, or organ confined prostate cancer. |
| NCT02343042 | Renal | Phase 1/2 | Karyopharm Therapeutics Inc | Adequate renal function within 28 days prior to C1D1. For Arms 1-11, estimated creatinine clearance (CrCl) calculated using the formula of Cockroft and Gault (1976). |
| NCT02402244 | Age | Not given | Children's Oncology Group | Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit |
| NCT02523014 | Age | Phase 2 | Alliance for Clinical Trials in Oncology | For patients with SMO/PTCH1 mutation: Age >= 30 years |
| NCT02523014 | Cardiac | Phase 2 | Alliance for Clinical Trials in Oncology | No personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest |
| NCT02523014 | Diabetes | Phase 2 | Alliance for Clinical Trials in Oncology | No uncontrolled diabetes defined as a known diabetic with HBA1C > 7.5 OR fasting glucose > 140 mg/dL. |
| NCT02523014 | Hepatic | Phase 2 | Alliance for Clinical Trials in Oncology | Total bilirubin =< 1.5 x upper limit of normal (ULN); except in case of Gilbert's disease |
| NCT02523014 | HIV | Phase 2 | Alliance for Clinical Trials in Oncology | such as known human immunodeficiency virus positivity |
| NCT02523014 | Performance status | Phase 2 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) performance status =< 2 |
| NCT02523014 | Pregnancy | Phase 2 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing: |
| NCT02523014 | Renal | Phase 2 | Alliance for Clinical Trials in Oncology | Creatinine OR =< 1.5 mg/dl x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance > 50 mL/min |
| NCT02582697 | Age | Phase 3 | University of Sydney | Age ≥ 11 years and ≤ 50 years on the date of randomisation |
| NCT02582697 | Cardiac | Phase 3 | University of Sydney | Significant cardiac disease resulting in inability to tolerate IV fluid hydration for cisplatin |
| NCT02582697 | Hepatic | Phase 3 | University of Sydney | Adequate liver function where bilirubin must be ≤1.5 x ULN, except participants with Gilbert's Syndrome where bilirubin must be ≤2.0 x ULN; ALT and AST must be ≤2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be ≤ 5 x ULN |
| NCT02582697 | Performance status | Phase 3 | University of Sydney | ECOG Performance Status of 0, 1, 2, or 3 |
| NCT02582697 | Prior malignancy | Phase 3 | University of Sydney | Other primary malignancy (EXCEPT adequately treated non-melanomatous carcinoma of the skin, germ cell tumour, or other malignancy treated at least 5 years previously with no evidence of recurrence) |
| NCT02582697 | Renal | Phase 3 | University of Sydney | Adequate renal function with estimated creatinine clearance of ≥60 ml/min according to the Cockcroft-Gault formula, unless calculated to be < 60 ml/min or borderline in which case GFR should be formally measured, eg. with EDTA scan |
| NCT02610426 | Cardiac | Not given | National Cancer Institute (NCI) | African American cases (based on a drop in left ventricular ejection fraction [LVEF] < 50 or a drop from baseline > 20 points) and African American controls |
| NCT02641145 | Cardiac | Not given | Brigham and Women's Hospital | Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy) |
| NCT02641145 | HIV | Not given | Brigham and Women's Hospital | Documented hypertrophic cardiomyopathy, HIV or chronic viral hepatitis |
| NCT02641145 | Pregnancy | Not given | Brigham and Women's Hospital | Pregnant state. For women in child bearing age, a urine pregnancy test will be performed prior to the PET and the cardiac MRI studies |
| NCT02641145 | Renal | Not given | Brigham and Women's Hospital | Subjects on dialysis will be excluded |
| NCT02734537 | Hepatic | Phase 2 | ECOG-ACRIN Cancer Research Group | Total bilirubin =< the upper limit of normal (ULN) within 4 weeks prior to randomization |
| NCT02734537 | Performance status | Phase 2 | ECOG-ACRIN Cancer Research Group | Patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1 within 2 weeks prior to randomization |
| NCT02734537 | Pregnancy | Phase 2 | ECOG-ACRIN Cancer Research Group | Women must not be pregnant or breast-feeding |
| NCT02734537 | Prior malignancy | Phase 2 | ECOG-ACRIN Cancer Research Group | Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer |
| NCT02734537 | Renal | Phase 2 | ECOG-ACRIN Cancer Research Group | Calculated creatinine clearance must be > 60 ml/min using the Cockcroft-Gault formula within 4 weeks prior to randomization |
| NCT02792270 | BMI | Not given | Massachusetts General Hospital | Body Mass Index (BMI) ≥ 20 kg/m2 |
| NCT02792270 | Diabetes | Not given | Massachusetts General Hospital | Diabetes mellitus |
| NCT02792270 | Performance status | Not given | Massachusetts General Hospital | Karnofsky Score ≥ 60% |
| NCT02792270 | Pregnancy | Not given | Massachusetts General Hospital | Current pregnancy and breast feeding |
| NCT02792270 | Prior malignancy | Not given | Massachusetts General Hospital | Other cancers diagnosed within the last 5 years (in situ and/or invasive) |
| NCT02896335 | Brain metastases | Phase 2 | Massachusetts General Hospital | Leptomeningeal involvement of cancer (Cohort 1). Leptomeningeal involvement is allowed for Cohort 2. |
| NCT02896335 | Cardiac | Phase 2 | Massachusetts General Hospital | baseline QTc <480ms |
| NCT02896335 | HIV | Phase 2 | Massachusetts General Hospital | HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with palbociclib. |
| NCT02896335 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status of 0, 1 or 2 (Karnofsky ≥ 60, see Appendix A). |
| NCT02896335 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study because the effect of palbociclib on a developing fetus is unknown. |
| NCT02947971 | Age | Not given | Massachusetts General Hospital | Health participants over the age of 18 but less than 85 years of age |
| NCT02947971 | Pregnancy | Not given | Massachusetts General Hospital | Participants who are pregnant. |
| NCT02977780 | Cardiac | Phase 2 | David Reardon, MD | Active uncontrolled cardiac disease, including cardiomyopathy, congestive heart failure (New York Heart Association functional classification of ≥2), unstable angina, myocardial infarction within 12 months of enrollment, or ventricular arrhythmia. |
| NCT02977780 | Diabetes | Phase 2 | David Reardon, MD | HbA1c ≥ 8% |
| NCT02977780 | Hepatic | Phase 2 | David Reardon, MD | Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNS [qualitative] is detected). |
| NCT02977780 | Performance status | Phase 2 | David Reardon, MD | Karnofsky performance status ≥60 |
| NCT02977780 | Pregnancy | Phase 2 | David Reardon, MD | Pregnant or breastfeeding. |
| NCT02977780 | Prior malignancy | Phase 2 | David Reardon, MD | History of a different malignancy, unless (a) have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy |
| NCT02977780 | Renal | Phase 2 | David Reardon, MD | Creatinine clearance ≥ 60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. |
| NCT02984761 | Performance status | Not given | VA Office of Research and Development | Karnofsky performance status greater than or equal to 70 |
| NCT02984761 | Pregnancy | Not given | VA Office of Research and Development | Positive Pregnancy test (for women <61 years of age or without prior hysterectomy) |
| NCT02984761 | Prior malignancy | Not given | VA Office of Research and Development | Prior history of IV malignancy, excluding follicular lymphoma, chronic lymphocytic leukemia, or hormone sensitive prostate cancer confined to the pelvis. |
| NCT03067181 | Age | Phase 3 | Children's Oncology Group | Standard risk 1: Patients must be < 11 years of age at enrollment |
| NCT03067181 | Brain metastases | Phase 3 | Children's Oncology Group | Patients must have had no prior radiation therapy with the exception of CNS irradiation of brain metastases |
| NCT03067181 | Hepatic | Phase 3 | Children's Oncology Group | Total bilirubin =< 2 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) |
| NCT03067181 | Language | Phase 3 | Children's Oncology Group | Able to fluently speak and read English |
| NCT03067181 | Performance status | Phase 3 | Children's Oncology Group | Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, 2 or 3 |
| NCT03067181 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential; (this criteria applies ONLY to patients who will receive chemotherapy [SR1 and SR2 patients]) |
| NCT03067181 | Prior malignancy | Phase 3 | Children's Oncology Group | Has received prior cisplatin- or carboplatin-based chemotherapy regimen for malignancy including diagnoses other than germ cell tumor |
| NCT03067181 | Renal | Phase 3 | Children's Oncology Group | Adequate renal function defined as: |
| NCT03093116 | Age | Phase 1/2 | Turning Point Therapeutics, Inc. | Age ≥12 (or age ≥ 20 as required by local regulation). |
| NCT03093116 | Brain metastases | Phase 1/2 | Turning Point Therapeutics, Inc. | Symptomatic brain metastases or leptomeningeal involvement. |
| NCT03093116 | Cardiac | Phase 1/2 | Turning Point Therapeutics, Inc. | Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs |
| NCT03093116 | Hepatic | Phase 1/2 | Turning Point Therapeutics, Inc. | Total serum bilirubin < 1.5 × ULN; |
| NCT03093116 | HIV | Phase 1/2 | Turning Point Therapeutics, Inc. | Known active infections (bacterial, fungal, viral including HIV positivity). |
| NCT03093116 | Performance status | Phase 1/2 | Turning Point Therapeutics, Inc. | ECOG PS 0-1. |
| NCT03093116 | Prior malignancy | Phase 1/2 | Turning Point Therapeutics, Inc. | History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years. |
| NCT03093116 | Renal | Phase 1/2 | Turning Point Therapeutics, Inc. | Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; |
| NCT03104491 | Cardiac | Phase 1/2 | Leland Metheny | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT03104491 | Hepatic | Phase 1/2 | Leland Metheny | Bilirubin > 2X institutional upper limit of normal |
| NCT03104491 | Performance status | Phase 1/2 | Leland Metheny | ECOG Performance status < 2 |
| NCT03104491 | Pregnancy | Phase 1/2 | Leland Metheny | Pregnant or breastfeeding women are excluded from this study |
| NCT03104491 | Prior malignancy | Phase 1/2 | Leland Metheny | Second active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) |
| NCT03104491 | Renal | Phase 1/2 | Leland Metheny | Creatinine clearance < 30ml/min |
| NCT03113643 | Brain metastases | Phase 1 | Dana-Farber Cancer Institute | Active CNS involvement by AML or BPDCN. |
| NCT03113643 | Cardiac | Phase 1 | Dana-Farber Cancer Institute | Left ventricular ejection fraction > institutional lower limit of normal by MUGA scan or echocardiogram within 30 days of first protocol treatment |
| NCT03113643 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5x ULN |
| NCT03113643 | HIV | Phase 1 | Dana-Farber Cancer Institute | Known positive status for HIV infection; known active hepatitis B or hepatitis C infection |
| NCT03113643 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study |
| NCT03113643 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Patients with known active advanced malignant solid tumors are excluded (except for basal or squamous skin cancers, or carcinomas in situ). Patients with additional hematologic malignancies that require treatment are excluded. |
| NCT03113643 | Renal | Phase 1 | Dana-Farber Cancer Institute | Serum creatinine < 1.5x ULN |
| NCT03126916 | Age | Phase 3 | Children's Oncology Group | Patient must be >= 365 days and =< 30 years of age at diagnosis |
| NCT03126916 | Cardiac | Phase 3 | Children's Oncology Group | Shortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by echocardiogram or radionuclide angiogram |
| NCT03126916 | Hepatic | Phase 3 | Children's Oncology Group | Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and |
| NCT03126916 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential |
| NCT03126916 | Prior malignancy | Phase 3 | Children's Oncology Group | Patients with INRG stage L2 tumors without amplification of MYCN regardless of tumor histology (may meet criteria for high risk classification but are not eligible for this trial) |
| NCT03126916 | Renal | Phase 3 | Children's Oncology Group | Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows: |
| NCT03150693 | Age | Phase 3 | Alliance for Clinical Trials in Oncology | Age >= 18 years and < 40 years |
| NCT03150693 | Hepatic | Phase 3 | Alliance for Clinical Trials in Oncology | Total bilirubin =< 1.5 x upper limit of normal (ULN), except for patients with known Gilbert's syndrome |
| NCT03150693 | Performance status | Phase 3 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) performance status 0-2 |
| NCT03150693 | Pregnancy | Phase 3 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects |
| NCT03150693 | Renal | Phase 3 | Alliance for Clinical Trials in Oncology | Calculated (calc.) creatinine clearance >= 50 mL/min by Cockcroft-Gault |
| NCT03151629 | Age | Not given | Prostate Cancer Clinical Trials Consortium | Males 21 years of age and above |
| NCT03151629 | Prior malignancy | Not given | Prostate Cancer Clinical Trials Consortium | No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin |
| NCT03191149 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | Participants may not have clinically symptomatic brain metastases, leptomeningeal disease, or spinal cord compression. |
| NCT03191149 | Cardiac | Phase 2 | National Cancer Institute (NCI) | must not have a left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN). If the LLN is not defined at a site, the LVEF must be >= 50% for the patient to be eligible |
| NCT03191149 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x upper limit of normal (ULN) if no liver metastases or =< 3 times ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases (within 4 weeks before registration) |
| NCT03191149 | Performance status | Phase 2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status =< 1 |
| NCT03191149 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Women must not be pregnant or breast-feeding because osimertinib (AZD9291) has been shown to cause fetal harm in animal models. |
| NCT03191149 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Participants may not have a second, clinically active, cancer. Patients with second cancers which have been treated with curative intent and/or are currently inactive are allowed |
| NCT03191149 | Renal | Phase 2 | National Cancer Institute (NCI) | Creatinine =< 1.5 x institutional upper limit of normal (within 4 weeks before registration) |
| NCT03216525 | Age | Phase 3 | Brigham and Women's Hospital | Man or woman between the ages of 18 and 85. |
| NCT03216525 | Cardiac | Phase 3 | Brigham and Women's Hospital | Patients with heart failure. |
| NCT03216525 | Hepatic | Phase 3 | Brigham and Women's Hospital | Patients with severe hepatic impairment. |
| NCT03216525 | Pregnancy | Phase 3 | Brigham and Women's Hospital | Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating, or not postmenopausal (no menses for at least 1 year) and of childbearing potential and not using an accepted method of birth control |
| NCT03216525 | Renal | Phase 3 | Brigham and Women's Hospital | Patients with end-stage renal disease. |
| NCT03219450 | Brain metastases | Phase 1 | Dana-Farber Cancer Institute | Participants with known CNS involvement should be excluded from this clinical trial |
| NCT03219450 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | total bilirubin within normal institutional limits |
| NCT03219450 | HIV | Phase 1 | Dana-Farber Cancer Institute | Known chronic infections with HIV, hepatitis B or C |
| NCT03219450 | Performance status | Phase 1 | Dana-Farber Cancer Institute | ECOG performance status 0 or 1 |
| NCT03219450 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because personalized neoantigen peptides and poly-ICLC are agents with unknown risks to the developing fetus. |
| NCT03219450 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Individuals with history of an invasive malignancy are ineligible except for the following circumstances: a) individuals with a history of invasive malignancy are eligible if they have been disease -free for at least 3 years |
| NCT03286335 | Language | Not given | Massachusetts General Hospital | Must be able to speak and comprehend English |
| NCT03286335 | Performance status | Not given | Massachusetts General Hospital | Karnofsky performance status ≥ 60 (see Appendix A) |
| NCT03286335 | Pregnancy | Not given | Massachusetts General Hospital | Pregnant or lactating women are excluded from this study because radiation is known to have teratogenic or abortifacient effects. |
| NCT03286335 | Prior malignancy | Not given | Massachusetts General Hospital | Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. |
| NCT03295981 | Pregnancy | Phase 3 | St. Louis University | Children and pregnancy |
| NCT03310879 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participants with symptomatic CNS metastases who are neurologically unstable and/or require radiation therapy are excluded. |
| NCT03310879 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT03310879 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) |
| NCT03310879 | HIV | Phase 2 | Dana-Farber Cancer Institute | Participants with known HIV-positive status are ineligible because these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. |
| NCT03310879 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status of 0-1 (see APPENDIX A). |
| NCT03310879 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because abemaciclib is an agent with the potential for teratogenic or abortifacient effects. |
| NCT03310879 | Renal | Phase 2 | Dana-Farber Cancer Institute | Serum Creatinine ≤ 1.5 × institutional ULN -OR- |
| NCT03394365 | Brain metastases | Phase 3 | Pierre Fabre Medicament | Untreated CNS PTLD or CNS PTLD for which the participant is actively receiving CNS-directed chemotherapy (systemic or intrathecal) or radiotherapy at enrollment. |
| NCT03394365 | Hepatic | Phase 3 | Pierre Fabre Medicament | Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin each < 5 × the upper limit of normal; however, ALT, AST, and total bilirubin each ≤ 10 × upper limit of normal is acceptable if the elevation is considered by the investigator to be due to EBV and/or PTLD involvement of the liver as long as there is no known evidence of significant liver dysfunction. |
| NCT03394365 | Performance status | Phase 3 | Pierre Fabre Medicament | Eastern Cooperative Oncology Group performance status ≤ 3 for participants aged ≥ 16 years |
| NCT03394365 | Pregnancy | Phase 3 | Pierre Fabre Medicament | Female who is breastfeeding or pregnant or female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception. |
| NCT03396341 | Age | Not given | Memorial Sloan Kettering Cancer Center | Female patient, age 25 years or older (given that women under this age are not generally recommended to receive BRCA1/2 genetic testing) |
| NCT03396341 | Language | Not given | Memorial Sloan Kettering Cancer Center | English-fluent; the surveys were designed and validated in English and are not currently available in other languages. |
| NCT03418961 | Cardiac | Phase 3 | SWOG Cancer Research Network | Patients must have LVEF >= 50% echocardiogram (2D or 3D) within 28 days prior to registration. |
| NCT03418961 | Hepatic | Phase 3 | SWOG Cancer Research Network | Serum bilirubin < 3.0 x institutional upper limit of normal (IULN) |
| NCT03418961 | Performance status | Phase 3 | SWOG Cancer Research Network | Patients must have a Zubrod Performance status of 0-2 |
| NCT03418961 | Pregnancy | Phase 3 | SWOG Cancer Research Network | Patients must not be pregnant or nursing due to potential fetal or nursing infant harm |
| NCT03418961 | Prior malignancy | Phase 3 | SWOG Cancer Research Network | No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer on active surveillance, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years |
| NCT03418961 | Renal | Phase 3 | SWOG Cancer Research Network | Patients must not be dialysis dependent |
| NCT03448926 | Age | Not given | PreludeDx | Patient must be 30 to 85 years old. |
| NCT03448926 | Pregnancy | Not given | PreludeDx | Patient is pregnant. |
| NCT03448926 | Prior malignancy | Not given | PreludeDx | Patient has had any prior ipsilateral or contralateral breast DCIS or invasive breast cancer. |
| NCT03452774 | Performance status | Not given | Massive Bio, Inc. | ECOG PS > 2; |
| NCT03471260 | Cardiac | Phase 1/2 | M.D. Anderson Cancer Center | QTc interval using Fridericia's formula (QTcF) > 450 msec. Bundle branch block and prolonged QTc interval are permitted after discussion with the PI. |
| NCT03471260 | Hepatic | Phase 1/2 | M.D. Anderson Cancer Center | Adequate hepatic function (direct bilirubin < 2 x ULN, ALT and/or AST < 3x ULN) unless deemed to be related to underlying leukemia. |
| NCT03471260 | HIV | Phase 1/2 | M.D. Anderson Cancer Center | Known active hepatitis B (HBV) or Hepatitis C (HCV) infection or known HIV infection. |
| NCT03471260 | Performance status | Phase 1/2 | M.D. Anderson Cancer Center | ECOG performance status of < 2. |
| NCT03471260 | Pregnancy | Phase 1/2 | M.D. Anderson Cancer Center | Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception |
| NCT03471260 | Prior malignancy | Phase 1/2 | M.D. Anderson Cancer Center | Patients with a concurrent active malignancy under treatment. |
| NCT03471260 | Renal | Phase 1/2 | M.D. Anderson Cancer Center | Adequate renal function including creatinine clearance > 30 ml/min based on the Cockcroft-Gault equation. |
| NCT03492151 | Pregnancy | Not given | Ohio State University Comprehensive Cancer Center | Women with known pregnancy at time of procedure |
| NCT03509961 | Age | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Age ≥ 1 year and ≤ 25 years |
| NCT03509961 | Brain metastases | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Patients with active CNS leukemia or any other active site of extramedullary disease at the time of enrollment are not permitted. |
| NCT03509961 | Cardiac | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Cardiac: Shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA), choice of test according to local standard of care. |
| NCT03509961 | Hepatic | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Hepatic: SGOT (AST) or SGPT (ALT) < 5 x upper limit of normal (ULN) for age. Conjugated bilirubin < 2.5 mg/dL, unless attributable to Gilbert's Syndrome. |
| NCT03509961 | HIV | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded. |
| NCT03509961 | Performance status | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Karnofsky Index or Lansky Play-Performance Scale ≥ 60 % on pre-transplant evaluation. |
| NCT03509961 | Pregnancy | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Pregnant or lactating females are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants. |
| NCT03509961 | Renal | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | Renal: Creatinine clearance or radioisotope GFR ≥ 60 mL/min/1.73 m2 or a serum creatinine based on age/gender. |
| NCT03516708 | Performance status | Phase 1/2 | Washington University School of Medicine | ECOG performance status 0, 1, or 2 |
| NCT03516708 | Pregnancy | Phase 1/2 | Washington University School of Medicine | Pregnant and/or breastfeeding. |
| NCT03526835 | Brain metastases | Phase 1/2 | Merus B.V. | Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry. |
| NCT03526835 | Cardiac | Phase 1/2 | Merus B.V. | Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA). |
| NCT03526835 | Performance status | Phase 1/2 | Merus B.V. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT03526835 | Pregnancy | Phase 1/2 | Merus B.V. | Pregnant or breastfeeding patients; patients of childbearing potential must use highly effective contraception methods prior to study entry, for the duration of study participation, and for 6 months after the last dose of MCLA-158. |
| NCT03526835 | Prior malignancy | Phase 1/2 | Merus B.V. | History of prior malignancies with the exception of excised cervical intraepithelial neoplasia or nonmelanoma skin cancer, or curatively treated cancer deemed at low risk for recurrence with no evidence of disease for 3 years. |
| NCT03535545 | Age | Phase 1 | Massachusetts General Hospital | Age: 40-80 years old; |
| NCT03535545 | BMI | Phase 1 | Massachusetts General Hospital | BMI > 33 (limit of the MRI table); |
| NCT03535545 | Pregnancy | Phase 1 | Massachusetts General Hospital | Pregnant or breastfeeding |
| NCT03535545 | Renal | Phase 1 | Massachusetts General Hospital | history of chronic kidney disease for subjects in groups 1-3 and 5; |
| NCT03535545 | Smoking | Phase 1 | Massachusetts General Hospital | No prior history of tobacco use. |
| NCT03550391 | Brain metastases | Phase 3 | Canadian Cancer Trials Group | Widespread definitive leptomeningeal metastasis. |
| NCT03550391 | Hepatic | Phase 3 | Canadian Cancer Trials Group | Diagnosis of chronic liver disease/cirrhosis of the liver (e.g. Child-Pugh class B or C). |
| NCT03550391 | Language | Phase 3 | Canadian Cancer Trials Group | Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French either alone or with assistance. |
| NCT03550391 | Performance status | Phase 3 | Canadian Cancer Trials Group | ECOG performance status 0, 1, or 2. |
| NCT03550391 | Pregnancy | Phase 3 | Canadian Cancer Trials Group | Pregnant or nursing women. |
| NCT03550391 | Renal | Phase 3 | Canadian Cancer Trials Group | Creatinine clearance must be ≥ 30 ml/min within 28 days prior to registration. |
| NCT03564340 | Brain metastases | Phase 1/2 | Regeneron Pharmaceuticals | Untreated or active primary brain tumor, central nervous system (CNS) metastases, or spinal cord compression, as described in the protocol |
| NCT03564340 | Cardiac | Phase 1/2 | Regeneron Pharmaceuticals | History and/or current cardiovascular disease, as defined in the protocol |
| NCT03595917 | Brain metastases | Phase 1 | Marlise Luskin, MD | Patients with asymptomatic central nervous system (CNS) disease are eligible and may be treated concurrently with intrathecal chemotherapy. |
| NCT03595917 | Cardiac | Phase 1 | Marlise Luskin, MD | Corrected QT interval (QTc) of > 480 milliseconds (ms) on baseline electrocardiogram (ECG) (using corrected QT interval per institutional standard). |
| NCT03595917 | Hepatic | Phase 1 | Marlise Luskin, MD | AST(SGOT)/ALT(SGPT) ≤ 3x institutional upper limit of normal unless felt to be clearly related to disease where ≤ 5x institutional upper limit of normal is permitted, after discussion with the overall PI. |
| NCT03595917 | HIV | Phase 1 | Marlise Luskin, MD | Known human immunodeficiency virus (HIV). Screening is not required. |
| NCT03595917 | Performance status | Phase 1 | Marlise Luskin, MD | ECOG performance status 0-3 (Appendix A). ECOG value of 3 is allowed after documented discussion with PI, if poor performance status is attributed to underlying disease. |
| NCT03595917 | Pregnancy | Phase 1 | Marlise Luskin, MD | Are pregnant or nursing at the time of screening. |
| NCT03595917 | Prior malignancy | Phase 1 | Marlise Luskin, MD | History of prior or concurrent malignancy requiring current treatment and/or whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. |
| NCT03595917 | Renal | Phase 1 | Marlise Luskin, MD | Creatinine ≤ 1.5x institutional upper limit of normal. |
| NCT03623958 | Pregnancy | Not given | Brigham and Women's Hospital | If participant is a pregnant woman or breast feeding they will not be eligible. |
| NCT03659448 | Hepatic | Phase 3 | Surgimab | Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the ULN or; |
| NCT03659448 | HIV | Phase 3 | Surgimab | Known positive test for human immunodeficiency virus (HIV) |
| NCT03659448 | Prior malignancy | Phase 3 | Surgimab | Other malignancies, either currently active or diagnosed in the last 5 years, except for adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma; |
| NCT03659448 | Renal | Phase 3 | Surgimab | Serum creatinine above 1.5 times the ULN or; |
| NCT03666000 | Brain metastases | Phase 1 | Imugene Limited | No active CNS disease, excluding PCNSL |
| NCT03666000 | HIV | Phase 1 | Imugene Limited | Seronegative for human immunodeficiency virus antibody. |
| NCT03666000 | Performance status | Phase 1 | Imugene Limited | Eastern Cooperative Oncology Group performance status score of 0 or 1. |
| NCT03666000 | Prior malignancy | Phase 1 | Imugene Limited | History of another primary malignancy |
| NCT03675893 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participants with known brain metastases should be excluded from this clinical trial |
| NCT03675893 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Inability to determine the corrected QT interval using Fridericia's formula (QTcF) on the ECG (i.e., unreadable or not interpretable) or QTcF>480 msec (determined by mean of triplicate ECGs at screening). |
| NCT03675893 | Diabetes | Phase 2 | Dana-Farber Cancer Institute | For Cohorts 6 and 7, participants must have HbA1c ≤6.4% and fasting plasma glucose (FPG) ≤140 mg/dL. |
| NCT03675893 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN). |
| NCT03675893 | HIV | Phase 2 | Dana-Farber Cancer Institute | Known HIV-positive participants are ineligible because of the increased risk of lethal infections when treated with marrow-suppressive therapy. |
| NCT03675893 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status of 0 or 1 |
| NCT03675893 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study |
| NCT03675893 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Individuals with a history of a different malignancy are ineligible with the following exceptions: individuals who have been treated and are disease-free for a minimum of 5 years prior to study enrollment |
| NCT03675893 | Renal | Phase 2 | Dana-Farber Cancer Institute | Creatinine ≤ 1.5 × institutional ULN, OR |
| NCT03686124 | Brain metastases | Phase 1/2 | Immatics US, Inc. | Patients with active brain metastases |
| NCT03686124 | Cardiac | Phase 1/2 | Immatics US, Inc. | History of cardiac conditions as per protocol |
| NCT03686124 | HIV | Phase 1/2 | Immatics US, Inc. | Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection. |
| NCT03686124 | Performance status | Phase 1/2 | Immatics US, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT03686124 | Pregnancy | Phase 1/2 | Immatics US, Inc. | Pregnant or breastfeeding |
| NCT03686124 | Prior malignancy | Phase 1/2 | Immatics US, Inc. | History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years |
| NCT03761121 | Pregnancy | Not given | Boston Children's Hospital | Women of childbearing age who are seeking to become pregnant, who are breastfeeding, or who suspect they may be pregnant; |
| NCT03816345 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required for at least 4 weeks |
| NCT03816345 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements |
| NCT03816345 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 2 x institutional upper limit of normal (ULN) |
| NCT03816345 | HIV | Phase 1 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT03816345 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Karnofsky >= 60) |
| NCT03816345 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Women must not be breastfeeding. |
| NCT03816345 | Renal | Phase 1 | National Cancer Institute (NCI) | Creatinine ULN OR glomerular filtration rate (GFR) >= 30 mL/min (if using the Cockcroft-Gault formula) |
| NCT03830320 | Cardiac | Phase 1 | Massachusetts General Hospital | Myocardial infarction within the last 3 months; |
| NCT03830320 | Pregnancy | Phase 1 | Massachusetts General Hospital | Pregnant or breastfeeding (a negative STAT quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate); |
| NCT03830801 | Age | Not given | Massachusetts General Hospital | Participants above 80 years of age |
| NCT03830801 | Pregnancy | Not given | Massachusetts General Hospital | Pregnant women. |
| NCT03851445 | Performance status | Phase 2/3 | SWOG Cancer Research Network | Patients must have Zubrod performance status 0-1 (see Section 10.2) documented within 28 days prior to Step 1 registration. |
| NCT03854110 | Brain metastases | Phase 1 | Persevere Therapeutics Inc. | Subjects with known central nervous system metastasis must have undergone brain targeted treatment and must be asymptomatic or radiographically and clinically stable |
| NCT03854110 | Cardiac | Phase 1 | Persevere Therapeutics Inc. | Baseline QTc interval >480 msec for female subjects or >450 msec for male subjects. |
| NCT03854110 | Hepatic | Phase 1 | Persevere Therapeutics Inc. | Serum total bilirubin ≤ 1.5 × ULN |
| NCT03854110 | Performance status | Phase 1 | Persevere Therapeutics Inc. | ECOG performance status of 0-1 |
| NCT03854110 | Pregnancy | Phase 1 | Persevere Therapeutics Inc. | Women of childbearing potential (WOCBP) must have a negative urine pregnancy test. |
| NCT03854110 | Prior malignancy | Phase 1 | Persevere Therapeutics Inc. | Diagnosis of any active malignancy other than platinum-resistant ovarian cancer within the past 2 years |
| NCT03854110 | Renal | Phase 1 | Persevere Therapeutics Inc. | Serum creatinine ≤ 1.5 X upper limit of normal (ULN) |
| NCT03858205 | Performance status | Not given | University of Southern California | Eastern Cooperative Oncology Group (ECOG) 0-2 |
| NCT03858205 | Pregnancy | Not given | University of Southern California | Patients must not be pregnant |
| NCT03866382 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | The patient may not have active brain metastases or epidural disease. |
| NCT03866382 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Congestive heart failure (CHF): New York Heart Association (NYHA) class III (moderate) or class IV (severe) at the time of screening. |
| NCT03866382 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x upper limit of normal (ULN). |
| NCT03866382 | HIV | Phase 2 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-positive patients are eligible if on stable dose of highly active antiretroviral therapy (HAART), no clinically significant drug-drug interactions are anticipated with the current HAART regimen, CD4 counts are greater than 350 and viral load is undetectable |
| NCT03866382 | Performance status | Phase 2 | National Cancer Institute (NCI) | Karnofsky performance status >= 80% |
| NCT03866382 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Pregnant women may not participate in this study because with cabozantinib, nivolumab, and ipilimumab have potential for teratogenic or abortifacient effects. |
| NCT03866382 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | No evidence of active malignancy, requiring systemic treatment within 2 years of registration |
| NCT03866382 | Renal | Phase 2 | National Cancer Institute (NCI) | Creatinine =< 1.5 x upper limit of normal (ULN) OR creatinine clearance >= 40 mL/min/1.73 m^2 (calculated using the Chronic Kidney Disease Epidemiology [CKD-EPI] equation or Cockcroft-Gault formula) for patients with creatinine levels above institutional normal |
| NCT03875716 | Cardiac | Not given | Dana-Farber Cancer Institute | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT03875716 | Hepatic | Not given | Dana-Farber Cancer Institute | AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal |
| NCT03875716 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status 0-1 (Karnofsky ≥70%, see Appendix A) |
| NCT03875716 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because of the teratogenic risks of radiation exposure to the developing fetus. |
| NCT03875716 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Prior history of head and neck cancer within 5 years. |
| NCT03875716 | Renal | Not given | Dana-Farber Cancer Institute | creatinine ≤ 1.5 times the institutional upper limit of normal OR |
| NCT03875716 | Smoking | Not given | Dana-Farber Cancer Institute | Patients with ≤20 pack-years of cumulative cigarette smoking. |
| NCT03922555 | Brain metastases | Phase 1 | Massachusetts General Hospital | Participants with enhancing disease on brain MRI. |
| NCT03922555 | Cardiac | Phase 1 | Massachusetts General Hospital | Participants with a history of myocardial infarction within the 6 months prior to screening. |
| NCT03922555 | Hepatic | Phase 1 | Massachusetts General Hospital | Aspartate aminotransferase (AST), Alanine Aminotransferase (ALT), and alkaline phosphatase (ALP) ≤3.0 x ULN. |
| NCT03922555 | HIV | Phase 1 | Massachusetts General Hospital | Participants with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C. |
| NCT03922555 | Pregnancy | Phase 1 | Massachusetts General Hospital | Participants who are pregnant or breast-feeding. |
| NCT03922555 | Prior malignancy | Phase 1 | Massachusetts General Hospital | Participants with known additional malignancy that is progressing or requires active treatment within 2 years of start of study drug. |
| NCT03922555 | Renal | Phase 1 | Massachusetts General Hospital | Serum creatinine ≤2.0 x ULN |
| NCT03937635 | Cardiac | Phase 3 | ECOG-ACRIN Cancer Research Group | Patients should not have New York Heart Association classification III or IV heart failure at baseline. |
| NCT03937635 | Hepatic | Phase 3 | ECOG-ACRIN Cancer Research Group | Bilirubin =< 1.5 mg/dL (within 28 days prior to randomization). |
| NCT03937635 | HIV | Phase 3 | ECOG-ACRIN Cancer Research Group | Human immunodeficiency virus (HIV)+ patients with undetectable HIV viral loads tested within 6 months are eligible. |
| NCT03937635 | Performance status | Phase 3 | ECOG-ACRIN Cancer Research Group | Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. |
| NCT03937635 | Pregnancy | Phase 3 | ECOG-ACRIN Cancer Research Group | Women must not be pregnant due to potential harm to the fetus from daratumumab and lenalidomide. |
| NCT03937635 | Prior malignancy | Phase 3 | ECOG-ACRIN Cancer Research Group | Patients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for the time period considered appropriate for cure of the specific cancer. For most diseases this time frame is 5 years. |
| NCT03937635 | Renal | Phase 3 | ECOG-ACRIN Cancer Research Group | Calculated creatinine clearance >= 30 mL/min (within 28 days prior to randomization). |
| NCT03959085 | Age | Phase 3 | Children's Oncology Group | Patients must be > 365 days and < 25 years of age |
| NCT03959085 | Hepatic | Phase 3 | Children's Oncology Group | Direct bilirubin < 2.0 mg/dL (34 micromoles/L) |
| NCT03959085 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant, since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT03959085 | Prior malignancy | Phase 3 | Children's Oncology Group | or for any cancer diagnosed prior to initiation of protocol therapy on AALL1732. |
| NCT03970447 | Brain metastases | Phase 2/3 | Global Coalition for Adaptive Research | Extensive leptomeningeal disease. |
| NCT03970447 | Cardiac | Phase 2/3 | Global Coalition for Adaptive Research | QTc > 470 msec |
| NCT03970447 | Performance status | Phase 2/3 | Global Coalition for Adaptive Research | Karnofsky performance status ≥ 60% performed within a 14-day window prior to randomization. |
| NCT03970447 | Prior malignancy | Phase 2/3 | Global Coalition for Adaptive Research | History of another malignancy in the previous 2 years, with a disease-free interval of < 2 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. |
| NCT03972657 | HIV | Phase 1/2 | Regeneron Pharmaceuticals | Uncontrolled infection with Human Immunodeficiency Virus (HIV), hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency |
| NCT03990896 | Brain metastases | Phase 2 | Massachusetts General Hospital | Has known, untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. |
| NCT03990896 | Hepatic | Phase 2 | Massachusetts General Hospital | Serum total bilirubin ≤ 1.5 X institutional ULN OR Direct bilirubin ≤ institutional ULN for subjects with total bilirubin levels > 1.5 ULN |
| NCT03990896 | HIV | Phase 2 | Massachusetts General Hospital | Has a known history of Human Immunodeficiency Virus (HIV). |
| NCT03990896 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status of ≤2. |
| NCT03990896 | Pregnancy | Phase 2 | Massachusetts General Hospital | Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 7 months after the last dose of trial treatment. |
| NCT03990896 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Has a known additional malignancy that is progressing or requires active treatment. |
| NCT03990896 | Renal | Phase 2 | Massachusetts General Hospital | Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X institutional upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN |
| NCT04024761 | Brain metastases | Phase 1 | Dana-Farber Cancer Institute | Extramedullary relapse involving immuno-privileged sites (e.g. CNS, testes, eyes). |
| NCT04024761 | Cardiac | Phase 1 | Dana-Farber Cancer Institute | LVEF >40%. |
| NCT04024761 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | AST(SGOT)/ALT(SGPT): ≤3 x institutional ULN |
| NCT04024761 | HIV | Phase 1 | Dana-Farber Cancer Institute | HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions with anti-retroviral agents used in this study. |
| NCT04024761 | Performance status | Phase 1 | Dana-Farber Cancer Institute | 1.5 ECOG performance status ≤2. |
| NCT04024761 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because of the unknown teratogenic risk of CIML NK cells and IL-2 |
| NCT04024761 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Individuals with a history of a different malignancy are ineligible except for the following circumstances |
| NCT04024761 | Renal | Phase 1 | Dana-Farber Cancer Institute | Serum creatinine ≤2.0mg/dL |
| NCT04031677 | Cardiac | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | Congestive heart failure |
| NCT04031677 | Diabetes | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | Uncontrolled severe illness, infection, medical condition (including uncontrolled diabetes), other than the primary LPS or LMS of the retroperitoneum. |
| NCT04031677 | Language | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | All patients recruited to STRASS 2 in participating centres (Australia +/- international sites) that are able to read, comprehend and write in English at a sufficient level to complete study materials. |
| NCT04031677 | Performance status | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | WHO performance status ≤ 2 |
| NCT04031677 | Pregnancy | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control method. |
| NCT04031677 | Prior malignancy | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | Other invasive malignancy within 5 years, with the exception of adequately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤ 6prostate cancer. |
| NCT04033497 | Pregnancy | Not given | Brigham and Women's Hospital | Pregnant women are excluded from this study because gadolinium-based agents have not been proven to be safe to administer to a developing fetus. Similarly, breastfeeding women will be excluded from this study. |
| NCT04033497 | Renal | Not given | Brigham and Women's Hospital | Participants who have chronic kidney disease stage IV-V or end stage renal disease. |
| NCT04045470 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). |
| NCT04045470 | Pregnancy | Not given | Dana-Farber Cancer Institute | Positive serum pregnancy test at screening visit. |
| NCT04049331 | Age | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Age: 18-54 years |
| NCT04049331 | BMI | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Body mass index (BMI) >45 kg/m2 |
| NCT04049331 | Brain metastases | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Men with brain cancer (potential cognitive impairment) |
| NCT04049331 | Cardiac | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Uncontrolled congestive heart failure |
| NCT04049331 | Diabetes | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Poorly controlled diabetes as defined by hemoglobin A1c >8.5%; Body mass index (BMI) >45 kg/m2 |
| NCT04049331 | Hepatic | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Serum creatinine >2.5 mg/dL; ALT 3x upper limit of normal |
| NCT04049331 | Prior malignancy | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Men with hormone-dependent cancers (breast, prostate or adenocarcinoma of unknown origin) |
| NCT04049331 | Renal | Phase 2 | Seattle Institute for Biomedical and Clinical Research | Serum creatinine >2.5 mg/dL; ALT 3x upper limit of normal |
| NCT04079179 | Age | Phase 2 | Carl Allen | Participant must be at least 6 months of age and less than 21 years of age at the time of enrollment |
| NCT04079179 | Cardiac | Phase 2 | Carl Allen | Fractional shortening (FS) of ≥ 30% or ejection fraction of ≥ 50% by echocardiogram at baseline |
| NCT04079179 | Hepatic | Phase 2 | Carl Allen | Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age |
| NCT04079179 | HIV | Phase 2 | Carl Allen | Known chronic human immunodeficiency virus (HIV). |
| NCT04079179 | Performance status | Phase 2 | Carl Allen | Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50% for patients ≤ 16 years of age. |
| NCT04079179 | Pregnancy | Phase 2 | Carl Allen | Female patients who are pregnant or lactating. |
| NCT04079179 | Prior malignancy | Phase 2 | Carl Allen | Other active malignancy or history of secondary malignancy. |
| NCT04079179 | Renal | Phase 2 | Carl Allen | Calculated creatinine clearance (or radioisotope GFR) ≥ 70 mL/min/1.73m^2 or serum creatinine based on age/gender as follows: |
| NCT04094610 | Age | Phase 1/2 | Turning Point Therapeutics, Inc. | Phase 1: Age <12 years; Phase 2: Age 12- 25 years |
| NCT04094610 | Brain metastases | Phase 1/2 | Turning Point Therapeutics, Inc. | Subjects with a primary CNS tumor or CNS metastases must be neurologically stable on a stable or decreasing dose of steroids for at least 7 days prior to enrollment. |
| NCT04094610 | Cardiac | Phase 1/2 | Turning Point Therapeutics, Inc. | Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTc) > 480 msec obtained from three ECGs, using the screening clinic ECG machine-derived QTc value |
| NCT04094610 | HIV | Phase 1/2 | Turning Point Therapeutics, Inc. | Known active infections requiring ongoing treatment (bacterial, fungal, viral including HIV positivity). |
| NCT04094610 | Performance status | Phase 1/2 | Turning Point Therapeutics, Inc. | Subjects must have a Lansky (< 16 years) or Karnofsky (≥ 16 years) score of at least 50. |
| NCT04104776 | Brain metastases | Phase 1/2 | Novartis Pharmaceuticals | Active or untreated symptomatic CNS metastases (with limited exceptions) |
| NCT04104776 | Cardiac | Phase 1/2 | Novartis Pharmaceuticals | Clinically significant cardiovascular disease, including uncontrolled arrhythmias or prolonged QTc |
| NCT04104776 | HIV | Phase 1/2 | Novartis Pharmaceuticals | Active HIV or hepatitis B/C infection |
| NCT04104776 | Performance status | Phase 1/2 | Novartis Pharmaceuticals | ECOG performance status 0-1 |
| NCT04104776 | Pregnancy | Phase 1/2 | Novartis Pharmaceuticals | Pregnancy, breastfeeding, or inability to comply with protocol requirements |
| NCT04104776 | Prior malignancy | Phase 1/2 | Novartis Pharmaceuticals | Concurrent malignancy requiring active treatment (with protocol-defined exceptions) |
| NCT04115254 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) |
| NCT04115254 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant women are excluded from this study. |
| NCT04134559 | Age | Phase 2 | Allison O'Neill, MD | Patients must be <30 years of age at the time of study enrollment. |
| NCT04134559 | Hepatic | Phase 2 | Allison O'Neill, MD | Total bilirubin < 1.5 x institutional upper limit of normal (ULN) |
| NCT04134559 | HIV | Phase 2 | Allison O'Neill, MD | Patients with a history of a positive test for human immunodeficiency virus or acquired immunodeficiency syndrome are not eligible. |
| NCT04134559 | Performance status | Phase 2 | Allison O'Neill, MD | Karnofsky performance status ≥ 60% for patients ≥ 16 years of age or Lansky ≥ 60% for patients < 16 years of age. |
| NCT04134559 | Pregnancy | Phase 2 | Allison O'Neill, MD | Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours of each treatment. |
| NCT04134559 | Renal | Phase 2 | Allison O'Neill, MD | Creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. |
| NCT04135807 | Cardiac | Early phase 1 | Oliver Jonas | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT04135807 | Hepatic | Early phase 1 | Oliver Jonas | Total bilirubin within normal institutional limits |
| NCT04135807 | Performance status | Early phase 1 | Oliver Jonas | Karnofsky Performance Score ≥ 60 (Appendix C). |
| NCT04135807 | Pregnancy | Early phase 1 | Oliver Jonas | Pregnant women are excluded from this study because agents released by the microdevice have the potential for teratogenic or abortifacient effects. |
| NCT04135807 | Renal | Early phase 1 | Oliver Jonas | Creatinine within normal institutional limits OR |
| NCT04181060 | Brain metastases | Phase 3 | National Cancer Institute (NCI) | Patients with untreated brain metastases or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required provided the metastatic lesions are non-hemorrhagic and are neurologically stable without glucocorticoid therapy |
| NCT04181060 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Patients with known history or current symptoms of cardiac disease, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better |
| NCT04181060 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN (obtained =< 14 days prior to randomization) |
| NCT04181060 | HIV | Phase 3 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT04181060 | Performance status | Phase 3 | National Cancer Institute (NCI) | Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 |
| NCT04181060 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used |
| NCT04181060 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT04181060 | Renal | Phase 3 | National Cancer Institute (NCI) | Total bilirubin and creatinine =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 14 days prior to randomization) |
| NCT04188535 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥60%) |
| NCT04196595 | Language | Not given | Apple Inc. | Be comfortable communicating in written and spoken English |
| NCT04230109 | Cardiac | Phase 2 | Massachusetts General Hospital | known cardiomyopathy (LVEF < 50%; new LVEF assessment is not specifically required for this trial) |
| NCT04230109 | Hepatic | Phase 2 | Massachusetts General Hospital | Adequate hepatic function (bilirubin ≤ 1.5 ULN, AST and ALT ≤ 2.5 X ULN and serum albumin > 3 g/dL). |
| NCT04230109 | HIV | Phase 2 | Massachusetts General Hospital | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to enrollment are eligible for this trial. |
| NCT04230109 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status = 0, 1 (Karnofsky ≥60%, see Appendix A) |
| NCT04230109 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant or breast-feeding women are excluded from this study because the safety of study medications is not established. |
| NCT04230109 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Participants currently receiving systemic therapy for any malignancy or having received systemic therapy for a malignancy in the preceding 3 years. |
| NCT04230109 | Renal | Phase 2 | Massachusetts General Hospital | Serum creatinine <1.5 mg/dL or creatinine clearance ≥50 mL/min (via the Cockcroft-Gault formula) for participants with creatinine levels above institutional upper limit of normal (ULN) |
| NCT04251052 | Age | Not given | NRG Oncology | Individuals 35-50 years of age, inclusive |
| NCT04251052 | Pregnancy | Not given | NRG Oncology | Individuals who are currently pregnant or plan to become pregnant in the future through assisted reproductive technologies and who have received proper counseling are eligible. |
| NCT04251052 | Prior malignancy | Not given | NRG Oncology | Individuals with a history of any prior cancer who have received cytotoxic chemotherapy within the past 30 days or radiotherapy to abdomen or pelvis at any prior time. |
| NCT04256317 | Age | Phase 2/3 | Taiho Oncology, Inc. | Aged 75 years or older, or b. Aged 18 to 74 years |
| NCT04256317 | Brain metastases | Phase 2/3 | Taiho Oncology, Inc. | Has known active central nervous system involvement from AML. |
| NCT04256317 | Cardiac | Phase 2/3 | Taiho Oncology, Inc. | Has a cardiovascular disability status of New York Heart Association Class >2. |
| NCT04256317 | Hepatic | Phase 2/3 | Taiho Oncology, Inc. | Has severe hepatic impairment |
| NCT04256317 | HIV | Phase 2/3 | Taiho Oncology, Inc. | Has known human immunodeficiency virus (HIV) infection. |
| NCT04256317 | Performance status | Phase 2/3 | Taiho Oncology, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. |
| NCT04256317 | Prior malignancy | Phase 2/3 | Taiho Oncology, Inc. | Has a history of other malignancies prior to study entry, with the exception of adequately treated in situ carcinoma of the breast or cervix uteri; localized basal cell carcinoma or squamous cell carcinoma of the skin; previous malignancy confined and surgically resected or adequately treated and controlled with other modalities; and any early stage malignancy for which no definitive therapy is required. |
| NCT04256317 | Renal | Phase 2/3 | Taiho Oncology, Inc. | Has severe renal impairment |
| NCT04267848 | Cardiac | Phase 3 | National Cancer Institute (NCI) | symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris |
| NCT04267848 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x upper limit of normal (ULN) |
| NCT04267848 | HIV | Phase 3 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT04267848 | Performance status | Phase 3 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-1 |
| NCT04267848 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects |
| NCT04267848 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 3 years. |
| NCT04267848 | Renal | Phase 3 | National Cancer Institute (NCI) | Calculated (Calc.) creatinine clearance >= 45 mL/min |
| NCT04269902 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Participants must not have any currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification |
| NCT04269902 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x upper limit of normal (ULN) within 28 days prior to registration |
| NCT04269902 | Language | Phase 3 | National Cancer Institute (NCI) | Participants who are able to complete patient reported outcome (PRO) forms in English, Spanish, French, German, Russian or Mandarin must be offered the opportunity to participate in the quality of life assessments. |
| NCT04269902 | Performance status | Phase 3 | National Cancer Institute (NCI) | Participants must have Eastern Cooperative Oncology Group (ECOG) performance status =< 2 |
| NCT04269902 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Participants must not be pregnant or nursing, as there are no safety data available for these drug regimens during pregnancy. |
| NCT04269902 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Participants with history of malignancy are allowed providing the cancer has not required active treatment within 2 years prior to registration (hormonal therapy is permissible). |
| NCT04269902 | Renal | Phase 3 | National Cancer Institute (NCI) | Creatinine clearance >= 30mL/min (by Cockcroft Gault) within 28 days prior to registration |
| NCT04293562 | Age | Phase 3 | Children's Oncology Group | Patients must be at least 6 months of age and less than 22 years of age at the time of study enrollment |
| NCT04293562 | Cardiac | Phase 3 | Children's Oncology Group | Patients with persistent cardiac dysfunction prior to enrollment, defined as ejection fraction (EF) < 50% (preferred method Biplane Simpson's EF) or if EF unavailable, shortening fraction (SF) < 24%. |
| NCT04293562 | Language | Phase 3 | Children's Oncology Group | NEUROPSYCHOLOGICAL TESTING: English-, French- or Spanish-speaking |
| NCT04293562 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT04293562 | Prior malignancy | Phase 3 | Children's Oncology Group | Any concurrent malignancy |
| NCT04294927 | Age | Not given | University Medical Center Nijmegen | BRCA1: 25-40 years |
| NCT04302025 | HIV | Phase 2 | Genentech, Inc. | Participants known to be positive for human immunodeficiency virus (HIV) are excluded if they meet any of the following criteria: cluster of differentiation 4 (CD4)+ T-cell count of <350 cells/microliters (cells/µL); detectable HIV viral load; history of an opportunistic infection within the past 12 months; on stable antiretroviral therapy for <4 weeks |
| NCT04302025 | Performance status | Phase 2 | Genentech, Inc. | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 |
| NCT04302025 | Pregnancy | Phase 2 | Genentech, Inc. | Pregnant or lactating, or intending to become pregnant during the study |
| NCT04302025 | Prior malignancy | Phase 2 | Genentech, Inc. | Malignancies other than the disease under study within 3 years prior to Cycle 1, Day 1, with the exception of participants with a negligible risk of metastasis or death and with expected curative outcome |
| NCT04305834 | Age | Phase 2 | City of Hope Medical Center | Age >= 70 years |
| NCT04305834 | Brain metastases | Phase 2 | City of Hope Medical Center | Absence of central nervous system (CNS) involvement unless they meet ONE of the following criteria: |
| NCT04305834 | Cardiac | Phase 2 | City of Hope Medical Center | History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest |
| NCT04305834 | Hepatic | Phase 2 | City of Hope Medical Center | In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN) |
| NCT04305834 | HIV | Phase 2 | City of Hope Medical Center | such as known human immunodeficiency virus positivity |
| NCT04305834 | Language | Phase 2 | City of Hope Medical Center | Ability to read and understand English or Spanish |
| NCT04305834 | Prior malignancy | Phase 2 | City of Hope Medical Center | Patients with a prior malignancy diagnosed within 2 years and with evidence of disease |
| NCT04305834 | Renal | Phase 2 | City of Hope Medical Center | Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula |
| NCT04322318 | Age | Phase 2 | Children's Oncology Group | Patients must be =< 30 years old at study enrollment |
| NCT04322318 | Cardiac | Phase 2 | Children's Oncology Group | Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by radionuclide angiogram (obtained within 21 days prior to enrollment and start of protocol therapy) |
| NCT04322318 | Hepatic | Phase 2 | Children's Oncology Group | Total bilirubin =< 1.5 x upper limit of normal (ULN) for age or direct bilirubin =< ULN for patients whose total bilirubin > 1.5 x ULN (performed within 7 days prior to enrollment) |
| NCT04322318 | Performance status | Phase 2 | Children's Oncology Group | Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. |
| NCT04322318 | Pregnancy | Phase 2 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT04322318 | Prior malignancy | Phase 2 | Children's Oncology Group | Patients with a history of bilateral Wilms tumor (synchronous or metachronous) |
| NCT04322318 | Renal | Phase 2 | Children's Oncology Group | Creatinine clearance or radioisotope GFR >= 60 mL/min/1.73 m^2 (performed within 7 days prior to enrollment) |
| NCT04363164 | Hepatic | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Bilirubin < 2.5 times institutional upper limit of normal (ULN) |
| NCT04363164 | HIV | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active uncontrolled infection, including known history of HIV/AIDS or hepatitis B or C. |
| NCT04363164 | Performance status | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | ECOG Performance status ≤2. |
| NCT04363164 | Renal | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Serum creatinine < 2.5 times ULN |
| NCT04368702 | Performance status | Not given | Brigham and Women's Hospital | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) |
| NCT04370587 | Brain metastases | Phase 1/2 | ImmVira Pharma Co. Ltd | History of or current central nervous system metastases. |
| NCT04370587 | Cardiac | Phase 1/2 | ImmVira Pharma Co. Ltd | Congestive heart failure, active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina, or clinically significant cardiac arrhythmias. |
| NCT04370587 | HIV | Phase 1/2 | ImmVira Pharma Co. Ltd | Active hepatitis B virus, hepatitis C virus, and HIV infection or a positive serological test at Screening within 14 days of dosing with T3011. |
| NCT04370587 | Performance status | Phase 1/2 | ImmVira Pharma Co. Ltd | Eastern Cooperative Oncology Group (ECOG) performance status 0-1. |
| NCT04370587 | Pregnancy | Phase 1/2 | ImmVira Pharma Co. Ltd | Pregnant or lactating. |
| NCT04373564 | Hepatic | Phase 4 | Guerbet | Alcoholic cirrhosis |
| NCT04373564 | Pregnancy | Phase 4 | Guerbet | Pregnant or nursing (lactating) women |
| NCT04373564 | Prior malignancy | Phase 4 | Guerbet | Malignant disease other than listed in indications |
| NCT04373564 | Renal | Phase 4 | Guerbet | Renal disease, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 |
| NCT04374305 | Age | Phase 2 | Scott R. Plotkin, MD, PhD | Participant is ≥ 12 years of age and has body weight at least 40 kg on Day 1 of treatment. |
| NCT04374305 | BMI | Phase 2 | Scott R. Plotkin, MD, PhD | Participant is ≥ 12 years of age and has body weight at least 40 kg on Day 1 of treatment. |
| NCT04374305 | Brain metastases | Phase 2 | Scott R. Plotkin, MD, PhD | Subjects with significantly increased risk of CNS hemorrhage are not eligible. |
| NCT04374305 | Cardiac | Phase 2 | Scott R. Plotkin, MD, PhD | Myocardial infarction within 6 months before the first dose of neratinib. |
| NCT04374305 | Hepatic | Phase 2 | Scott R. Plotkin, MD, PhD | ALT/aspartate aminotransferase (AST) ≤ 2.5 × institutional upper limit of normal (ULN); |
| NCT04374305 | HIV | Phase 2 | Scott R. Plotkin, MD, PhD | Have a known history of HIV infection. Testing is not required in the absence of history. |
| NCT04374305 | Performance status | Phase 2 | Scott R. Plotkin, MD, PhD | Karnofsky performance status ≥ 70 or ECOG PS 0 or 1 (see Appendix A). |
| NCT04374305 | Pregnancy | Phase 2 | Scott R. Plotkin, MD, PhD | Pregnant women are excluded from this study because the experimental agents may have the potential for teratogenic or abortifacient effects. |
| NCT04374305 | Prior malignancy | Phase 2 | Scott R. Plotkin, MD, PhD | History of a different malignancy, unless (a) have been disease-free for at least 2 years and are deemed by the treating investigator to be at low risk for recurrence of that malignancy. |
| NCT04374305 | Renal | Phase 2 | Scott R. Plotkin, MD, PhD | Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2, using the modification of diet in renal disease (MDRD) equation |
| NCT04389632 | Brain metastases | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | Known active central nervous system metastases. |
| NCT04389632 | Performance status | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 |
| NCT04389632 | Prior malignancy | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death. |
| NCT04410796 | Age | Phase 2 | Memorial Sloan Kettering Cancer Center | Post-menopausal defined as aged more than 50 years |
| NCT04410796 | Cardiac | Phase 2 | Memorial Sloan Kettering Cancer Center | Mean resting corrected QT interval (QTc) > 470 msec where QT interval is corrected for heart rate using Frederica's formula (QTcF). |
| NCT04410796 | Hepatic | Phase 2 | Memorial Sloan Kettering Cancer Center | AST, ALT ≤ 2.5 x ULN with no liver metastases or < 5x ULN with the presence of liver metastases |
| NCT04410796 | HIV | Phase 2 | Memorial Sloan Kettering Cancer Center | active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). |
| NCT04410796 | Performance status | Phase 2 | Memorial Sloan Kettering Cancer Center | Karnofsky performance status (KPS)≥70%, |
| NCT04410796 | Pregnancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Pregnant or lactating women |
| NCT04410796 | Renal | Phase 2 | Memorial Sloan Kettering Cancer Center | Creatinine clearance ≥ 60 mL/min calculated by Cockcroft and Gault equation |
| NCT04421560 | Brain metastases | Phase 1/2 | Dana-Farber Cancer Institute | Patients who cannot undergo MRI brain |
| NCT04421560 | Cardiac | Phase 1/2 | Dana-Farber Cancer Institute | Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (New York Heart Association > Class 2), unstable angina, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification |
| NCT04421560 | Diabetes | Phase 1/2 | Dana-Farber Cancer Institute | Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin >8% or poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of >8%. |
| NCT04421560 | Hepatic | Phase 1/2 | Dana-Farber Cancer Institute | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN(≤5 × ULN for participants with liver metastases) |
| NCT04421560 | HIV | Phase 1/2 | Dana-Farber Cancer Institute | Has known history of HIV/AIDS |
| NCT04421560 | Performance status | Phase 1/2 | Dana-Farber Cancer Institute | Subjects must have a Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. |
| NCT04421560 | Pregnancy | Phase 1/2 | Dana-Farber Cancer Institute | Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must have a negative serum pregnancy test within 72 hours prior to registration. |
| NCT04421560 | Prior malignancy | Phase 1/2 | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. |
| NCT04421560 | Renal | Phase 1/2 | Dana-Farber Cancer Institute | Serum creatinine ≤1.5 x institutional ULN OR Measured or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN (Creatinine clearance should be calculated per institutional standard) |
| NCT04429542 | HIV | Phase 1 | Bicara Therapeutics | Known cases of human immunodeficiency virus (HIV) are excluded if patients have a CD4+ T-cell (CD4+) count <250 cells/uL. |
| NCT04429542 | Performance status | Phase 1 | Bicara Therapeutics | Patient must have a performance status of ≤1 on the Eastern Cooperative Oncology Group Performance Scale. |
| NCT04429542 | Pregnancy | Phase 1 | Bicara Therapeutics | Pregnant or breastfeeding women. |
| NCT04429542 | Prior malignancy | Phase 1 | Bicara Therapeutics | Known history of a hematologic malignancy (or solid tumor other than the ones indicated for this study), unless the patient has undergone potentially curative therapy with no evidence of that disease for 2 years. |
| NCT04434040 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | congestive heart failure of New York Heart Association Class III or IV, myocardial infarction (<6 months prior to enrollment) unstable angina pectoris, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease, in the opinion of the investigator |
| NCT04434040 | Diabetes | Phase 2 | Dana-Farber Cancer Institute | uncontrolled Type I or Type II diabetes mellitus |
| NCT04434040 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 × institutional upper limit of normal (ULN). |
| NCT04434040 | HIV | Phase 2 | Dana-Farber Cancer Institute | Participants known to be positive for the human immunodeficiency virus (HIV), Hepatitis B antigen (HepBsAg), or Hepatitis C virus (HCV) RNA are ineligible. |
| NCT04434040 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG Performance Status of 0 or 1 |
| NCT04434040 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because the effects of sacituzumab govitecan and atezolizumab on a developing fetus are unknown. |
| NCT04434040 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Participants with history of prior malignancy other than breast cancer are eligible if they have been disease-free for at least 5 years prior to enrollment with the exception of patients with thyroid cancer that has been definitively treated without spread to regional lymph nodes. |
| NCT04434040 | Renal | Phase 2 | Dana-Farber Cancer Institute | Serum creatinine < 1.5 x institutional ULN |
| NCT04442724 | Pregnancy | Not given | Cedars-Sinai Medical Center | Pregnant or nursing women are excluded |
| NCT04442724 | Prior malignancy | Not given | Cedars-Sinai Medical Center | Previous malignancy other than TCC that, in the opinion of the treating investigator, is likely to interfere with protocol treatment |
| NCT04442724 | Renal | Not given | Cedars-Sinai Medical Center | Adequate renal function: Serum creatinine < 2 mg/dL OR calculated creatinine clearance (CrCl) > 30ml/min |
| NCT04468061 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms. |
| NCT04468061 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Total bilirubin ≤1.5 × institutional upper limit of normal (ULN)(or ≤2.0 x ULN in patients with documented Gilbert's Syndrome) |
| NCT04468061 | HIV | Phase 2 | Dana-Farber Cancer Institute | HIV-positive participants are ineligible due to the potential for pharmacokinetic interactions of combination antiretroviral therapy with study drugs and the increased risk of fatal infections when treated with marrow-suppressive therapy. |
| NCT04468061 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status 0-1 (Karnofsky > 60%, see Appendix A). |
| NCT04468061 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | participants who are breast-feeding are not eligible for enrollment. |
| NCT04468061 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Individuals with a history of a second malignancy are ineligible except for the following circumstances. |
| NCT04468061 | Renal | Phase 2 | Dana-Farber Cancer Institute | Serum creatinine ≤1.5 × institutional ULN OR creatinine clearance ≥ 30 mL/min/ 1.73m2 for participants with creatinine levels above institutional ULN. |
| NCT04485286 | BMI | Phase 2 | Massachusetts General Hospital | BMI > 33 (limit of the PET-MRI table) |
| NCT04485286 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test is required for females having child-bearing potential before the subject can participate); |
| NCT04485286 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational imaging and standard treatment regimen are eligible for this trial. |
| NCT04485286 | Renal | Phase 2 | Massachusetts General Hospital | eGFR of less than 30 mL/min/1.73 m2 within the past 90 days; |
| NCT04485286 | Smoking | Phase 2 | Massachusetts General Hospital | No tobacco use within the prior 6 months. |
| NCT04504604 | Language | Not given | TargetCancer Foundation | Ability to read, write and communicate in English. |
| NCT04504604 | Performance status | Not given | TargetCancer Foundation | Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. |
| NCT04504604 | Pregnancy | Not given | TargetCancer Foundation | Pregnancy or breastfeeding. |
| NCT04504604 | Prior malignancy | Not given | TargetCancer Foundation | Concurrent active malignancy requiring treatment within 1 year of enrollment, at the discretion of treating physician. |
| NCT04511806 | Age | Not given | Emory University | Be less than 21 years of age at the time of enrollment |
| NCT04516447 | Prior malignancy | Phase 1 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy. |
| NCT04545957 | Performance status | Not given | Brigham and Women's Hospital | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) |
| NCT04553770 | Age | Phase 2 | Jonsson Comprehensive Cancer Center | Age >= 60 years, or |
| NCT04553770 | Cardiac | Phase 2 | Jonsson Comprehensive Cancer Center | Normal cardiac function (left ventricular ejection fraction [LVEF] >= 50%) based on echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization/enrollment |
| NCT04553770 | Hepatic | Phase 2 | Jonsson Comprehensive Cancer Center | Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 3 x ULN (within 14 days before randomization/enrollment) |
| NCT04553770 | HIV | Phase 2 | Jonsson Comprehensive Cancer Center | Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. |
| NCT04553770 | Performance status | Phase 2 | Jonsson Comprehensive Cancer Center | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT04553770 | Pregnancy | Phase 2 | Jonsson Comprehensive Cancer Center | Is pregnant or lactating, or planning to become pregnant |
| NCT04553770 | Prior malignancy | Phase 2 | Jonsson Comprehensive Cancer Center | Has multiple primary malignancies within 3 years, except: |
| NCT04553770 | Renal | Phase 2 | Jonsson Comprehensive Cancer Center | Creatinine clearance >= 30 mL/min as calculated using the Cockcroft-Gault equation or serum creatinine =< 1.5 x upper limit of normal (ULN) (within 14 days before randomization/enrollment) |
| NCT04566328 | Cardiac | Phase 3 | ECOG-ACRIN Cancer Research Group | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. |
| NCT04566328 | Hepatic | Phase 3 | ECOG-ACRIN Cancer Research Group | Total bilirubin =< 1.5 x ULN (institutional upper limit of normal) (obtained =< 14 days prior to Step 1 registration) |
| NCT04566328 | HIV | Phase 3 | ECOG-ACRIN Cancer Research Group | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial |
| NCT04566328 | Performance status | Phase 3 | ECOG-ACRIN Cancer Research Group | Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 (PS 3 allowed if secondary to pain) |
| NCT04566328 | Pregnancy | Phase 3 | ECOG-ACRIN Cancer Research Group | Women must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. |
| NCT04566328 | Prior malignancy | Phase 3 | ECOG-ACRIN Cancer Research Group | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT04566328 | Renal | Phase 3 | ECOG-ACRIN Cancer Research Group | Calculated creatinine clearance > 30 mL/min (obtained =< 14 days prior to Step 1 registration) |
| NCT04575935 | Performance status | Phase 3 | M.D. Anderson Cancer Center | ECOG performance status 0-2 |
| NCT04575935 | Pregnancy | Phase 3 | M.D. Anderson Cancer Center | Negative pregnancy test by blood or urine (within 14 days prior to surgery) |
| NCT04575935 | Prior malignancy | Phase 3 | M.D. Anderson Cancer Center | Disease free of other active malignancies in the previous five years, except basal and squamous cell carcinomas of the skin |
| NCT04585750 | Brain metastases | Phase 1/2 | PMV Pharmaceuticals, Inc | History of leptomeningeal disease or spinal cord compression |
| NCT04585750 | Cardiac | Phase 1/2 | PMV Pharmaceuticals, Inc | Heart conditions such as unstable angina within 6 months prior to screening, uncontrolled hypertension, a heart attack within 6 months prior to screening, congestive heart failure, prolongation of QT interval, or other rhythm abnormalities |
| NCT04585750 | HIV | Phase 1/2 | PMV Pharmaceuticals, Inc | Known history of HIV infection |
| NCT04585750 | Performance status | Phase 1/2 | PMV Pharmaceuticals, Inc | Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 |
| NCT04585750 | Prior malignancy | Phase 1/2 | PMV Pharmaceuticals, Inc | Known, active malignancy, except for treated cervical intraepithelial neoplasia, or non-melanoma skin cancer |
| NCT04585958 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with brain metastases should be stable and off steroids and at least 4 weeks from radiation at the time of registration |
| NCT04585958 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Patients with a medical history of myocardial infarction within 6 months before randomization/enrollment, symptomatic congestive heart failure (CHF) (New York Heart Association class IIb to IV) |
| NCT04585958 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), (< 3 x ULN in the presence of documented Gilbert's syndrome or liver metastases at baseline) |
| NCT04585958 | HIV | Phase 1 | National Cancer Institute (NCI) | Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements: |
| NCT04585958 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%) |
| NCT04585958 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Pregnant women are excluded from this study |
| NCT04585958 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, and other solid tumors curatively treated |
| NCT04585958 | Renal | Phase 1 | National Cancer Institute (NCI) | Creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2 (using the Cockcroft-Gault Equation) |
| NCT04588922 | Brain metastases | Phase 1/2 | Sellas Life Sciences Group | Symptomatic central nervous system (CNS) metastases or primary lymphoma such as primary CNS lymphoma, leptomeningeal disease, or spinal cord compression. |
| NCT04588922 | Cardiac | Phase 1/2 | Sellas Life Sciences Group | Average QTcF ≥ 450 msec (males) or ≥ 470 msec (females) on screening ECG. |
| NCT04588922 | Hepatic | Phase 1/2 | Sellas Life Sciences Group | Total bilirubin ≤ 1.5 × upper limit of normal (ULN) except for patients with Gilbert's syndrome |
| NCT04588922 | HIV | Phase 1/2 | Sellas Life Sciences Group | Patients with known HIV infection except if: |
| NCT04588922 | Performance status | Phase 1/2 | Sellas Life Sciences Group | Eastern cooperative oncology group (ECOG) performance status 0-2. |
| NCT04588922 | Pregnancy | Phase 1/2 | Sellas Life Sciences Group | Pregnant or breast-feeding females. |
| NCT04588922 | Prior malignancy | Phase 1/2 | Sellas Life Sciences Group | Concurrent malignancy within 5 years (for AML patients, 2 years) prior to entry |
| NCT04588922 | Renal | Phase 1/2 | Sellas Life Sciences Group | Measured or calculated (determined by the Cockcroft-Gault equation) serum creatinine clearance (CrCl) ≥ 60 mL/min |
| NCT04590326 | Brain metastases | Phase 1/2 | Regeneron Pharmaceuticals | Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol |
| NCT04590326 | Cardiac | Phase 1/2 | Regeneron Pharmaceuticals | Has history of clinically significant cardiovascular disease as defined in the protocol |
| NCT04590326 | Performance status | Phase 1/2 | Regeneron Pharmaceuticals | Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT04590326 | Prior malignancy | Phase 1/2 | Regeneron Pharmaceuticals | Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol |
| NCT04613596 | Brain metastases | Phase 2/3 | Mirati Therapeutics Inc. | Any untreated brain lesions > 2.0 cm in size |
| NCT04616560 | Age | Phase 2 | National Cancer Institute (NCI) | patients enrolling on the Phase 2 component of the study must be from at least 12 to 39 years of age at the time of study enrollment |
| NCT04616560 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | Patients who have spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms are not eligible |
| NCT04616560 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Corrected QT interval (QTc) prolongation to < 480 ms based on average triplicate 12-lead electrocardiogram (ECG) |
| NCT04616560 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Bilirubin (sum of conjugated + unconjugated or total) =< 1.5 x upper limit of normal (ULN) for age. |
| NCT04616560 | HIV | Phase 2 | National Cancer Institute (NCI) | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of enrollment are eligible |
| NCT04616560 | Performance status | Phase 2 | National Cancer Institute (NCI) | Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1. |
| NCT04616560 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Pregnant, planning to become pregnant, or breast-feeding women will not be entered on this study. |
| NCT04616560 | Renal | Phase 2 | National Cancer Institute (NCI) | Estimated glomerular filtration rate (GFR) (eGFR) ≥ 70 mL/min/1.73 m^2 (> 70mL/min/1.73 m^2 for patients > 17 years old) |
| NCT04620187 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | baseline left systolic ventricular ejection fraction (LVEF) ≥ 50% within 1 month prior to study registration |
| NCT04620187 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | total bilirubin ≤ 2.0 g/dL |
| NCT04620187 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status ≤ 1 (Karnofsky ≥ 60%, see Appendix A) |
| NCT04620187 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant or lactating women. |
| NCT04620187 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or requires active treatment. |
| NCT04620187 | Renal | Phase 2 | Dana-Farber Cancer Institute | creatinine clearance ≥50 mL/min/1.73 m2 for participants with creatinine levels above institutional normal |
| NCT04634357 | Age | Phase 1/2 | Eureka Therapeutics Inc. | Age ≥ 1 year and ≤ 21 years. |
| NCT04634357 | Hepatic | Phase 1/2 | Eureka Therapeutics Inc. | Child-Pugh score of A6 or better. |
| NCT04634357 | HIV | Phase 1/2 | Eureka Therapeutics Inc. | Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled. |
| NCT04634357 | Performance status | Phase 1/2 | Eureka Therapeutics Inc. | Lansky or Karnofsky Performance Scale ≥ 70. |
| NCT04634357 | Pregnancy | Phase 1/2 | Eureka Therapeutics Inc. | Pregnant or lactating women. |
| NCT04634357 | Prior malignancy | Phase 1/2 | Eureka Therapeutics Inc. | Any known active malignancy (other than HB, HCN-NOS, or HCC). |
| NCT04635111 | Hepatic | Not given | Daiichi Sankyo | Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 × upper limit of normal (ULN) with concurrent total bilirubin (TBIL) >2 × ULN |
| NCT04636710 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status ≤2 |
| NCT04641247 | Pregnancy | Phase 2 | GlaxoSmithKline | Participant is pregnant or is expecting to conceive children while receiving study drug or for up to 180 days after the last dose of study drug. |
| NCT04644211 | Age | Phase 2 | Massachusetts General Hospital | Essential thrombocythemia patients who are high risk by IPSET-R criteria (age > 60 with JAK2 V617F mutation and/or history of thrombosis).1 Polycythemia vera patients who are high risk by NCCN guidelines (age > 60 and/or history of thrombosis). |
| NCT04644211 | Cardiac | Phase 2 | Massachusetts General Hospital | Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better. |
| NCT04644211 | Hepatic | Phase 2 | Massachusetts General Hospital | AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN |
| NCT04644211 | HIV | Phase 2 | Massachusetts General Hospital | For participants with evidence of chronic human immunodeficiency virus (HIV) infection, they must be negative for HBV DNA, HCV RNA, or hepatitis B surface antigen (BsAg) on suppressive therapy, if indicated. |
| NCT04644211 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status ≤2 (Karnofsky ≥60%) |
| NCT04644211 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study because ruxolitinib is a Class C agent with the potential for teratogenic or abortifacient effects. |
| NCT04644211 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Participants with a prior or concurrent malignancy not receiving treatment for concurrent cancer diagnosis and/or prior concurrent malignancy within 5 years except for basal cell carcinoma or squamous cell carcinoma of the skin. |
| NCT04644211 | Renal | Phase 2 | Massachusetts General Hospital | creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2 |
| NCT04655404 | Age | Early phase 1 | Nationwide Children's Hospital | Patients ≤ 21 years of age (birth to 21 years of age) at the time of study enrollment will be eligible. |
| NCT04655404 | Hepatic | Early phase 1 | Nationwide Children's Hospital | Total bilirubin ≤ 2.5 × institutional upper limit of normal AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal |
| NCT04655404 | Performance status | Early phase 1 | Nationwide Children's Hospital | Karnofsky ≥ 50% for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age |
| NCT04655404 | Pregnancy | Early phase 1 | Nationwide Children's Hospital | Pregnant or breast-feeding women will not be entered on this study |
| NCT04655404 | Prior malignancy | Early phase 1 | Nationwide Children's Hospital | Patients must not have received any prior anti-cancer chemotherapy. |
| NCT04655404 | Renal | Early phase 1 | Nationwide Children's Hospital | Serum creatinine within normal institutional limits, or Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 |
| NCT04656041 | Brain metastases | Phase 2 | Massachusetts General Hospital | History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance or drug intake. |
| NCT04656041 | Cardiac | Phase 2 | Massachusetts General Hospital | myocardial infarction within the last 12 months |
| NCT04656041 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status ≤ 1 |
| NCT04656041 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study because radiation therapy and the chemotherapy agents to be used have the potential for teratogenic or abortifacient effects. |
| NCT04656041 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Treatment of other invasive carcinomas within the last five years with greater than 5% risk of recurrence at time of eligibility screening. |
| NCT04657068 | Brain metastases | Phase 1/2 | Artios Pharma Ltd | Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment |
| NCT04657068 | Cardiac | Phase 1/2 | Artios Pharma Ltd | Moderate or severe cardiovascular disease |
| NCT04657068 | Hepatic | Phase 1/2 | Artios Pharma Ltd | Acceptable hematologic, renal, hepatic, and coagulation functions independent of transfusions and granulocyte colony-stimulating factor |
| NCT04657068 | HIV | Phase 1/2 | Artios Pharma Ltd | one or more opportunistic HIV/AIDs-related infections within the past 12 months |
| NCT04657068 | Performance status | Phase 1/2 | Artios Pharma Ltd | Performance status of 0-1 on the ECOG Scale |
| NCT04657068 | Pregnancy | Phase 1/2 | Artios Pharma Ltd | Women who are pregnant, breast feeding, or who plan to become pregnant while in the study or within 7 months after the last administration of study treatment |
| NCT04657068 | Prior malignancy | Phase 1/2 | Artios Pharma Ltd | malignancy prior to the one currently being treated that is not in remission |
| NCT04657068 | Renal | Phase 1/2 | Artios Pharma Ltd | Acceptable hematologic, renal, hepatic, and coagulation functions independent of transfusions and granulocyte colony-stimulating factor |
| NCT04665206 | Brain metastases | Phase 1/2 | Vivace Therapeutics, Inc | Active brain metastases or primary CNS (central nervous system) tumors. |
| NCT04665206 | Cardiac | Phase 1/2 | Vivace Therapeutics, Inc | Corrected QT (QTcF) interval > 470 msec (using Fridericia's correction formula). |
| NCT04665206 | HIV | Phase 1/2 | Vivace Therapeutics, Inc | Known HIV positive or active Hepatitis B or Hepatitis C |
| NCT04665206 | Performance status | Phase 1/2 | Vivace Therapeutics, Inc | ECOG: 0-1. |
| NCT04665206 | Pregnancy | Phase 1/2 | Vivace Therapeutics, Inc | Women who are pregnant or breastfeeding |
| NCT04665206 | Prior malignancy | Phase 1/2 | Vivace Therapeutics, Inc | Additional active malignancy that may confound the assessment of the study endpoints |
| NCT04665739 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | No known central nervous system metastases unless treated and clinically stable for at least 14 days prior to registration |
| NCT04665739 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN |
| NCT04665739 | HIV | Phase 2 | National Cancer Institute (NCI) | Patients with known human immunodeficiency virus (HIV) infections on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial |
| NCT04665739 | Performance status | Phase 2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status 0-2 |
| NCT04665739 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Not pregnant and not nursing |
| NCT04665739 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | No other currently active malignancy that requires therapy or is expected to require therapy during the study (excluding non-melanoma skin cancers or in situ carcinomas, such as breast or cervical) |
| NCT04665739 | Renal | Phase 2 | National Cancer Institute (NCI) | Creatinine =< 1.5 x upper limit of normal (ULN) OR calculated creatinine clearance >= 40 mL/min |
| NCT04669171 | Brain metastases | Phase 1/2 | Enterome | Uncontrolled central nervous system (CNS) metastasis. |
| NCT04669171 | HIV | Phase 1/2 | Enterome | Patients with history or presence of human immunodeficiency virus and/or potentially active hepatitis B virus/hepatitis C virus infection. |
| NCT04669171 | Performance status | Phase 1/2 | Enterome | ECOG performance status 0 to 2 |
| NCT04669171 | Pregnancy | Phase 1/2 | Enterome | Males or non-pregnant, non-lactating, females. |
| NCT04669171 | Prior malignancy | Phase 1/2 | Enterome | Other malignancy or prior malignancy with a disease-free interval of less than 3 years. |
| NCT04671667 | Age | Phase 2 | National Cancer Institute (NCI) | Patient must be between 18 and 79 years of age |
| NCT04671667 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Patients with New York Heart Association class III or IV heart failure are not eligible |
| NCT04671667 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (obtained =< 28 days prior to protocol randomization) |
| NCT04671667 | HIV | Phase 2 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial as long as they have not been HIV-infected with a history of Kaposi sarcoma and/or multicentric Castleman disease |
| NCT04671667 | Performance status | Phase 2 | National Cancer Institute (NCI) | Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT04671667 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. |
| NCT04671667 | Renal | Phase 2 | National Cancer Institute (NCI) | Creatinine clearance > 30 ml/min using the Cockcroft-Gault formula (obtained =< 28 days prior to protocol randomization) |
| NCT04674267 | Age | Not given | Dana-Farber Cancer Institute | Patients who are age 65+ at time of initial consult at DF/BWCC |
| NCT04674267 | Language | Not given | Dana-Farber Cancer Institute | Not proficient in English, Spanish, Haitian Creole, Portuguese, Traditional Chinese, Arabic, or Russian |
| NCT04678401 | Age | Phase 1 | Dana-Farber Cancer Institute | Age ≥18 to 65 years for Cohort A and B. Age ≥18 to 75 years for Cohort C. |
| NCT04678401 | Brain metastases | Phase 1 | Dana-Farber Cancer Institute | Participants with extramedullary disease at immune privileged sites (e.g., CNS, testes, eye) are excluded |
| NCT04678401 | Cardiac | Phase 1 | Dana-Farber Cancer Institute | Cardiac Ejection Fraction ≥ 45%, and no evidence of pulmonary hypertension |
| NCT04678401 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | Hepatic: Total bilirubin within normal institutional limits (exception permitted in Gilbert's Syndrome after discussion with study PI, on a case-by-case basis); and AST (SGOT)/ALT (SGPT) <2x institutional upper limit of normal |
| NCT04678401 | HIV | Phase 1 | Dana-Farber Cancer Institute | HIV-positive participants on combination antiretroviral therapy are ineligible |
| NCT04678401 | Performance status | Phase 1 | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥60, see Appendix A). |
| NCT04678401 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because radiation and conditioning chemotherapy has the potential for teratogenic or abortifacient effects. |
| NCT04678401 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Participants with a history of another non-hematologic malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years |
| NCT04678401 | Renal | Phase 1 | Dana-Farber Cancer Institute | Renal: Serum Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2 (see Appendix B) for participants with creatinine levels above institutional normal. |
| NCT04684368 | Age | Phase 2 | Children's Oncology Group | Patients must be >= 3 years and < 30 years at the time of study enrollment |
| NCT04684368 | Hepatic | Phase 2 | Children's Oncology Group | Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) |
| NCT04684368 | Language | Phase 2 | Children's Oncology Group | English-, Spanish-, or French- speaking |
| NCT04684368 | Pregnancy | Phase 2 | Children's Oncology Group | Female patients who are pregnant, since fetal toxicities and teratogenic effects have been noted for several of the study drugs |
| NCT04684368 | Renal | Phase 2 | Children's Oncology Group | Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows (within 7 days prior to enrollment): |
| NCT04701645 | Cardiac | Phase 1 | Brigham and Women's Hospital | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT04701645 | Pregnancy | Phase 1 | Brigham and Women's Hospital | Pregnant women are excluded from this study because of the possible increased dose of radiation from imaging associated with the microdevice placement and the potential risk to the pregnancy of the biopsy/device placement in an abdominal lesion. |
| NCT04704323 | Brain metastases | Phase 1 | Catapult Therapeutics | Subjects with active known central nervous system (CNS) lymphoma. |
| NCT04704323 | Cardiac | Phase 1 | Catapult Therapeutics | New York Heart Association Class (NYHA) III and IV congestive heart failure, myocardial infraction within the previous 6 months, ejection fraction (EF) < 40%, life-threatening arrhythmias, or unstable angina brain metastasis or psychiatric illness that would limit compliance with trial requirement. |
| NCT04704323 | Hepatic | Phase 1 | Catapult Therapeutics | Adequate liver function as indicated by aspartate transaminase (AST)/ alanine transaminase (ALT) ≤ 2.5 times upper limit of normal (ULN), unless directly attributable to the subject's tumor (in this case, acceptable levels are ≤ 5 x ULN). |
| NCT04704323 | HIV | Phase 1 | Catapult Therapeutics | Subjects who are known to be human immunodeficiency virus (HIV)-positive. |
| NCT04704323 | Performance status | Phase 1 | Catapult Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2. |
| NCT04704323 | Pregnancy | Phase 1 | Catapult Therapeutics | Pregnant or lactating women. |
| NCT04704323 | Prior malignancy | Phase 1 | Catapult Therapeutics | History of previous cancer < 2 years before the trial, except controlled disease using systemic therapy with curative intent, surgical therapy with curative intent or skin cancer, cancer in situ, and prostate cancer on the "watch and wait" approach. |
| NCT04704323 | Renal | Phase 1 | Catapult Therapeutics | Renal function as defined by creatinine clearance (CrCl)≥ 45 mL/min/1.73m2 (by CKD-EPI formula). |
| NCT04724018 | Brain metastases | Phase 1/2 | Dana-Farber Cancer Institute | Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis. |
| NCT04724018 | Cardiac | Phase 1/2 | Dana-Farber Cancer Institute | Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better. |
| NCT04724018 | Diabetes | Phase 1/2 | Dana-Farber Cancer Institute | Patients with uncontrolled diabetes. Uncontrolled diabetes is defined as hemoglobin A1C >8% or 7-8% with associated diabetes symptoms that are otherwise not explained |
| NCT04724018 | Hepatic | Phase 1/2 | Dana-Farber Cancer Institute | AST(SGOT)/ALT(SGPT) ≤2.5x institutional ULN OR |
| NCT04724018 | HIV | Phase 1/2 | Dana-Farber Cancer Institute | Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT04724018 | Performance status | Phase 1/2 | Dana-Farber Cancer Institute | ECOG performance status 0-1. |
| NCT04724018 | Pregnancy | Phase 1/2 | Dana-Farber Cancer Institute | Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. |
| NCT04724018 | Prior malignancy | Phase 1/2 | Dana-Farber Cancer Institute | Have an active second malignancy. Subjects with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to start of therapy on trial (Cycle 1 Day 1 [C1D1]), or subjects with surgically-cured tumors with low risk of recurrence are allowed to enroll. |
| NCT04724018 | Renal | Phase 1/2 | Dana-Farber Cancer Institute | Glomerular filtration rate (GFR) ≥30 mL/min/1.73 m2 (by Cockcroft Gault formula) |
| NCT04726241 | Age | Phase 1/2 | PedAL BCU, LLC | Patients must be less than 22 years of age at the time of study enrollment |
| NCT04752137 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant or nursing patients |
| NCT04752137 | Renal | Phase 2 | Massachusetts General Hospital | Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist |
| NCT04752722 | Cardiac | Phase 1/2 | enGene, Inc. | Significant cardiovascular risk (e.g., coronary stenting within 8 weeks, myocardial infarction within 6 months). |
| NCT04752722 | Hepatic | Phase 1/2 | enGene, Inc. | Total bilirubin must be ≤1.5 x the upper limit of normal (ULN). |
| NCT04752722 | HIV | Phase 1/2 | enGene, Inc. | Known human immunodeficiency virus, Hepatitis B, or Hepatitis C infection. |
| NCT04752722 | Performance status | Phase 1/2 | enGene, Inc. | Performance Status: Eastern Cooperative Oncology Group 0, 1, and 2. |
| NCT04752722 | Pregnancy | Phase 1/2 | enGene, Inc. | Male or non-pregnant, non-lactating female, 18 years or older. |
| NCT04752722 | Prior malignancy | Phase 1/2 | enGene, Inc. | Active malignancies (i.e., progressing or requiring treatment change in the last 24 months). |
| NCT04752722 | Renal | Phase 1/2 | enGene, Inc. | Adequate renal function with creatinine clearance >30 mL/min |
| NCT04771572 | Brain metastases | Phase 1 | Newave Pharmaceutical Inc | Subjects with known and active central nervous system (CNS) involvement at Screening. |
| NCT04771572 | Cardiac | Phase 1 | Newave Pharmaceutical Inc | baseline prolongation of the heart rate-corrected QT (QTcF) interval ≥ 480 ms |
| NCT04771572 | Hepatic | Phase 1 | Newave Pharmaceutical Inc | Hepatic function criteria: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN; bilirubin ≤ 1.5 × ULN |
| NCT04771572 | HIV | Phase 1 | Newave Pharmaceutical Inc | Known poorly controlled human immunodeficiency virus (HIV) |
| NCT04771572 | Performance status | Phase 1 | Newave Pharmaceutical Inc | Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2. |
| NCT04771572 | Pregnancy | Phase 1 | Newave Pharmaceutical Inc | A female subject is pregnant or breast-feeding. |
| NCT04771572 | Prior malignancy | Phase 1 | Newave Pharmaceutical Inc | Subject has a history of other malignancies within past 12 months that are active and could result in competing risks. |
| NCT04771572 | Renal | Phase 1 | Newave Pharmaceutical Inc | Renal function criteria: Serum creatinine ≤ ULN (per local institution reference range) or Calculated creatinine clearance (Cr Cl) ≥ 60 mL/min using 24-hour CrCl OR by Cockcroft-Gault formula using actual body weight. |
| NCT04777994 | Brain metastases | Phase 1 | Calico Life Sciences LLC | Untreated brain or meningeal metastases (i.e., subjects with history of metastases are eligible provided they do not require ongoing steroid treatment and have shown clinical and radiographic stability for at least 28 days after definitive therapy) |
| NCT04777994 | Cardiac | Phase 1 | Calico Life Sciences LLC | QT interval corrected for heart rate < 470 msec (using Fridericia's correction), and no clinically significant electrocardiographic findings. |
| NCT04777994 | Hepatic | Phase 1 | Calico Life Sciences LLC | Recent history (within 6 months) of Childs-Pugh B or C classification of liver disease. |
| NCT04777994 | HIV | Phase 1 | Calico Life Sciences LLC | History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. |
| NCT04777994 | Performance status | Phase 1 | Calico Life Sciences LLC | An Eastern Cooperative Oncology Group (ECOG) performance status <= 2. |
| NCT04777994 | Prior malignancy | Phase 1 | Calico Life Sciences LLC | History of other malignancy, with the following exceptions: |
| NCT04787042 | Brain metastases | Phase 1/2 | Simcha IL-18, Inc. | Presence of known active CNS metastases and/or carcinomatous meningitis. |
| NCT04787042 | Performance status | Phase 1/2 | Simcha IL-18, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT04787042 | Prior malignancy | Phase 1/2 | Simcha IL-18, Inc. | History of another malignancy |
| NCT04789486 | Cardiac | Phase 1/2 | Dana-Farber Cancer Institute | Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. |
| NCT04789486 | HIV | Phase 1/2 | Dana-Farber Cancer Institute | Known HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AGuIX. |
| NCT04789486 | Performance status | Phase 1/2 | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). |
| NCT04789486 | Pregnancy | Phase 1/2 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because AGuIX is contrast agent with the potential for teratogenic or abortifacient effects. |
| NCT04789486 | Renal | Phase 1/2 | Dana-Farber Cancer Institute | Creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal. |
| NCT04792489 | Age | Phase 2 | Miltenyi Biomedicine GmbH | Age ≥70 years |
| NCT04792489 | Cardiac | Phase 2 | Miltenyi Biomedicine GmbH | left ventricular ejection fraction (LVEF) < 50% |
| NCT04792489 | Hepatic | Phase 2 | Miltenyi Biomedicine GmbH | aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal (ULN) |
| NCT04792489 | HIV | Phase 2 | Miltenyi Biomedicine GmbH | Known history of infection with human immunodeficiency virus (HIV) |
| NCT04792489 | Performance status | Phase 2 | Miltenyi Biomedicine GmbH | ECOG status is 2 at screening |
| NCT04792489 | Pregnancy | Phase 2 | Miltenyi Biomedicine GmbH | Pregnant or breast-feeding woman |
| NCT04792489 | Prior malignancy | Phase 2 | Miltenyi Biomedicine GmbH | Previous or concurrent malignancy with the following exceptions: |
| NCT04792489 | Renal | Phase 2 | Miltenyi Biomedicine GmbH | calculated creatinine clearance (Cockcroft and Gault) < 60 mL/min |
| NCT04794322 | Age | Not given | Massachusetts General Hospital | Age less than 30 years |
| NCT04794322 | Pregnancy | Not given | Massachusetts General Hospital | Currently pregnant |
| NCT04794322 | Prior malignancy | Not given | Massachusetts General Hospital | Prior history of known ovarian or endometrial cancer |
| NCT04796012 | Age | Phase 1/2 | University of Texas Southwestern Medical Center | Age ≥ 6 months and ≤ 30 years |
| NCT04796012 | Brain metastases | Phase 1/2 | University of Texas Southwestern Medical Center | Patients with CNS malignancy or asymptomatic CNS metastases may be enrolled, provided all of the following criteria are met. |
| NCT04796012 | Cardiac | Phase 1/2 | University of Texas Southwestern Medical Center | Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina |
| NCT04796012 | Hepatic | Phase 1/2 | University of Texas Southwestern Medical Center | Total bilirubin ≤1.5 x upper limit of normal (ULN) for age (Patients with known Gilbert disease: serum bilirubin ≤ 3 x ULN) |
| NCT04796012 | HIV | Phase 1/2 | University of Texas Southwestern Medical Center | Negative HIV and hepatitis B surface antigen (HBsAg) tests at screening |
| NCT04796012 | Performance status | Phase 1/2 | University of Texas Southwestern Medical Center | Lansky Performance Status (patients < 16 years old) or Karnofsky Performance Status (patients ≥ 16 years old) ≥ 50 |
| NCT04796012 | Renal | Phase 1/2 | University of Texas Southwestern Medical Center | Creatinine ≤ 1.5 x ULN for age or creatinine clearance (or radioisotope glomerular filtration rate) ≥ 70 mL/min/1.73 m2 |
| NCT04802759 | Brain metastases | Phase 1/2 | Hoffmann-La Roche | History of leptomeningeal disease |
| NCT04802759 | Cardiac | Phase 1/2 | Hoffmann-La Roche | Baseline left ventricular ejection fraction (LVEF) ≥50% as measured by ECHO or MUGA scans |
| NCT04802759 | Diabetes | Phase 1/2 | Hoffmann-La Roche | History of Type 1 or Type 2 diabetes mellitus requiring insulin |
| NCT04802759 | HIV | Phase 1/2 | Hoffmann-La Roche | Positive HIV test at screening or at any time prior to screening |
| NCT04802759 | Performance status | Phase 1/2 | Hoffmann-La Roche | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 |
| NCT04802759 | Pregnancy | Phase 1/2 | Hoffmann-La Roche | Pregnant or breastfeeding, or intending to become pregnant during study treatment or within 5 months for atezolizumab |
| NCT04802759 | Prior malignancy | Phase 1/2 | Hoffmann-La Roche | History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death |
| NCT04803201 | Brain metastases | Phase 2 | Alliance for Clinical Trials in Oncology | Patients with known central nervous system involvement are excluded |
| NCT04803201 | Cardiac | Phase 2 | Alliance for Clinical Trials in Oncology | Patients must have documented left ventricular ejection fraction of >= 45% |
| NCT04803201 | Hepatic | Phase 2 | Alliance for Clinical Trials in Oncology | Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 3.0 x upper limit of normal (ULN) |
| NCT04803201 | HIV | Phase 2 | Alliance for Clinical Trials in Oncology | No active viral infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. |
| NCT04803201 | Performance status | Phase 2 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) performance status =< 2 |
| NCT04803201 | Pregnancy | Phase 2 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. |
| NCT04803201 | Prior malignancy | Phase 2 | Alliance for Clinical Trials in Oncology | No concurrent malignancy requiring active therapy within the last 3 years with the exception of basal cell carcinoma limited to the skin, squamous cell carcinoma limited to the skin, carcinoma in situ of the cervix, breast or localized prostate cancer. |
| NCT04803201 | Renal | Phase 2 | Alliance for Clinical Trials in Oncology | Calculated creatinine clearance >= 30 mL/min by Cockcroft-Gault formula |
| NCT04812366 | Cardiac | Phase 2 | University of British Columbia | New York Heart Association Class II to IV heart disease |
| NCT04812366 | Diabetes | Phase 2 | University of British Columbia | Participants with uncontrolled hypertension or diabetes. |
| NCT04812366 | HIV | Phase 2 | University of British Columbia | Active or known human immunodeficiency virus (HIV) with detectable viral load; |
| NCT04812366 | Performance status | Phase 2 | University of British Columbia | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix II) |
| NCT04839614 | BMI | Not given | Dana-Farber Cancer Institute | BMI < 35 |
| NCT04839614 | Language | Not given | Dana-Farber Cancer Institute | include inability to read an English informed consent form, and unwillingness to provide informed consent. |
| NCT04839614 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant participants will be excluded from this study. |
| NCT04839614 | Smoking | Not given | Dana-Farber Cancer Institute | This includes active smokers, prior bariatric surgery, active substance abuse, recent suicide attempt, bulimia nervosa, large abdominal hernias, or poorly controlled psychiatric illness |
| NCT04840602 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x IULN (institutional upper limit of the norm) (within 14 days prior to registration) |
| NCT04840602 | HIV | Phase 2 | National Cancer Institute (NCI) | Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration |
| NCT04840602 | Performance status | Phase 2 | National Cancer Institute (NCI) | Participants must have Zubrod performance status =< 2 |
| NCT04840602 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Participants must not be pregnant or nursing because venetoclax has not been studied in pregnant or nursing women |
| NCT04840602 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years or watchful waiting is appropriate in the opinion of the treating physician. |
| NCT04840602 | Renal | Phase 2 | National Cancer Institute (NCI) | Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) >= 30 mL/min. Values must be obtained within 14 days prior to registration |
| NCT04842266 | Age | Not given | Massachusetts General Hospital | Patient is a skeletally mature patient 21 years of age or older (closed epiphyseal plates) |
| NCT04851119 | Age | Phase 1/2 | Children's Oncology Group | PART A: Patients must be >= 12 months and =< 21 years of age at the time of study enrollment |
| NCT04851119 | Brain metastases | Phase 1/2 | Children's Oncology Group | Patients with known central nervous system (CNS) metastasis, except for craniopharyngeal tumors, will be excluded |
| NCT04851119 | Hepatic | Phase 1/2 | Children's Oncology Group | PATIENTS WITH SOLID TUMORS: Bilirubin (sum of conjugated + unconjugated or total) =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment) |
| NCT04851119 | Performance status | Phase 1/2 | Children's Oncology Group | Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. |
| NCT04851119 | Pregnancy | Phase 1/2 | Children's Oncology Group | Pregnant or breast-feeding women will not be entered on this study |
| NCT04851119 | Renal | Phase 1/2 | Children's Oncology Group | Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a creatinine based on age/gender as follows (within 7 days prior to enrollment): |
| NCT04855656 | Brain metastases | Phase 1 | Debiopharm International SA | Uncontrolled, symptomatic brain metastases. |
| NCT04855656 | Performance status | Phase 1 | Debiopharm International SA | Lansky performance status ≥50% for patients ≤16 years of age, or ECOG score of 0, 1, (or 2 for module 1) for patients >16 years of age. |
| NCT04855656 | Pregnancy | Phase 1 | Debiopharm International SA | Patients who are pregnant or breastfeeding. |
| NCT04855695 | Brain metastases | Phase 1/2 | Austin I Kim | Participants with known leptomeningeal or brain metastases. |
| NCT04855695 | Cardiac | Phase 1/2 | Austin I Kim | Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization. |
| NCT04855695 | Hepatic | Phase 1/2 | Austin I Kim | Total bilirubin ≤ 2 times the upper limit of normal, unless there is disease involvement of the liver, hemolysis, or a known history of Gilbert's disease, in which case direct bilirubin must be ≤ 3 times the upper limit of normal |
| NCT04855695 | HIV | Phase 1/2 | Austin I Kim | Patients with human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection. |
| NCT04855695 | Performance status | Phase 1/2 | Austin I Kim | ECOG performance status ≤2 (Karnofsky ≥60%) |
| NCT04855695 | Pregnancy | Phase 1/2 | Austin I Kim | Lactating or pregnant women are excluded from this study |
| NCT04855695 | Prior malignancy | Phase 1/2 | Austin I Kim | Participants who have a history of other malignancies except: |
| NCT04855695 | Renal | Phase 1/2 | Austin I Kim | Creatinine clearance (CrCl) ≥ 50 ml/min using 24-hour urine collection for creatinine clearance or calculated CrCl or calculated glomerular filtration rate (GFR) ≥ 50 ml/min/1.73 m2 using the CKD-EPI equation |
| NCT04870944 | Age | Phase 1/2 | Children's Oncology Group | Patients must be >= 12 months and =< 21 years of age at the time of study enrollment |
| NCT04870944 | Brain metastases | Phase 1/2 | Children's Oncology Group | Part A: Patients with relapsed or refractory solid tumors or lymphoma, including patients with CNS tumors or known CNS metastases (including untreated or progressive) are eligible |
| NCT04870944 | Cardiac | Phase 1/2 | Children's Oncology Group | Ejection fraction of >= 50% by gated radionuclide study |
| NCT04870944 | Hepatic | Phase 1/2 | Children's Oncology Group | Bilirubin (sum of conjugated + unconjugated or total) =< 1.5 x upper limit of normal (ULN) for age |
| NCT04870944 | Performance status | Phase 1/2 | Children's Oncology Group | Patients must have a performance status corresponding to Easter Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. |
| NCT04870944 | Pregnancy | Phase 1/2 | Children's Oncology Group | Pregnant or breast-feeding women will not be entered on this study |
| NCT04870944 | Renal | Phase 1/2 | Children's Oncology Group | Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a creatinine based on age/sex as follows |
| NCT04870944 | Smoking | Phase 1/2 | Children's Oncology Group | CYP1A2 (e.g., ciprofloxacin, enoxacin, fluvoxamine, smoking) are not eligible |
| NCT04879329 | Performance status | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 |
| NCT04883671 | Cardiac | Not given | Dana-Farber Cancer Institute | Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. |
| NCT04883671 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status of 0-2 |
| NCT04883671 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant or lactating women. |
| NCT04883671 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or requires active treatment. |
| NCT04890613 | Brain metastases | Phase 1 | Senhwa Biosciences, Inc. | Untreated, unstable brain or meningeal metastases or tumor. |
| NCT04890613 | Cardiac | Phase 1 | Senhwa Biosciences, Inc. | A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms). |
| NCT04890613 | Hepatic | Phase 1 | Senhwa Biosciences, Inc. | AST/ALT ≤ 2.5× the upper limit of normal (ULN). |
| NCT04890613 | HIV | Phase 1 | Senhwa Biosciences, Inc. | patients who are known to be serologically positive for human immunodeficiency virus (HIV), patients with known active hepatitis (i.e., hepatitis B or C). |
| NCT04890613 | Performance status | Phase 1 | Senhwa Biosciences, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 within 14 days of registration. |
| NCT04890613 | Pregnancy | Phase 1 | Senhwa Biosciences, Inc. | Female patients who are pregnant or nursing. |
| NCT04890613 | Prior malignancy | Phase 1 | Senhwa Biosciences, Inc. | Other malignancies within 5 years except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin, or ductal carcinoma in situ of the breast that has been surgically cured. |
| NCT04890613 | Renal | Phase 1 | Senhwa Biosciences, Inc. | Calculated creatinine clearance > 51mL/min (Cockcroft-Gault formula) |
| NCT04892173 | Age | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | Age greater than or equal to (>=) 60 years old |
| NCT04892173 | Cardiac | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | New York Heart Association Class 3 |
| NCT04892173 | Performance status | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | Eastern cooperative oncology group (ECOG) performance status 0 to 1 |
| NCT04892173 | Prior malignancy | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | Prior or concurrent primary malignancy (including second synchronous head & neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent |
| NCT04892173 | Renal | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | Estimated creatinine clearance >= 30 and less than (<) 50 milliliters/minute (mL/min) (per Cockcroft-Gault equation), |
| NCT04893109 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Left ventricular ejection fraction (LVEF) ≥ 50% |
| NCT04893109 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Patients with active liver disease, for example due to hepatitis B virus, hepatitis C virus, autoimmune hepatic disorder, or sclerosing cholangitis |
| NCT04893109 | Language | Phase 2 | Dana-Farber Cancer Institute | Must be able to read and understand English in order to participate in the quality of life surveys. |
| NCT04893109 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG Performance Status 0 or 1 |
| NCT04893109 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women |
| NCT04893109 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Patients with a history of previous invasive breast cancer. |
| NCT04893109 | Renal | Phase 2 | Dana-Farber Cancer Institute | renal failure requiring dialysis |
| NCT04899908 | Performance status | Phase 2 | Brigham and Women's Hospital | Karnofsky performance status of at least 70 (i.e. at minimum, "cares for self" but "unable to carry on normal activity or do active work") |
| NCT04899908 | Pregnancy | Phase 2 | Brigham and Women's Hospital | Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. |
| NCT04899908 | Renal | Phase 2 | Brigham and Women's Hospital | Estimated glomerular filtration rate of ≥ 60 mL/min/1.73m2 |
| NCT04900623 | Age | Phase 2 | Jonathan Schoenfeld, MD, MPH | Age 22 years or older |
| NCT04900623 | Cardiac | Phase 2 | Jonathan Schoenfeld, MD, MPH | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT04900623 | Performance status | Phase 2 | Jonathan Schoenfeld, MD, MPH | ECOG performance status ≤ 2 |
| NCT04900623 | Pregnancy | Phase 2 | Jonathan Schoenfeld, MD, MPH | Pregnant or lactating women. |
| NCT04900623 | Prior malignancy | Phase 2 | Jonathan Schoenfeld, MD, MPH | Has a known additional malignancy that is progressing or requires active treatment. |
| NCT04900818 | Brain metastases | Phase 1 | I-Mab Biopharma US Limited | Known active CNS metastases and/or carcinomatous meningitis. |
| NCT04900818 | Cardiac | Phase 1 | I-Mab Biopharma US Limited | New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, severe/unstable angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack (TIA), arterial embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) in the previous 6 months |
| NCT04900818 | HIV | Phase 1 | I-Mab Biopharma US Limited | Diagnosis of immunodeficiency such as known active HIV |
| NCT04900818 | Performance status | Phase 1 | I-Mab Biopharma US Limited | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 with adequate organ function |
| NCT04900818 | Prior malignancy | Phase 1 | I-Mab Biopharma US Limited | Second malignancy within the last 3 years with the exception of cutaneous squamous cell carcinoma or cutaneous basal cell carcinoma or cervical carcinoma in situ |
| NCT04900935 | Language | Not given | Massachusetts General Hospital | Ability to respond in English or Spanish |
| NCT04900935 | Pregnancy | Not given | Massachusetts General Hospital | Pregnant women |
| NCT04910685 | Cardiac | Phase 2/3 | Blueprint Medicines Corporation | Participant has a QT interval corrected using Fridericia's formula (QTcF) > > 470 milliseconds (msec) (for females) or > 450 msec (for males). |
| NCT04910685 | Performance status | Phase 2/3 | Blueprint Medicines Corporation | Participant must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2. |
| NCT04910685 | Prior malignancy | Phase 2/3 | Blueprint Medicines Corporation | Participant has a history of a primary malignancy that has been diagnosed or required therapy within 3 years. |
| NCT04924075 | Cardiac | Phase 2 | Merck Sharp & Dohme LLC | Clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or arterial bypass (CABG) or Percutaneous transluminal coronary angioplasty (PTCA) ≤6 months from study entry, or New York Heart Association Class III or IV congestive heart failure |
| NCT04924075 | Prior malignancy | Phase 2 | Merck Sharp & Dohme LLC | History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years |
| NCT04928677 | Age | Phase 1 | Memorial Sloan Kettering Cancer Center | Patients must be aged 12 months up to but not including 22 years at the time of study registration. |
| NCT04928677 | Brain metastases | Phase 1 | Memorial Sloan Kettering Cancer Center | Patients with documented CNS tumor, CNS metastasis, CNS ischemia and/or infarction, whether symptomatic or discovered incidentally without clinical symptoms, will be excluded from study participation. |
| NCT04928677 | Cardiac | Phase 1 | Memorial Sloan Kettering Cancer Center | Patients with a baseline QTc > 480. (as measured using Bazett formula; Refer to Bazett, Heart, 1920). |
| NCT04928677 | Hepatic | Phase 1 | Memorial Sloan Kettering Cancer Center | Total Bilirubin (sum of conjugated + unconjugated) ≤ 3 times institutional upper limit of normal (ULN) for age |
| NCT04928677 | Performance status | Phase 1 | Memorial Sloan Kettering Cancer Center | Patients must have Karnofsky Performance Score (for patients > 16 years of age) or Lansky Performance Score (for patients ≤ 16 years of age) ≥ 50% assessed within 2 weeks of study enrollment. |
| NCT04928677 | Pregnancy | Phase 1 | Memorial Sloan Kettering Cancer Center | Patients must not be pregnant or breast-feeding; |
| NCT04928677 | Renal | Phase 1 | Memorial Sloan Kettering Cancer Center | GFR ≥ 50 mL/min/1.73 m^2 as measured using urine creatinine clearance, serum cystatin c, radioisotope GFR, or serum creatinine as measured by the Schwartz equation (Refer to Schwartz, et al. J Am Soc Neph, 2009) |
| NCT04943848 | Age | Phase 1 | Ann & Robert H Lurie Children's Hospital of Chicago | Subjects ages > or = to 12 months and < or = 18 years |
| NCT04943848 | Performance status | Phase 1 | Ann & Robert H Lurie Children's Hospital of Chicago | Performance score: Karnofsky >50% of subjects >16 years of age and Lansky > or = 50 for subjects < or = 16 years of age. |
| NCT04972942 | Age | Phase 1 | New York Medical College | 0-39yrs |
| NCT04972942 | Cardiac | Phase 1 | New York Medical College | Clinically significant cardiac disease |
| NCT04972942 | HIV | Phase 1 | New York Medical College | Seropositive for HIV, hepatitis B or hepatitis C |
| NCT04972942 | Performance status | Phase 1 | New York Medical College | Performance status ≥ 60% |
| NCT04972942 | Pregnancy | Phase 1 | New York Medical College | Must not be pregnant or actively breast feeding |
| NCT04986579 | Performance status | Phase 2 | Dana-Farber Cancer Institute | with a ECOG PS≤2 |
| NCT04986579 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Known hematological malignancies (i.e. leukemia or lymphoma) |
| NCT04988555 | Brain metastases | Phase 1/2 | Sumitomo Pharma America, Inc. | Has active central nervous system leukemia (prophylactic intrathecal chemotherapy is allowed). |
| NCT04988555 | Cardiac | Phase 1/2 | Sumitomo Pharma America, Inc. | Has a left ventricular ejection fraction (LVEF) <50%, as determined by ECHO |
| NCT04988555 | Diabetes | Phase 1/2 | Sumitomo Pharma America, Inc. | diabetes mellitus with more than 2 episodes of ketoacidosis in the prior 6 months |
| NCT04988555 | Hepatic | Phase 1/2 | Sumitomo Pharma America, Inc. | Total bilirubin ≤1.5 the upper limit of normal (ULN) (or ≤2.0 ULN for patients with known Gilbert's syndrome) |
| NCT04988555 | HIV | Phase 1/2 | Sumitomo Pharma America, Inc. | Have a known detectable viral load for human immunodeficiency virus or hepatitis C, or evidence of hepatitis B surface antigen, all being indicative of active infection. |
| NCT04988555 | Performance status | Phase 1/2 | Sumitomo Pharma America, Inc. | Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2. |
| NCT04988555 | Pregnancy | Phase 1/2 | Sumitomo Pharma America, Inc. | Are pregnant or breastfeeding or planning to become pregnant. |
| NCT04988555 | Renal | Phase 1/2 | Sumitomo Pharma America, Inc. | Clearance of creatinine level ≥ 50 ml/min, assessed by the CPK-EPI formula (2021 version and Cystatin C not required) |
| NCT04996875 | Cardiac | Phase 2 | Cogent Biosciences, Inc. | Clinically significant cardiac disease |
| NCT04996875 | HIV | Phase 2 | Cogent Biosciences, Inc. | Seropositive for human immunodeficiency virus (HIV) 1 or 2 |
| NCT04996875 | Performance status | Phase 2 | Cogent Biosciences, Inc. | ECOG (0 to 3) |
| NCT04996875 | Prior malignancy | Phase 2 | Cogent Biosciences, Inc. | Diagnosed with or treated for malignancy other than the disease under study within the prior 3 years before enrollment |
| NCT04997096 | Language | Not given | Dana-Farber Cancer Institute | Able to read, write, and understand English |
| NCT05006131 | Diabetes | Not given | Beth Israel Deaconess Medical Center | New-onset diabetes, age > 50 years with weight loss. |
| NCT05006716 | Brain metastases | Phase 1/2 | BeOne Medicines | Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by B-cell malignancy, regardless of whether participants had received treatment for central nervous system disease |
| NCT05006716 | Performance status | Phase 1/2 | BeOne Medicines | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 |
| NCT05006716 | Prior malignancy | Phase 1/2 | BeOne Medicines | Prior malignancy (other than the disease under study) within the past 2 years, except in situ malignancies that have been curatively resected |
| NCT05009992 | Age | Phase 2 | University of California, San Francisco | Age 2 to 39 years |
| NCT05009992 | BMI | Phase 2 | University of California, San Francisco | Participant body weight must be above the minimum necessary for the participant to receive ONC201 (at least 10 kilograms (kg)) |
| NCT05009992 | Brain metastases | Phase 2 | University of California, San Francisco | Evidence of disseminated disease, including diffuse leptomeningeal disease or evidence of CSF dissemination, with the exception of Cohort 5. |
| NCT05009992 | Cardiac | Phase 2 | University of California, San Francisco | ECG must be obtained to verify the Corrected QT Interval (QTc). If an abnormal reading is obtained, the ECG should be repeated in triplicate. QTC < 470 msec. |
| NCT05009992 | Hepatic | Phase 2 | University of California, San Francisco | Serum glutamate pyruvate transaminase (SGPT)(alanine aminotransferase (ALT)) =< 3 x ULN AND |
| NCT05009992 | HIV | Phase 2 | University of California, San Francisco | Participants with a known disorder that affects their immune system, such as human immunodeficiency virus (HIV) or hepatitis B or C, or an auto-immune disorder requiring systemic cytotoxic or immunosuppressive therapy. |
| NCT05009992 | Performance status | Phase 2 | University of California, San Francisco | Karnofsky >= 50 for participants > 16 years of age and Lansky >= 50 for participants =< 16 years of age. |
| NCT05009992 | Pregnancy | Phase 2 | University of California, San Francisco | Female participants of childbearing potential must not be pregnant or breast-feeding. |
| NCT05009992 | Prior malignancy | Phase 2 | University of California, San Francisco | Known additional malignancy that is progressing or requires active treatment within 3 years of start of study drug. |
| NCT05009992 | Renal | Phase 2 | University of California, San Francisco | Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR |
| NCT05010005 | Brain metastases | Phase 1 | Memorial Sloan Kettering Cancer Center | Known central nervous system or meningeal involvement by TCL (in the absence of symptoms, investigation into central nervous system involvement is not required). |
| NCT05010005 | HIV | Phase 1 | Memorial Sloan Kettering Cancer Center | Patients with HIV infection if they meet either of the below criteria: |
| NCT05010005 | Performance status | Phase 1 | Memorial Sloan Kettering Cancer Center | Performance status, as assessed in the ECOG grading system, ≤2 |
| NCT05010005 | Pregnancy | Phase 1 | Memorial Sloan Kettering Cancer Center | Pregnant women. (Lactating women must agree not to breast feed while taking study medications). |
| NCT05010005 | Prior malignancy | Phase 1 | Memorial Sloan Kettering Cancer Center | Receiving therapy for another primary malignancy (other than T-cell lymphoma). |
| NCT05013892 | Brain metastases | Phase 2 | Massachusetts General Hospital | Leptomeningeal disease (by any one or more of clinical assessment, radiographic assessment, or cerebrospinal fluid study) |
| NCT05013892 | Language | Phase 2 | Massachusetts General Hospital | Fluency in English, able to complete questionnaires and neurocognitive testing |
| NCT05013892 | Performance status | Phase 2 | Massachusetts General Hospital | Karnofsky Performance Status ≥ 70 |
| NCT05013892 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant or unwilling to use appropriate contraception to prevent pregnancy during the time of radiation therapy |
| NCT05019703 | Brain metastases | Phase 2 | M.D. Anderson Cancer Center | History of leptomeningeal disease |
| NCT05019703 | Cardiac | Phase 2 | M.D. Anderson Cancer Center | Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 14 days before first dose of study treatment |
| NCT05019703 | Hepatic | Phase 2 | M.D. Anderson Cancer Center | Moderate to severe hepatic impairment (Child-Pugh B or C) |
| NCT05019703 | HIV | Phase 2 | M.D. Anderson Cancer Center | Negative human immunodeficiency virus (HIV) test at screening |
| NCT05019703 | Performance status | Phase 2 | M.D. Anderson Cancer Center | Eastern Cooperative Oncology Group (ECOG) of 0, 1 or 2. Use Karnofsky >= 50 for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age |
| NCT05019703 | Pregnancy | Phase 2 | M.D. Anderson Cancer Center | Women of childbearing potential must not be pregnant at screening. |
| NCT05019703 | Renal | Phase 2 | M.D. Anderson Cancer Center | Creatinine clearance >= 50 mL/min (adults > 18 years of age, calculated using the Cockcroft-Gault formula) or >= 50 mL/min/1.73m^2 (pediatrics patients age 12 - 17, calculated using the Bedside Schwartz equation) |
| NCT05019716 | Age | Phase 1/2 | National Cancer Institute (NCI) | Age >= 12 years. Patients 12-17 years of age must be >= 40 kg at enrollment. |
| NCT05019716 | Brain metastases | Phase 1/2 | National Cancer Institute (NCI) | Participants with known untreated central nervous system (CNS) metastases. |
| NCT05019716 | Cardiac | Phase 1/2 | National Cancer Institute (NCI) | QT interval by Fridericia (QTcF) < 450 ms (machine or manual read allowed). |
| NCT05019716 | Hepatic | Phase 1/2 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) for age. |
| NCT05019716 | HIV | Phase 1/2 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 3 months are eligible for this trial as long as their anti-retroviral therapy does not have the potential for drug-drug interactions as judged by the treating investigator. |
| NCT05019716 | Performance status | Phase 1/2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status of =< 2 (Karnofsky >= 60%) for patients >= 16 years of age, Lansky >= 50% if < 16 years of age. |
| NCT05019716 | Pregnancy | Phase 1/2 | National Cancer Institute (NCI) | Pregnant women are excluded from this study because ZEN003694 is a bromodomain and extraterminal domain (BET) inhibitor with the potential for teratogenic or abortifacient effects. |
| NCT05019716 | Prior malignancy | Phase 1/2 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for treatment in the phase 1 portion, but not in the non-thoracic, non-BRD4 exploratory cohort. |
| NCT05019716 | Renal | Phase 1/2 | National Cancer Institute (NCI) | Calculated creatinine clearance >= 60 mL/min (based on the calculated Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] glomerular filtration rate estimation for adults or 60 mL/min/1.73m^2 for patients 12-17 years as calculated based on bedside Schwartz formula). |
| NCT05023018 | Brain metastases | Phase 2 | Neonc Technologies, Inc. | Leptomeningeal involvement of the patient's tumor. |
| NCT05023018 | Hepatic | Phase 2 | Neonc Technologies, Inc. | Total serum bilirubin ≤ 1.5 x laboratory upper limit of normal (ULN) except participants with Gilbert's Syndrome who can have a total serum bilirubin of <5 x laboratory upper limit of normal (ULN) |
| NCT05023018 | Performance status | Phase 2 | Neonc Technologies, Inc. | Patient must have an ECOG performance status of 0-2 or KPS ≥ 60. |
| NCT05023018 | Pregnancy | Phase 2 | Neonc Technologies, Inc. | Patient must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. |
| NCT05023018 | Prior malignancy | Phase 2 | Neonc Technologies, Inc. | Patient has a history of new diagnosis or treatment of cancer other than high-grade meningioma within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin. |
| NCT05023018 | Renal | Phase 2 | Neonc Technologies, Inc. | Creatinine clearance (meas or calc) ≥60mL/min for participants with creatinine levels >1.5x laboratory upper limit of normal (ULN) |
| NCT05024929 | Pregnancy | Not given | Children's Hospital of Philadelphia | Females who are pregnant or breastfeeding are excluded due to the potential risks of the RAI used in the WBS to the fetus/neonate. |
| NCT05061550 | Cardiac | Phase 2 | AstraZeneca | uncontrolled cardiac arrhythmia |
| NCT05061550 | HIV | Phase 2 | AstraZeneca | Active or uncontrolled infections including HBA, HBV, HCV, and HIV. |
| NCT05061550 | Performance status | Phase 2 | AstraZeneca | WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT05061550 | Prior malignancy | Phase 2 | AstraZeneca | History of another primary malignancy. |
| NCT05076942 | Brain metastases | Phase 2 | University Medical Center Groningen | Known brain or spinal cord metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids |
| NCT05076942 | Cardiac | Phase 2 | University Medical Center Groningen | Unstable angina, myocardial infarction, cerebrovascular accident, > Class II congestive heart failure according to the New York Heart Association Classification for Congestive Heart Failure (see Appendix B) within 6 months before enrollment |
| NCT05076942 | Hepatic | Phase 2 | University Medical Center Groningen | Total bilirubin < 1.25 x ULN Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN |
| NCT05076942 | Performance status | Phase 2 | University Medical Center Groningen | Performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Scale (Appendix A) |
| NCT05076942 | Pregnancy | Phase 2 | University Medical Center Groningen | Pregnant female or nursing mother |
| NCT05076942 | Prior malignancy | Phase 2 | University Medical Center Groningen | No other carcinomas, other than basal cell carcinomas, within last 5 years |
| NCT05076942 | Renal | Phase 2 | University Medical Center Groningen | Creatinine clearance ≥ 40 ml/min measured by the Cockroft Gault formula |
| NCT05080673 | Age | Not given | NRG Oncology | Participants greater than or equal to 45 and less than 70 years of age at the time of colonoscopy. |
| NCT05080673 | Language | Not given | NRG Oncology | Participants must be able to read or understand English or Spanish. |
| NCT05080673 | Prior malignancy | Not given | NRG Oncology | Previous malignancies unless the patient has been disease-free for 5 or more years prior to randomization and is deemed by the physician to be at low risk for recurrence. |
| NCT05098132 | Brain metastases | Phase 1/2 | Synthekine | Known active central nervous system metastases |
| NCT05104983 | Age | Phase 2 | Darcy Krueger | 0-6 months of age at the time of enrollment (subject must be <7 months of chronological age at time of randomization and treatment initiation) |
| NCT05123482 | Brain metastases | Phase 1/2 | AstraZeneca | Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study. |
| NCT05123482 | Cardiac | Phase 1/2 | AstraZeneca | Symptomatic heart failure (NYHA class ≥ 2). |
| NCT05123482 | HIV | Phase 1/2 | AstraZeneca | Active infection including tuberculosis and HBV, HCV or HIV |
| NCT05123482 | Performance status | Phase 1/2 | AstraZeneca | Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1 |
| NCT05128825 | Brain metastases | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Clinically or radiographically unstable brain metastases or leptomeningeal disease that requires immediate treatment. Subjects with asymptomatic brain metastases are eligible. |
| NCT05128825 | Cardiac | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Myocardial impairment resulting in heart failure (NYHA Class II-IV) |
| NCT05128825 | HIV | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Subjects who are known to be immunocompromised or HIV-positive on highly active anti-retroviral therapy. |
| NCT05128825 | Performance status | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | ECOG 0-1 |
| NCT05128825 | Pregnancy | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Pregnant or lactating female subject or female subject of childbearing potential who has a positive serum pregnancy test within 14 days prior to C1D1. |
| NCT05128825 | Prior malignancy | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | History of another malignancy in the previous 2 years, unless cured by surgery alone and continuously disease free. |
| NCT05128825 | Renal | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Acute kidney injury requiring intervention or intravenous fluid in the last 14 days or presence of indwelling urinary catheter or percutaneous nephrostomy. |
| NCT05129605 | Age | Not given | Massachusetts General Hospital | Men 35-74 years old |
| NCT05132283 | Pregnancy | Not given | Brigham and Women's Hospital | Pregnancy |
| NCT05132283 | Renal | Not given | Brigham and Women's Hospital | Severely impaired renal function with an EGFR < 30 mL/min/body surface area |
| NCT05136196 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | Participants with treated brain metastases must have no evidence of progression on the follow-up brain imaging after central nervous system (CNS)-directed therapy |
| NCT05136196 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Participants must not have experienced myocardial infarction or thromboembolic event requiring anticoagulation within 90 days prior to step 1 registration, unless clinically stable with ongoing medical management |
| NCT05136196 | Diabetes | Phase 2 | National Cancer Institute (NCI) | Exceptions: * Type 1 diabetes mellitus |
| NCT05136196 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) or =< 3 x ULN for participants with Gilbert's disease (within 28 days prior to step 2 registration) |
| NCT05136196 | HIV | Phase 2 | National Cancer Institute (NCI) | Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test within 6 months prior to step 1 registration |
| NCT05136196 | Performance status | Phase 2 | National Cancer Institute (NCI) | Participants must have a Zubrod Performance Status 0 or 1 |
| NCT05136196 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Participants must not be pregnant or nursing due to the known safety profiles of the drugs in this study. |
| NCT05136196 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT05136196 | Renal | Phase 2 | National Cancer Institute (NCI) | Measured (OR calculated) creatinine clearance >= 30 mL/min using the following Cockcroft-Gault Formula. |
| NCT05137054 | Brain metastases | Phase 1 | Regeneron Pharmaceuticals | Participants with known MM brain lesions or meningeal involvement |
| NCT05137054 | Cardiac | Phase 1 | Regeneron Pharmaceuticals | Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan |
| NCT05137054 | Hepatic | Phase 1 | Regeneron Pharmaceuticals | Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol |
| NCT05137054 | Performance status | Phase 1 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance status ≤1 |
| NCT05137054 | Renal | Phase 1 | Regeneron Pharmaceuticals | Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol |
| NCT05142800 | Age | Not given | Massachusetts General Hospital | Females between 18 and 80 years of age |
| NCT05155501 | Age | Not given | Weill Medical College of Cornell University | Age ≥40 years or ≤80 years |
| NCT05155501 | Language | Not given | Weill Medical College of Cornell University | Able to read and speak English or Spanish |
| NCT05168930 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participants with known central nervous system (CNS) involvement |
| NCT05168930 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to study entry. |
| NCT05168930 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | AST (SGOT) and ALT (SGPT) ≤ 4 × institutional ULN |
| NCT05168930 | HIV | Phase 2 | Dana-Farber Cancer Institute | Known history of human immunodeficiency virus (HIV) |
| NCT05168930 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status ≤ 2 (Karnofsky ≥ 60%, see Appendix A). |
| NCT05168930 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study |
| NCT05168930 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | History of other malignancies, with the following exceptions: |
| NCT05168930 | Renal | Phase 2 | Dana-Farber Cancer Institute | Serum Creatinine ≤ 1.5 × institutional ULN, OR |
| NCT05174169 | Cardiac | Phase 2/3 | NRG Oncology | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. |
| NCT05174169 | HIV | Phase 2/3 | NRG Oncology | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT05174169 | Performance status | Phase 2/3 | NRG Oncology | The patient must have an ECOG performance status of 0 or 1. |
| NCT05174169 | Pregnancy | Phase 2/3 | NRG Oncology | Pregnancy or lactation at the time of Step 1/Study entry. |
| NCT05174169 | Prior malignancy | Phase 2/3 | NRG Oncology | Other invasive malignancy within 5 years before Step 1/Study entry. |
| NCT05176483 | Brain metastases | Phase 1 | Exelixis | Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. |
| NCT05176483 | Cardiac | Phase 1 | Exelixis | Corrected QT interval calculated by the Fridericia formula (QTcF) > 460 ms for females and > 450 ms for males per electrocardiogram (ECG) within 14 days before first dose of study treatment. |
| NCT05176483 | Pregnancy | Phase 1 | Exelixis | Pregnant or lactating females. |
| NCT05176483 | Prior malignancy | Phase 1 | Exelixis | Any other active malignancy within two years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. |
| NCT05183035 | Age | Phase 3 | PedAL BCU, LLC | Participants must be >28 days of age and < 22 years of age at enrollment. |
| NCT05183035 | Cardiac | Phase 3 | PedAL BCU, LLC | No pre-treatment diminished left ventricular function on echocardiography (shortening fraction [SF] < 25% or ejection fraction [EF] < 40%) |
| NCT05183035 | Hepatic | Phase 3 | PedAL BCU, LLC | Direct bilirubin < 1.5 x upper limit of normal (ULN), and |
| NCT05183035 | HIV | Phase 3 | PedAL BCU, LLC | Known hepatitis C virus (HCV), hepatitis B virus (HBV) (known positive hepatitis B virus (HBV) surface antigen (HBsAg) results), or human immunodeficiency virus (HIV) infection. |
| NCT05183035 | Performance status | Phase 3 | PedAL BCU, LLC | Participants must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2 (≥ 50% Lansky or Karnofsky score). |
| NCT05183035 | Pregnancy | Phase 3 | PedAL BCU, LLC | Participants who are pregnant or breast-feeding. |
| NCT05183035 | Renal | Phase 3 | PedAL BCU, LLC | Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60ml/min/1.73 m^2, or |
| NCT05216432 | Cardiac | Phase 1 | Relay Therapeutics, Inc. | Mean resting corrected QT interval (QTc) >460 msec |
| NCT05216432 | Diabetes | Phase 1 | Relay Therapeutics, Inc. | Type 1 or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥140 mg/dL and glycosylated hemoglobin (HbA1c) ≥7.0%. |
| NCT05216432 | Performance status | Phase 1 | Relay Therapeutics, Inc. | Patient has ECOG performance status of 0-1 |
| NCT05232916 | HIV | Phase 3 | Greenwich LifeSciences, Inc. | Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. |
| NCT05232916 | Performance status | Phase 3 | Greenwich LifeSciences, Inc. | ECOG 0-2 |
| NCT05232916 | Prior malignancy | Phase 3 | Greenwich LifeSciences, Inc. | Other malignancies except adequately treated in situ carcinoma of the cervix or basal cell or squamous cell carcinoma of the skin |
| NCT05235165 | Age | Phase 3 | Children's Oncology Group | Patients must be < 50 years at the time of enrollment. |
| NCT05243797 | Performance status | Phase 3 | European Myeloma Network B.V. | Have an ECOG performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment |
| NCT05245500 | Brain metastases | Phase 1 | Bristol-Myers Squibb | Active brain metastases or carcinomatous meningitis. |
| NCT05245500 | Performance status | Phase 1 | Bristol-Myers Squibb | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT05265429 | Age | Not given | Dana-Farber Cancer Institute | Age 45 and under at lung cancer diagnosis |
| NCT05280314 | Hepatic | Phase 2 | IO Biotech | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN |
| NCT05280314 | HIV | Phase 2 | IO Biotech | HIV-infected patients with a history of Kaposi sarcoma and/or Multicentric Castleman Disease |
| NCT05280314 | Performance status | Phase 2 | IO Biotech | Eastern Cooperative Oncology Group (ECOG) performance score status of 0 or 1 |
| NCT05280314 | Pregnancy | Phase 2 | IO Biotech | Women of childbearing potential: Negative urine or serum pregnancy within 72 hours prior to receiving the first dose of trial medication. |
| NCT05280314 | Prior malignancy | Phase 2 | IO Biotech | Additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. |
| NCT05280314 | Renal | Phase 2 | IO Biotech | Creatinine or measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine or creatinine clearance) ≤1.5 × upper limit of normal (ULN) or ≥30 mL/min for patient with creatinine levels >1.5 × institutional ULN |
| NCT05281237 | Age | Not given | Beth Israel Deaconess Medical Center | Participants must be at least 22 years old and able to provide consent |
| NCT05281237 | Pregnancy | Not given | Beth Israel Deaconess Medical Center | Subject is pregnant or breastfeeding |
| NCT05287451 | Age | Not given | M.D. Anderson Cancer Center | Age 25-40 years for BRCA1 mutation carriers, 25-45 years for BRCA2 and 30-50 years for BRIP1, RAD51C, RAD51D, and PALB2. |
| NCT05292664 | Age | Phase 1 | Andrew E. Place, MD | Age ≤ 40 years of age, except the following subjects that must be <18 years to enroll |
| NCT05292664 | Brain metastases | Phase 1 | Andrew E. Place, MD | Individuals with isolated CNS or testicular relapse. |
| NCT05292664 | Cardiac | Phase 1 | Andrew E. Place, MD | Ejection fraction ≥ 50% or shortening fraction of ≥ 24% on screening echocardiogram. |
| NCT05292664 | Hepatic | Phase 1 | Andrew E. Place, MD | Serum alanine aminotransferase (ALT) ≤5X upper limit of normal (ULN) |
| NCT05292664 | HIV | Phase 1 | Andrew E. Place, MD | Patients known to have human immunodeficiency virus (HIV) infection; baseline testing for HIV is not required. |
| NCT05292664 | Performance status | Phase 1 | Andrew E. Place, MD | Lansky/Karnofsky performance status ≥ 50% |
| NCT05292664 | Pregnancy | Phase 1 | Andrew E. Place, MD | All females of childbearing potential must refrain from breastfeeding during study participation |
| NCT05292664 | Prior malignancy | Phase 1 | Andrew E. Place, MD | Individuals with a history of a different malignancy are ineligible except for the following circumstances: |
| NCT05304585 | Age | Phase 3 | Children's Oncology Group | Patients must be =< 21 years at the time of enrollment. |
| NCT05304585 | Hepatic | Phase 3 | Children's Oncology Group | Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment), and |
| NCT05304585 | Performance status | Phase 3 | Children's Oncology Group | Patients must have a Lansky (for patients =< 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of >= 50. |
| NCT05304585 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT05304585 | Renal | Phase 3 | Children's Oncology Group | Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine (within 7 days prior to enrollment) based on age/gender as follows: |
| NCT05304962 | Performance status | Phase 1 | Regor Pharmaceuticals Inc. | ECOG Performance Status 0 to 1 |
| NCT05304962 | Pregnancy | Phase 1 | Regor Pharmaceuticals Inc. | Pregnant or planning to become pregnant |
| NCT05313243 | Brain metastases | Phase 2 | Yale University | Known active CNS metastases and/or carcinomatous meningitis. |
| NCT05313243 | Cardiac | Phase 2 | Yale University | Active myocarditis, regardless of etiology; or New York Heart Association (NYHA) functional classification III-IV heart failure. |
| NCT05313243 | Hepatic | Phase 2 | Yale University | Clinically significant history of liver disease, including current alcohol abuse or cirrhosis. |
| NCT05313243 | HIV | Phase 2 | Yale University | Has a known history of Human Immunodeficiency Virus (HIV). |
| NCT05313243 | Performance status | Phase 2 | Yale University | Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. |
| NCT05313243 | Pregnancy | Phase 2 | Yale University | Pregnant or breast-feeding females. |
| NCT05313243 | Prior malignancy | Phase 2 | Yale University | Disease free of prior malignancies for ≥ 1 year with exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast. |
| NCT05315700 | Brain metastases | Phase 1/2 | ORIC Pharmaceuticals | CNS involvement, which is either previously treated and controlled, or untreated and asymptomatic |
| NCT05315700 | Cardiac | Phase 1/2 | ORIC Pharmaceuticals | History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months |
| NCT05315700 | HIV | Phase 1/2 | ORIC Pharmaceuticals | Known, symptomatic human immunodeficiency virus (HIV) infection |
| NCT05315700 | Performance status | Phase 1/2 | ORIC Pharmaceuticals | ECOG performance status of 0 or 1 |
| NCT05319314 | Brain metastases | Phase 1/2 | Lyell Immunopharma, Inc. | Active central nervous system (CNS) involvement by malignancy on magnetic resonance imaging (MRI) or contrast-enhanced computed tomography (CT) |
| NCT05319314 | HIV | Phase 1/2 | Lyell Immunopharma, Inc. | History of or active viral infection including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) |
| NCT05319314 | Performance status | Phase 1/2 | Lyell Immunopharma, Inc. | Eastern Cooperative Oncology Group performance status of 0 or 1 |
| NCT05319314 | Pregnancy | Phase 1/2 | Lyell Immunopharma, Inc. | Pregnant or breast-feeding women |
| NCT05327686 | Brain metastases | Phase 2 | NRG Oncology | Patients with untreated or unstable brain metastases or cranial epidural disease |
| NCT05327686 | Cardiac | Phase 2 | NRG Oncology | Active New York (NY) Heart Association class 3-4 heart failure symptoms |
| NCT05327686 | Hepatic | Phase 2 | NRG Oncology | Total bilirubin =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) (within 45 days prior to registration) |
| NCT05327686 | HIV | Phase 2 | NRG Oncology | Patients with known human immunodeficiency virus (HIV) on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT05327686 | Performance status | Phase 2 | NRG Oncology | Karnofsky performance status >= 60 within 45 days prior to registration |
| NCT05327686 | Pregnancy | Phase 2 | NRG Oncology | Pregnancy and individuals unwilling to discontinue nursing. |
| NCT05327686 | Prior malignancy | Phase 2 | NRG Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05327686 | Renal | Phase 2 | NRG Oncology | Calculated (Calc.) creatinine clearance >= 30 mL/min (within 45 days prior to registration) |
| NCT05335928 | Pregnancy | Phase 3 | Massachusetts General Hospital | Female who is pregnant, breastfeeding, or is considering becoming pregnant during the study or for approximately 90 days after the last dose of study drug. |
| NCT05349227 | Language | Not given | Pack Health | Can read and speak English; |
| NCT05356117 | Diabetes | Not given | Dana-Farber Cancer Institute | uncontrolled diabetes |
| NCT05356117 | Language | Not given | Dana-Farber Cancer Institute | Speak English or Spanish. |
| NCT05356117 | Pregnancy | Not given | Dana-Farber Cancer Institute | Patients who are pregnant due to the unknown effects of exercise on the developing fetus. |
| NCT05356117 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Patients with other active malignancies are ineligible for this study. |
| NCT05356117 | Smoking | Not given | Dana-Farber Cancer Institute | Does not smoke (no smoking during previous 12 months). |
| NCT05372354 | Brain metastases | Phase 1/2 | Bristol-Myers Squibb | Known active or history of central nervous system (CNS) involvement of MM |
| NCT05372354 | Cardiac | Phase 1/2 | Bristol-Myers Squibb | Impaired cardiac function or clinically significant cardiac disease |
| NCT05372354 | Performance status | Phase 1/2 | Bristol-Myers Squibb | Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. |
| NCT05372354 | Pregnancy | Phase 1/2 | Bristol-Myers Squibb | Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP). |
| NCT05372614 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with radiographically new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible only if has no progressive clinical symptoms and if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy |
| NCT05372614 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Patients must have left ventricular ejection fraction (LVEF) >= 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization/enrollment |
| NCT05372614 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 × institutional upper limit of normal (ULN), (< 3 × ULN in the presence of documented Gilbert's syndrome or liver metastases at baseline) (within 14 days of enrollment) |
| NCT05372614 | HIV | Phase 1 | National Cancer Institute (NCI) | Patients who are human immunodeficiency virus (HIV)-positive may participate IF they meet the following eligibility requirements: |
| NCT05372614 | Performance status | Phase 1 | National Cancer Institute (NCI) | Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%) |
| NCT05372614 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Pregnant women are excluded from this study because DS-8201a is a HER2 antibody conjugated to a topoisomerase 1 inhibitor agent with the potential for teratogenic or abortifacient effects. |
| NCT05372614 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with active additional malignancy or a personal history of additional malignancy that may affect outcome of disease under treatment |
| NCT05372614 | Renal | Phase 1 | National Cancer Institute (NCI) | Creatinine =< 1.5 x institutional ULN OR Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 (using the Cockcroft-Gault equation) (within 14 days of enrollment) |
| NCT05372640 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression |
| NCT05372640 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Patients should be New York Heart Association Functional Classification of class 2B or better |
| NCT05372640 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) for age. |
| NCT05372640 | HIV | Phase 1 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT05372640 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status =< 2 for participants >= 16 years of age, Lansky >= 50% if < 16 years of age |
| NCT05372640 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Women of childbearing potential must have a negative pregnancy test within 7 days of starting treatment |
| NCT05372640 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05372640 | Renal | Phase 1 | National Cancer Institute (NCI) | Serum or plasma creatinine =< 1.5 x institutional ULN OR calculated creatinine clearance >= 50 mL/min |
| NCT05375643 | Language | Not given | Nadine Jackson, MD, MPH | Speaks a language other than English, Spanish, Haitian Creole, Russian, Portuguese, Arabic, or Traditional Chinese |
| NCT05377996 | Brain metastases | Phase 1/2 | Day One Biopharmaceuticals, Inc. | Untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis. |
| NCT05377996 | Cardiac | Phase 1/2 | Day One Biopharmaceuticals, Inc. | Clinically significant cardiovascular disease |
| NCT05377996 | Hepatic | Phase 1/2 | Day One Biopharmaceuticals, Inc. | History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver diseases. |
| NCT05377996 | Performance status | Phase 1/2 | Day One Biopharmaceuticals, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 |
| NCT05377996 | Prior malignancy | Phase 1/2 | Day One Biopharmaceuticals, Inc. | Diagnosis of additional malignancy that required active treatment (including surgery, systemic therapy, and radiation) within 2 years prior to screening, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix. |
| NCT05379985 | Brain metastases | Phase 1/2 | Revolution Medicines, Inc. | Active, untreated brain metastases |
| NCT05379985 | Performance status | Phase 1/2 | Revolution Medicines, Inc. | Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT05381597 | Language | Phase 2/3 | Boston University | English-speaking |
| NCT05381597 | Pregnancy | Phase 2/3 | Boston University | Women who are pregnant or currently breastfeeding |
| NCT05382338 | Age | Phase 3 | Children's Oncology Group | Patients must be >= 4 years and =< 21 years of age at the time of enrollment |
| NCT05382338 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT05382338 | Renal | Phase 3 | Children's Oncology Group | Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility |
| NCT05382559 | Brain metastases | Phase 1 | Astellas Pharma Inc | Participant has leptomeningeal disease as a manifestation of the current malignancy. |
| NCT05382559 | Cardiac | Phase 1 | Astellas Pharma Inc | Participant has a corrected QT interval (single electrocardiogram [ECG]) using Fridericia's formula (QTcF) > 450 milliseconds (msec) (men) or >470 msec (women) during screening. |
| NCT05382559 | Hepatic | Phase 1 | Astellas Pharma Inc | Participant with active hepatitis B (including acute hepatitis B virus [HBV] or chronic HBV) or hepatitis C virus [HCV] (ribonucleic acid [RNA] detected by qualitative assay). |
| NCT05382559 | HIV | Phase 1 | Astellas Pharma Inc | Participant has a known history of human immunodeficiency virus [HIV] infection. |
| NCT05382559 | Performance status | Phase 1 | Astellas Pharma Inc | Participant has an ECOG performance status of 0, 1 or 2 for dose escalation, and 0 or 1 for dose expansion. |
| NCT05382559 | Pregnancy | Phase 1 | Astellas Pharma Inc | Female participant must agree not to breastfeed starting at screening and throughout the study period and for 6 months after study intervention administration. |
| NCT05382559 | Prior malignancy | Phase 1 | Astellas Pharma Inc | Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years, except for local malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast, which are allowed. |
| NCT05384626 | Age | Phase 1/2 | Nuvalent Inc. | DDI sub-study Cohorts G and H only: age 18-60 years, inclusive |
| NCT05386108 | Brain metastases | Phase 1/2 | Stemline Therapeutics, Inc. | In Phase 2, participants must have at least one active and measurable brain metastasis per RECIST version 1.1. |
| NCT05386108 | Cardiac | Phase 1/2 | Stemline Therapeutics, Inc. | History of pulmonary embolism (PE), cardiovascular accident (CVA), myocardial infarction (MI) in the past 6 months from screening visit. |
| NCT05386108 | Hepatic | Phase 1/2 | Stemline Therapeutics, Inc. | In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × upper limit of normal (ULN). If the participant has liver metastases, ALT and AST ≤5.0 × ULN. |
| NCT05386108 | HIV | Phase 1/2 | Stemline Therapeutics, Inc. | Participants known to be human immunodeficiency virus positive (HIV+) are allowed as long as they have undetectable viral load (viral suppression) at baseline. |
| NCT05386108 | Performance status | Phase 1/2 | Stemline Therapeutics, Inc. | Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 |
| NCT05386108 | Pregnancy | Phase 1/2 | Stemline Therapeutics, Inc. | Females who are pregnant or breastfeeding. |
| NCT05386108 | Prior malignancy | Phase 1/2 | Stemline Therapeutics, Inc. | Participant has a concurrent malignancy or malignancy within 3 years of enrollment, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or second primary breast cancer; and any other malignancy that is considered in complete remission by the Investigator(s) that is approved by the Medical Monitor. |
| NCT05386108 | Renal | Phase 1/2 | Stemline Therapeutics, Inc. | Creatinine clearance (per Cockcroft-Gault formula) ≥50 mL/minute |
| NCT05408845 | Brain metastases | Phase 2 | NRG Oncology | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy |
| NCT05408845 | Cardiac | Phase 2 | NRG Oncology | Left ventricular ejection fraction (LVEF) >= 50% assessed by echocardiogram or multigated acquisition (MUGA) scan within 30 days prior to registration |
| NCT05408845 | Hepatic | Phase 2 | NRG Oncology | HER2-positive cohort: Total bilirubin =< 1.5 x ULN (within 14 days prior to registration) (Not applicable to patients with known Gilbert's syndrome) (within 14 days prior to registration) |
| NCT05408845 | HIV | Phase 2 | NRG Oncology | Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial. |
| NCT05408845 | Performance status | Phase 2 | NRG Oncology | Zubrod (Eastern Cooperative Oncology Group [ECOG]) Performance Status of 0-2 within 14 days prior to registration |
| NCT05408845 | Pregnancy | Phase 2 | NRG Oncology | Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. |
| NCT05408845 | Prior malignancy | Phase 2 | NRG Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05408845 | Renal | Phase 2 | NRG Oncology | Serum creatinine =< 1.5 x upper limit of normal (ULN) OR calculated creatinine clearance (CrCl) >= 30 mL/min by the Cockcroft-Gault formula (within 14 days prior to registration) |
| NCT05410977 | Prior malignancy | Not given | Mayo Clinic | Patient has known cancer (stage I-IV) within 5 years prior to current sample collection |
| NCT05417594 | BMI | Phase 1/2 | AstraZeneca | BMI > 30.0 kg/m2 or body weight > 100.0 kg |
| NCT05417594 | Brain metastases | Phase 1/2 | AstraZeneca | Participants with leptomeningeal disease (LMD) unless the LMD is of low volume or is previously treated and the participant is asymptomatic or minimal symptoms. |
| NCT05417594 | Cardiac | Phase 1/2 | AstraZeneca | Left ventricular ejection fraction (LVEF) ≥ 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before start of treatment. |
| NCT05417594 | Diabetes | Phase 1/2 | AstraZeneca | Participants with insulin-dependent diabetes. |
| NCT05417594 | Hepatic | Phase 1/2 | AstraZeneca | Participants with an INR >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants. |
| NCT05417594 | HIV | Phase 1/2 | AstraZeneca | Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). |
| NCT05417594 | Performance status | Phase 1/2 | AstraZeneca | Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks. |
| NCT05417594 | Pregnancy | Phase 1/2 | AstraZeneca | Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment. |
| NCT05417594 | Prior malignancy | Phase 1/2 | AstraZeneca | History of another primary malignancy. |
| NCT05422794 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy |
| NCT05422794 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Patients should be New York Heart Association Functional Classification of class 2B or better |
| NCT05422794 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (or =< 2.0 x ULN in patients with documented Gilbert's Syndrome) |
| NCT05422794 | HIV | Phase 1 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial as long as their anti-retroviral therapy does not have the potential for drug-drug interactions as judged by the treating investigator |
| NCT05422794 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) |
| NCT05422794 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Pregnant women are excluded from this study |
| NCT05422794 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT05422794 | Renal | Phase 1 | National Cancer Institute (NCI) | Serum or plasma creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 60 mL/min (based on the calculated chronic kidney disease epidemiology (CKD-EPI) glomerular filtration rate estimation |
| NCT05428007 | Brain metastases | Phase 2 | NYU Langone Health | Patients with untreated brain metastases, carcinomatosis meningitis or current ocular/uveal melanoma are excluded. |
| NCT05428007 | Prior malignancy | Phase 2 | NYU Langone Health | Patients with previous non-melanoma malignancies are excluded unless a complete resection or remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period |
| NCT05434234 | HIV | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | Known human immunodeficiency virus (HIV) infection |
| NCT05434234 | Performance status | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 |
| NCT05434234 | Pregnancy | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | Women who are breastfeeding or pregnant as confirmed by pregnancy tests performed within 7 days before the first dose |
| NCT05443126 | Brain metastases | Phase 1/2 | Ellipses Pharma | Spinal cord compression or brain metastases. Patients with stable brain metastases can be enrolled. |
| NCT05443126 | Cardiac | Phase 1/2 | Ellipses Pharma | congestive heart failure Grade III-IV according to the New York Heart Association, myocardial infarction, or unstable angina within the previous 6 months |
| NCT05443126 | Hepatic | Phase 1/2 | Ellipses Pharma | Impaired hepatic or renal function, inadequate bone marrow reserve or organ function |
| NCT05443126 | HIV | Phase 1/2 | Ellipses Pharma | Participants with active HIV infection. Patients living with HIV may be eligible if they have adequate CD4+ T-cell count and no history of AIDS-defining opportunistic infections in the past 12 months |
| NCT05443126 | Performance status | Phase 1/2 | Ellipses Pharma | ECOG performance status of 0 or 1 and life expectancy >3 months at screening |
| NCT05443126 | Renal | Phase 1/2 | Ellipses Pharma | Chronic glomerulonephritis or renal transplant |
| NCT05465174 | Age | Phase 2 | Sabine Mueller, MD, PhD | Age 1 to 39 years. |
| NCT05465174 | Cardiac | Phase 2 | Sabine Mueller, MD, PhD | Clinically significant active cardiovascular disease, or history of myocardial infarction, or deep vein thrombosis/pulmonary embolism within 6 months prior to registration, ongoing cardiomyopathy, or current prolonged QT interval corrected for heart rate by Fridericia's formula (QTcF) interval > 440 ms based on triplicate ECG average. |
| NCT05465174 | Hepatic | Phase 2 | Sabine Mueller, MD, PhD | Serum glutamic-pyruvic transaminase (SGPT)((alanine aminotransferase (ALT)) <= 3 x ULN. |
| NCT05465174 | Performance status | Phase 2 | Sabine Mueller, MD, PhD | Performance Score: Karnofsky >= 50 for participants > 16 years of age and Lansky >= 50 for participants <= 16 years of age. |
| NCT05465174 | Pregnancy | Phase 2 | Sabine Mueller, MD, PhD | Women of childbearing potential must not be pregnant or breast-feeding. |
| NCT05465174 | Renal | Phase 2 | Sabine Mueller, MD, PhD | A serum creatinine < 1.5 Upper Limit normal (ULN) based on age and gender. |
| NCT05467891 | Cardiac | Phase 2 | Oana Danciu | QTcF interval at screening < 450 msec (QT interval using Fridericia's correction) |
| NCT05467891 | Hepatic | Phase 2 | Oana Danciu | Aspartate aminotransferase (AST): ≤ 2.5 × ULN except for patients with liver metastasis, who are only included if the AST is < 5 × ULN |
| NCT05467891 | Performance status | Phase 2 | Oana Danciu | ECOG Performance Status of 0-1 within 28 days prior to registration. |
| NCT05467891 | Pregnancy | Phase 2 | Oana Danciu | Pregnant or breastfeeding or planning to become pregnant during the trial |
| NCT05467891 | Prior malignancy | Phase 2 | Oana Danciu | Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial. |
| NCT05467891 | Renal | Phase 2 | Oana Danciu | Estimated glomerular filtration rate (eGFR): ≥ 30 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) formula |
| NCT05468034 | Brain metastases | Not given | Indiana University | Active, untreated brain metastases |
| NCT05468034 | Cardiac | Not given | Indiana University | NYHA class III or IV congestive heart failure |
| NCT05468034 | Performance status | Not given | Indiana University | ECOG performance status of 0-2 |
| NCT05469893 | Brain metastases | Phase 2 | Irene Ghobrial, MD | Known active Central Nervous System (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. |
| NCT05469893 | Cardiac | Phase 2 | Irene Ghobrial, MD | New York Heart Association stage III or IV congestive heart failure, 2) Myocardial infarction or coronary artery bypass graft ≤6 months prior to randomization,3) History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration,4) History of severe non-ischemic cardiomyopathy |
| NCT05469893 | Diabetes | Phase 2 | Irene Ghobrial, MD | Uncontrolled diabetes defined by Hemoglobin A1C > 8.5 |
| NCT05469893 | Hepatic | Phase 2 | Irene Ghobrial, MD | Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.) |
| NCT05469893 | HIV | Phase 2 | Irene Ghobrial, MD | Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) or SARS-CoV-2 (COVID- 19). |
| NCT05469893 | Performance status | Phase 2 | Irene Ghobrial, MD | Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1, or 2 |
| NCT05469893 | Pregnancy | Phase 2 | Irene Ghobrial, MD | Pregnant or breast-feeding or planning to become pregnant while enrolled in this study or within 90 days after receiving the last dose of study drug. |
| NCT05469893 | Prior malignancy | Phase 2 | Irene Ghobrial, MD | Diagnosed or treated for another malignancy within 2 years of enrollment |
| NCT05469893 | Renal | Phase 2 | Irene Ghobrial, MD | Estimated creatinine clearance (CLcr) ≥60 mL/min |
| NCT05475925 | Brain metastases | Phase 1/2 | Dren Bio | Active or suspected malignant central nervous system involvement. |
| NCT05475925 | Cardiac | Phase 1/2 | Dren Bio | History of clinically significant cardiac disease or congestive heart failure greater than New York Heart Association (NYHA) Class II. |
| NCT05475925 | HIV | Phase 1/2 | Dren Bio | Infection with human immunodeficiency virus (HIV) type 1 or 2 (HIV-1 or HIV-2). |
| NCT05475925 | Prior malignancy | Phase 1/2 | Dren Bio | Active known second malignancy. |
| NCT05486572 | Age | Not given | VA Office of Research and Development | Age 18-75 |
| NCT05486572 | BMI | Not given | VA Office of Research and Development | Unable to fit on MRI machine due to weight (weight >400lbs) or body habitus |
| NCT05486572 | Pregnancy | Not given | VA Office of Research and Development | Currently pregnant |
| NCT05486572 | Renal | Not given | VA Office of Research and Development | Glomerular Filtration Rate (GFR) <30 ml/min |
| NCT05498428 | Brain metastases | Phase 2 | Janssen Research & Development, LLC | Participant has symptomatic brain metastases. |
| NCT05498428 | Cardiac | Phase 2 | Janssen Research & Development, LLC | prolonged corrected QT interval by Fridericia (QTcF) interval greater than (>) 480 milliseconds (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease |
| NCT05498428 | Hepatic | Phase 2 | Janssen Research & Development, LLC | Other clinically active liver disease of infectious origin |
| NCT05498428 | Performance status | Phase 2 | Janssen Research & Development, LLC | Participant must have eastern cooperative oncology group (ECOG) status of 0 or 1 |
| NCT05498428 | Prior malignancy | Phase 2 | Janssen Research & Development, LLC | May have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s) |
| NCT05501704 | Cardiac | Phase 2 | Jose Pablo Leone | severe cardiac disease, congestive heart failure (CHF) of New York Heart Association (NYHA) Class III or higher |
| NCT05501704 | Hepatic | Phase 2 | Jose Pablo Leone | Total bilirubin ≤ 2.0 x ULN (institutional). |
| NCT05501704 | HIV | Phase 2 | Jose Pablo Leone | such as known human immunodeficiency virus positivity |
| NCT05501704 | Language | Phase 2 | Jose Pablo Leone | Non-English-speaking patients are eligible but will be exempt from patient-completed questionnaires. |
| NCT05501704 | Performance status | Phase 2 | Jose Pablo Leone | ECOG performance status ≤ 2. |
| NCT05501704 | Prior malignancy | Phase 2 | Jose Pablo Leone | Prior endocrine therapy, systemic therapy, radiation therapy, or investigational therapy for any other malignancy within the past 12 months. |
| NCT05501704 | Renal | Phase 2 | Jose Pablo Leone | Serum creatinine ≤ 3.0 x ULN (institutional) |
| NCT05503797 | Age | Phase 2 | Fore Biotherapeutics | Male and female, ≥8 years of age, and weighing ≥25 kg. |
| NCT05503797 | Brain metastases | Phase 2 | Fore Biotherapeutics | Participant has CNS metastases. |
| NCT05503797 | Cardiac | Phase 2 | Fore Biotherapeutics | history of QTc abnormalities |
| NCT05503797 | Hepatic | Phase 2 | Fore Biotherapeutics | Grade ≥2 changes in AST, ALT, GGT, or bilirubin attributed to prior immune checkpoint inhibitor treatment are exclusionary, even if resolved. |
| NCT05503797 | HIV | Phase 2 | Fore Biotherapeutics | HIV infection with exceptions; discuss with treating physician. |
| NCT05519241 | Brain metastases | Phase 1 | VA Office of Research and Development | History or evidence of uncontrollable central nervous system (CNS) disease |
| NCT05519241 | Cardiac | Phase 1 | VA Office of Research and Development | NYHA (New York Heart Association) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction |
| NCT05519241 | Hepatic | Phase 1 | VA Office of Research and Development | Total bilirubin 2.0 X ULN (< 3 x ULN for patients with Gilbert's syndrome) |
| NCT05519241 | Performance status | Phase 1 | VA Office of Research and Development | Performance status: ECOG performance status of 0, 1, or 2 or Karnofsky performance status of 50 or higher |
| NCT05519241 | Pregnancy | Phase 1 | VA Office of Research and Development | Women who are pregnant or nursing |
| NCT05519241 | Prior malignancy | Phase 1 | VA Office of Research and Development | Any other malignancy diagnosed within 3 years of trial entry with the exception of: |
| NCT05519241 | Renal | Phase 1 | VA Office of Research and Development | Calculated glomerular filtration rate (GFR) 50 mL/min/1.73m2 |
| NCT05533697 | Brain metastases | Phase 1/2 | ModernaTX, Inc. | Participant has active central nervous system tumors or metastases. |
| NCT05533697 | Performance status | Phase 1/2 | ModernaTX, Inc. | Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1. |
| NCT05533697 | Pregnancy | Phase 1/2 | ModernaTX, Inc. | Participant who is pregnant, breastfeeding, or is of childbearing potential, defined as those who are capable of becoming pregnant who are not willing to employ a highly effective method of contraception during dosing and for 90 days after the last dose of mRNA-4359 or 4 months after the last dose of pembrolizumab or 5 months after the last dose of ipilimumab/nivolumab administrations, whichever is longer. |
| NCT05533775 | Brain metastases | Phase 1/2 | Hoffmann-La Roche | Isolated CNS disease of mature B-NHL without systemic involvement, and primary CNS lymphoma |
| NCT05533775 | HIV | Phase 1/2 | Hoffmann-La Roche | Negative HIV test at screening, with the following exception: Individuals with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count ≥200/uL, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months |
| NCT05533775 | Performance status | Phase 1/2 | Hoffmann-La Roche | Adequate performance status, as assessed according to the Lansky or Karnofsky Performance Status scales: Participants < 16 years old: Lansky Performance Status ≥ 50%; Participants ≥ 16 years old: Karnofsky Performance Status ≥ 50% |
| NCT05535192 | Age | Not given | Dana-Farber Cancer Institute | Women age >=65 |
| NCT05535192 | BMI | Not given | Dana-Farber Cancer Institute | BMI between 18-50 kg/m2 |
| NCT05535192 | Language | Not given | Dana-Farber Cancer Institute | Ability to understand, speak, and read English. |
| NCT05536141 | Performance status | Phase 1 | Arcus Biosciences, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1 |
| NCT05544019 | Brain metastases | Phase 1 | Schrödinger, Inc. | Subject has symptomatic or active CNS involvement of disease. |
| NCT05544019 | Performance status | Phase 1 | Schrödinger, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT05544019 | Prior malignancy | Phase 1 | Schrödinger, Inc. | Subject has previous invasive malignancy in the last 2 years. |
| NCT05547321 | Brain metastases | Phase 1 | Oncomatryx Biopharma S.L. | History of uncontrolled brain metastasis. |
| NCT05547321 | Cardiac | Phase 1 | Oncomatryx Biopharma S.L. | Uncontrolled or significant cardiovascular disease defined by the New York Hearth Association (NYHA) classification III or IV. |
| NCT05547321 | Hepatic | Phase 1 | Oncomatryx Biopharma S.L. | Total bilirubin ≤1.5 times upper limit of normal (ULN). |
| NCT05547321 | HIV | Phase 1 | Oncomatryx Biopharma S.L. | Patients positive for human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must meet the following criteria: |
| NCT05547321 | Performance status | Phase 1 | Oncomatryx Biopharma S.L. | ECOG performance status 0-1. |
| NCT05547321 | Pregnancy | Phase 1 | Oncomatryx Biopharma S.L. | Women who are pregnant or breastfeeding or trying to become pregnant. |
| NCT05547321 | Prior malignancy | Phase 1 | Oncomatryx Biopharma S.L. | Clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, breast ductal carcinoma in situ or localized non-melanoma skin cancers. |
| NCT05547321 | Renal | Phase 1 | Oncomatryx Biopharma S.L. | For Part 2 only:, CrCL should be ≥30 mL/min. |
| NCT05548296 | Brain metastases | Phase 2 | Acrivon Therapeutics | Participant with known symptomatic brain metastases requiring > 10 mg/day of prednisolone (or its equivalent). |
| NCT05548296 | Cardiac | Phase 2 | Acrivon Therapeutics | corrected QT based on Fridericia's formula (QTcF) > 450 msec (for men) or > 470 msec (for women). |
| NCT05548296 | Hepatic | Phase 2 | Acrivon Therapeutics | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); ≤ 5 × ULN if liver metastases are present. |
| NCT05548296 | HIV | Phase 2 | Acrivon Therapeutics | Participants has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2. |
| NCT05548296 | Performance status | Phase 2 | Acrivon Therapeutics | Participant must have an Eastern Cooperative Oncology Group Performance Status 0 or 1. |
| NCT05548296 | Renal | Phase 2 | Acrivon Therapeutics | Renal function is defined as Glomerular filtration rate (GFR) ≥ 50 mL/min/1.73m2. |
| NCT05549297 | Brain metastases | Phase 3 | Immunocore Ltd | known untreated or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis |
| NCT05549297 | Performance status | Phase 3 | Immunocore Ltd | Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 |
| NCT05549297 | Pregnancy | Phase 3 | Immunocore Ltd | Pregnant or lactating women |
| NCT05549297 | Prior malignancy | Phase 3 | Immunocore Ltd | history of a malignant disease other than those being treated in this study |
| NCT05553782 | Performance status | Early phase 1 | Brigham and Women's Hospital | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. |
| NCT05553782 | Pregnancy | Early phase 1 | Brigham and Women's Hospital | Pregnant women are excluded from this study because of the possible increased dose of radiation from imaging associated with the device placement and the potential risk to the pregnancy of the surgery/device placement. |
| NCT05554393 | Age | Phase 2 | National Cancer Institute (NCI) | Age 18-59 years at time of induction therapy |
| NCT05554393 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Cardiac ejection fraction >= 50% (echocardiography or MUGA) (if clinically indicated must be done within 14 days of enrollment) |
| NCT05554393 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin =< 2 x institutional upper limit of normal (ULN) (must be done within 10 days of enrollment) |
| NCT05554393 | HIV | Phase 2 | National Cancer Institute (NCI) | Patients with known human immunodeficiency virus (HIV) infection who are on effective anti-retroviral therapy and have undetectable viral load within 6 months of enrollment are eligible for this trial |
| NCT05554393 | Performance status | Phase 2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status =< 3 |
| NCT05554393 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Pregnant women are excluded from this study because venetoclax, cytarabine and azacitidine have the potential for teratogenic or abortifacient effects. |
| NCT05554393 | Renal | Phase 2 | National Cancer Institute (NCI) | Calculated creatinine clearance >= 30 mL/min; Clearance to be calculated using Cockcroft formula (must be done within 10 days of enrollment) |
| NCT05554406 | Age | Phase 2 | National Cancer Institute (NCI) | Participants must be between 18 and 59 years of age |
| NCT05554406 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Participants must have adequate cardiac function as determined by echocardiography or MUGA scan with an ejection fraction >= 50% within 28 days prior to registration |
| NCT05554406 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin =< 2.0 x ULN (or 5.0 x ULN if the participant has a history of Gilbert's disease) within 28 days prior to registration |
| NCT05554406 | HIV | Phase 2 | National Cancer Institute (NCI) | Participants with a known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load on the most recent test results obtained within 6 months prior to registration |
| NCT05554406 | Performance status | Phase 2 | National Cancer Institute (NCI) | Participants must have Zubrod performance status =< 3 as determined by a complete medical history and physical exam (H&P) completed within 7 days prior to registration |
| NCT05554406 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Participants must not be pregnant or nursing. |
| NCT05554406 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Participants with a prior or concurrent malignancy whose natural history (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT05554406 | Renal | Phase 2 | National Cancer Institute (NCI) | Participants must have adequate kidney function as evidenced by creatinine clearance >= 30mL/min (by Cockcroft Gault) within 7 days prior to registration |
| NCT05564377 | Performance status | Phase 2 | National Cancer Institute (NCI) | Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky performance status of >= 50% |
| NCT05573126 | Cardiac | Phase 1/2 | Ellipses Pharma | Congestive heart failure Grades II-IV according to the New York Heart Association at the time of screening |
| NCT05579366 | Age | Phase 1/2 | Genmab | Age 18 to 65 years (inclusive). |
| NCT05579366 | Performance status | Phase 1/2 | Genmab | An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. |
| NCT05592015 | Cardiac | Phase 2 | Jonathan Brammer | Unstable angina or myocardial infarction within the past 2 months |
| NCT05592015 | Hepatic | Phase 2 | Jonathan Brammer | Total bilirubin =< 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin > 1.5 x ULN permitted) |
| NCT05592015 | HIV | Phase 2 | Jonathan Brammer | Patients with human immunodeficiency virus (HIV), positive hepatitis B surface antigen or hepatitis C antibody will be excluded. |
| NCT05592015 | Performance status | Phase 2 | Jonathan Brammer | Eastern cooperative oncology group (ECOG) performance status =< 2 |
| NCT05592015 | Pregnancy | Phase 2 | Jonathan Brammer | For females of childbearing potential: Positive pregnancy test or lactating |
| NCT05592015 | Prior malignancy | Phase 2 | Jonathan Brammer | Active, concurrent malignancy unless deemed related to T-LGLL by principal investigator (PI). Early stage skin cancers, prostate cancer, permitted if under no active therapy |
| NCT05592015 | Renal | Phase 2 | Jonathan Brammer | Serum creatinine =< 2 x the upper limit of normal (ULN) |
| NCT05592626 | Brain metastases | Phase 1/2 | Marengo Therapeutics, Inc. | Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet the following at the time of enrollment: |
| NCT05592626 | Hepatic | Phase 1/2 | Marengo Therapeutics, Inc. | Hepatic metastases unless adequately treated, either locally (e.g., by surgery, radiofrequency ablation, or chemoembolization) or systemically or both, and stable for 3 months. |
| NCT05592626 | HIV | Phase 1/2 | Marengo Therapeutics, Inc. | Participants who are known to be human immunodeficiency virus positive or hepatitis B or C positive and have uncontrolled disease. |
| NCT05592626 | Pregnancy | Phase 1/2 | Marengo Therapeutics, Inc. | Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation). |
| NCT05592626 | Prior malignancy | Phase 1/2 | Marengo Therapeutics, Inc. | Second primary invasive malignancy not in remission for ≥ 1 year. |
| NCT05602363 | Brain metastases | Phase 1 | Carna Biosciences, Inc. | Known central nervous system (CNS) involvement by systemic lymphoma |
| NCT05602363 | Cardiac | Phase 1 | Carna Biosciences, Inc. | Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months before planned start of docirbrutinib, or prolongation of the QT interval corrected for heart rate using Fridericia's Formula (QTcF) >470 msec on at least 2 of 3 consecutive ECGs, and mean QTcF >470 msec on all 3 ECGs, during Screening |
| NCT05602363 | HIV | Phase 1 | Carna Biosciences, Inc. | Positive for HIV. For patients with unknown HIV status, HIV testing will be performed at Screening |
| NCT05602363 | Performance status | Phase 1 | Carna Biosciences, Inc. | ECOG Performance Status 0 to 2 |
| NCT05602363 | Pregnancy | Phase 1 | Carna Biosciences, Inc. | Pregnant or lactating. |
| NCT05602363 | Prior malignancy | Phase 1 | Carna Biosciences, Inc. | Active second malignancy unless in remission with life expectancy >2 years |
| NCT05607420 | Brain metastases | Phase 1/2 | Cellectis S.A. | Evidence of active central nervous system (CNS) lymphoma or previous CNS involvement of R/R B-NHL |
| NCT05607420 | Cardiac | Phase 1/2 | Cellectis S.A. | Any known uncontrolled cardiovascular disease within 3 months of enrollment |
| NCT05607420 | Performance status | Phase 1/2 | Cellectis S.A. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT05607420 | Prior malignancy | Phase 1/2 | Cellectis S.A. | Evidence of another uncontrolled malignancy within 2 years prior to Screening (except in situ nonmelanoma skin cell cancers and/or carcinoma in-situ of the cervix) |
| NCT05608252 | Brain metastases | Phase 1/2 | Adrienne G. Waks | Participants with active brain metastases or with known carcinomatous meningitis. |
| NCT05608252 | Cardiac | Phase 1/2 | Adrienne G. Waks | Adequate cardiac function with left ventricular ejection fraction ≥ 50% by echocardiography (ECHO) or multiple-gated acquisition (MUGA) scan. |
| NCT05608252 | Diabetes | Phase 1/2 | Adrienne G. Waks | uncontrolled diabetes mellitus |
| NCT05608252 | HIV | Phase 1/2 | Adrienne G. Waks | Known history of testing positive for HIV with history of an AIDS-defining opportunistic infection within the past 12 months |
| NCT05608252 | Performance status | Phase 1/2 | Adrienne G. Waks | ECOG performance status <2. |
| NCT05608252 | Pregnancy | Phase 1/2 | Adrienne G. Waks | Pregnant women are excluded from this study because effect of combination VS-766, abemaciclib, and fulvestrant on a developing fetus is unknown. |
| NCT05608252 | Prior malignancy | Phase 1/2 | Adrienne G. Waks | Individuals with a history of a second malignancy are ineligible except for the following circumstances. |
| NCT05608252 | Renal | Phase 1/2 | Adrienne G. Waks | Adequate renal function with a creatinine clearance rate of ≥ 50 mL/min as calculated by the Cockcroft-Gault formula. |
| NCT05614739 | Brain metastases | Phase 1 | Eli Lilly and Company | Untreated or uncontrolled CNS metastases. |
| NCT05614739 | Cardiac | Phase 1 | Eli Lilly and Company | Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF). |
| NCT05614739 | Hepatic | Phase 1 | Eli Lilly and Company | Active liver disease or clinically significant hepatic impairment. |
| NCT05614739 | Performance status | Phase 1 | Eli Lilly and Company | Have an Eastern Cooperative Oncology Group (ECOG) performance status of: |
| NCT05614739 | Pregnancy | Phase 1 | Eli Lilly and Company | Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. |
| NCT05614739 | Renal | Phase 1 | Eli Lilly and Company | Are on hemodialysis or similar. |
| NCT05621291 | Age | Not given | National Cancer Institute (NCI) | Age >=1 year and <= 25 years old at the time of CD19 CART infusion |
| NCT05621291 | Cardiac | Not given | National Cancer Institute (NCI) | Co-morbidities precluding myeloablative HCT. Note: Determination of co-morbidities precluding myeloablative HCT will be made by the treating transplant (HCT) physician and documented in the research record. This does not require that the participant is immediately fully eligible for HCT, only that there are no long-term comorbidities that would preclude a myeloablative approach (e.g., renal failure, severe cardiac failure, long-term oxygen requirement). |
| NCT05624996 | Performance status | Phase 3 | NRG Oncology | Eastern Cooperative Oncology Group (ECOG) performance status 0-2 |
| NCT05624996 | Pregnancy | Phase 3 | NRG Oncology | Participants who are pregnant or unwilling to discontinue nursing |
| NCT05624996 | Prior malignancy | Phase 3 | NRG Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT05624996 | Renal | Phase 3 | NRG Oncology | Creatinine clearance >= 25 mL/min by the Cockcroft-Gault (C-G) equation |
| NCT05625659 | Age | Not given | American College of Radiology | Age >60 years old |
| NCT05625659 | Diabetes | Not given | American College of Radiology | History of diabetes mellitus |
| NCT05625659 | Pregnancy | Not given | American College of Radiology | Women must not be pregnant or breast-feeding. |
| NCT05625659 | Renal | Not given | American College of Radiology | Women with known or suspected renal impairment. |
| NCT05633654 | Cardiac | Phase 3 | Gilead Sciences | Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of < 50% |
| NCT05633654 | Performance status | Phase 3 | Gilead Sciences | Eastern Cooperative Oncology Group (ECOG) performance status 0-1. |
| NCT05633654 | Prior malignancy | Phase 3 | Gilead Sciences | history of any prior (ipsi- or contralateral) invasive breast cancer. |
| NCT05640999 | Language | Phase 2 | Canadian Cancer Trials Group | Patient is able (i.e. sufficiently fluent) and willing to complete the patient-reported outcomes (PRO) questionnaires in either English, French or a validated language |
| NCT05640999 | Performance status | Phase 2 | Canadian Cancer Trials Group | Patients' Eastern Cooperative Group (ECOG) performance status must be 0, 1, or 2. |
| NCT05640999 | Prior malignancy | Phase 2 | Canadian Cancer Trials Group | Patients with a history of other malignancies, except: carcinoma in-situ without evidence of invasive disease when resected, adequately treated non-melanoma skin cancer, or other tumours curatively treated with no evidence of disease for ≥ 5 years. |
| NCT05642455 | Age | Phase 1/2 | USWM CT, LLC | (A) Synovial Sarcoma: 2 to 17 years (B) MPNST, Neuroblastoma and Osteosarcoma: 2 to 21 years |
| NCT05642455 | Brain metastases | Phase 1/2 | USWM CT, LLC | Known central nervous system (CNS) metastases. |
| NCT05642455 | Cardiac | Phase 1/2 | USWM CT, LLC | Clinically significant cardiovascular disease |
| NCT05642455 | HIV | Phase 1/2 | USWM CT, LLC | Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus |
| NCT05642455 | Performance status | Phase 1/2 | USWM CT, LLC | (A) Subjects ≥16: Eastern Cooperative Oncology Group (ECOG) 0 or 1 (B) Subjects 2 to 16: Lansky score ≥ 80 |
| NCT05642455 | Pregnancy | Phase 1/2 | USWM CT, LLC | Pregnant or breastfeeding |
| NCT05642455 | Prior malignancy | Phase 1/2 | USWM CT, LLC | Other prior malignancy that is not considered by the Investigator to be in complete remission |
| NCT05642572 | Brain metastases | Phase 2 | SWOG Cancer Research Network | Participants with symptomatic CNS metastasis (brain metastases or leptomeningeal disease) must be neurologically stable and have a stable or decreasing corticosteroid requirement for at least 5 days before sub-study randomization |
| NCT05642572 | Cardiac | Phase 2 | SWOG Cancer Research Network | Participants must have an electrocardiogram (ECG) performed, with a Fridericia's Correction Formula (QTcF) =< 470 msec, within 28 days prior to sub-study randomization |
| NCT05642572 | Hepatic | Phase 2 | SWOG Cancer Research Network | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN. Participants with history of liver metastasis must have AST =< 5 x ULN (within 28 days prior to sub-study randomization) |
| NCT05642572 | HIV | Phase 2 | SWOG Cancer Research Network | Participants with known human immunodeficiency virus (HIV) infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load within 6 months prior to sub-study randomization |
| NCT05642572 | Performance status | Phase 2 | SWOG Cancer Research Network | Participants' most recent Zubrod performance status must be 0-1 and be documented within 28 days prior to sub-study randomization |
| NCT05642572 | Pregnancy | Phase 2 | SWOG Cancer Research Network | Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped) |
| NCT05642572 | Prior malignancy | Phase 2 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT05642572 | Renal | Phase 2 | SWOG Cancer Research Network | Participants must have a serum creatinine =< the IULN OR calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study randomization |
| NCT05646862 | Brain metastases | Phase 3 | Hoffmann-La Roche | Any history of leptomeningeal disease or carcinomatous meningitis |
| NCT05646862 | Diabetes | Phase 3 | Hoffmann-La Roche | Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes |
| NCT05646862 | Hepatic | Phase 3 | Hoffmann-La Roche | Clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis |
| NCT05646862 | HIV | Phase 3 | Hoffmann-La Roche | Participants with known human immunodeficiency virus infection that meet specific criteria |
| NCT05646862 | Performance status | Phase 3 | Hoffmann-La Roche | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 |
| NCT05646862 | Pregnancy | Phase 3 | Hoffmann-La Roche | Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or at least 60 days after the final dose of study treatment |
| NCT05646862 | Prior malignancy | Phase 3 | Hoffmann-La Roche | History of other malignancy within 5 years prior to screening, except for cancers with very low risk of recurrence |
| NCT05652686 | Performance status | Phase 1/2 | Phanes Therapeutics | ECOG performance status of 0 or 1. |
| NCT05652686 | Pregnancy | Phase 1/2 | Phanes Therapeutics | Women who are pregnant or lactating. |
| NCT05655949 | BMI | Phase 2 | Beth Israel Deaconess Medical Center | Body weight >30 kg |
| NCT05655949 | Cardiac | Phase 2 | Beth Israel Deaconess Medical Center | New York Heart Association (NYHA) Class III or IV heart failure |
| NCT05655949 | Hepatic | Phase 2 | Beth Israel Deaconess Medical Center | Bilirubin ≤1.5 x ULN |
| NCT05655949 | HIV | Phase 2 | Beth Israel Deaconess Medical Center | Active, untreated HIV, HBV, or HCV |
| NCT05655949 | Performance status | Phase 2 | Beth Israel Deaconess Medical Center | ECOG performance status ≤1 |
| NCT05655949 | Pregnancy | Phase 2 | Beth Israel Deaconess Medical Center | Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy. |
| NCT05655949 | Prior malignancy | Phase 2 | Beth Israel Deaconess Medical Center | Previous malignancies, except for adequately treated non-melanoma skin cancer, in-situ cancer, or any other cancer from which the subject has been disease-free for at least 3 years |
| NCT05655949 | Renal | Phase 2 | Beth Israel Deaconess Medical Center | Serum creatinine ≤ 1.5 mg/dL OR |
| NCT05660369 | Cardiac | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Left ventricular ejection fraction >50% as determined by TTE. |
| NCT05660369 | Hepatic | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Total bilirubin ≤ institutional upper limit of normal (ULN); For patients with Gilbert's syndrome, total bilirubin can be ≤ 3xULN. |
| NCT05660369 | HIV | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Human immunodeficiency virus (HIV)-infected participants are not eligible. |
| NCT05660369 | Performance status | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Karnofsky ≥60% |
| NCT05660369 | Pregnancy | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CARv3-TEAM-E , breastfeeding should be discontinued if the mother is treated with CARv3-TEAM-E. |
| NCT05660369 | Prior malignancy | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Participant has no prior history of malignancy, unless the subject has been free of the disease for ≥5 years with the exception of the following noninvasive malignancies: |
| NCT05660369 | Renal | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | CrCl ≥ 60 mL/min |
| NCT05668962 | Brain metastases | Phase 2 | Massachusetts General Hospital | Participants with treated brain metastases are eligible if the patient is asymptomatic AND follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. |
| NCT05668962 | Cardiac | Phase 2 | Massachusetts General Hospital | history of myocardial infarction within 6 months prior to planned start of study treatment |
| NCT05668962 | Diabetes | Phase 2 | Massachusetts General Hospital | serious ongoing intercurrent illness, such as hypertension or diabetes, despite optimal treatment |
| NCT05668962 | Hepatic | Phase 2 | Massachusetts General Hospital | total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) OR <3.0 x institutional ULN for participants with Gilbert syndrome |
| NCT05668962 | HIV | Phase 2 | Massachusetts General Hospital | Known human immunodeficiency virus (HIV)-infected participants on effective anti- retroviral therapy with an undetectable viral load within 6 months are eligible for this trial. |
| NCT05668962 | Performance status | Phase 2 | Massachusetts General Hospital | Participants ≥ 16 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. |
| NCT05668962 | Pregnancy | Phase 2 | Massachusetts General Hospital | Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. |
| NCT05668962 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT05668962 | Renal | Phase 2 | Massachusetts General Hospital | creatinine ≤ institutional ULN OR creatinine clearance ≥30 mL/min |
| NCT05669430 | Brain metastases | Phase 1/2 | GV20 Therapeutics | Symptomatic central nervous system (CNS) malignancy or metastasis |
| NCT05669430 | Cardiac | Phase 1/2 | GV20 Therapeutics | Participant with heart disease or unstable arrhythmia |
| NCT05669430 | Hepatic | Phase 1/2 | GV20 Therapeutics | Participants with liver metastases unless approved by the Sponsor |
| NCT05669430 | Performance status | Phase 1/2 | GV20 Therapeutics | ECOG performance status of 0 or 1 |
| NCT05669430 | Pregnancy | Phase 1/2 | GV20 Therapeutics | Pregnant or nursing women |
| NCT05669430 | Prior malignancy | Phase 1/2 | GV20 Therapeutics | Disease-free of active second/secondary or prior malignancies for ≥ 2 years |
| NCT05673148 | Brain metastases | Phase 2 | Alliance for Clinical Trials in Oncology | Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. |
| NCT05673148 | Cardiac | Phase 2 | Alliance for Clinical Trials in Oncology | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better |
| NCT05673148 | Hepatic | Phase 2 | Alliance for Clinical Trials in Oncology | Total bilirubin =< 1.5 x ULN |
| NCT05673148 | HIV | Phase 2 | Alliance for Clinical Trials in Oncology | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT05673148 | Performance status | Phase 2 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) performance status: 0-2 |
| NCT05673148 | Pregnancy | Phase 2 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, because this study involves an agent or treatment that has known genotoxic, mutagenic, and teratogenic effects. |
| NCT05673148 | Prior malignancy | Phase 2 | Alliance for Clinical Trials in Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05673148 | Renal | Phase 2 | Alliance for Clinical Trials in Oncology | Creatinine =< 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance >= 30 mL/min |
| NCT05675410 | Age | Phase 3 | National Cancer Institute (NCI) | Patients must be 5 to 60 years of age at the time of enrollment |
| NCT05675410 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Shortening fraction of >= 27% by echocardiogram (ECHO), multigated acquisition scan (MUGA), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of >= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment) |
| NCT05675410 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin =< 2 x upper limit of normal (ULN) (within 28 days prior to enrollment) |
| NCT05675410 | HIV | Phase 3 | National Cancer Institute (NCI) | Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT05675410 | Performance status | Phase 3 | National Cancer Institute (NCI) | Patients >= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2 |
| NCT05675410 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT05675410 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT05675410 | Renal | Phase 3 | National Cancer Institute (NCI) | Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility |
| NCT05677490 | Brain metastases | Phase 3 | Alliance for Clinical Trials in Oncology | No untreated, symptomatic brain metastasis. Patients with treated brain metastases are eligible if the following criteria are met |
| NCT05677490 | Cardiac | Phase 3 | Alliance for Clinical Trials in Oncology | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better |
| NCT05677490 | Diabetes | Phase 3 | Alliance for Clinical Trials in Oncology | No medical condition such as uncontrolled infection or uncontrolled diabetes mellitus which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient |
| NCT05677490 | Hepatic | Phase 3 | Alliance for Clinical Trials in Oncology | Total bilirubin =< 1.5 x ULN |
| NCT05677490 | HIV | Phase 3 | Alliance for Clinical Trials in Oncology | Patients positive for human immunodeficiency virus (HIV) are eligible only if they meet all of the following: |
| NCT05677490 | Performance status | Phase 3 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 |
| NCT05677490 | Pregnancy | Phase 3 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects |
| NCT05677490 | Prior malignancy | Phase 3 | Alliance for Clinical Trials in Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05677490 | Renal | Phase 3 | Alliance for Clinical Trials in Oncology | Creatinine =< 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance >= 30 mL/min |
| NCT05683418 | Brain metastases | Phase 1 | Totus Medicines | Known active central nervous system (CNS) metastases |
| NCT05683418 | Diabetes | Phase 1 | Totus Medicines | Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2 |
| NCT05683418 | Performance status | Phase 1 | Totus Medicines | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT05684692 | Cardiac | Phase 2 | Massachusetts General Hospital | Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. |
| NCT05684692 | Hepatic | Phase 2 | Massachusetts General Hospital | ALT/aspartate aminotransferase (AST) ≤ 2.5 × institutional upper limit of normal (ULN); |
| NCT05684692 | HIV | Phase 2 | Massachusetts General Hospital | Have a known history of HIV infection. Testing is not required in the absence of history. |
| NCT05684692 | Performance status | Phase 2 | Massachusetts General Hospital | Karnofsky performance status ≥ 70 or ECOG PS 0 or 1 (see Appendix A). |
| NCT05684692 | Pregnancy | Phase 2 | Massachusetts General Hospital | Participants who are lactating women are excluded from this study because there are no data on the presence of erenumab-aooe in human milk, the effects on the breastfed infant, or the effects on milk production. |
| NCT05684692 | Prior malignancy | Phase 2 | Massachusetts General Hospital | History of a malignancy in the last 3 years, unless (a) have been disease-free for at least 2 years or (b) are deemed by the treating investigator to be at low risk for progression or recurrence of that malignancy (e.g., carcinoma in situ, basal cell carcinoma, Gleason 6 prostate cancer) in the next 2 years |
| NCT05684692 | Renal | Phase 2 | Massachusetts General Hospital | Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2, using the modification of diet in renal disease (MDRD) equation |
| NCT05687110 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the patient is asymptomatic and the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy |
| NCT05687110 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Fridericia's formula-corrected QT interval (QTcF) =< 480 ms |
| NCT05687110 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 × institutional upper limit of normal (ULN) |
| NCT05687110 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group Performance (ECOG) performance status =< 2 (Karnofsky >= 60%) |
| NCT05687110 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Pregnant women are excluded from this study because novobiocin is a POLtheta inhibitor agent with the potential for teratogenic or abortifacient effects. |
| NCT05687110 | Renal | Phase 1 | National Cancer Institute (NCI) | Glomerular filtration rate (GFR) >= 60 mL/min (via the chronic kidney disease epidemiology [CKD-EPI] glomerular filtration rate estimation) |
| NCT05687136 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required during the first cycle of therapy. |
| NCT05687136 | Cardiac | Phase 1 | National Cancer Institute (NCI) | QTcF (using the Fridericia correction calculation) of >= 470 msec |
| NCT05687136 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN). |
| NCT05687136 | HIV | Phase 1 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT05687136 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern cooperative oncology group (ECOG) performance status =< 2 (Karnofsky >= 60%). |
| NCT05687136 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. |
| NCT05687136 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT05687136 | Renal | Phase 1 | National Cancer Institute (NCI) | Glomerular filtration rate (GFR) >= 60 mL/min/1.73m^2. |
| NCT05692024 | HIV | Phase 1/2 | Massachusetts General Hospital | Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection. |
| NCT05692024 | Pregnancy | Phase 1/2 | Massachusetts General Hospital | Pregnant or breastfeeding. |
| NCT05692024 | Prior malignancy | Phase 1/2 | Massachusetts General Hospital | Presence of synchronous (at the same time) malignancy for which the patient is currently receiving active treatment. |
| NCT05696626 | Brain metastases | Phase 3 | LeonaBio | Brain metastases are allowed only if the following 4 parameters hold: |
| NCT05696626 | Cardiac | Phase 3 | LeonaBio | History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec. |
| NCT05696626 | HIV | Phase 3 | LeonaBio | Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). |
| NCT05696626 | Performance status | Phase 3 | LeonaBio | Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 |
| NCT05696626 | Pregnancy | Phase 3 | LeonaBio | Positive serum pregnancy test (only if premenopausal). |
| NCT05696626 | Prior malignancy | Phase 3 | LeonaBio | History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery. |
| NCT05706766 | Cardiac | Not given | Dana-Farber Cancer Institute | History of unstable angina, abnormal resting ECG and/or unstable angina or a heart attack in the previous month |
| NCT05706766 | Language | Not given | Dana-Farber Cancer Institute | Speak English. |
| NCT05706766 | Pregnancy | Not given | Dana-Farber Cancer Institute | women of child-bearing potential must agree to undergo a pregnancy test and to use adequate contraception |
| NCT05706766 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Patients with other active malignancies requiring active therapy. |
| NCT05710848 | Cardiac | Phase 1/2 | SURGE Therapeutics | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT05710848 | Hepatic | Phase 1/2 | SURGE Therapeutics | Serum bilirubin 1.5 × institutional upper limit of normal (ULN); |
| NCT05710848 | Performance status | Phase 1/2 | SURGE Therapeutics | Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 |
| NCT05710848 | Renal | Phase 1/2 | SURGE Therapeutics | Creatinine CL 60 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine CL |
| NCT05711615 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are not eligible |
| NCT05711615 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Patients with known history of clinically significant cardiac disease, or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better |
| NCT05711615 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) |
| NCT05711615 | HIV | Phase 1 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT05711615 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) |
| NCT05711615 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. |
| NCT05711615 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05711615 | Renal | Phase 1 | National Cancer Institute (NCI) | Glomerular filtration rate (GFR) >= 51 mL/min/1.73 m^2 (per institutional estimate based on creatinine level) |
| NCT05714839 | Brain metastases | Phase 1/2 | GlaxoSmithKline | Participant is exhibiting signs of meningeal or central nervous system involvement with MM. |
| NCT05714839 | Cardiac | Phase 1/2 | GlaxoSmithKline | Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system. |
| NCT05714839 | Hepatic | Phase 1/2 | GlaxoSmithKline | Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. |
| NCT05714839 | HIV | Phase 1/2 | GlaxoSmithKline | Known Human immunodeficiency virus (HIV) infection, unless the participant can meet specific criteria. |
| NCT05714839 | Performance status | Phase 1/2 | GlaxoSmithKline | Eastern cooperative oncology group-performance status (ECOG-PS) of 0 to 2. |
| NCT05714839 | Pregnancy | Phase 1/2 | GlaxoSmithKline | A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: |
| NCT05714839 | Prior malignancy | Phase 1/2 | GlaxoSmithKline | Presence of malignancies other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the Principal investigator (PI) and GlaxoSmithKline (GSK) Medical Director, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM). |
| NCT05714839 | Renal | Phase 1/2 | GlaxoSmithKline | Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible. |
| NCT05715684 | Age | Not given | Brigham and Women's Hospital | Patients between the ages 18 and 85 years |
| NCT05715684 | Cardiac | Not given | Brigham and Women's Hospital | A history of heart failure. |
| NCT05715684 | Hepatic | Not given | Brigham and Women's Hospital | Patients with severe hepatic impairment as defined by Child-Pugh Class C. |
| NCT05715684 | Language | Not given | Brigham and Women's Hospital | Non-English-speaking patients |
| NCT05715684 | Pregnancy | Not given | Brigham and Women's Hospital | Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating |
| NCT05715684 | Prior malignancy | Not given | Brigham and Women's Hospital | Be undergoing treatment for another type of cancer concurrently |
| NCT05715684 | Renal | Not given | Brigham and Women's Hospital | Patients with end-stage renal disease as defined by GFR <15. |
| NCT05726370 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Those with known brain metastases should be excluded from this clinical trial |
| NCT05726370 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | total bilirubin ≤ institutional upper limit of normal (ULN) |
| NCT05726370 | HIV | Phase 2 | Dana-Farber Cancer Institute | Has a known history of human immunodeficiency virus (HIV) infection. |
| NCT05726370 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status 0 or 1 (Karnofsky ≥70%, see Appendix A) |
| NCT05726370 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix B), not breastfeeding |
| NCT05726370 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. |
| NCT05726370 | Renal | Phase 2 | Dana-Farber Cancer Institute | creatinine ≤ institutional ULN OR |
| NCT05730816 | Cardiac | Phase 2 | Brigham and Women's Hospital | Sinus bradycardia, defined as a heart rate (HR) <55 beats per minute (bpm) detected on any ECG in the preceding 6 months |
| NCT05730816 | Pregnancy | Phase 2 | Brigham and Women's Hospital | Pregnant/breastfeeding |
| NCT05730816 | Renal | Phase 2 | Brigham and Women's Hospital | eGFR<45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. |
| NCT05732831 | Brain metastases | Phase 1/2 | Tango Therapeutics, Inc. | Central nervous system metastases associated with progressive neurological symptoms |
| NCT05732831 | Cardiac | Phase 1/2 | Tango Therapeutics, Inc. | Clinically relevant cardiovascular disease |
| NCT05732831 | Hepatic | Phase 1/2 | Tango Therapeutics, Inc. | Current active liver disease from any cause |
| NCT05732831 | HIV | Phase 1/2 | Tango Therapeutics, Inc. | Known to be HIV positive, unless all of the following criteria are met: |
| NCT05732831 | Performance status | Phase 1/2 | Tango Therapeutics, Inc. | ECOG Performance Score of 0 to 1 |
| NCT05732831 | Pregnancy | Phase 1/2 | Tango Therapeutics, Inc. | A female patient who is pregnant or lactating |
| NCT05732831 | Prior malignancy | Phase 1/2 | Tango Therapeutics, Inc. | Active prior or concurrent malignancy. |
| NCT05735080 | Brain metastases | Phase 1/2 | Incyclix Bio | Have central nervous system (CNS) metastases or spinal cord compression that is associated with progressive neurological symptoms or requires corticosteroids (within 4 weeks of enrollment) to control the CNS disease. |
| NCT05735080 | Cardiac | Phase 1/2 | Incyclix Bio | Resting QTcF > 470 msec, a history of prolonged QT syndrome or Torsades de pointes, or a familial history of prolonged QT syndrome. |
| NCT05735080 | Hepatic | Phase 1/2 | Incyclix Bio | Part A and B: Total bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN; ≤ 5 × ULN in the presence of liver metastases |
| NCT05735080 | HIV | Phase 1/2 | Incyclix Bio | Known HIV infection, including AIDS-related illness |
| NCT05735080 | Performance status | Phase 1/2 | Incyclix Bio | ECOG performance status score of 0 or 1. |
| NCT05735080 | Pregnancy | Phase 1/2 | Incyclix Bio | Negative pregnancy test |
| NCT05735080 | Prior malignancy | Phase 1/2 | Incyclix Bio | History of other malignancies, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated a) in situ carcinoma of the uterine cervix, b) prostate cancer, or c) superficial bladder cancer; or (3) other curatively treated solid tumor with no evidence of disease for ≥ 3 years. |
| NCT05735080 | Renal | Phase 1/2 | Incyclix Bio | Estimated glomerular filtration rate (eGFR) of ≥60 mL/min |
| NCT05735184 | Brain metastases | Phase 1 | Kura Oncology, Inc. | Active central nervous system (CNS) involvement by AML. |
| NCT05735184 | Cardiac | Phase 1 | Kura Oncology, Inc. | Mean QT interval corrected for heart rate by Fredericia's formula (QTcF) |
| NCT05735184 | HIV | Phase 1 | Kura Oncology, Inc. | Known clinically active human immunodeficiency virus, active hepatitis B or active hepatitis C infection |
| NCT05735184 | Performance status | Phase 1 | Kura Oncology, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 |
| NCT05735184 | Pregnancy | Phase 1 | Kura Oncology, Inc. | Women who are pregnant or lactating |
| NCT05735184 | Prior malignancy | Phase 1 | Kura Oncology, Inc. | An active malignancy and currently receiving chemotherapy for that malignancy or disease that is uncontrolled/progressing |
| NCT05740839 | Age | Not given | Dana-Farber Cancer Institute | At time of study are a young adult, aged 18-45 years. |
| NCT05740839 | Brain metastases | Not given | Dana-Farber Cancer Institute | Patients with evidence of progressive CNS or systemic cancer in the last 3 months. |
| NCT05740839 | Language | Not given | Dana-Farber Cancer Institute | Speak English and/or Spanish. |
| NCT05740839 | Pregnancy | Not given | Dana-Farber Cancer Institute | People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses. |
| NCT05740839 | Smoking | Not given | Dana-Farber Cancer Institute | Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included. |
| NCT05765500 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Patients with brain metastases will be excluded from the study as intermittent hormonal therapy is not standard of care treatment for this population. |
| NCT05765500 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 6 months. |
| NCT05765500 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | total bilirubin ≤ institutional upper limit of normal (ULN) unless known or suspected Gilbert syndrome |
| NCT05765500 | HIV | Phase 2 | Dana-Farber Cancer Institute | Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT05765500 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). |
| NCT05765500 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. |
| NCT05765500 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT05765500 | Renal | Phase 2 | Dana-Farber Cancer Institute | creatinine ≤ institutional ULN OR |
| NCT05768139 | Brain metastases | Phase 1/2 | Eli Lilly and Company | Has symptomatic brain or spinal metastases |
| NCT05768139 | Diabetes | Phase 1/2 | Eli Lilly and Company | Has an established diagnosis of uncontrolled diabetes mellitus (defined as HbA1c ≥8% and/or FBG ≥140 mg/dL [7.7 mmol/L] and/or requiring or required insulin). |
| NCT05768139 | Performance status | Phase 1/2 | Eli Lilly and Company | Has an ECOG performance status score of 0 or 1 at screening |
| NCT05768139 | Prior malignancy | Phase 1/2 | Eli Lilly and Company | Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancers being studied |
| NCT05773144 | Language | Not given | AdventHealth Translational Research Institute | Can read and speak English |
| NCT05773144 | Pregnancy | Not given | AdventHealth Translational Research Institute | Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks |
| NCT05773144 | Prior malignancy | Not given | AdventHealth Translational Research Institute | Concurrently actively treated other (non-colon) cancer |
| NCT05774899 | Brain metastases | Phase 1/2 | Michael J. Dennis, MD | Participant has untreated or clinically symptomatic CNS metastases and/or carcinomatous meningitis |
| NCT05774899 | Cardiac | Phase 1/2 | Michael J. Dennis, MD | Corrected QTcF >450 msec for males and >470 msec for females in screening |
| NCT05774899 | Hepatic | Phase 1/2 | Michael J. Dennis, MD | Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3x ULN Total serum bilirubin ≤1.5x ULN |
| NCT05774899 | HIV | Phase 1/2 | Michael J. Dennis, MD | known human immunodeficiency virus positivity |
| NCT05774899 | Performance status | Phase 1/2 | Michael J. Dennis, MD | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 |
| NCT05774899 | Pregnancy | Phase 1/2 | Michael J. Dennis, MD | Female subjects of childbearing potential should have a negative serum pregnancy test within 7 days before start of study treatment. |
| NCT05774899 | Prior malignancy | Phase 1/2 | Michael J. Dennis, MD | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT05774899 | Renal | Phase 1/2 | Michael J. Dennis, MD | Serum creatinine ≤1.5x ULN or serum creatinine clearance (CrCl) ≥50 mL/min (estimated by Cockcroft-Gault formula) |
| NCT05779423 | Brain metastases | Phase 2 | Massachusetts General Hospital | Participants with new or progressive asymptomatic brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy. |
| NCT05779423 | Hepatic | Phase 2 | Massachusetts General Hospital | Total bilirubin ≤3 institutional upper limit of normal (ULN) |
| NCT05779423 | HIV | Phase 2 | Massachusetts General Hospital | Known Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT05779423 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG PS ≤2 |
| NCT05779423 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study because immune checkpoint inhibitors have the potential for teratogenic or abortifacient effects. |
| NCT05779423 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT05779423 | Renal | Phase 2 | Massachusetts General Hospital | CrCL > 30 ml/min |
| NCT05783609 | Brain metastases | Phase 2 | Reid Merryman, MD | Active CNS lymphoma |
| NCT05783609 | Cardiac | Phase 2 | Reid Merryman, MD | Patients with New York Heart Association Class III or IV heart failure or known ejection fraction of <45%. |
| NCT05783609 | Hepatic | Phase 2 | Reid Merryman, MD | Total bilirubin < 1.5 X ULN, unless Gilbert syndrome, in which case direct bilirubin must be < 1.5 x ULN |
| NCT05783609 | HIV | Phase 2 | Reid Merryman, MD | Known history of seropositivity for human immunodeficiency virus (HIV). |
| NCT05783609 | Performance status | Phase 2 | Reid Merryman, MD | Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. (Appendix A) |
| NCT05783609 | Prior malignancy | Phase 2 | Reid Merryman, MD | Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 2 years. |
| NCT05783609 | Renal | Phase 2 | Reid Merryman, MD | Estimated CrCl (Cockcroft Gault) ≥ 45ml/min |
| NCT05784922 | Age | Not given | Massachusetts General Hospital | Must be 50-80 years old |
| NCT05784922 | Language | Not given | Massachusetts General Hospital | Must speak English or Spanish |
| NCT05785741 | Brain metastases | Phase 1/2 | DualityBio Inc. | Has clinically active central nervous system (CNS) metastases, defined as untreated, or symptomatic, or requiring therapy with glucocorticoids or anticonvulsants to control associated symptoms. |
| NCT05785741 | Cardiac | Phase 1/2 | DualityBio Inc. | Has LVEF ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment. |
| NCT05785741 | Hepatic | Phase 1/2 | DualityBio Inc. | Subjects have active viral (any etiology) hepatitis are excluded. |
| NCT05785741 | HIV | Phase 1/2 | DualityBio Inc. | Know human immunodeficiency virus (HIV) infection. |
| NCT05785741 | Performance status | Phase 1/2 | DualityBio Inc. | Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1. |
| NCT05785741 | Pregnancy | Phase 1/2 | DualityBio Inc. | Is a lactating mother (women who are willing to temporarily interrupt breastfeeding will also be excluded), or pregnant as confirmed by serum pregnancy tests performed within 7 days prior to Cycle 1 Day 1. |
| NCT05785741 | Prior malignancy | Phase 1/2 | DualityBio Inc. | Has multiple primary malignancies within 5 years before enrollment, except adequately resected non-melanoma skin cancer (e.g., resected basal or squamous cell skin cancer), curatively treated in-situ disease (e.g., carcinoma in situ of the cervix or breast), other solid tumors curatively treated (e.g., < T1 urothelial carcinoma), or contralateral breast cancer. |
| NCT05786924 | Brain metastases | Phase 1/2 | Institut de Recherches Internationales Servier | Part 2A3: Advanced/metastatic NSCLC with KRAS non-G12C or BRAF mutations or alterations and active CNS metastatic disease |
| NCT05786924 | Cardiac | Phase 1/2 | Institut de Recherches Internationales Servier | Clinically significant cardiovascular disease. |
| NCT05786924 | Pregnancy | Phase 1/2 | Institut de Recherches Internationales Servier | Females who are pregnant or breastfeeding. |
| NCT05786924 | Prior malignancy | Phase 1/2 | Institut de Recherches Internationales Servier | Evidence of active malignancy (other than study-specific malignancies) requiring systemic therapy within the next 2 years. |
| NCT05789303 | Cardiac | Phase 2 | University of Chicago | Class III or IV heart failure as defined by the New York Heart Association functional classification system |
| NCT05789303 | Hepatic | Phase 2 | University of Chicago | Subject must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. |
| NCT05789303 | HIV | Phase 2 | University of Chicago | Subject with HIV infection will be excluded unless certain T-cell count, viral load and clinical qualifications are met as confirmed by the study doctor |
| NCT05789303 | Performance status | Phase 2 | University of Chicago | Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 |
| NCT05789303 | Pregnancy | Phase 2 | University of Chicago | Subjects must not be pregnant or lactating. |
| NCT05789303 | Prior malignancy | Phase 2 | University of Chicago | Subject must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years |
| NCT05789303 | Renal | Phase 2 | University of Chicago | Subject must not have presence of active renal condition (infection, requirement for dialysis or any other condition that could affect Subject's safety). |
| NCT05795101 | BMI | Phase 2 | Filipa Lynce, MD | Body weight >30 kg |
| NCT05795101 | Brain metastases | Phase 2 | Filipa Lynce, MD | History of leptomeningeal carcinomatosis |
| NCT05795101 | Cardiac | Phase 2 | Filipa Lynce, MD | LVEF ≥ 50% within 28 days prior to enrollment |
| NCT05795101 | Hepatic | Phase 2 | Filipa Lynce, MD | Total bilirubin ≤1.5 × institutional upper limit of normal (ULN)(or ≤2.0 x ULN in patients with documented Gilbert's Syndrome) |
| NCT05795101 | HIV | Phase 2 | Filipa Lynce, MD | Known to have previously tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) |
| NCT05795101 | Performance status | Phase 2 | Filipa Lynce, MD | ECOG performance status 0-1 (Karnofsky > 60%, see Appendix A). |
| NCT05795101 | Pregnancy | Phase 2 | Filipa Lynce, MD | Female patients who are pregnant, breastfeeding or of reproductive potential who are not willing to employ effective birth control from screening to 6 months after the last dose of durvalumab and at least 7 months after the final administration of trastuzumab deruxtecan due to the potential for teratogenic effects. |
| NCT05795101 | Prior malignancy | Phase 2 | Filipa Lynce, MD | History of another primary malignancy, except for Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study treatment and of low potential risk for recurrence. |
| NCT05795101 | Renal | Phase 2 | Filipa Lynce, MD | Serum creatinine ≤1.5 × institutional ULN OR creatinine clearance ≥ 30 mL/min/ 1.73m2 for participants with creatinine levels above institutional ULN. |
| NCT05796375 | Language | Phase 2 | White River Junction Veterans Affairs Medical Center | Ability to consent in English or Spanish |
| NCT05796375 | Pregnancy | Phase 2 | White River Junction Veterans Affairs Medical Center | Pregnancy or lactation. |
| NCT05797168 | Brain metastases | Phase 1/2 | AstraZeneca | Patients with brain metastases unless, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to first dose of study intervention. |
| NCT05797168 | Cardiac | Phase 1/2 | AstraZeneca | Mean resting QTcF > 470 msec obtained from triplicate electrocardiograms (ECGs) and averaged, recorded within 5 minutes. |
| NCT05797168 | HIV | Phase 1/2 | AstraZeneca | or known HIV infection that is not well controlled. |
| NCT05797168 | Performance status | Phase 1/2 | AstraZeneca | Eastern Cooperative Oncology Group Performance Status of 0 or 1. |
| NCT05797168 | Pregnancy | Phase 1/2 | AstraZeneca | For women only - currently pregnant (confirmed with positive pregnancy test or suspected), lactating, breastfeeding, or intention to become pregnant during the study period. |
| NCT05797168 | Prior malignancy | Phase 1/2 | AstraZeneca | History of another malignancy except for: |
| NCT05800366 | Brain metastases | Phase 2 | Jennifer Crombie, MD | Known history of central nervous system or neurologic disease including stroke or intracranial hemorrhage within 3 months prior to enrollment or seizure disorder |
| NCT05800366 | Cardiac | Phase 2 | Jennifer Crombie, MD | Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO) |
| NCT05800366 | Diabetes | Phase 2 | Jennifer Crombie, MD | type 1 diabetes on a stable dose of insulin are eligible |
| NCT05800366 | Hepatic | Phase 2 | Jennifer Crombie, MD | AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN |
| NCT05800366 | HIV | Phase 2 | Jennifer Crombie, MD | Known history of HIV or HTLV-1 seropositive status. |
| NCT05800366 | Performance status | Phase 2 | Jennifer Crombie, MD | ECOG Performance Status of 0, 1, or 2 (see Appendix A) |
| NCT05800366 | Pregnancy | Phase 2 | Jennifer Crombie, MD | Lactating or pregnant. |
| NCT05800366 | Prior malignancy | Phase 2 | Jennifer Crombie, MD | History of other malignancies, except: |
| NCT05800366 | Renal | Phase 2 | Jennifer Crombie, MD | Adequate renal function defined by serum creatinine ≤1.5 x ULN or creatinine clearance (by Cockcroft-Gault) ≥ 40 ml/min |
| NCT05812807 | Hepatic | Phase 3 | Alliance for Clinical Trials in Oncology | Total Bilirubin =<1.5 x upper limit of normal (ULN) |
| NCT05812807 | Performance status | Phase 3 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 |
| NCT05812807 | Pregnancy | Phase 3 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. |
| NCT05812807 | Prior malignancy | Phase 3 | Alliance for Clinical Trials in Oncology | No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed |
| NCT05812807 | Renal | Phase 3 | Alliance for Clinical Trials in Oncology | Estimated glomerular filtration rate (eGFR) >= 15 mL/min/1.73m^2 |
| NCT05836324 | Brain metastases | Phase 1 | Incyte Corporation | Brain or CNS metastases untreated or that have progressed. |
| NCT05836324 | Cardiac | Phase 1 | Incyte Corporation | History of clinically significant or uncontrolled cardiac disease. |
| NCT05836324 | HIV | Phase 1 | Incyte Corporation | Active HBV, active HCV, or HIV positive. |
| NCT05836324 | Performance status | Phase 1 | Incyte Corporation | ECOG performance status score of 0 or 1. |
| NCT05836324 | Prior malignancy | Phase 1 | Incyte Corporation | Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years. |
| NCT05842603 | Performance status | Not given | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT05850234 | Brain metastases | Phase 1/2 | AstraZeneca | Known active or prior history of central nervous system involvement or exhibits clinical signs of meningeal involvement of MM. |
| NCT05850234 | Cardiac | Phase 1/2 | AstraZeneca | Participant has significant cardiac, neurological, or psychiatric conditions. |
| NCT05850234 | Performance status | Phase 1/2 | AstraZeneca | ECOG performance status of 0 or 1. |
| NCT05850234 | Prior malignancy | Phase 1/2 | AstraZeneca | Participant has a history of a prior non-hematologic malignancy, unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years. |
| NCT05862012 | Brain metastases | Phase 1 | Ichnos Sciences SA | Active malignant central nervous system involvement |
| NCT05862012 | Performance status | Phase 1 | Ichnos Sciences SA | Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less |
| NCT05862012 | Pregnancy | Phase 1 | Ichnos Sciences SA | Female subjects who are lactating and breastfeeding or have a positive pregnancy test during the screening period or on Day 1 before first dose of ISB 2001. |
| NCT05865301 | Age | Not given | Stanford University | Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age. |
| NCT05872295 | Brain metastases | Phase 1 | Iksuda Therapeutics Ltd. | Central nervous system metastatic disease unless treated with definitive local therapy (surgical resection, stereotactic radiotherapy, or whole brain radiotherapy) and participant is clinically, radiologically and neurologically stable for at least 4 weeks prior to the first dose of study drug not on steroid therapy or are on a stable or decreasing dose of steroids for at least 7 days prior to first dose of study drug. Prophylactic anticonvulsant medications are allowed. |
| NCT05872295 | Cardiac | Phase 1 | Iksuda Therapeutics Ltd. | Clinically significant cardiovascular disease or condition |
| NCT05872295 | Hepatic | Phase 1 | Iksuda Therapeutics Ltd. | Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional upper limit of normal (ULN) ≤ 5 x ULN if liver metastases present |
| NCT05872295 | Performance status | Phase 1 | Iksuda Therapeutics Ltd. | Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (or equivalent Karnofsky PS) |
| NCT05872295 | Prior malignancy | Phase 1 | Iksuda Therapeutics Ltd. | Active second malignancy or history of another malignancy within the last 2 years with the exception of: |
| NCT05872295 | Renal | Phase 1 | Iksuda Therapeutics Ltd. | Creatinine clearance > 45/mL/min (using the Cockcroft-Gault equation) |
| NCT05874921 | Pregnancy | Not given | UroGen Pharma Ltd. | Pregnancy or lactation. |
| NCT05877599 | Brain metastases | Phase 1 | AstraZeneca | Known, active primary central nervous system (CNS) malignancy |
| NCT05877599 | Cardiac | Phase 1 | AstraZeneca | History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment. |
| NCT05877599 | Prior malignancy | Phase 1 | AstraZeneca | Any another primary malignancy within the 3 years prior to enrollment |
| NCT05879926 | Cardiac | Phase 3 | NRG Oncology | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. |
| NCT05879926 | Hepatic | Phase 3 | NRG Oncology | AST(aspartate aminotransferase)(SGOT)/ALT (alanine transminase)(SGPT): greater than 3 × institutional ULN; |
| NCT05879926 | HIV | Phase 3 | NRG Oncology | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT05879926 | Performance status | Phase 3 | NRG Oncology | The patient must have an ECOG performance status of less than or equal to 2 (or Karnofsky greater than or equal to 60%). |
| NCT05879926 | Pregnancy | Phase 3 | NRG Oncology | Pregnancy or lactation at the time of pre-entry. |
| NCT05879926 | Prior malignancy | Phase 3 | NRG Oncology | History of ipsilateral or contralateral invasive breast cancer. |
| NCT05879926 | Renal | Phase 3 | NRG Oncology | Renal function of GFR (glomular filtration rate) less than 30 mL/min/1.73m2. |
| NCT05886049 | Age | Phase 1 | National Cancer Institute (NCI) | Patients ages 18-75 years at time of diagnosis |
| NCT05886049 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Ejection fraction >= 50% (or >= 45% if no evidence of congestive heart failure [CHF] or other cardiac symptoms) by transthoracic echocardiogram (TTE) or multi-gated acquisition (MUGA) scan |
| NCT05886049 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except for patients with Gilbert's syndrome where required to be ≤ 3 x institutional ULN |
| NCT05886049 | HIV | Phase 1 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT05886049 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) |
| NCT05886049 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Pregnant women are excluded from this study |
| NCT05886049 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05886049 | Renal | Phase 1 | National Cancer Institute (NCI) | Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 (via the Chronic Kidney Disease Epidemiology [CKD-EPI] glomerular filtration rate estimation) |
| NCT05894239 | Brain metastases | Phase 3 | Hoffmann-La Roche | Any history of leptomeningeal disease or carcinomatous meningitis |
| NCT05894239 | Cardiac | Phase 3 | Hoffmann-La Roche | LVEF (left ventricular ejection fraction) of at least 50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) |
| NCT05894239 | Diabetes | Phase 3 | Hoffmann-La Roche | Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes |
| NCT05894239 | Hepatic | Phase 3 | Hoffmann-La Roche | Clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis |
| NCT05894239 | Performance status | Phase 3 | Hoffmann-La Roche | Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 |
| NCT05898594 | Age | Not given | Massachusetts General Hospital | Aged 50-80 years. |
| NCT05898594 | Prior malignancy | Not given | Massachusetts General Hospital | Individuals with a history of lung cancer. |
| NCT05898594 | Smoking | Not given | Massachusetts General Hospital | Have a self-reported history of smoking. |
| NCT05901285 | Brain metastases | Phase 1 | Vaxiion Therapeutics | Known CNS metastases or leptomeningeal carcinomatosis, unless adequately treated and clinically stable off steroids for ≥ 14 days from the first injection of VAX014 |
| NCT05901285 | Cardiac | Phase 1 | Vaxiion Therapeutics | ≤ 12 months from prior MI |
| NCT05901285 | Hepatic | Phase 1 | Vaxiion Therapeutics | Total bilirubin ≤ 1.5 x ULN |
| NCT05901285 | HIV | Phase 1 | Vaxiion Therapeutics | Known active infection with tuberculosis or HIV |
| NCT05901285 | Performance status | Phase 1 | Vaxiion Therapeutics | ECOG Performance Status of 0, 1, or 2 |
| NCT05901285 | Pregnancy | Phase 1 | Vaxiion Therapeutics | [Females] pregnant or breastfeeding |
| NCT05901285 | Prior malignancy | Phase 1 | Vaxiion Therapeutics | Any other malignancy likely to require treatment in the next 2 years |
| NCT05901285 | Renal | Phase 1 | Vaxiion Therapeutics | Serum creatinine ≤ 1.5 x ULN or estimated GFR ≥ 60 mL/min/1.73 m2 (per MDRD GFR formula) |
| NCT05914766 | Language | Not given | Massachusetts General Hospital | Able to complete study procedures English or with the assistance of an interpreter |
| NCT05918640 | Brain metastases | Phase 1/2 | Children's Hospital of Philadelphia | Subjects with known brain metastases. |
| NCT05918640 | Cardiac | Phase 1/2 | Children's Hospital of Philadelphia | Left ventricular ejection fraction (LVEF) or shortening fraction (SF) per institutional norm LVEF ≥50% OR SF ≥28%. |
| NCT05918640 | Hepatic | Phase 1/2 | Children's Hospital of Philadelphia | Alanine aminotransferase (ALT) ≤ 2.5X upper limit of normal. For the purposes of this study the upper limit of normal for ALT is 45 U/L. |
| NCT05918640 | Performance status | Phase 1/2 | Children's Hospital of Philadelphia | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 (age >16 years) or Lansky of at least 70 (age <16 years). |
| NCT05918640 | Pregnancy | Phase 1/2 | Children's Hospital of Philadelphia | Subjects who are pregnant or breastfeeding. |
| NCT05918640 | Renal | Phase 1/2 | Children's Hospital of Philadelphia | Creatinine Calculated creatinine clearance (by the Schwartz equation for patients <18 years of age and Cockroft-Gault formula (Appendix B) for patients ≥18 years of age) or radionuclide glomerular filtration rate (GFR) ≥ 50 mL/min /m2 or a serum creatinine less than or equal to the age/gender valued below |
| NCT05919264 | Brain metastases | Phase 1/2 | Parabilis Medicines, Inc. | Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases. |
| NCT05919264 | Cardiac | Phase 1/2 | Parabilis Medicines, Inc. | Unstable/inadequate cardiac function. |
| NCT05919264 | Performance status | Phase 1/2 | Parabilis Medicines, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT05919264 | Pregnancy | Phase 1/2 | Parabilis Medicines, Inc. | Pregnant, lactating, or planning to become pregnant. |
| NCT05920356 | Brain metastases | Phase 3 | Amgen | Symptomatic (treated or untreated) brain metastases |
| NCT05920356 | Cardiac | Phase 3 | Amgen | Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina |
| NCT05920356 | Performance status | Phase 3 | Amgen | Eastern Cooperative Oncology Group (ECOG) ≤ 1 |
| NCT05922501 | Cardiac | Phase 2 | Massachusetts General Hospital | Congestive heart failure (New York Heart Association [NYHA] Class 3 or 4) |
| NCT05922501 | Diabetes | Phase 2 | Massachusetts General Hospital | Diabetes mellitus with > 2 episodes of ketoacidosis in the preceding 12 months |
| NCT05922501 | Hepatic | Phase 2 | Massachusetts General Hospital | Serum bilirubin values < 1.5 × ULN. Isolated bilirubin ≥ 1.5 × ULN is acceptable if bilirubin is fractionated and direction bilirubin <35%. |
| NCT05922501 | HIV | Phase 2 | Massachusetts General Hospital | Seropositive for HIV infection |
| NCT05922501 | Performance status | Phase 2 | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (see Appendix A). |
| NCT05922501 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnancy or lactation or planned lactation (breastfeeding). |
| NCT05922501 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Prior history of malignancies, other than MM, unless the patient has completed definitive treatment and has been free of the disease for ≥ 3 years. |
| NCT05922501 | Renal | Phase 2 | Massachusetts General Hospital | Calculated creatinine clearance of ≥ 30 mL/min by Modified Diet in Renal Disease (MDRD) formula or Cockcroft-Gault formula |
| NCT05926102 | Prior malignancy | Not given | VA Office of Research and Development | personal history of prostate cancer |
| NCT05929768 | Cardiac | Phase 3 | SWOG Cancer Research Network | Participants must have left ventricular ejection fraction >= 50% as assessed by either echocardiography (ECHO) or multigated acquisition scan (MUGA) assessed within 28 days prior to registration. |
| NCT05929768 | Diabetes | Phase 3 | SWOG Cancer Research Network | Participants with history of diabetes must not have uncontrolled diabetes in the opinion of the treating investigator |
| NCT05929768 | Hepatic | Phase 3 | SWOG Cancer Research Network | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional upper limit of normal (ULN) (within 28 days prior to randomization) |
| NCT05929768 | HIV | Phase 3 | SWOG Cancer Research Network | Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load test on the most recent test results obtained within 6 months prior to randomization |
| NCT05929768 | Language | Phase 3 | SWOG Cancer Research Network | Participants who can complete questionnaires in English, Spanish, or French must be offered the opportunity to participate in the Patient-Reported Outcome study |
| NCT05929768 | Performance status | Phase 3 | SWOG Cancer Research Network | Participants must have Zubrod performance status of 0-2 |
| NCT05929768 | Pregnancy | Phase 3 | SWOG Cancer Research Network | Participants must not be pregnant or nursing. |
| NCT05929768 | Prior malignancy | Phase 3 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the treatment regimen |
| NCT05929768 | Renal | Phase 3 | SWOG Cancer Research Network | Participants must have a serum creatinine =< the IULN OR calculated creatinine clearance >= 50 mL/min/1.73m^2 using the following Cockcroft-Gault Formula. |
| NCT05939414 | Prior malignancy | Phase 3 | Novartis Pharmaceuticals | Diagnosed at screening with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. |
| NCT05941507 | Brain metastases | Phase 1/2 | LigaChem Biosciences, Inc. | Active or progressing central nervous system (CNS) metastases or any evidence of leptomeningeal disease. |
| NCT05941507 | Hepatic | Phase 1/2 | LigaChem Biosciences, Inc. | Aspartate aminotransferase (AST) ≤2.5 x ULN; alanine aminotransferase (ALT) ≤2.5 x ULN (AST, ALT ≤5 x ULN if liver metastases present) |
| NCT05941507 | Performance status | Phase 1/2 | LigaChem Biosciences, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT05946213 | Performance status | Phase 3 | NRG Oncology | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 |
| NCT05948943 | Diabetes | Phase 2/3 | Novartis Pharmaceuticals | Participant has an established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus at the time of informed consent. |
| NCT05950945 | Brain metastases | Phase 3 | Daiichi Sankyo | Has spinal cord compression or clinically active central nervous system metastases. |
| NCT05950945 | Cardiac | Phase 3 | Daiichi Sankyo | Has a corrected QT interval prolongation. |
| NCT05950945 | HIV | Phase 3 | Daiichi Sankyo | known uncontrolled active human immunodeficiency virus (HIV) infection |
| NCT05950945 | Performance status | Phase 3 | Daiichi Sankyo | Has an Eastern Cooperative Oncology Group performance status of 0 or 1. |
| NCT05950945 | Pregnancy | Phase 3 | Daiichi Sankyo | Is pregnant or breastfeeding or planning to become pregnant. |
| NCT05950945 | Prior malignancy | Phase 3 | Daiichi Sankyo | Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral BC. |
| NCT05967689 | Brain metastases | Phase 2 | Taiho Oncology, Inc. | Participants with brain metastasis must be neurologically stable. |
| NCT05967689 | Cardiac | Phase 2 | Taiho Oncology, Inc. | History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification. |
| NCT05967689 | HIV | Phase 2 | Taiho Oncology, Inc. | Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment. |
| NCT05967689 | Performance status | Phase 2 | Taiho Oncology, Inc. | Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17. |
| NCT05967689 | Pregnancy | Phase 2 | Taiho Oncology, Inc. | Is pregnant, lactating, or planning to become pregnant. |
| NCT05967689 | Prior malignancy | Phase 2 | Taiho Oncology, Inc. | History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met: |
| NCT05976490 | Language | Not given | Massachusetts General Hospital | Able to speak and read in English |
| NCT05983432 | Brain metastases | Phase 1 | SystImmune Inc. | Participants with primary tumors in the central nervous system (CNS) and active or untreated CNS metastases and/or carcinomatous meningitis should be excluded. |
| NCT05983432 | Cardiac | Phase 1 | SystImmune Inc. | Subjects with prolonged QT interval (QTc >470 msec), complete left bundle branch block, Grade 3 atrioventricular block |
| NCT05983432 | Hepatic | Phase 1 | SystImmune Inc. | Total bilirubin（TBIL≤1.5 ULN, AST and ALT without liver metastasis ≤2.5 ULN, AST and ALT with liver metastasis ≤5.0 ULN |
| NCT05983432 | HIV | Phase 1 | SystImmune Inc. | Known Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active Hepatitis B virus infection (HBV-DNA copy number> the lower limit of detection) or active Hepatitis C virus infection (HCV antibody positive and HCV-RNA > the lower limit of detection) |
| NCT05983432 | Performance status | Phase 1 | SystImmune Inc. | Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1 |
| NCT05983432 | Pregnancy | Phase 1 | SystImmune Inc. | Participants who are pregnant or breastfeeding |
| NCT05983432 | Prior malignancy | Phase 1 | SystImmune Inc. | Other malignant tumors were diagnosed within 5 years prior to the first administration with the following exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after radical resection |
| NCT05983432 | Renal | Phase 1 | SystImmune Inc. | Renal function: Creatinine clearance ≥50 mL/min (According to the Cockcroft and Gault equation) |
| NCT05985161 | Hepatic | Phase 2 | Memorial Sloan Kettering Cancer Center | Total bilirubin < 1.5 × upper limit of normal (ULN) (except patients with Gilbert's syndrome, who must have a total bilirubin of <3 × ULN) |
| NCT05985161 | Performance status | Phase 2 | Memorial Sloan Kettering Cancer Center | Karnofsky ≥ 60% for patients > 16 years of age and Lansky ≥ 60 for patients ≤ 16 years of age. |
| NCT05985161 | Pregnancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Pregnant or breast-feeding women will not be entered on this study |
| NCT05985161 | Renal | Phase 2 | Memorial Sloan Kettering Cancer Center | Renal Function: Adequate function (within 14 days prior to C1D1) defined as a GFR ≥ 50 ml/min/1.73 m2 determined via any of these methods: |
| NCT05987241 | Cardiac | Phase 2/3 | National Cancer Institute (NCI) | New York Heart Association Class III heart failure |
| NCT05987241 | Hepatic | Phase 2/3 | National Cancer Institute (NCI) | Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN |
| NCT05987241 | HIV | Phase 2/3 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible. |
| NCT05987241 | Performance status | Phase 2/3 | National Cancer Institute (NCI) | ECOG performance status 0-2 |
| NCT05987241 | Pregnancy | Phase 2/3 | National Cancer Institute (NCI) | Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects |
| NCT05987241 | Prior malignancy | Phase 2/3 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT05987241 | Renal | Phase 2/3 | National Cancer Institute (NCI) | Not currently requiring hemodialysis |
| NCT06000787 | Performance status | Not given | Brigham and Women's Hospital | Karnofsky ≥ 50 for age >16 or Lansky ≥ 50 for age ≤ 16 |
| NCT06000787 | Pregnancy | Not given | Brigham and Women's Hospital | Pregnancy or breastfeeding |
| NCT06001749 | Brain metastases | Phase 2 | Yvan Beaussant, MD, MSci | Participants with brain tumors or brain metastases that haven't been successfully treated |
| NCT06001749 | Cardiac | Phase 2 | Yvan Beaussant, MD, MSci | Participants who have a history of myocardial infarction, coronary artery disease or heart failure |
| NCT06001749 | Hepatic | Phase 2 | Yvan Beaussant, MD, MSci | Participants with a diagnosis of cirrhosis or liver failure |
| NCT06001749 | Performance status | Phase 2 | Yvan Beaussant, MD, MSci | Participants must have an ECOG Performance Status ≤ 2 |
| NCT06001749 | Pregnancy | Phase 2 | Yvan Beaussant, MD, MSci | Women who are pregnant, nursing, or able to become pregnant and are not practicing an effective means of birth control. |
| NCT06001788 | Brain metastases | Phase 1 | Kura Oncology, Inc. | Has clinically active central nervous system leukemia. |
| NCT06001788 | Cardiac | Phase 1 | Kura Oncology, Inc. | Has a mean corrected QT interval (QTcF) > 480ms. |
| NCT06001788 | Performance status | Phase 1 | Kura Oncology, Inc. | Has an Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2. |
| NCT06001788 | Pregnancy | Phase 1 | Kura Oncology, Inc. | Participant is pregnant or lactating. |
| NCT06022939 | Cardiac | Phase 3 | SWOG Cancer Research Network | Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2 or better |
| NCT06022939 | Diabetes | Phase 3 | SWOG Cancer Research Network | Participants must not have uncontrolled diabetes within 28 days prior to registration |
| NCT06022939 | Hepatic | Phase 3 | SWOG Cancer Research Network | Direct bilirubin =< 2.0 mg/dL (within 28 days prior to registration) |
| NCT06022939 | HIV | Phase 3 | SWOG Cancer Research Network | Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration |
| NCT06022939 | Language | Phase 3 | SWOG Cancer Research Network | Participants who can complete PRO, QOL, PRO-CTCAE questionnaires, etc. forms in English, Spanish and French must participate in the patient-reported outcomes and quality of life |
| NCT06022939 | Performance status | Phase 3 | SWOG Cancer Research Network | Participant must have Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0, 1, or 2 (PS = 3 may be allowed if secondary to neuropathy) |
| NCT06022939 | Pregnancy | Phase 3 | SWOG Cancer Research Network | Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped) |
| NCT06022939 | Prior malignancy | Phase 3 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT06022939 | Renal | Phase 3 | SWOG Cancer Research Network | Participants must have a serum creatinine =< the institutional (I)ULN OR measured OR calculated creatinine clearance >= 30 mL/min using the following Cockcroft-Gault formula. |
| NCT06026111 | Language | Not given | Dana-Farber Cancer Institute | Ability to communicate and complete written forms in English. |
| NCT06026111 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Development of second malignancy (except for basal cell carcinoma or squamous cell carcinoma of the skin) that requires concurrent treatment, which would interfere with this study. |
| NCT06026319 | Brain metastases | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Presence of active CNS disease |
| NCT06026319 | Cardiac | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Left ventricular ejection fraction > 40% |
| NCT06026319 | Hepatic | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Adequate hepatic function defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 × upper limit of normal (ULN) and direct bilirubin < 1.5 × ULN. |
| NCT06026319 | Performance status | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%) |
| NCT06026319 | Pregnancy | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Pregnant or lactating women. |
| NCT06026319 | Prior malignancy | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Subjects with second malignancies if the second malignancy has required therapy in the last 3 years or is not in complete remission; exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy other than hormonal therapy. |
| NCT06026319 | Renal | Phase 1 | Marcela V. Maus, M.D.,Ph.D. | Adequate renal function defined by creatinine clearance >60 ml/min using the Cockcroft-Gault formula. |
| NCT06031688 | Brain metastases | Phase 2 | SWOG Cancer Research Network | Participants must not have leptomeningeal disease, spinal cord compression or brain metastases unless: |
| NCT06031688 | Cardiac | Phase 2 | SWOG Cancer Research Network | Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better |
| NCT06031688 | Hepatic | Phase 2 | SWOG Cancer Research Network | Participants must not have cirrhosis at a level of Child-Pugh B (or worse) OR any degree of cirrhosis AND a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis |
| NCT06031688 | HIV | Phase 2 | SWOG Cancer Research Network | Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy and have undetectable viral load test on the most recent test results obtained within 6 months prior to sub-study randomization |
| NCT06031688 | Performance status | Phase 2 | SWOG Cancer Research Network | Participants' most recent Zubrod performance status must be 0-1 and be documented within 28 days prior to sub-study randomization |
| NCT06031688 | Pregnancy | Phase 2 | SWOG Cancer Research Network | Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). |
| NCT06031688 | Prior malignancy | Phase 2 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT06031688 | Renal | Phase 2 | SWOG Cancer Research Network | Participants must have a serum creatinine =< the institutional upper limit of normal (IULN) or calculated creatinine clearance >= 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study randomization |
| NCT06034002 | Cardiac | Phase 1 | Incyte Corporation | History of clinically significant or uncontrolled cardiac disease. |
| NCT06034002 | HIV | Phase 1 | Incyte Corporation | Active or chronic HBV or active HCV or known history of HIV. |
| NCT06034002 | Prior malignancy | Phase 1 | Incyte Corporation | Presence of any hematological malignancy other than ET, PMF, or post-ET MF. |
| NCT06038318 | Age | Not given | Dana-Farber Cancer Institute | All genders ≥ 12 and ≤ 25 years of age at baseline |
| NCT06038318 | Language | Not given | Dana-Farber Cancer Institute | Participant is able to speak English or Spanish language (for PRISM sessions) |
| NCT06040125 | Language | Not given | Dana-Farber Cancer Institute | Speak English. |
| NCT06040125 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Patients receiving treatment for other active malignancies (except basal cell carcinoma). |
| NCT06040541 | Brain metastases | Phase 1 | Revolution Medicines, Inc. | Known or suspected leptomeningeal or active brain metastases or spinal cord compression |
| NCT06040541 | Performance status | Phase 1 | Revolution Medicines, Inc. | ECOG performance status 0 or 1 |
| NCT06042569 | Age | Phase 2 | City of Hope Medical Center | Age: >= 65 years by the time of study registration |
| NCT06043674 | Brain metastases | Phase 2 | Christine Ryan | Current or past history of central nervous system (CNS) disease involvement or history of leptomeningeal disease. |
| NCT06043674 | Cardiac | Phase 2 | Christine Ryan | Patients with any one of the following currently or in the previous 6 months will be excluded: myocardial infarction, congenital long QT syndrome, torsade de pointes, unstable angina, or coronary/peripheral artery bypass graft. |
| NCT06043674 | Hepatic | Phase 2 | Christine Ryan | Total bilirubin < 1.5 X ULN |
| NCT06043674 | HIV | Phase 2 | Christine Ryan | History of Human Immunodeficiency Virus (HIV): |
| NCT06043674 | Performance status | Phase 2 | Christine Ryan | ECOG performance status of 0-2 (Appendix A). |
| NCT06043674 | Pregnancy | Phase 2 | Christine Ryan | Patients who are pregnant, breast-feeding, or intending to become pregnant during the study. |
| NCT06043674 | Prior malignancy | Phase 2 | Christine Ryan | History of other malignancies, except: |
| NCT06043674 | Renal | Phase 2 | Christine Ryan | Creatinine < 2.0 x ULN (upper limit of normal) or estimated CrCl > 50 ml/min according to Cockcroft/Gault formula |
| NCT06047379 | Brain metastases | Phase 1/2 | Neonc Technologies, Inc. | Patient with history of known leptomeningeal involvement. |
| NCT06047379 | Cardiac | Phase 1/2 | Neonc Technologies, Inc. | Patient has a corrected QT interval (using Fridericia's correction formula) (QTcF) of >470 msec, a history of additional risk factors for TdP (e.g. heart failure, hypokalemia), and/or the use of concomitant medications that prolong QT/QTc interval. |
| NCT06047379 | Hepatic | Phase 1/2 | Neonc Technologies, Inc. | Total bilirubin within normal institutional limits |
| NCT06047379 | Performance status | Phase 1/2 | Neonc Technologies, Inc. | Patient with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype must have a Karnofsky Performance Status (KPS) of ≥ 60. |
| NCT06047379 | Pregnancy | Phase 1/2 | Neonc Technologies, Inc. | A negative serum pregnancy test will be required of all female patients of child-bearing potential within seven days prior to the receipt of NEO212. |
| NCT06047379 | Prior malignancy | Phase 1/2 | Neonc Technologies, Inc. | Patient has prior history or new diagnosis of secondary cancer within five years prior to the date of informed consent, except for basal cell carcinoma or squamous cell carcinoma of the skin. |
| NCT06047379 | Renal | Phase 1/2 | Neonc Technologies, Inc. | Creatinine clearance (CrCl) of >60 mL/min (using the Cockcroft-Gault formula or 24- hour urine collection). |
| NCT06052488 | Language | Not given | MGH Institute of Health Professions | Non-English speaking |
| NCT06053658 | Brain metastases | Phase 2 | M.D. Anderson Cancer Center | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy. |
| NCT06053658 | Cardiac | Phase 2 | M.D. Anderson Cancer Center | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. |
| NCT06053658 | Hepatic | Phase 2 | M.D. Anderson Cancer Center | total bilirubin ≤ institutional upper limit of normal (ULN) |
| NCT06053658 | HIV | Phase 2 | M.D. Anderson Cancer Center | Active human immunodeficiency virus (HIV) infection unless patients are on effective anti-retroviral therapy with undetectable viral load within 6 months. |
| NCT06053658 | Performance status | Phase 2 | M.D. Anderson Cancer Center | Eastern Cooperative Oncology Group (ECOG) Appendix 1 performance status ≤2 (Karnofsky ≥60%). |
| NCT06053658 | Pregnancy | Phase 2 | M.D. Anderson Cancer Center | Pregnant women are excluded from this study because tivozanib and nivolumab are agents with the potential for teratogenic or abortifacient effects. |
| NCT06053658 | Prior malignancy | Phase 2 | M.D. Anderson Cancer Center | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06053658 | Renal | Phase 2 | M.D. Anderson Cancer Center | eGFR ≥30 ml/min |
| NCT06055296 | Language | Not given | University of California, San Diego | understands written and spoken English or Spanish |
| NCT06055296 | Prior malignancy | Not given | University of California, San Diego | Participants will not be eligible if their child has second malignancy/relapse |
| NCT06056635 | BMI | Not given | Boston Children's Hospital | Pre-pregnancy maternal BMI greater than 40 |
| NCT06056908 | Prior malignancy | Not given | Boston Children's Hospital | cancer predisposition will be excluded |
| NCT06058377 | Age | Phase 3 | National Cancer Institute (NCI) | Participants must not have received any prior treatment for their current breast cancer |
| NCT06058377 | BMI | Phase 3 | National Cancer Institute (NCI) | Participants must have body weight > 30 kg |
| NCT06058377 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better |
| NCT06058377 | Diabetes | Phase 3 | National Cancer Institute (NCI) | Participants must not have uncontrolled diabetes defined as hemoglobin A1c of 9.0% or greater, within 28 days prior to Step 2: Randomization |
| NCT06058377 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 × institutional ULN (within 28 days prior to Step 2: Randomization) |
| NCT06058377 | HIV | Phase 3 | National Cancer Institute (NCI) | Participants with history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have an undetectable viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization |
| NCT06058377 | Language | Phase 3 | National Cancer Institute (NCI) | Participants who can complete questionnaires in English, or Spanish must be offered the opportunity to participate in the Quality of Life study |
| NCT06058377 | Performance status | Phase 3 | National Cancer Institute (NCI) | Participants must have Zubrod Performance Status of 0-2 |
| NCT06058377 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Participants must not be pregnant or nursing. |
| NCT06058377 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT06058377 | Renal | Phase 3 | National Cancer Institute (NCI) | Participants must have a calculated creatinine clearance >= 50 mL/min using the Cockcroft-Gault Formula. |
| NCT06059391 | Cardiac | Phase 2 | City of Hope Medical Center | RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50% Note: To be performed within 45 days prior to day 1 of protocol therapy |
| NCT06059391 | Hepatic | Phase 2 | City of Hope Medical Center | RECIPIENTS: Total bilirubin ≤ 2 X upper limit of normal (ULN) (unless has Gilbert's disease) |
| NCT06059391 | HIV | Phase 2 | City of Hope Medical Center | Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo, hepatitis C virus (HCV)*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]) |
| NCT06059391 | Performance status | Phase 2 | City of Hope Medical Center | RECIPIENTS: Karnofsky performance score ≥ 70 or ECOG ≤ 2 |
| NCT06059391 | Pregnancy | Phase 2 | City of Hope Medical Center | DONORS: Females only: Pregnant or breastfeeding |
| NCT06059391 | Renal | Phase 2 | City of Hope Medical Center | RECIPIENTS: Creatinine clearance of ≥ 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula |
| NCT06062745 | Cardiac | Phase 1 | Brigham and Women's Hospital | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT06062745 | Performance status | Phase 1 | Brigham and Women's Hospital | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) |
| NCT06062745 | Prior malignancy | Phase 1 | Brigham and Women's Hospital | Participants with other known malignancy requiring treatment |
| NCT06064097 | Age | Phase 2 | National Cancer Institute (NCI) | Patients must be ≤ 21 years of age at the time of study enrollment |
| NCT06064097 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Ejection fraction of ≥ 50% by radionuclide angiogram |
| NCT06064097 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy) |
| NCT06064097 | HIV | Phase 2 | National Cancer Institute (NCI) | Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis |
| NCT06064097 | Performance status | Phase 2 | National Cancer Institute (NCI) | Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60% |
| NCT06064097 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab |
| NCT06064097 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission |
| NCT06064097 | Renal | Phase 2 | National Cancer Institute (NCI) | Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy) |
| NCT06064877 | Brain metastases | Phase 3 | AVEO Pharmaceuticals, Inc. | Known or suspected untreated and uncontrolled brain metastases or leptomeningeal carcinomatosis |
| NCT06064877 | Cardiac | Phase 3 | AVEO Pharmaceuticals, Inc. | Cardiac failure New York Heart Association class III or IV |
| NCT06064877 | Performance status | Phase 3 | AVEO Pharmaceuticals, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with a life expectancy of at least 12 weeks |
| NCT06064877 | Pregnancy | Phase 3 | AVEO Pharmaceuticals, Inc. | Female participants who are pregnant or breastfeeding |
| NCT06064877 | Prior malignancy | Phase 3 | AVEO Pharmaceuticals, Inc. | History of prior malignancy within 2 years prior to randomization |
| NCT06067347 | Pregnancy | Not given | Massachusetts General Hospital | pregnant women |
| NCT06067841 | Brain metastases | Phase 1 | Bristol-Myers Squibb | Participant must not have history of brain metastases. |
| NCT06067841 | Cardiac | Phase 1 | Bristol-Myers Squibb | Participant must not have impaired cardiac function or clinically significant cardiac disease. |
| NCT06067841 | Performance status | Phase 1 | Bristol-Myers Squibb | Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. |
| NCT06084234 | Age | Phase 4 | University of Texas Southwestern Medical Center | Adult patients ages 18-85 with cirrhosis |
| NCT06084234 | HIV | Phase 4 | University of Texas Southwestern Medical Center | In patients living with HIV: CD4+ T cell count less than 100 cells/mm3 within 60 days prior to consent |
| NCT06084234 | Pregnancy | Phase 4 | University of Texas Southwestern Medical Center | Known pregnancy at consent |
| NCT06084234 | Prior malignancy | Phase 4 | University of Texas Southwestern Medical Center | Presence of another active cancer besides non-melanomatous skin cancer or indolent cancer under active surveillance (e.g., prostate cancer or renal cell carcinoma) within the 2 years prior to consent |
| NCT06089083 | Language | Not given | University of California, San Francisco | Does not speak a language for which the consent form and study materials are available |
| NCT06090539 | Brain metastases | Phase 1/2 | Bristol-Myers Squibb | Participants must not have known or suspected central nervous system involvement. |
| NCT06090539 | Performance status | Phase 1/2 | Bristol-Myers Squibb | Participants must not have an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2. |
| NCT06090539 | Pregnancy | Phase 1/2 | Bristol-Myers Squibb | Participants must accept and follow pregnancy prevention plan. |
| NCT06091254 | Brain metastases | Phase 3 | Regeneron Pharmaceuticals | Central Nervous System (CNS) lymphoma or leptomeningeal lymphoma |
| NCT06091254 | Performance status | Phase 3 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 |
| NCT06091865 | Brain metastases | Phase 3 | Regeneron Pharmaceuticals | Primary Central Nervous System (CNS) lymphoma or known involvement by non-primary CNS NHL and history or current relevant CNS pathology |
| NCT06091865 | HIV | Phase 3 | Regeneron Pharmaceuticals | uncontrolled infection with Human Immunodeficiency Virus (HIV) |
| NCT06091865 | Performance status | Phase 3 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance status ≤2 |
| NCT06096844 | Age | Phase 3 | National Cancer Institute (NCI) | Patient must be ≥ 70 years of age |
| NCT06096844 | Performance status | Phase 3 | National Cancer Institute (NCI) | Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 |
| NCT06098430 | Language | Not given | St. Jude Children's Research Hospital | Patient or their adult proxy must have verbal and written English language proficiency. |
| NCT06099093 | Cardiac | Phase 4 | Brigham and Women's Hospital | Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. |
| NCT06099743 | Language | Not given | Massachusetts General Hospital | English speaking |
| NCT06099769 | Brain metastases | Phase 2 | Memorial Sloan Kettering Cancer Center | History of brain metastases or leptomeningeal disease. |
| NCT06099769 | Cardiac | Phase 2 | Memorial Sloan Kettering Cancer Center | Confirmed QT interval with Fridericia correction (QTcF) > 480 msec. |
| NCT06099769 | Performance status | Phase 2 | Memorial Sloan Kettering Cancer Center | ECOG performance status 0-2. |
| NCT06099769 | Pregnancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Pregnant patients are not eligible for study. |
| NCT06099769 | Prior malignancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Patients must not have another active malignancy that requires treatment. |
| NCT06106945 | Brain metastases | Phase 1/2 | AstraZeneca | Participants exhibiting clinical signs of central nervous system involvement of MM; |
| NCT06106945 | Cardiac | Phase 1/2 | AstraZeneca | Participants who have severe cardiovascular disease which is not adequately controlled; |
| NCT06106945 | Performance status | Phase 1/2 | AstraZeneca | Eastern Cooperative Oncology Group performance status of ≤ 2 in module 1, or 0 or 1 in modules 2 and 3; |
| NCT06116682 | Brain metastases | Phase 2 | SWOG Cancer Research Network | Participants with asymptomatic CNS metastasis (brain metastases or leptomeningeal disease) must be clinically stable and asymptomatic for at least 14 days prior to sub-study registration |
| NCT06116682 | Cardiac | Phase 2 | SWOG Cancer Research Network | Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better |
| NCT06116682 | Diabetes | Phase 2 | SWOG Cancer Research Network | Participants with known diabetes as determined by the treating investigator must show evidence of controlled disease within 14 days prior to sub-study registration |
| NCT06116682 | Hepatic | Phase 2 | SWOG Cancer Research Network | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN (within 28 days prior to sub-study registration) |
| NCT06116682 | HIV | Phase 2 | SWOG Cancer Research Network | Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy and have undetectable viral load test on the most recent test results obtained within 6 months prior to sub-study registration |
| NCT06116682 | Performance status | Phase 2 | SWOG Cancer Research Network | Participants' most recent Zubrod performance status must be 0-2 and be documented within 28 days prior to sub-study registration |
| NCT06116682 | Pregnancy | Phase 2 | SWOG Cancer Research Network | Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped) |
| NCT06116682 | Prior malignancy | Phase 2 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT06116682 | Renal | Phase 2 | SWOG Cancer Research Network | Participants must have a serum creatinine ≤ the institutional upper limit of normal (IULN) or calculated creatinine clearance ≥ 45 mL/min using the following Cockcroft-Gault Formula. |
| NCT06117709 | Age | Not given | Dana-Farber Cancer Institute | Age ≥ 21 years |
| NCT06117709 | Language | Not given | Dana-Farber Cancer Institute | Inability to understand, speak, or read English |
| NCT06118086 | HIV | Phase 1/2 | Remix Therapeutics | Evidence of active HIV infection. |
| NCT06118086 | Performance status | Phase 1/2 | Remix Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06118086 | Pregnancy | Phase 1/2 | Remix Therapeutics | Pregnancy or participants planning to become pregnant during the duration of the study, or lactation. |
| NCT06118086 | Prior malignancy | Phase 1/2 | Remix Therapeutics | Concurrent or previous other malignancy (other than adenoid cystic carcinoma, hematologic malignancies, or primary central nervous system [CNS] malignancies) ≤ 2 years of enrollment, except curatively treated malignancies including basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix. |
| NCT06118723 | Age | Not given | Jasper Gerritsen | Age ≥18 years and ≤90 years |
| NCT06118723 | Prior malignancy | Not given | Jasper Gerritsen | Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin |
| NCT06119581 | Brain metastases | Phase 3 | Eli Lilly and Company | Have known active central nervous system metastases and/or carcinomatous meningitis. |
| NCT06119581 | Performance status | Phase 3 | Eli Lilly and Company | Must have an ECOG performance status of 0 or 1. |
| NCT06119581 | Pregnancy | Phase 3 | Eli Lilly and Company | Not be breastfeeding during treatment |
| NCT06119581 | Renal | Phase 3 | Eli Lilly and Company | Only for participants with mild to moderate renal insufficiency: Unable to avoid aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs) two days before (5 days for long acting NSAIDs), day of, and two days after administration of pemetrexed |
| NCT06121843 | Performance status | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Eastern Cooperative Oncology Group performance status of 0-1. |
| NCT06122077 | Pregnancy | Not given | Freenome Holdings Inc. | Known to be pregnant |
| NCT06122077 | Prior malignancy | Not given | Freenome Holdings Inc. | History of any malignancy within prior 5 years of enrollment (except for non- melanoma skin cancer) |
| NCT06122077 | Smoking | Not given | Freenome Holdings Inc. | Current or former smokers with a cumulative smoking history of ≥ 20 pack-year |
| NCT06122896 | Age | Early phase 1 | Dana-Farber Cancer Institute | Individuals with pathogenic/likely pathogenic germline variants in STK11, and age ≥30 years. |
| NCT06122896 | Pregnancy | Early phase 1 | Dana-Farber Cancer Institute | Pregnant women are unlikely to be undergoing screening procedures and will not be considered eligible but can consent to the study at a later date. |
| NCT06122896 | Prior malignancy | Early phase 1 | Dana-Farber Cancer Institute | Individuals with active or prior pancreatic ductal adenocarcinoma diagnosis. |
| NCT06123338 | Brain metastases | Phase 2 | Memorial Sloan Kettering Cancer Center | Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis |
| NCT06123338 | Cardiac | Phase 2 | Memorial Sloan Kettering Cancer Center | Left ventricular ejection fraction <50% within 1 month of screening by MUGA or echocardiogram. |
| NCT06123338 | Hepatic | Phase 2 | Memorial Sloan Kettering Cancer Center | AST and ALT: ≤ 2.5 X ULN |
| NCT06123338 | HIV | Phase 2 | Memorial Sloan Kettering Cancer Center | Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). |
| NCT06123338 | Performance status | Phase 2 | Memorial Sloan Kettering Cancer Center | ECOG performance status 0-1. |
| NCT06123338 | Pregnancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. |
| NCT06123338 | Prior malignancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Has been diagnosed or treated for another malignancy in the past 3 years (not including non-melanoma skin cancer) |
| NCT06123338 | Renal | Phase 2 | Memorial Sloan Kettering Cancer Center | Creatinine clearance: ≥ 50 mL/minute Hepatic |
| NCT06123988 | Cardiac | Not given | University of Miami | Unstable cardiac disease |
| NCT06123988 | Diabetes | Not given | University of Miami | Insulin-dependent diabetes |
| NCT06123988 | Language | Not given | University of Miami | Able to speak, read, and understand English or Spanish |
| NCT06124157 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with central nervous system (CNS) involvement |
| NCT06124157 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Patients with congenital long QT syndrome, history of ventricular arrhythmias, or heart block |
| NCT06124157 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Direct bilirubin < 2.0 mg/dL (34.2 micromoles/L) (must be performed within 7 days prior to enrollment unless otherwise indicated) |
| NCT06124157 | HIV | Phase 2 | National Cancer Institute (NCI) | HIV-infected patients are eligible if on effective anti-retroviral therapy that does not interact with planned study agents and with undetectable viral load within 6 months of treatment |
| NCT06124157 | Performance status | Phase 2 | National Cancer Institute (NCI) | Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of ≤ 2 or Karnofsky and Lansky performance scores ≥ 50%. |
| NCT06124157 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Pregnancy and breast feeding |
| NCT06124157 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | ALL developing after a previous cancer treated with cytotoxic chemotherapy |
| NCT06124157 | Renal | Phase 2 | National Cancer Institute (NCI) | For pediatric patients (age 1-17 years): a glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m^2, as determined by one of the following methods (must be performed within 7 days prior to enrollment unless otherwise indicated): |
| NCT06127407 | Cardiac | Phase 3 | Servier Bio-Innovation LLC | Have LVEF <40% by ECHO scan (or by other methods according to institutional practice) obtained within 28 days prior to randomization. |
| NCT06127407 | Pregnancy | Phase 3 | Servier Bio-Innovation LLC | Pregnant or lactating women. |
| NCT06127407 | Prior malignancy | Phase 3 | Servier Bio-Innovation LLC | Have a history of another primary cancer, with the exception of: a) curatively resected non-melanoma skin cancer; b) curatively treated carcinoma in situ; or c) pT1-2 prostatic cancer Gleason score <6 or d) participant is free of other primary solid or liquid tumor for ≥ 1 year prior to the start of study treatment and, in the opinion of the Investigator, the disease will not affect participant's outcome in the setting of current chondrosarcoma diagnosis. |
| NCT06128551 | Brain metastases | Phase 1/2 | Revolution Medicines, Inc. | Active brain metastases |
| NCT06128551 | Performance status | Phase 1/2 | Revolution Medicines, Inc. | ECOG performance status 0 or 1 |
| NCT06131840 | Brain metastases | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | Active cerebral/meningeal disease related to the underlying malignancy. Participants with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior central nervous system disease has been treated and the participant is clinically stable |
| NCT06131840 | Performance status | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1 |
| NCT06131840 | Prior malignancy | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. |
| NCT06136546 | Age | Phase 2 | Massachusetts General Hospital | Aged 25-50 years |
| NCT06136546 | Cardiac | Phase 2 | Massachusetts General Hospital | uncontrolled cardiovascular, endocrine, hematologic, hepatic, renal or neurologic disease |
| NCT06136546 | Diabetes | Phase 2 | Massachusetts General Hospital | stable medical conditions such as diabetes and cardiovascular disease, will be allowed in the study |
| NCT06136546 | Hepatic | Phase 2 | Massachusetts General Hospital | History of liver abnormalities |
| NCT06136546 | HIV | Phase 2 | Massachusetts General Hospital | chronic infection (e.g., hepatitis B or C or HIV) or history of Covid 19 infection within the past 6 months or with persisting symptoms. |
| NCT06136546 | Language | Phase 2 | Massachusetts General Hospital | Able to read and understand English and willing to provide informed consent/comply with the study protocol |
| NCT06136546 | Prior malignancy | Phase 2 | Massachusetts General Hospital | cancer history |
| NCT06136546 | Renal | Phase 2 | Massachusetts General Hospital | uncontrolled cardiovascular, endocrine, hematologic, hepatic, renal or neurologic disease |
| NCT06137144 | Age | Phase 1/2 | AstraZeneca | Participants must be at least 50 years of age or older at study entry. |
| NCT06137144 | Brain metastases | Phase 1/2 | AstraZeneca | Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression. |
| NCT06137144 | Cardiac | Phase 1/2 | AstraZeneca | Any of the following ECG cardiac criteria: Mean resting QTcF > 470 msec, clinically important abnormalities in rhythm, conduction or morphology, and/or any factors that increase the risk of QTc prolongation or risk of arrhythmic events. |
| NCT06137144 | HIV | Phase 1/2 | AstraZeneca | Known to have tested positive for HIV. |
| NCT06137144 | Performance status | Phase 1/2 | AstraZeneca | Adequate adult (ECOG) or adolescent (Karnofsy or Lanksy) Performance Score assessments |
| NCT06137144 | Pregnancy | Phase 1/2 | AstraZeneca | Pregnant (confirmed with positive pregnancy test) or breastfeeding or intends to become pregnant during the study. |
| NCT06137144 | Prior malignancy | Phase 1/2 | AstraZeneca | History of another primary malignancy. |
| NCT06138275 | Cardiac | Phase 2 | Massachusetts General Hospital | left ventricular ejection fraction (LVEF) ≥40% as determined by a multiple gated acquisition scan (MUGA) scan or echocardiogram (ECHO). |
| NCT06138275 | Hepatic | Phase 2 | Massachusetts General Hospital | Serum total bilirubin <2 mg/dL; and |
| NCT06138275 | HIV | Phase 2 | Massachusetts General Hospital | Active hepatitis B virus, hepatitis C virus, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), HIV, or any active, uncontrolled bacterial, fungal, or viral infection. |
| NCT06138275 | Language | Phase 2 | Massachusetts General Hospital | Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged) |
| NCT06138275 | Performance status | Phase 2 | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 |
| NCT06138275 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study because elranatamab is an anti-BCMA bispecific antibody agent with the potential for teratogenic or abortifacient effects. |
| NCT06138275 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ. |
| NCT06138275 | Renal | Phase 2 | Massachusetts General Hospital | Calculated creatinine clearance ≥30 mL/min by Cockcroft-Gault equation. |
| NCT06138561 | Age | Not given | Dana-Farber Cancer Institute | Age ≥65-years-old (study will limit total enrollment of patients between ages 65-70 to 20% of the total study population) |
| NCT06138561 | Language | Not given | Dana-Farber Cancer Institute | patient reported outcomes that will be in English or Spanish either alone or with assistance of study researcher or family |
| NCT06138587 | Cardiac | Phase 1 | Dana-Farber Cancer Institute | LVEF >40%. |
| NCT06138587 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | AST(SGOT)/ALT(SGPT): ≤3 x institutional ULN |
| NCT06138587 | HIV | Phase 1 | Dana-Farber Cancer Institute | HIV-positive patients are excluded due to the potential for interaction between antiretroviral therapy as well as the risk for lethal infection in the context of marrow-suppressive therapy. |
| NCT06138587 | Performance status | Phase 1 | Dana-Farber Cancer Institute | ECOG performance status <= 2 (Karnofsky >= 60%, see Appendix C). |
| NCT06138587 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because of the unknown teratogenic risk of CIML NK cells and IL-2 |
| NCT06138587 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Individuals with a history of a different malignancy are ineligible except for the following circumstances: 1. History of other malignancy and have had complete remission of disease for at least 2 years; |
| NCT06138587 | Renal | Phase 1 | Dana-Farber Cancer Institute | Serum creatinine </= 2.0mg/dL |
| NCT06140524 | Cardiac | Phase 2 | Regeneron Pharmaceuticals | Clinically significant cardiac or vascular disease within 3 months of study enrollment, as described in the protocol |
| NCT06140524 | HIV | Phase 2 | Regeneron Pharmaceuticals | Uncontrolled Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection |
| NCT06140524 | Performance status | Phase 2 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance status ≤1 |
| NCT06140524 | Renal | Phase 2 | Regeneron Pharmaceuticals | Estimated glomerular filtration rate (GFR) ≥30 mL/min/1.73 m^2 by the Modification of Diet in Renal Disease (MDRD) equation |
| NCT06146725 | Age | Not given | Jasper Gerritsen | Age ≥18 years and ≤90 years |
| NCT06146725 | Prior malignancy | Not given | Jasper Gerritsen | Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin |
| NCT06146738 | Age | Not given | Jasper Gerritsen | Age ≥18 years and ≤90 years |
| NCT06146738 | Prior malignancy | Not given | Jasper Gerritsen | Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin |
| NCT06150664 | Brain metastases | Phase 1 | Compass Therapeutics | Symptomatic or uncontrolled central nervous system and brain metastasis or active leptomeningeal disease. |
| NCT06150664 | Cardiac | Phase 1 | Compass Therapeutics | QTc interval (using Fridericia correction calculation) > 480 msec |
| NCT06150664 | Hepatic | Phase 1 | Compass Therapeutics | Adequate hepatic function defined as serum total bilirubin ≤ 1.5 × ULN, AST/ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases) |
| NCT06150664 | HIV | Phase 1 | Compass Therapeutics | Patients with evidence of active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection. |
| NCT06150664 | Performance status | Phase 1 | Compass Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT06150664 | Pregnancy | Phase 1 | Compass Therapeutics | Patient is a pregnant or lactating WOCBP |
| NCT06150664 | Prior malignancy | Phase 1 | Compass Therapeutics | History of primary malignancy other than the malignancy under study will be excluded, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate >90%). |
| NCT06150664 | Renal | Phase 1 | Compass Therapeutics | Adequate renal function defined as creatinine clearance ≥ 30mL/min by Cockcroft-Gault equation |
| NCT06152575 | Brain metastases | Phase 3 | Pfizer | Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement. |
| NCT06152575 | Performance status | Phase 3 | Pfizer | ECOG (Eastern Cooperative Oncology Group) performance status ≤2. |
| NCT06152575 | Pregnancy | Phase 3 | Pfizer | Not pregnant or breastfeeding and willing to use contraception. |
| NCT06152575 | Prior malignancy | Phase 3 | Pfizer | Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ) |
| NCT06152809 | Cardiac | Phase 1 | Dana-Farber Cancer Institute | left ventricular ejection fraction ≥ 40% |
| NCT06152809 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | AST(SGOT)/ALT(SGPT): ≤3 x institutional ULN |
| NCT06152809 | HIV | Phase 1 | Dana-Farber Cancer Institute | HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions with anti-retroviral agents used in this study. |
| NCT06152809 | Performance status | Phase 1 | Dana-Farber Cancer Institute | ECOG performance status ≤2 (see Appendix A) |
| NCT06152809 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because of the unknown teratogenic risk of CIML NK cells and IL-2 |
| NCT06152809 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Individuals with a history of a different malignancy are ineligible except for the following circumstances: 1. History of other malignancy and have had complete remission of disease for at least 2 years; 2. Diagnosed and treated within the past 2 years for: nonmetastatic melanoma, surgically resected (not needing systemic chemotherapy) squamous cell carcinoma of skin and nonmetastatic prostate cancer not needing systemic chemotherapy. |
| NCT06152809 | Renal | Phase 1 | Dana-Farber Cancer Institute | creatinine clearance ≥ 45 mL/min; calculated by the Cockcroft Gault formula |
| NCT06153251 | Brain metastases | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma. |
| NCT06153251 | Performance status | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06162221 | Brain metastases | Phase 1/2 | Revolution Medicines, Inc. | Primary central nervous system (CNS) tumors |
| NCT06162221 | Performance status | Phase 1/2 | Revolution Medicines, Inc. | ECOG PS is 0 to 1 |
| NCT06163534 | Prior malignancy | Not given | Tempus AI | Clinical evidence of an active second invasive malignancy within <2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers |
| NCT06167317 | Brain metastases | Phase 1 | Gilead Sciences | Have known active central nervous system (CNS) metastases |
| NCT06167317 | Cardiac | Phase 1 | Gilead Sciences | QT interval > 470 msec |
| NCT06167317 | HIV | Phase 1 | Gilead Sciences | Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. |
| NCT06167317 | Performance status | Phase 1 | Gilead Sciences | Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. |
| NCT06167317 | Pregnancy | Phase 1 | Gilead Sciences | Pregnant or lactating females |
| NCT06167317 | Prior malignancy | Phase 1 | Gilead Sciences | Have an active second malignancy |
| NCT06171750 | Brain metastases | Phase 1 | Ankyra Therapeutics, Inc | known active central nervous system (CNS) metastases |
| NCT06171750 | Cardiac | Phase 1 | Ankyra Therapeutics, Inc | baseline electrocardiogram (EKG) without evidence of acute ischemia or prolonged QTc interval > 460 msec |
| NCT06171750 | Hepatic | Phase 1 | Ankyra Therapeutics, Inc | adequate bone marrow, hepatic and renal function |
| NCT06171750 | HIV | Phase 1 | Ankyra Therapeutics, Inc | HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease |
| NCT06171750 | Performance status | Phase 1 | Ankyra Therapeutics, Inc | ECOG performance status 0-1 |
| NCT06171750 | Pregnancy | Phase 1 | Ankyra Therapeutics, Inc | a woman of childbearing potential (WOCBP) who has a positive serum pregnancy test (within 72 hours) prior to the start of treatment or female participant who is breastfeeding |
| NCT06171750 | Renal | Phase 1 | Ankyra Therapeutics, Inc | adequate bone marrow, hepatic and renal function |
| NCT06172296 | Age | Phase 3 | National Cancer Institute (NCI) | ≤ 30 years at the time of initial diagnosis with high-risk disease |
| NCT06172296 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram |
| NCT06172296 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age |
| NCT06172296 | HIV | Phase 3 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT06172296 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT06172296 | Renal | Phase 3 | National Cancer Institute (NCI) | or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard) |
| NCT06176261 | Brain metastases | Phase 2 | Nancy Lin, MD | Cohorts A and B: Presence of newly diagnosed brain metastases or brain metastases progressing after prior local and/or systemic therapy. |
| NCT06176261 | Cardiac | Phase 2 | Nancy Lin, MD | Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan. |
| NCT06176261 | Diabetes | Phase 2 | Nancy Lin, MD | Note that if a patient has controlled diabetes mellitus, but is unable to monitor blood glucose at home, they will be excluded from the trial. |
| NCT06176261 | Hepatic | Phase 2 | Nancy Lin, MD | Total bilirubin ≤ 1.5 institutional ULN if no liver metastases; or ≤ 3 x ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. |
| NCT06176261 | Performance status | Phase 2 | Nancy Lin, MD | ECOG Performance Status 0-2 |
| NCT06176261 | Pregnancy | Phase 2 | Nancy Lin, MD | Pregnant or lactating women are excluded from participation due to potential teratogenic effects of study drug. |
| NCT06176261 | Prior malignancy | Phase 2 | Nancy Lin, MD | A history of malignancy other than breast cancer, except (a) adequately resected non-melanoma skin cancer, (b) curatively treated in situ disease, or (c) other solid tumors curatively treated, with no evidence of disease for ≥ 3 years. |
| NCT06176261 | Renal | Phase 2 | Nancy Lin, MD | Serum creatinine ≤ 1.5 mg/dL (or glomerular filtration rate ≥ 30 ml/min as determined by the Cockcroft-Gault equation) |
| NCT06179160 | Performance status | Phase 1 | Incyte Corporation | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06179160 | Prior malignancy | Phase 1 | Incyte Corporation | Known additional invasive malignancy within 1 year of the first dose of study drug |
| NCT06183437 | Cardiac | Phase 4 | Dinesh Thavendiranathan | Patients with cardiac devices i.e. defibrillator, CRT, pacemaker, etc. |
| NCT06183437 | Renal | Phase 4 | Dinesh Thavendiranathan | chronic kidney disease (CKD) |
| NCT06184750 | Age | Phase 2 | National Cancer Institute (NCI) | Participants ≥ 18 and ≤ 55 years old will be enrolled. |
| NCT06184750 | HIV | Phase 2 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients are eligible to participate if they are on effective anti-retroviral therapy with undetectable viral load within the prior 6 months |
| NCT06184750 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Pregnant women are excluded from this study because tamoxifen a category D agent with the potential for teratogenic or abortifacient effects. |
| NCT06184750 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Prior invasive cancer ≥ T1 (other than non-melanoma skin cancer), unless curatively treated, and all treatment was completed > 5 years prior to enrollment |
| NCT06188741 | Age | Phase 2 | University of Alabama at Birmingham | Age: > 1 (>12 months) and ≤8 years of age at the time of study enrollment. |
| NCT06196008 | Language | Not given | City of Hope Medical Center | Ability to read and understand English or Spanish and willingness to complete participant-reported outcomes and assessments |
| NCT06202183 | Age | Not given | Dana-Farber Cancer Institute | Age at diagnosis 18-50 years; due to the specificity of the study question those outside the age bracket will not be included |
| NCT06202183 | Language | Not given | Dana-Farber Cancer Institute | Ability to communicate and complete written forms in English |
| NCT06202183 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Patient with other active malignancies (excluding basal cell carcinoma). |
| NCT06202820 | Cardiac | Not given | Dana-Farber Cancer Institute | History of major adverse cardiac event, including myocardial infarction, new congestive heart failure (CHF) or CHF exacerbation, or stroke, within the past 24 weeks due to complicated comorbidities that necessitate close collaboration between the participant and their cardiologist. |
| NCT06203210 | Cardiac | Phase 3 | Daiichi Sankyo | Has uncontrolled or significant cardiovascular (CV) disease. |
| NCT06203210 | Performance status | Phase 3 | Daiichi Sankyo | Has ECOG PS of less than or equal to (≤)1 within 7 days prior to Cycle 1 Day 1 (C1D1). |
| NCT06205485 | Cardiac | Phase 3 | Canadian Cancer Trials Group | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. |
| NCT06205485 | HIV | Phase 3 | Canadian Cancer Trials Group | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT06205485 | Language | Phase 3 | Canadian Cancer Trials Group | Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French or Spanish. |
| NCT06205485 | Performance status | Phase 3 | Canadian Cancer Trials Group | Patient must have an ECOG performance of <2 (or Karnofsty ≥ 60%). |
| NCT06205485 | Prior malignancy | Phase 3 | Canadian Cancer Trials Group | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06205485 | Renal | Phase 3 | Canadian Cancer Trials Group | Estimated creatinine clearance of ≥ 50ml/min |
| NCT06212479 | Pregnancy | Not given | Hercules | Self-certify that they are pregnant; |
| NCT06234423 | Brain metastases | Phase 1 | OnCusp Therapeutics, Inc. | Active or progressing brain metastases or evidence of leptomeningeal disease. |
| NCT06234423 | Cardiac | Phase 1 | OnCusp Therapeutics, Inc. | Left ventricular ejection fraction (LVEF) ≥50% as per echocardiography (ECHO) or multi-gated acquisition scan (MUGA). |
| NCT06234423 | Hepatic | Phase 1 | OnCusp Therapeutics, Inc. | Serum total bilirubin ≤ 1.5 x the upper limit of normal (ULN). |
| NCT06234423 | HIV | Phase 1 | OnCusp Therapeutics, Inc. | known human immunodeficiency virus (HIV). |
| NCT06234423 | Performance status | Phase 1 | OnCusp Therapeutics, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and life expectancy of ≥12 weeks. |
| NCT06234423 | Pregnancy | Phase 1 | OnCusp Therapeutics, Inc. | Pregnant or breast-feeding females. |
| NCT06234423 | Prior malignancy | Phase 1 | OnCusp Therapeutics, Inc. | Prior history of malignancy other than inclusion diagnosis within 3 years prior to first dose of the study drug. |
| NCT06234423 | Renal | Phase 1 | OnCusp Therapeutics, Inc. | Creatinine clearance (CrCl) ≥45 mL/min as calculated by the Cockcroft-Gault method. |
| NCT06239194 | Brain metastases | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | Known untreated, active, or uncontrolled brain metastases |
| NCT06239194 | Cardiac | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | Any clinically significant cardiac disease |
| NCT06239194 | HIV | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | Known positivity with human immunodeficiency virus (HIV) |
| NCT06239194 | Performance status | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT06239220 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. |
| NCT06239220 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | evidence of symptomatic congestive heart failure, unstable angina pectoris, stroke, or ventricular arrhythmia within 6 months of enrollment. |
| NCT06239220 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Total bilirubin ≤ upper limit of normal (ULN) |
| NCT06239220 | HIV | Phase 2 | Dana-Farber Cancer Institute | Patients with HIV are eligible if their plasma HIV viral load is undetectable at baseline on antiretroviral therapy. |
| NCT06239220 | Performance status | Phase 2 | Dana-Farber Cancer Institute | Have a performance status of 0 or 1 on the ECOG Performance Scale (see Appendix A). |
| NCT06239220 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Subjects who are pregnant, or breastfeeding, or expecting to conceive or father children within the projected duration of the trial |
| NCT06239220 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or requires active treatment. |
| NCT06239220 | Renal | Phase 2 | Dana-Farber Cancer Institute | Serum creatinine ≤1.5x ULN or creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above 1.5x ULN |
| NCT06239272 | Age | Phase 1/2 | St. Jude Children's Research Hospital | Patients must be 1-30 years at the time of the biopsy that established the diagnosis of NRSTS. |
| NCT06239272 | Brain metastases | Phase 1/2 | St. Jude Children's Research Hospital | Patients with known primary CNS sarcoma or CNS metastases are not eligible. |
| NCT06239272 | Cardiac | Phase 1/2 | St. Jude Children's Research Hospital | Ejection fraction of > 55% by echocardiogram or cardiac MRI |
| NCT06239272 | Hepatic | Phase 1/2 | St. Jude Children's Research Hospital | Total bilirubin < 1.5 x upper limit of normal (ULN) for age |
| NCT06239272 | HIV | Phase 1/2 | St. Jude Children's Research Hospital | HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with pazopanib. |
| NCT06239272 | Performance status | Phase 1/2 | St. Jude Children's Research Hospital | Lansky performance status score ≥ 60 for patients ≤ 16 years of age. Karnofsky performance status score ≥ 60 for patients >16 years of age. |
| NCT06239272 | Pregnancy | Phase 1/2 | St. Jude Children's Research Hospital | Pregnancy and Breast Feeding Female patients who are pregnant are ineligible due to risks of fetal and teratogenic adverse events as seen in animal/human studies. |
| NCT06239272 | Renal | Phase 1/2 | St. Jude Children's Research Hospital | Creatinine clearance or radioisotope GFR > 70 mL/min/1.73 m2, or |
| NCT06244771 | Brain metastases | Phase 1/2 | Frontier Medicines Corporation | Leptomeningeal disease or carcinomatous meningitis |
| NCT06244771 | Performance status | Phase 1/2 | Frontier Medicines Corporation | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 |
| NCT06247787 | Age | Phase 1 | Children's Oncology Group | Patients must be ≥ 1 year and ≤ 18 years of age at the time of study enrollment |
| NCT06247787 | Brain metastases | Phase 1 | Children's Oncology Group | Patients with isolated or refractory CNS or isolated or refractory testicular relapse are not eligible |
| NCT06247787 | Cardiac | Phase 1 | Children's Oncology Group | Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% by gated radionuclide study |
| NCT06247787 | Hepatic | Phase 1 | Children's Oncology Group | Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age |
| NCT06247787 | Performance status | Phase 1 | Children's Oncology Group | Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky (≥ 50) for patients > 16 years of age and Lansky for patients ≤ 16 years of age (≥ 50) |
| NCT06247787 | Pregnancy | Phase 1 | Children's Oncology Group | Pregnant or breast-feeding women will not be entered on this study |
| NCT06247787 | Renal | Phase 1 | Children's Oncology Group | Estimated glomerular filtration rate (GFR) (eGFR) ≥ 70 mL/min/1.73 m^2 OR |
| NCT06252753 | Prior malignancy | Not given | AstraZeneca | Second primary malignancy prior to HCC or BTC diagnosis |
| NCT06253871 | Brain metastases | Phase 1 | Iambic Therapeutics, Inc | Participants requiring immediate local therapy for brain metastases |
| NCT06253871 | Cardiac | Phase 1 | Iambic Therapeutics, Inc | Clinically significant cardiac disease |
| NCT06253871 | Diabetes | Phase 1 | Iambic Therapeutics, Inc | Uncontrolled diabetes |
| NCT06253871 | Hepatic | Phase 1 | Iambic Therapeutics, Inc | Current active liver disease including hepatitis A, hepatitis B , or hepatitis C |
| NCT06253871 | HIV | Phase 1 | Iambic Therapeutics, Inc | Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Participants with well-controlled HIV (e.g., CD4 >350/mm3 and undetectable viral load) are eligible |
| NCT06253871 | Performance status | Phase 1 | Iambic Therapeutics, Inc | Eastern Cooperative Oncology Group (ECOG) performance score 0-1 |
| NCT06256588 | Hepatic | Phase 3 | GlaxoSmithKline | Has cirrhosis of any stage or current unstable liver biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice. |
| NCT06256588 | Performance status | Phase 3 | GlaxoSmithKline | Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT06256588 | Pregnancy | Phase 3 | GlaxoSmithKline | Is pregnant, breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention. |
| NCT06256588 | Prior malignancy | Phase 3 | GlaxoSmithKline | Has cancer outside of the oropharynx, larynx, hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary head and neck cancer. Has more than one primary HNSCC tumor. |
| NCT06265272 | BMI | Not given | Massachusetts General Hospital | Inability to fit in the scanner: weight > 300 lbs or BMI > 33 |
| NCT06265272 | Pregnancy | Not given | Massachusetts General Hospital | Pregnancy |
| NCT06265688 | Brain metastases | Phase 1 | CytomX Therapeutics | Known active central nervous system (CNS) involvement by malignancy |
| NCT06265688 | Performance status | Phase 1 | CytomX Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 |
| NCT06265688 | Pregnancy | Phase 1 | CytomX Therapeutics | Pregnant or breast feeding |
| NCT06265688 | Prior malignancy | Phase 1 | CytomX Therapeutics | Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated |
| NCT06265727 | Brain metastases | Phase 1/2 | Corbus Pharmaceuticals Inc. | Active of uncontrolled CNS metastases |
| NCT06265727 | Cardiac | Phase 1/2 | Corbus Pharmaceuticals Inc. | History of and/or current cardiovascular events or conditions in the previous 6 months |
| NCT06265727 | Diabetes | Phase 1/2 | Corbus Pharmaceuticals Inc. | Hemoglobin A1C (HbA1C) >/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy |
| NCT06265727 | Hepatic | Phase 1/2 | Corbus Pharmaceuticals Inc. | Chronic severe liver disease or live cirrhosis |
| NCT06265727 | Prior malignancy | Phase 1/2 | Corbus Pharmaceuticals Inc. | History of solid tumors other than the diseases under study |
| NCT06271291 | Language | Not given | Mayo Clinic | Is not able to speak or read English |
| NCT06273176 | Age | Not given | Erasmus Medical Center | Age ≥18 years and ≤90 years |
| NCT06274047 | Brain metastases | Phase 3 | M.D. Anderson Cancer Center | other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy |
| NCT06274047 | Cardiac | Phase 3 | M.D. Anderson Cancer Center | Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization. |
| NCT06274047 | Hepatic | Phase 3 | M.D. Anderson Cancer Center | Bilirubin2 = ≤1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) = ≤ 2.5 x ULN Alanine aminotransferase (ALT) = ≤ 2.5 x ULN |
| NCT06274047 | HIV | Phase 3 | M.D. Anderson Cancer Center | Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis). |
| NCT06274047 | Language | Phase 3 | M.D. Anderson Cancer Center | Ability to understand English or Spanish language as determined by the site investigator or protocol designee. |
| NCT06274047 | Performance status | Phase 3 | M.D. Anderson Cancer Center | ECOG Performance Status ≤ 2. |
| NCT06274047 | Prior malignancy | Phase 3 | M.D. Anderson Cancer Center | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06274047 | Renal | Phase 3 | M.D. Anderson Cancer Center | eGFR = ≥ 30 mL/min using MDRD Formula |
| NCT06274788 | Cardiac | Not given | Fresenius Kabi | Patient has hemodynamic instability due to any major cardiac anomaly. |
| NCT06274788 | Hepatic | Not given | Fresenius Kabi | Patient has known cirrhosis (liver biopsy is not required under this protocol). |
| NCT06274788 | Prior malignancy | Not given | Fresenius Kabi | cancer |
| NCT06274788 | Renal | Not given | Fresenius Kabi | Patient has renal failure and requires renal replacement therapy. |
| NCT06275126 | Age | Not given | Weill Medical College of Cornell University | Female aged 18-44 |
| NCT06275126 | Language | Not given | Weill Medical College of Cornell University | English or Spanish speaking |
| NCT06283251 | Age | Not given | Dana-Farber Cancer Institute | Child is <18 years at time of enrollment |
| NCT06283927 | Age | Not given | Jasper Gerritsen | Age ≥18 years and ≤90 years |
| NCT06284486 | Brain metastases | Phase 1/2 | M.D. Anderson Cancer Center | Clinically active central nervous system (CNS) leukemia. |
| NCT06284486 | Cardiac | Phase 1/2 | M.D. Anderson Cancer Center | Baseline ejection fraction must be > 40%. |
| NCT06284486 | Hepatic | Phase 1/2 | M.D. Anderson Cancer Center | Adequate hepatic function (direct bilirubin < 1.5x upper limit of normal (ULN) unless increase is due leukemic involvement, and AST and/or ALT < 3x ULN unless considered due to leukemic involvement, in which case direct bilirubin or AST and/or ALT < 5x ULN will be considered eligible). |
| NCT06284486 | HIV | Phase 1/2 | M.D. Anderson Cancer Center | Known active hepatitis B (HBV) or Hepatitis C (HCV) or HIV infection. |
| NCT06284486 | Performance status | Phase 1/2 | M.D. Anderson Cancer Center | ECOG performance status of ≤ 2. (if aged ≥18 years) |
| NCT06284486 | Pregnancy | Phase 1/2 | M.D. Anderson Cancer Center | Female subjects who are pregnant or breast-feeding. |
| NCT06284486 | Prior malignancy | Phase 1/2 | M.D. Anderson Cancer Center | Participants with a concurrent active malignancy under treatment. |
| NCT06284486 | Renal | Phase 1/2 | M.D. Anderson Cancer Center | Adequate renal function with an estimated glomerular filtration rate ≥ 60 mL/min based on local institutional practice for age-appropriate determination. |
| NCT06292780 | Cardiac | Phase 1/2 | Regeneron Pharmaceuticals | Myocardial infarction within the past 6 months prior to the first screening visit |
| NCT06292780 | Performance status | Phase 1/2 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance score ≤2 at screening |
| NCT06293898 | Brain metastases | Phase 1 | SystImmune Inc. | Participants with primary tumors in the central nervous system (CNS) and active or untreated CNS metastases and/or carcinomatous meningitis should be excluded. |
| NCT06293898 | Cardiac | Phase 1 | SystImmune Inc. | No serious cardiac dysfunction, left ventricular ejection fraction ≥50% |
| NCT06293898 | Hepatic | Phase 1 | SystImmune Inc. | Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (≤3×ULN for participants with Gilbert's syndrome or liver metastasis at baseline) |
| NCT06293898 | HIV | Phase 1 | SystImmune Inc. | Participants with known human immunodeficiency virus (HIV) infection (HIV antibody positive). |
| NCT06293898 | Performance status | Phase 1 | SystImmune Inc. | Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 |
| NCT06293898 | Pregnancy | Phase 1 | SystImmune Inc. | Participants who are pregnant, breastfeeding, or planning to become pregnant during the study |
| NCT06293898 | Prior malignancy | Phase 1 | SystImmune Inc. | Participants with other prior malignancies except for: basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years prior to screening |
| NCT06293898 | Renal | Phase 1 | SystImmune Inc. | In dose escalation and dose finding: Creatinine (Cr) clearance ≥50 mL/minute (Cockcroft-Gault equation) or estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m^2 (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation) |
| NCT06297226 | Brain metastases | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Active or history of central nervous system involvement with MM. |
| NCT06297226 | Performance status | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06297941 | Brain metastases | Phase 1 | Remix Therapeutics | Active central nervous system (CNS) leukemia or a confirmed diagnosis of CNS leukemia. |
| NCT06297941 | HIV | Phase 1 | Remix Therapeutics | Evidence of active HIV infection. |
| NCT06297941 | Performance status | Phase 1 | Remix Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06297941 | Pregnancy | Phase 1 | Remix Therapeutics | Currently pregnant, have intentions to become pregnant during the study duration, or are currently lactating. |
| NCT06297941 | Prior malignancy | Phase 1 | Remix Therapeutics | Concurrent or previous other malignancy ≤ 2 years of enrollment, except curatively treated malignancies including basal or squamous cell skin cancer, breast cancer, prostate intraepithelial neoplasm, and carcinoma in situ of the cervix. |
| NCT06302595 | Age | Not given | Brigham and Women's Hospital | Age > 30 years |
| NCT06302595 | Cardiac | Not given | Brigham and Women's Hospital | No recent or ongoing active ischemic heart disease. |
| NCT06302621 | Age | Phase 1 | Massachusetts General Hospital | Serum Creatinine ≤ 1.5 × ULN OR calculated creatinine clearance ≥ 60ml/min |
| NCT06302621 | Brain metastases | Phase 1 | Massachusetts General Hospital | Active central nervous system (CNS) metastases are not eligible. |
| NCT06302621 | Cardiac | Phase 1 | Massachusetts General Hospital | Fridericia's corrected QT interval (QTcF) > 480 ms on ECG conducted during Screening |
| NCT06302621 | Hepatic | Phase 1 | Massachusetts General Hospital | Child-Pugh B and C cirrhosis |
| NCT06302621 | HIV | Phase 1 | Massachusetts General Hospital | Known human immunodeficiency virus (HIV) and on anti-retroviral therapy for HIV(excluded due to potential drug-drug interactions between anti-retroviral medications and study treatment but HIV itself is not an exclusion). |
| NCT06302621 | Performance status | Phase 1 | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) 0-1. |
| NCT06302621 | Pregnancy | Phase 1 | Massachusetts General Hospital | Pregnancy during the study or within 30 days of the last dose of study intervention. |
| NCT06302621 | Prior malignancy | Phase 1 | Massachusetts General Hospital | Patients with a history of another primary malignancy that is currently clinically significant, and has potential for metastases or currently requires active intervention |
| NCT06311214 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease. |
| NCT06311214 | Cardiac | Phase 2 | National Cancer Institute (NCI) | LVEF ≥50% within 28 days before enrollment |
| NCT06311214 | Diabetes | Phase 2 | National Cancer Institute (NCI) | History of uncontrolled diabetes mellitus within 3 months before the first dose of study treatment. Uncontrolled diabetes mellitus is defined as hemoglobin A1c ≥ 8% or hemoglobin A1c between 7 and < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained |
| NCT06311214 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN). Documented Gilbert syndrome is allowed if total bilirubin is ≤ 3 × ULN |
| NCT06311214 | HIV | Phase 2 | National Cancer Institute (NCI) | Human immunodeficiency virus-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this study |
| NCT06311214 | Performance status | Phase 2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group performance status of 0-2 based on most recent assessment (Karnofsky ≥ 50%) |
| NCT06311214 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Pregnant women are excluded from the study because the study drugs are investigational or approved agents with the potential for teratogenic or abortifacient effects. |
| NCT06311214 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational agents are eligible for this study |
| NCT06311214 | Renal | Phase 2 | National Cancer Institute (NCI) | Creatinine ≤ institutional ULN OR glomerular filtration rate ≥ 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2 |
| NCT06312176 | Performance status | Phase 3 | Merck Sharp & Dohme LLC | Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization |
| NCT06312644 | Pregnancy | Not given | Alexion Pharmaceuticals, Inc. | Female participant must have a medically confirmed qualifying pregnancy (prospectively or retrospectively identified). |
| NCT06313437 | Age | Phase 1 | Richard Stone, MD | Patients must be ≥ 18 and < 75 years old. |
| NCT06313437 | Brain metastases | Phase 1 | Richard Stone, MD | Subject has known active CNS involvement with AML. |
| NCT06313437 | Cardiac | Phase 1 | Richard Stone, MD | LVEF ≥ 50% by MUGA or ECHO at screening. |
| NCT06313437 | Hepatic | Phase 1 | Richard Stone, MD | aspartate aminotransferase (AST) ≤ 2.5 × ULN* |
| NCT06313437 | HIV | Phase 1 | Richard Stone, MD | Subject has tested positive for HIV |
| NCT06313437 | Performance status | Phase 1 | Richard Stone, MD | Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2. |
| NCT06313437 | Pregnancy | Phase 1 | Richard Stone, MD | Females of childbearing potential (i.e., not postmenopausal for at least 1 year or not surgically sterile) must have negative results by a serum or urine pregnancy test performed within 7 days of day 1. |
| NCT06313437 | Prior malignancy | Phase 1 | Richard Stone, MD | Subject has a history of other malignancies prior to study entry, with the exception of: |
| NCT06313437 | Renal | Phase 1 | Richard Stone, MD | Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 60 mL/min; determined by the Cockcroft Gault formula. |
| NCT06317649 | Cardiac | Phase 2 | National Cancer Institute (NCI) | If the QTcF is prolonged (> 450 ms for males and > 460 ms for females), they should be treated on the Tier Advancement Pathway (TAP) instead of MM1OA-EA02. |
| NCT06317649 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN (must be obtained ≤ 14 days prior to randomization) |
| NCT06317649 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used |
| NCT06317649 | Renal | Phase 2 | National Cancer Institute (NCI) | Creatinine clearance ≥ 30 mL/min (must be obtained ≤ 14 days prior to randomization) |
| NCT06317662 | Age | Phase 2 | National Cancer Institute (NCI) | Infants (aged 365 days or less) on the date of diagnosis are eligible |
| NCT06321484 | Age | Phase 1 | Dana-Farber Cancer Institute | Age ≥18 years and <85 years old. |
| NCT06321484 | Cardiac | Phase 1 | Dana-Farber Cancer Institute | Left ventricular ejection fraction (cardiac function) ≥ 40% |
| NCT06321484 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | AST(SGOT)/ALT(SGPT) ≤3 x institutional ULN |
| NCT06321484 | HIV | Phase 1 | Dana-Farber Cancer Institute | HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions with anti-retroviral agents used in this study. |
| NCT06321484 | Performance status | Phase 1 | Dana-Farber Cancer Institute | ECOG performance status of 0 or 1. |
| NCT06321484 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study |
| NCT06321484 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06321484 | Renal | Phase 1 | Dana-Farber Cancer Institute | Serum creatinine ≤ 2.0 mg/dL OR glomerular filtration rate (GFR) ≥40 mL/min/1.73 m2 |
| NCT06322888 | Age | Not given | Dana-Farber Cancer Institute | Women aged 18-59 |
| NCT06322888 | Language | Not given | Dana-Farber Cancer Institute | English speaking and able to read English. |
| NCT06322888 | Pregnancy | Not given | Dana-Farber Cancer Institute | Not pregnant or breastfeeding |
| NCT06322888 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Prior history of breast cancer; prior DCIS is allowable as long as participant is not taking endocrine therapy and has at least 1 breast that has not been irradiated |
| NCT06324357 | Brain metastases | Phase 1/2 | Boehringer Ingelheim | Presence of uncontrolled and/or symptomatic brain metastases, or leptomeningeal disease |
| NCT06324357 | Cardiac | Phase 1/2 | Boehringer Ingelheim | Mean resting corrected QT interval (QT interval corrected for heart rate by Fridericia´s formula (QTcF)) >470 msec. |
| NCT06324357 | Performance status | Phase 1/2 | Boehringer Ingelheim | Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 |
| NCT06333262 | Brain metastases | Phase 2 | Inhye Ahn | Known or suspected Richter's transformation or known central nervous system involvement. |
| NCT06333262 | Cardiac | Phase 2 | Inhye Ahn | Significant cardiovascular disease such as uncontrolled arrhythmia, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction < 40% by any methods in the 12 months prior to study therapy. |
| NCT06333262 | HIV | Phase 2 | Inhye Ahn | Patients who have tested positive for HIV are excluded due to potential drug-drug interactions between anti-retroviral medications and pirtobrutinib and risk of opportunistic infections with both HIV and irreversible BTK inhibitors. |
| NCT06333262 | Performance status | Phase 2 | Inhye Ahn | Eastern Cooperative Oncology Group performance status ≤ 2 |
| NCT06333262 | Pregnancy | Phase 2 | Inhye Ahn | Pregnancy, lactation or plan to breastfeed during the study or within 6 months of the last dose of study treatment. |
| NCT06333262 | Prior malignancy | Phase 2 | Inhye Ahn | History of other malignancies with life expectancy of < 2 years. |
| NCT06357533 | Brain metastases | Phase 3 | AstraZeneca | History of leptomeningeal carcinomatosis |
| NCT06357533 | HIV | Phase 3 | AstraZeneca | known HIV infection that is not well controlled |
| NCT06357533 | Performance status | Phase 3 | AstraZeneca | ECOG performance status of 0 or 1 |
| NCT06357533 | Prior malignancy | Phase 3 | AstraZeneca | History of another primary malignancy within 3 years |
| NCT06359041 | Age | Phase 1/2 | Cabaletta Bio | Age ≥18 and ≤70 years of age |
| NCT06359041 | Cardiac | Phase 1/2 | Cabaletta Bio | Significant lung or cardiac impairment |
| NCT06359041 | Hepatic | Phase 1/2 | Cabaletta Bio | Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections. |
| NCT06359041 | Renal | Phase 1/2 | Cabaletta Bio | Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections. |
| NCT06365060 | Pregnancy | Not given | Tufts Medical Center | Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible |
| NCT06366347 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Active brain metastases (e.g., stable for < 8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsant therapy. Corticoid therapy is allowed if administered as stable dose for at least 1 month before starting study treatment). |
| NCT06366347 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Participants with personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. |
| NCT06366347 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Total bilirubin ≤1.5 × ULN Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted. |
| NCT06366347 | HIV | Phase 2 | Dana-Farber Cancer Institute | such as known human immunodeficiency virus positivity |
| NCT06366347 | Performance status | Phase 2 | Dana-Farber Cancer Institute | Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix A) |
| NCT06366347 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Females who are pregnant or lactating. |
| NCT06366347 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Other malignant disease with disease-free ≤ 3 years except: curatively treated carcinoma in situ of the cervix, basal cell carcinoma of the skin, or ductal carcinoma in situ (DCIS) of the breast or any other cancer deemed by the investigator to be at low risk for recurrence of that malignancy. |
| NCT06366347 | Renal | Phase 2 | Dana-Farber Cancer Institute | Creatinine ≤ 1.5 × institutional ULN, OR |
| NCT06368817 | Age | Phase 2 | Children's Oncology Group | Patients must be ≥ 3 years and < 30 years at the time of study enrollment |
| NCT06368817 | Hepatic | Phase 2 | Children's Oncology Group | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age |
| NCT06368817 | Performance status | Phase 2 | Children's Oncology Group | Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. |
| NCT06368817 | Pregnancy | Phase 2 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT06368817 | Prior malignancy | Phase 2 | Children's Oncology Group | Patients with any of the following malignant pathological elements are not eligible: |
| NCT06368817 | Renal | Phase 2 | Children's Oncology Group | For pediatric patients (age 3-17 years): A serum creatinine based on age/sex as follows (Must be performed within 7 days prior to enrollment unless otherwise indicated): |
| NCT06369155 | Brain metastases | Phase 2 | Joyce Liu, MD | Participants with known leptomeningeal disease are not eligible. |
| NCT06369155 | Cardiac | Phase 2 | Joyce Liu, MD | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. |
| NCT06369155 | Hepatic | Phase 2 | Joyce Liu, MD | total bilirubin ≤ institutional upper limit of normal (ULN) or |
| NCT06369155 | HIV | Phase 2 | Joyce Liu, MD | participants who are on antiretroviral therapy that includes strong inhibitors or inducers of CYP3A4 are not eligible |
| NCT06369155 | Performance status | Phase 2 | Joyce Liu, MD | ECOG performance status 0, 1, or 2 (see Appendix A) |
| NCT06369155 | Pregnancy | Phase 2 | Joyce Liu, MD | Pregnant women are excluded from this study |
| NCT06369155 | Prior malignancy | Phase 2 | Joyce Liu, MD | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06369155 | Renal | Phase 2 | Joyce Liu, MD | creatinine ≤ 1.5x institutional ULN or estimated CrCl≥ 60 mL/min |
| NCT06375044 | Brain metastases | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. |
| NCT06375044 | Hepatic | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Adequate hematologic, hepatic, and renal function. |
| NCT06375044 | HIV | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS). |
| NCT06375044 | Performance status | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. |
| NCT06375044 | Pregnancy | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial. |
| NCT06375044 | Prior malignancy | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Current or previous other malignancy within 3 years of study entry, except basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast. |
| NCT06375044 | Renal | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Adequate hematologic, hepatic, and renal function. |
| NCT06377852 | Age | Phase 3 | American Society of Clinical Oncology | Aged 60 years or older |
| NCT06377852 | Brain metastases | Phase 3 | American Society of Clinical Oncology | Rapidly progressive brain metastases. Note: only applies to patients with known brain metastases. Brain imaging not required for enrollment. |
| NCT06377852 | Cardiac | Phase 3 | American Society of Clinical Oncology | Baseline QTc ≤ 480 ms (only for ribociclib patients) |
| NCT06377852 | Prior malignancy | Phase 3 | American Society of Clinical Oncology | Prior or concurrent malignancies that are undergoing active treatment. |
| NCT06380751 | Brain metastases | Phase 3 | AstraZeneca | Spinal cord compression, brain metastases, carcinomatous meningitis, or leptomeningeal disease |
| NCT06380751 | Cardiac | Phase 3 | AstraZeneca | Cardiac criteria, including history of arrythmia and cardiovascular disease |
| NCT06380751 | HIV | Phase 3 | AstraZeneca | Evidence of active and uncontrolled HIV infection |
| NCT06380751 | Performance status | Phase 3 | AstraZeneca | ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks |
| NCT06380751 | Prior malignancy | Phase 3 | AstraZeneca | History of another primary malignancy |
| NCT06385080 | Brain metastases | Phase 1/2 | Janssen Research & Development, LLC | Participant with untreated brain metastases leptomeningeal disease, or spinal cord compression not definitively treated with surgery or radiation |
| NCT06385080 | Cardiac | Phase 1/2 | Janssen Research & Development, LLC | Participant with a history of clinically significant cardiovascular disease |
| NCT06385080 | Performance status | Phase 1/2 | Janssen Research & Development, LLC | Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 |
| NCT06395103 | Hepatic | Phase 1/2 | Merck Sharp & Dohme LLC | Known history of liver cirrhosis. |
| NCT06395103 | HIV | Phase 1/2 | Merck Sharp & Dohme LLC | History of human immunodeficiency virus (HIV) infection. |
| NCT06395519 | Brain metastases | Phase 1/2 | 858 Therapeutics, Inc. | Symptomatic untreated or progressing brain metastases. |
| NCT06395519 | Cardiac | Phase 1/2 | 858 Therapeutics, Inc. | Resting ECG with QT interval calculated using the Fridericia's formula (QTcF) >470 msec on 2 or more timepoints within a 24-hour period |
| NCT06395519 | Hepatic | Phase 1/2 | 858 Therapeutics, Inc. | Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per Investigator assessment). |
| NCT06395519 | Performance status | Phase 1/2 | 858 Therapeutics, Inc. | ECOG performance status 0-1. |
| NCT06395519 | Prior malignancy | Phase 1/2 | 858 Therapeutics, Inc. | Known other previous/current malignancy requiring treatment within ≤2 years except for limited disease treated with curative intent |
| NCT06395519 | Renal | Phase 1/2 | 858 Therapeutics, Inc. | Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease |
| NCT06398639 | Age | Not given | Adam S. Kibel, MD | Participants must be between 40-69 years of age. |
| NCT06398639 | Cardiac | Not given | Adam S. Kibel, MD | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT06398639 | Prior malignancy | Not given | Adam S. Kibel, MD | No history of prostate cancer. |
| NCT06401330 | Age | Phase 3 | Children's Oncology Group | Patients must be < 30 years old at enrollment. |
| NCT06401330 | Cardiac | Phase 3 | Children's Oncology Group | Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% (within 7 days prior to enrollment) |
| NCT06401330 | Hepatic | Phase 3 | Children's Oncology Group | Serum total bilirubin ≤ 1.5 X upper limit of normal (ULN) OR direct bilirubin ≤ 3X ULN for subjects with total bilirubin levels > 1.5 ULN (within 7 days prior to enrollment). |
| NCT06401330 | Performance status | Phase 3 | Children's Oncology Group | Karnofsky performance status must be ≥ 50 for patients > 16 years of age and the Lansky performance status must be ≥ 50 for patients ≤ 16 years of age. |
| NCT06401330 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential. |
| NCT06401421 | Performance status | Not given | Exact Sciences Corporation | ECOG performance status 0 or 1. |
| NCT06401421 | Pregnancy | Not given | Exact Sciences Corporation | Known pregnancy at time of enrollment. |
| NCT06401421 | Prior malignancy | Not given | Exact Sciences Corporation | Synchronous diagnosis of another invasive cancer, other than this breast cancer, except for non-melanoma skin cancers. |
| NCT06412198 | Brain metastases | Phase 1/2 | M.D. Anderson Cancer Center | Participants with symptomatic leptomeningeal disease. |
| NCT06412198 | Hepatic | Phase 1/2 | M.D. Anderson Cancer Center | Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0x ULN (if associated with liver metastases ≤5x ULN) |
| NCT06412198 | HIV | Phase 1/2 | M.D. Anderson Cancer Center | Known human immunodeficiency virus (HIV) infection or acute or chronic hepatitis B (HBV) or C (HCV) infection as tested in a CLIA certified lab using a positive HIV antibody test. |
| NCT06412198 | Performance status | Phase 1/2 | M.D. Anderson Cancer Center | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06412198 | Pregnancy | Phase 1/2 | M.D. Anderson Cancer Center | Pregnancy. Women of child-bearing potential must have a negative serum or urine pregnancy test during screening |
| NCT06412198 | Renal | Phase 1/2 | M.D. Anderson Cancer Center | Calculated creatinine clearance (determined as per Cockcroft-Gault) ≥ 60mL/min at screening |
| NCT06422806 | Brain metastases | Phase 3 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy |
| NCT06422806 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Patient must have a left ventricular ejection fraction (LVEF) > 50% by either MUGA scan or echocardiogram obtained within 28 days prior to randomization |
| NCT06422806 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin < 1.2 mg/dL (must be obtained ≤ 7 days prior to protocol randomization) |
| NCT06422806 | HIV | Phase 3 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial |
| NCT06422806 | Performance status | Phase 3 | National Cancer Institute (NCI) | Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT06422806 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. |
| NCT06422806 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT06422806 | Renal | Phase 3 | National Cancer Institute (NCI) | Creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (must be obtained ≤ 7 days prior to protocol randomization) |
| NCT06424327 | Prior malignancy | Not given | Memorial Sloan Kettering Cancer Center | Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years |
| NCT06425926 | Brain metastases | Phase 1/2 | Georgiamune Inc | Has known leptomeningeal disease, spinal cord compression, or brain metastases, except participants with the following: |
| NCT06425926 | Cardiac | Phase 1/2 | Georgiamune Inc | Has known structural cardiac disease |
| NCT06425926 | Hepatic | Phase 1/2 | Georgiamune Inc | including acceptable cardiac, renal, and hepatic functions |
| NCT06425926 | HIV | Phase 1/2 | Georgiamune Inc | including known hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) |
| NCT06425926 | Performance status | Phase 1/2 | Georgiamune Inc | ECOG performance status 0-1 |
| NCT06425926 | Pregnancy | Phase 1/2 | Georgiamune Inc | Non pregnant participants; female participants of child bearing potential with non-sterile partners agree to use an effective form of contraception |
| NCT06425926 | Renal | Phase 1/2 | Georgiamune Inc | including acceptable cardiac, renal, and hepatic functions |
| NCT06426628 | Age | Not given | Veracyte, Inc. | 29 - 85 years of age |
| NCT06426628 | Prior malignancy | Not given | Veracyte, Inc. | Active cancer (other than non-melanoma skin cancer) |
| NCT06426628 | Smoking | Not given | Veracyte, Inc. | Current or former smoker (>100 cigarettes in a lifetime) |
| NCT06427954 | Language | Not given | Massachusetts General Hospital | Sufficient English proficiency to utilize THRIVE in English (Note: patients can complete outcome measures in Spanish if preferred). |
| NCT06427954 | Performance status | Not given | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 0-2 (i.e., fully active to at least ambulatory and up and about more than 50% of waking hours). |
| NCT06428019 | Performance status | Phase 3 | AbbVie | Eastern Cooperative Oncology Group (ECOG) performance status <= 2. |
| NCT06428019 | Renal | Phase 3 | AbbVie | Creatinine clearance (CrCl) >= 30 mL/min using the Cockcroft-Gault formula are eligible for inclusion. |
| NCT06431594 | Brain metastases | Phase 1 | GlaxoSmithKline | Evidence of brain metastasis unless asymptomatic; |
| NCT06431594 | Cardiac | Phase 1 | GlaxoSmithKline | Mean Fridericia-corrected QT interval (QTcF) QTcF >450 msec or QTcF >480 msec for participants with bundle branch blocK; |
| NCT06433947 | Brain metastases | Phase 1 | Opna Bio LLC | Known central nervous system involvement by multiple myeloma |
| NCT06433947 | Diabetes | Phase 1 | Opna Bio LLC | Poorly controlled Type 2 diabetes |
| NCT06433947 | Prior malignancy | Phase 1 | Opna Bio LLC | Active known second malignancy with exception of adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer; adequately treated Stage 1 cancer from which the subject is currently in remission and has been in remission for ≥2 years; low-risk prostate cancer with a Gleason score <7 and a PSA level <10 ng/mL; any other cancer from which the subject has been disease-free for ≥3 years |
| NCT06435429 | Brain metastases | Phase 3 | Jazz Pharmaceuticals | Has clinically confirmed leptomeningeal disease, in the opinion of the investigator. |
| NCT06435429 | Cardiac | Phase 3 | Jazz Pharmaceuticals | Has uncontrolled or significant cardiovascular disease. |
| NCT06435429 | HIV | Phase 3 | Jazz Pharmaceuticals | Has an infection with HIV-1 or HIV-2, with the exception of participants with well-controlled HIV. |
| NCT06435429 | Pregnancy | Phase 3 | Jazz Pharmaceuticals | Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy. |
| NCT06439693 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Known or concurrent leptomeningeal disease on screening MRI |
| NCT06439693 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Left ventricular ejection fraction (LVEF) ≥50%, as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) documented within 12 weeks prior to first dose of study treatment |
| NCT06439693 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Total bilirubin ≤ 1.5 x ULN (institutional) or direct bilirubin within normal limits in patients with a history of Gilbert's syndrome. |
| NCT06439693 | HIV | Phase 2 | Dana-Farber Cancer Institute | Participants with concurrent human immunodeficiency virus (HIV) infection are eligible provided the following criteria are met: |
| NCT06439693 | Performance status | Phase 2 | Dana-Farber Cancer Institute | Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 |
| NCT06439693 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study because of potential for teratogenic or abortifacient effects of study drugs. |
| NCT06439693 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Prior history of invasive breast carcinoma |
| NCT06439693 | Renal | Phase 2 | Dana-Farber Cancer Institute | Serum creatinine ≤ 1.5 x ULN (institutional) OR calculated GFR ≥60mL/min |
| NCT06440135 | Cardiac | Phase 1 | Massachusetts General Hospital | Current or history of ventricular or life-threatening arrhythmias or diagnosis of long-QT syndrome |
| NCT06440135 | Hepatic | Phase 1 | Massachusetts General Hospital | AST (SGOT), ALT (SGPT) and Alkaline phosphatase < 3x institutional upper limit of normal (ULN) |
| NCT06440135 | Performance status | Phase 1 | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) performance status 0-2. |
| NCT06440135 | Pregnancy | Phase 1 | Massachusetts General Hospital | Persons who are pregnant or lactating. |
| NCT06440135 | Prior malignancy | Phase 1 | Massachusetts General Hospital | History of other malignancy(ies) unless |
| NCT06440135 | Renal | Phase 1 | Massachusetts General Hospital | Calculated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula) |
| NCT06445062 | Performance status | Phase 1/2 | Revolution Medicines, Inc. | ECOG PS is 0 to 1 |
| NCT06450171 | Age | Not given | Dana-Farber Cancer Institute | Age ≥ 22 for patients with TP53 germline pathogenic variants, age ≥ 35 for all other variants in cancer predisposing genes |
| NCT06450171 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Individuals diagnosed with invasive malignancy within 3 years of enrollment |
| NCT06451497 | Brain metastases | Phase 1 | Zumutor Biologics Inc. | The patient has a history of uncontrolled brain metastasis. |
| NCT06451497 | Cardiac | Phase 1 | Zumutor Biologics Inc. | The patient has baseline QTc (using the Fridericia correction calculation) >470 msec in patients without pacemaker. |
| NCT06451497 | Hepatic | Phase 1 | Zumutor Biologics Inc. | Total bilirubin ≤1.5 times upper limit of normal (ULN). |
| NCT06451497 | HIV | Phase 1 | Zumutor Biologics Inc. | Patients positive for human immunodeficiency virus (HIV) can be enrolled only in Part 2 of the trial, but HIV-positive patients must meet the following criteria: a. have CD4+ T cell (CD4+) counts ≥350 cells/μL. |
| NCT06451497 | Performance status | Phase 1 | Zumutor Biologics Inc. | The patient has Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. |
| NCT06451497 | Prior malignancy | Phase 1 | Zumutor Biologics Inc. | The patient has clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers. |
| NCT06451497 | Renal | Phase 1 | Zumutor Biologics Inc. | estimated creatinine clearance (CrCL) using the Cockcroft- Gault formula ≥30 mL/minute. |
| NCT06457503 | Brain metastases | Phase 4 | Coherus Oncology, Inc. | Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal), as determined on computerized tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments. |
| NCT06462365 | Age | Phase 1 | Tr1X, Inc. | Subjects > 65-year-old receiving MAC conditioning will only be eligible if they have a HSCT-comorbidity index score < 5. |
| NCT06462365 | Cardiac | Phase 1 | Tr1X, Inc. | Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction. |
| NCT06462365 | Hepatic | Phase 1 | Tr1X, Inc. | Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction. |
| NCT06462365 | HIV | Phase 1 | Tr1X, Inc. | HIV positive. |
| NCT06462365 | Performance status | Phase 1 | Tr1X, Inc. | Karnofsky performance status ≥ 70 %. |
| NCT06462365 | Pregnancy | Phase 1 | Tr1X, Inc. | Subjects that are pregnant, breast feeding or aim to become pregnant during the study period. |
| NCT06462365 | Renal | Phase 1 | Tr1X, Inc. | Any subject with a history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction. |
| NCT06465069 | Brain metastases | Phase 1 | Eli Lilly and Company | Individual with known or suspected uncontrolled CNS metastases |
| NCT06465069 | Cardiac | Phase 1 | Eli Lilly and Company | Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms |
| NCT06465069 | Diabetes | Phase 1 | Eli Lilly and Company | Individual with uncontrolled diabetes |
| NCT06465069 | Performance status | Phase 1 | Eli Lilly and Company | Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT06465069 | Pregnancy | Phase 1 | Eli Lilly and Company | Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention |
| NCT06469281 | Brain metastases | Phase 1 | Regeneron Pharmaceuticals | Known history or presence of clinically relevant central nervous system (CNS) pathology, as described in the protocol |
| NCT06469281 | Cardiac | Phase 1 | Regeneron Pharmaceuticals | Inadequate cardiovascular, renal and hepatic function, as described in the protocol |
| NCT06469281 | Hepatic | Phase 1 | Regeneron Pharmaceuticals | Inadequate cardiovascular, renal and hepatic function, as described in the protocol |
| NCT06469281 | Performance status | Phase 1 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 |
| NCT06469281 | Renal | Phase 1 | Regeneron Pharmaceuticals | Inadequate cardiovascular, renal and hepatic function, as described in the protocol |
| NCT06469307 | Language | Not given | Dana-Farber Cancer Institute | English speaking |
| NCT06469307 | Pregnancy | Not given | Dana-Farber Cancer Institute | Patients and non-patient community members who are pregnant are eligible. |
| NCT06472089 | Language | Not given | Massachusetts General Hospital | Ability to read and respond to survey questions in English, Spanish or with minimal assistance from an interpreter. |
| NCT06472128 | Language | Not given | Massachusetts General Hospital | Ability to comprehend and speak English as the digital apps are only available in English |
| NCT06475235 | Diabetes | Phase 1 | Dana-Farber Cancer Institute | Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin >8% |
| NCT06475235 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. |
| NCT06475235 | HIV | Phase 1 | Dana-Farber Cancer Institute | Participants must have negative HIV serology. |
| NCT06475235 | Performance status | Phase 1 | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥70% will be considered if related to PCNSL, see Appendix A). |
| NCT06475235 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment |
| NCT06475235 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. |
| NCT06475235 | Renal | Phase 1 | Dana-Farber Cancer Institute | Creatinine ≤1.5 x ULN OR Measured or calculated creatinine clearance ≥40 mL/min for participant with creatinine levels >1.5 × institutional ULN (Creatinine clearance (CrCl) should be calculated per institutional standard.) |
| NCT06484062 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Subject has symptomatic central nervous system (CNS) involvement with AML |
| NCT06484062 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Left ventricular ejection fraction (LVEF) < 40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan obtained within 30 days prior to the start of study treatment |
| NCT06484062 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin; in that case a cut off of ≤ 4 × institutional ULN will be used) |
| NCT06484062 | HIV | Phase 1 | National Cancer Institute (NCI) | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT06484062 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 |
| NCT06484062 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Pregnant and lactating women are excluded from this study |
| NCT06484062 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT06484062 | Renal | Phase 1 | National Cancer Institute (NCI) | Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73m^2 |
| NCT06486454 | Pregnancy | Not given | HistoSonics, Inc. | Subject is pregnant or planning to become pregnant or nursing (lactating) during the study period |
| NCT06488378 | Brain metastases | Phase 1 | Dana-Farber Cancer Institute | Patients with a history of treated central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: |
| NCT06488378 | Cardiac | Phase 1 | Dana-Farber Cancer Institute | Participants with a QTcF of >470msec on screening ECG |
| NCT06488378 | Hepatic | Phase 1 | Dana-Farber Cancer Institute | total bilirubin ≤ 1.5x institutional upper limit of normal (ULN) |
| NCT06488378 | HIV | Phase 1 | Dana-Farber Cancer Institute | HIV-infected participants must have well-controlled HIV on ART, defined as: |
| NCT06488378 | Performance status | Phase 1 | Dana-Farber Cancer Institute | ECOG performance ≤ 2. |
| NCT06488378 | Pregnancy | Phase 1 | Dana-Farber Cancer Institute | Female participants must be postmenopausal or must have a negative serum pregnancy test performed during screening. |
| NCT06488378 | Prior malignancy | Phase 1 | Dana-Farber Cancer Institute | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06488378 | Renal | Phase 1 | Dana-Farber Cancer Institute | Creatinine clearance ≥ 51 mL/min (using Cockcroft-Gault equation) |
| NCT06492616 | Prior malignancy | Phase 3 | Stemline Therapeutics, Inc. | History of any prior (ipsilateral and/or contralateral) invasive breast cancer. |
| NCT06496256 | Diabetes | Not given | Palette Life Sciences, Inc. | History of uncontrolled diabetes (e.g. symptomatic hyperglycemia that is not controlled with medical management; fasting blood glucose >300 mg/dL). |
| NCT06496256 | Hepatic | Not given | Palette Life Sciences, Inc. | Serum AST/ALT >2.5 times the institutional upper limit of normal |
| NCT06496256 | HIV | Not given | Palette Life Sciences, Inc. | History of acquired immunodeficiency syndrome (AIDS). Patients with controlled HIV infection (CD4+ T-cell counts ≥ 350 cells/µL) and no history of AIDS-defining opportunistic infections may be included. |
| NCT06496256 | Performance status | Not given | Palette Life Sciences, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT06496256 | Renal | Not given | Palette Life Sciences, Inc. | Creatinine >2.0 mg/dL |
| NCT06498635 | BMI | Phase 3 | National Cancer Institute (NCI) | Participants must have body weight > 30 kg |
| NCT06498635 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Aspartate transaminase (AST)/alanine transaminase (ALT) ≤ 3 × institutional ULN (within 28 days prior to randomization) |
| NCT06498635 | HIV | Phase 3 | National Cancer Institute (NCI) | Participants with a known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to randomization |
| NCT06498635 | Language | Phase 3 | National Cancer Institute (NCI) | Participants who can complete FACT-L, FACT-BRM, and PRO-CTCAE questionnaires forms in English, or Spanish must agree to participate in the patient-reported outcome study |
| NCT06498635 | Performance status | Phase 3 | National Cancer Institute (NCI) | Participant must have Zubrod performance status of 0-2 |
| NCT06498635 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Participants must not be pregnant or nursing |
| NCT06498635 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT06498635 | Renal | Phase 3 | National Cancer Institute (NCI) | Participants must have a calculated creatinine clearance ≥ 40 mL/min using the following Cockcroft-Gault formula. |
| NCT06502171 | Cardiac | Phase 1 | Girish Dhall, MD | Baseline QTc interval >450 msec |
| NCT06502171 | Diabetes | Phase 1 | Girish Dhall, MD | Uncontrolled diabetes, severe malnutrition, chronic liver or renal disease |
| NCT06502171 | Hepatic | Phase 1 | Girish Dhall, MD | Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) < 2.5x the upper limit of normal (ULN). |
| NCT06502171 | HIV | Phase 1 | Girish Dhall, MD | A known history of HIV seropositivity or known immunodeficiency. |
| NCT06502171 | Performance status | Phase 1 | Girish Dhall, MD | Participants must have Karnofsky ³ 50%. |
| NCT06502171 | Pregnancy | Phase 1 | Girish Dhall, MD | Pregnant or lactating women. |
| NCT06502171 | Prior malignancy | Phase 1 | Girish Dhall, MD | Patients with high-grade glioma, atypical or malignant peripheral nerve sheath tumor, or other malignancy who received treatment in the last 12 months. |
| NCT06502171 | Renal | Phase 1 | Girish Dhall, MD | Maximum serum creatinine based on age/gender as per institutional standards OR a creatinine clearance, radioisotope GFR, or calculated creatinine clearance using the Cockcroft-Gault equation ³70ml/min/1.73 m2. |
| NCT06510309 | Cardiac | Phase 2 | Gottfried von Keudell, MD PhD | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT06510309 | HIV | Phase 2 | Gottfried von Keudell, MD PhD | HIV-positive patients on combination antiretroviral therapy are eligible if their HIV is under adequate control with an antiretroviral regimen that has been stable for > 4 weeks, as long as the CD4 count is >300. |
| NCT06510309 | Performance status | Phase 2 | Gottfried von Keudell, MD PhD | ECOG performance status ≤1 |
| NCT06510309 | Pregnancy | Phase 2 | Gottfried von Keudell, MD PhD | Pregnant women or participants unwilling to adhere to institutional guidelines for highly effective contraception for 12 months after the last dose of rituximab are excluded from this study |
| NCT06510361 | Brain metastases | Phase 2 | Beth Israel Deaconess Medical Center | Patients with known or suspected CNS involvement or leptomeningeal disease are excluded given concern for potentially increased risk of neurologic toxicity with epcoritamab. |
| NCT06510361 | Cardiac | Phase 2 | Beth Israel Deaconess Medical Center | Uncontrolled underlying cardiac conditions including but not limited to congestive heart failure grade III or IV (by NYHA) or EF <45%, unstable angina pectoris, acute myocardial infarction < 6 months, cardiac arrhythmia |
| NCT06510361 | Hepatic | Phase 2 | Beth Israel Deaconess Medical Center | Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN). In patients with suspected/known Gilbert's disease total bilirubin up to 3x ULN will be allowed |
| NCT06510361 | HIV | Phase 2 | Beth Israel Deaconess Medical Center | Patients with HIV will be excluded |
| NCT06510361 | Performance status | Phase 2 | Beth Israel Deaconess Medical Center | ECOG performance status ≤ 2 |
| NCT06510361 | Pregnancy | Phase 2 | Beth Israel Deaconess Medical Center | Pregnant or breastfeeding women or participants unwilling to adhere to institutional guidelines for highly effective contraception for the duration of the therapy are excluded. |
| NCT06510361 | Prior malignancy | Phase 2 | Beth Israel Deaconess Medical Center | Participants with a history of prior malignancy will be eligible if all treatment of that malignancy was completed at least 2 years prior to enrollment to this study, the treatment was considered "curable-intent", and there is currently no evidence of disease. |
| NCT06510361 | Renal | Phase 2 | Beth Israel Deaconess Medical Center | Creatinine ≤ institutional ULN OR creatinine clearance > 45 ml/min (by Cockcroft-Gault estimate or 24-hr creatinine clearance measurement) |
| NCT06510491 | Brain metastases | Phase 2 | Gottfried von Keudell, MD PhD | Patients with known or suspected CNS involvement or leptomeningeal disease (i.e. BingNeel Syndrome) are excluded |
| NCT06510491 | Cardiac | Phase 2 | Gottfried von Keudell, MD PhD | Uncontrolled underlying cardiac conditions including but not limited to: congestive heart failure grade III or IV (by NYHA) or EF < 45%, unstable angina pectoris, acute myocardial infarction < 6 months, uncontrolled cardiac arrhythmia |
| NCT06510491 | Hepatic | Phase 2 | Gottfried von Keudell, MD PhD | total bilirubin ≤ 1.5 institutional upper limit of normal (ULN). |
| NCT06510491 | HIV | Phase 2 | Gottfried von Keudell, MD PhD | Patients with HIV may be enrolled if they are on stable antiretroviral therapy, have an undetectable viral load, and CD4 count > 250 cells/mm3. |
| NCT06510491 | Performance status | Phase 2 | Gottfried von Keudell, MD PhD | ECOG performance status £ 2 |
| NCT06510491 | Pregnancy | Phase 2 | Gottfried von Keudell, MD PhD | Pregnant or breastfeeding women or participants unwilling to adhere to institutional guidelines for highly effective contraception for the duration of the therapy are excluded. |
| NCT06510491 | Prior malignancy | Phase 2 | Gottfried von Keudell, MD PhD | Participants with a history of prior malignancy will be eligible if all treatment of that malignancy was completed at least 2 years before registration |
| NCT06510491 | Renal | Phase 2 | Gottfried von Keudell, MD PhD | creatinine clearance >45 ml/min (by Cockcroft-Gault estimate or 24-hr creatinine clearance measurement) |
| NCT06515613 | Brain metastases | Phase 1 | Context Therapeutics Inc. | Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression. |
| NCT06517901 | Prior malignancy | Not given | Albany Medical College | Previous diagnosis of prostate cancer |
| NCT06518551 | Brain metastases | Phase 1/2 | Omar Nadeem, MD | Known central nervous system involvement. |
| NCT06518551 | Cardiac | Phase 1/2 | Omar Nadeem, MD | Any active, or uncontrolled cardiovascular conditions, including but not limited to uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, grade 3 thromboembolic event or myocardial infarction within the past 6 months. |
| NCT06518551 | Hepatic | Phase 1/2 | Omar Nadeem, MD | Total Bilirubin ≤ 1.5 X upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) |
| NCT06518551 | HIV | Phase 1/2 | Omar Nadeem, MD | Known seropositive for active viral infection with human immunodeficiency virus (HIV) hepatitis B (HBV) or hepatitis C viral (HCV). |
| NCT06518551 | Performance status | Phase 1/2 | Omar Nadeem, MD | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) |
| NCT06518551 | Pregnancy | Phase 1/2 | Omar Nadeem, MD | Female patients who are pregnant or lactating. |
| NCT06518551 | Prior malignancy | Phase 1/2 | Omar Nadeem, MD | Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low risk prostate cancer after curative therapy |
| NCT06518551 | Renal | Phase 1/2 | Omar Nadeem, MD | Creatinine clearance ≥ 30 ml/min according to the Cockroft-Gault formula: |
| NCT06518564 | Brain metastases | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | Participants with clinically controlled brain metastases, which is defined as individuals with central nervous system metastases that have been treated for, are asymptomatic, and have discontinued corticosteroids for > 14 days or are on a stable or decreasing steroid dose (for the treatment of brain metastases) may be enrolled. Participants with meningeal carcinomatosis are excluded. |
| NCT06518564 | Cardiac | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | Calculated QTc average (using the Fridericia correction calculation) of > 470 msec that does not resolve with correction of electrolyte abnormalities. |
| NCT06518564 | Hepatic | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN) in the case of documented Gilbert's syndrome, total bilirubin ≤3 x ULN is allowed |
| NCT06518564 | HIV | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | Participants with HIV infection are eligible if they are on effective antiretroviral therapy with undetectable viral load within 6 months, provided there is no expected drug-drug interaction |
| NCT06518564 | Performance status | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | ECOG performance status 0, 1, or 2 (reference Appendix A for ECOG performance status criteria). |
| NCT06518564 | Pregnancy | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | Pregnant women are excluded from this study because avelumab and M1774 are agents with the potential for teratogenic or abortifacient effects. |
| NCT06518564 | Prior malignancy | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | Individuals with a history of a different malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years or if they are deemed by the investigator to be at low risk for recurrence of that malignancy. |
| NCT06518564 | Renal | Phase 2 | Panagiotis Konstantinopoulos, MD, PhD | Creatinine clearance ≥ 60 mL/min as estimated by the Cockcroft-Gault formula or institutional standard method OR |
| NCT06523868 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable) |
| NCT06524544 | Brain metastases | Phase 3 | National Cancer Institute (NCI) | Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and are not using steroids > 10 mg of prednisone (or equivalent) daily for brain metastases for at least 7 days prior to randomization |
| NCT06524544 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (obtained ≤ 14 days prior to randomization) |
| NCT06524544 | HIV | Phase 3 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible |
| NCT06524544 | Language | Phase 3 | National Cancer Institute (NCI) | Patient must be English or Spanish speaking to be eligible for the HRQOL component of the study. |
| NCT06524544 | Performance status | Phase 3 | National Cancer Institute (NCI) | Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2. |
| NCT06524544 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. |
| NCT06524544 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Patients with prior or concurrent malignancy that is not considered clinically significant and whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (at the discretion of the treating physician) are eligible |
| NCT06524544 | Renal | Phase 3 | National Cancer Institute (NCI) | Creatinine clearance (CrCl) ≥ 30 mL/min (obtained ≤ 14 days prior to randomization) NOTE: CrCl is estimated using the Cockcroft-Gault formula (or can be measured by 24-hour urine collection if needed) |
| NCT06532279 | Cardiac | Phase 2 | NRG Oncology | No valvular heart disease. |
| NCT06532279 | Hepatic | Phase 2 | NRG Oncology | Total bilirubin =< 2 x institutional upper limit of normal (ULN) (not applicable to patients with known Gilbert's syndrome). |
| NCT06532279 | Performance status | Phase 2 | NRG Oncology | Zubrod performance status of 0-2. |
| NCT06532279 | Prior malignancy | Phase 2 | NRG Oncology | No prior unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ, basal cell skin carcinoma, resected T1-2N0M0 differentiated thyroid cancers, Ta bladder cancers, or low risk prostate cancer. |
| NCT06532279 | Renal | Phase 2 | NRG Oncology | Adequate renal function defined as creatinine clearance (CrCL) > 50 mL/min by the Cockcroft-Gault formula. |
| NCT06532565 | Brain metastases | Phase 1 | Gilead Sciences | Have known active central nervous system (CNS) metastases and/or leptomeningeal disease (LMD). |
| NCT06532565 | Cardiac | Phase 1 | Gilead Sciences | Myocardial infarction or unstable angina pectoris within 6 months of enrollment. |
| NCT06532565 | HIV | Phase 1 | Gilead Sciences | Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. |
| NCT06532565 | Performance status | Phase 1 | Gilead Sciences | Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. |
| NCT06532565 | Pregnancy | Phase 1 | Gilead Sciences | Positive serum pregnancy test or participant who is breastfeeding. |
| NCT06532565 | Prior malignancy | Phase 1 | Gilead Sciences | Have an active second malignancy. |
| NCT06533761 | Performance status | Phase 1 | Stelexis BioSciences | Eastern Cooperative Oncology Group (ECOG) performance status ≤2. |
| NCT06533826 | Brain metastases | Phase 2 | Ana C Garrido-Castro, MD | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy, there is no requirement for corticosteroids, and the patient is asymptomatic. |
| NCT06533826 | Cardiac | Phase 2 | Ana C Garrido-Castro, MD | For T-DXd cohorts, baseline LVEF ≥ 50% prior to registration, as measured by echocardiogram (or multiple-gated acquisition [MUGA] scan if an echocardiogram cannot be performed or is inconclusive). |
| NCT06533826 | Hepatic | Phase 2 | Ana C Garrido-Castro, MD | Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) (or ≤ 3.0 x ULN in patients with documented Gilbert's Syndrome) |
| NCT06533826 | HIV | Phase 2 | Ana C Garrido-Castro, MD | Known human immunodeficiency virus (HIV) infection that is not well controlled. |
| NCT06533826 | Performance status | Phase 2 | Ana C Garrido-Castro, MD | ECOG performance status 0-1 (Karnofsky > 60%). |
| NCT06533826 | Pregnancy | Phase 2 | Ana C Garrido-Castro, MD | Women who are pregnant or breastfeeding or planning to become pregnant. |
| NCT06533826 | Prior malignancy | Phase 2 | Ana C Garrido-Castro, MD | Individuals with a history of a second malignancy are ineligible except for the following circumstances: |
| NCT06533826 | Renal | Phase 2 | Ana C Garrido-Castro, MD | Serum or plasma creatinine ≤ 1.5 × institutional ULN OR creatinine clearance (as calculated using the Cockcroft-Gault equation) ≥ 30 mL/min/ 1.73m2 for participants with creatinine levels above institutional ULN. |
| NCT06534060 | Brain metastases | Phase 2 | March Biosciences Inc | Active CNS lymphoma. |
| NCT06534060 | Cardiac | Phase 2 | March Biosciences Inc | Cardiac: left ventricular ejection fraction (LVEF) ≥ 50% by Echo or radionuclide scan. |
| NCT06534060 | Hepatic | Phase 2 | March Biosciences Inc | Aspartate aminotransferase / alanine aminotransferase < 3 × ULN (5 x ULN if liver involvement). |
| NCT06534060 | HIV | Phase 2 | March Biosciences Inc | HIV infection. |
| NCT06534060 | Performance status | Phase 2 | March Biosciences Inc | Karnofsky performance score ≥ 70% or higher. |
| NCT06534060 | Pregnancy | Phase 2 | March Biosciences Inc | For females of childbearing potential (defined as < 24 months of amenorrhea or not surgically sterile [absence of ovaries and/or uterus]), a negative serum pregnancy test must be documented at screening, and prior to lymphodepletion (conditioning). |
| NCT06534060 | Prior malignancy | Phase 2 | March Biosciences Inc | History of any malignancy within 2 years with the exception of cured stage 1 cancers or CIS and potentially indolent cancers not requiring active treatment or controlled with hormone therapy. |
| NCT06534060 | Renal | Phase 2 | March Biosciences Inc | Renal: calculated creatinine clearance > 30 mL/min. |
| NCT06538376 | Pregnancy | Not given | Brigham and Women's Hospital | Special populations, including women with known pregnancy, prisoners, or institutionalized individuals |
| NCT06541990 | Language | Not given | Massachusetts General Hospital | Ability to complete study procedures English |
| NCT06543537 | Language | Not given | Dana-Farber Cancer Institute | Able to speak, understand, and respond to questions written in English |
| NCT06549465 | HIV | Phase 2 | Convergent Therapeutics | Participants with HIV are eligible if they are well-controlled |
| NCT06549465 | Prior malignancy | Phase 2 | Convergent Therapeutics | A known malignancy that is progressing or has required active treatment within the past 3 years other than CRPC, which is expected to alter life expectancy or may interfere with CRPC disease assessment |
| NCT06550141 | Brain metastases | Phase 2 | Marcela V. Maus, M.D.,Ph.D. | No evidence of active CNS disease regardless of prior CNS history. |
| NCT06550141 | Cardiac | Phase 2 | Marcela V. Maus, M.D.,Ph.D. | Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings |
| NCT06550141 | Hepatic | Phase 2 | Marcela V. Maus, M.D.,Ph.D. | Serum ALT/AST ≤2.5 per institutional ULN |
| NCT06550141 | Performance status | Phase 2 | Marcela V. Maus, M.D.,Ph.D. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. |
| NCT06550141 | Pregnancy | Phase 2 | Marcela V. Maus, M.D.,Ph.D. | Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T |
| NCT06550141 | Prior malignancy | Phase 2 | Marcela V. Maus, M.D.,Ph.D. | History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years. |
| NCT06550141 | Renal | Phase 2 | Marcela V. Maus, M.D.,Ph.D. | Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min |
| NCT06551142 | Brain metastases | Phase 1 | GlaxoSmithKline | Primary brain tumor or evidence of brain metastasis (unless meeting the following criteria at the same time: asymptomatic; medically stable for at least 4 weeks prior to initial dosing; no steroid treatment required for at least 4 weeks prior to initial dosing; and no midline shift due to herniation) |
| NCT06551142 | Cardiac | Phase 1 | GlaxoSmithKline | Has QT interval, corrected for heart rate (QTc) >450 msec or QTc >480 msec for participants with bundle branch block. |
| NCT06551142 | Performance status | Phase 1 | GlaxoSmithKline | Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose. |
| NCT06552260 | Brain metastases | Early phase 1 | Ugonma Chukwueke | Has presence of diffuse leptomeningeal disease or extracranial disease. |
| NCT06552260 | Cardiac | Early phase 1 | Ugonma Chukwueke | Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better. |
| NCT06552260 | Hepatic | Early phase 1 | Ugonma Chukwueke | Aspartate aminotransferase (AST [SGOT]) > 1.5 x ULN; |
| NCT06552260 | HIV | Early phase 1 | Ugonma Chukwueke | Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. |
| NCT06552260 | Language | Early phase 1 | Ugonma Chukwueke | Ability to understand and the willingness to sign a written informed consent document. (Providing consents in as many languages as possible is encouraged) |
| NCT06552260 | Performance status | Early phase 1 | Ugonma Chukwueke | Karnofsky Performance Status of ≥ 60. |
| NCT06552260 | Pregnancy | Early phase 1 | Ugonma Chukwueke | Pregnant or lactating female. |
| NCT06552260 | Prior malignancy | Early phase 1 | Ugonma Chukwueke | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06552260 | Renal | Early phase 1 | Ugonma Chukwueke | Serum creatinine > 1.5 mg/dL or a calculated creatinine clearance < 60 mL/min; and |
| NCT06561048 | Brain metastases | Phase 3 | Corvus Pharmaceuticals, Inc. | Participants who have T-cell lymphoma with active central nervous system involvement. |
| NCT06561048 | Hepatic | Phase 3 | Corvus Pharmaceuticals, Inc. | Aspartate aminotransferase and alanine transaminase ≤ 2.5 × ULN (≤ 5 × ULN for participants with liver metastases) |
| NCT06561048 | HIV | Phase 3 | Corvus Pharmaceuticals, Inc. | Known to be positive for HIV, or positive test for chronic hepatitis B virus (HBV) infection |
| NCT06561048 | Performance status | Phase 3 | Corvus Pharmaceuticals, Inc. | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. |
| NCT06561048 | Pregnancy | Phase 3 | Corvus Pharmaceuticals, Inc. | Females who are pregnant, lactating, or intend to become pregnant during their participation in the study |
| NCT06561048 | Prior malignancy | Phase 3 | Corvus Pharmaceuticals, Inc. | History of invasive prior malignancy that required systemic therapy within last 3 years. |
| NCT06561048 | Renal | Phase 3 | Corvus Pharmaceuticals, Inc. | Calculated creatinine clearance (CrCl) according to Cockcroft-Gault formula and based on ideal body weight or 24-hour urine CrCl ≥ 50 mL/minute |
| NCT06561347 | Brain metastases | Phase 2 | Massachusetts General Hospital | Participants with known CNS involvement by WM |
| NCT06561347 | Cardiac | Phase 2 | Massachusetts General Hospital | Any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification |
| NCT06561347 | Hepatic | Phase 2 | Massachusetts General Hospital | AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal, or ≤5 X institutional ULN with documented liver metastases |
| NCT06561347 | HIV | Phase 2 | Massachusetts General Hospital | Participants with known history of Human Immunodeficiency Virus (HIV) |
| NCT06561347 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) |
| NCT06561347 | Pregnancy | Phase 2 | Massachusetts General Hospital | Female participants who are pregnant, breastfeeding, or planning to become pregnant or breastfeed while enrolled in this study |
| NCT06561347 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancers. |
| NCT06561347 | Renal | Phase 2 | Massachusetts General Hospital | Creatinine clearance ≥30 mL/min using the Cockcroft-Gault formula |
| NCT06561685 | Brain metastases | Phase 1 | Eli Lilly and Company | Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement |
| NCT06561685 | Cardiac | Phase 1 | Eli Lilly and Company | Significant cardiovascular disease |
| NCT06561685 | Performance status | Phase 1 | Eli Lilly and Company | Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 |
| NCT06561685 | Pregnancy | Phase 1 | Eli Lilly and Company | Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention |
| NCT06561685 | Prior malignancy | Phase 1 | Eli Lilly and Company | Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment |
| NCT06563596 | Brain metastases | Phase 2 | Reid Merryman, MD | Known central nervous system involvement |
| NCT06563596 | Cardiac | Phase 2 | Reid Merryman, MD | Patients with 1) New York Heart Association Class III or IV heart failure or known ejection fraction of <45%, 2) MI within 6 months prior to screening, 3) unstable angina within 3 months before screening, or 4) history of clinically significant arrhythmias within 6 months of screening (eg sustained Vtach, Vfib, torsades de pointes). |
| NCT06563596 | Hepatic | Phase 2 | Reid Merryman, MD | Total bilirubin < 1.5 X ULN, unless Gilbert syndrome, in which case direct bilirubin must be < 1.5 x ULN |
| NCT06563596 | Performance status | Phase 2 | Reid Merryman, MD | Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. |
| NCT06563596 | Pregnancy | Phase 2 | Reid Merryman, MD | Patients who are pregnant, breast-feeding, or intending to become pregnant during the study. |
| NCT06563596 | Prior malignancy | Phase 2 | Reid Merryman, MD | Prior history of another malignancy (except for non-melanoma skin cancer, in situ cervical or breast cancer, or Gleason 6 prostate cancer managed with observation) unless disease free for at least 2 years OR unless the likelihood of relapse is very low in the opinion of the treating physician. |
| NCT06563596 | Renal | Phase 2 | Reid Merryman, MD | Estimated CrCl (based on Cockcroft Gault or MDRD) ≥ 45ml/min or ≥ 45ml/min/1.73m2 |
| NCT06564038 | Age | Phase 1/2 | AstraZeneca | Participant must be no older than 79 years of age at the time of signing ICF. |
| NCT06564038 | Brain metastases | Phase 1/2 | AstraZeneca | Central nervous system (CNS) lymphoma. |
| NCT06564038 | Cardiac | Phase 1/2 | AstraZeneca | Left ventricular ejection fraction (LVEF) ≥50%. |
| NCT06564038 | Performance status | Phase 1/2 | AstraZeneca | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. |
| NCT06564233 | Language | Not given | Victor Wang | Not fluent in English. |
| NCT06565052 | Language | Not given | Dana-Farber Cancer Institute | English-Speaking. |
| NCT06565052 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer. |
| NCT06567743 | Pregnancy | Phase 2 | CG Oncology, Inc. | Pregnant or breastfeeding. |
| NCT06569147 | Cardiac | Phase 1/2 | Dana-Farber Cancer Institute | AL Amyloidosis Cardiac stage I, II or IIIa disease based on the 2013 European Modification of the 2004 Standard Mayo Clinic Staging in participants with advanced cardiac involvement |
| NCT06569147 | Hepatic | Phase 1/2 | Dana-Farber Cancer Institute | Direct bilirubin ≤1.5 × institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN |
| NCT06569147 | HIV | Phase 1/2 | Dana-Farber Cancer Institute | Participants seropositive for the human immunodeficiency virus (HIV). |
| NCT06569147 | Performance status | Phase 1/2 | Dana-Farber Cancer Institute | ECOG performance status ≤2 or Karnofsky ≥60% |
| NCT06569147 | Pregnancy | Phase 1/2 | Dana-Farber Cancer Institute | Women who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study |
| NCT06569147 | Prior malignancy | Phase 1/2 | Dana-Farber Cancer Institute | Participants with an active malignancy (including lymphoma) with the following exceptions: adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer; adequately treated stage I cancer from which the patient is currently in remission and has been for over 2 years |
| NCT06569147 | Renal | Phase 1/2 | Dana-Farber Cancer Institute | Creatinine: Calculated clearance ≥30 mL/min using Cockcault-Groft equation |
| NCT06580314 | Brain metastases | Phase 3 | NRG Oncology | Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression and patients are neurologically stable off steroid therapy |
| NCT06580314 | Cardiac | Phase 3 | NRG Oncology | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better |
| NCT06580314 | Hepatic | Phase 3 | NRG Oncology | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled) |
| NCT06580314 | Performance status | Phase 3 | NRG Oncology | Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 |
| NCT06580314 | Pregnancy | Phase 3 | NRG Oncology | Not pregnant and not nursing |
| NCT06580314 | Renal | Phase 3 | NRG Oncology | Creatinine clearance (CrCL) of > 30 mL/min by the Cockcroft-Gault formula |
| NCT06581406 | Brain metastases | Phase 2/3 | Replimune, Inc. | Any central nervous system (CNS) involvement of melanoma, including carcinomatous meningitis. |
| NCT06581406 | HIV | Phase 2/3 | Replimune, Inc. | Known acute or chronic Hepatitis B or C infection or human immunodeficiency virus (HIV) infection or any other uncontrolled infection. |
| NCT06581406 | Performance status | Phase 2/3 | Replimune, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. |
| NCT06585410 | Performance status | Phase 3 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 |
| NCT06586957 | Brain metastases | Phase 1 | NiKang Therapeutics, Inc. | Known active CNS metastases and/or carcinomatous meningitis |
| NCT06586957 | Cardiac | Phase 1 | NiKang Therapeutics, Inc. | Left ventricular ejection fraction (LVEF) <50% as measured by echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 4 weeks prior to first dose |
| NCT06586957 | Hepatic | Phase 1 | NiKang Therapeutics, Inc. | Childs-Pugh class B or C cirrhosis or any other clinically significant liver disorder |
| NCT06586957 | HIV | Phase 1 | NiKang Therapeutics, Inc. | Known human immunodeficiency virus (HIV), active hepatitis B or C infection |
| NCT06586957 | Prior malignancy | Phase 1 | NiKang Therapeutics, Inc. | History of another malignancy with exceptions |
| NCT06588478 | Brain metastases | Phase 2 | Loxo Oncology, Inc. | Have known or suspected history of central nervous system involvement by CLL/SLL |
| NCT06588478 | Performance status | Phase 2 | Loxo Oncology, Inc. | Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2. |
| NCT06588478 | Prior malignancy | Phase 2 | Loxo Oncology, Inc. | Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. |
| NCT06589596 | Brain metastases | Phase 1 | BeOne Medicines | Active leptomeningeal disease or symptomatic spinal cord compression |
| NCT06589596 | Cardiac | Phase 1 | BeOne Medicines | QT interval corrected by Fridericia's method (QTcF) > 470 ms based on the screening triplicate 12-lead ECG records and/or a history of additional risk factors for torsade de pointes (eg, heart failure, hypokalemia, or a family history of Long QT Syndrome) |
| NCT06589596 | HIV | Phase 1 | BeOne Medicines | Known human immunodeficiency virus (HIV) infection. |
| NCT06589596 | Performance status | Phase 1 | BeOne Medicines | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 or Karnofsky Performance Scale (KPS) ≥ 70 |
| NCT06589596 | Pregnancy | Phase 1 | BeOne Medicines | Female participants who are pregnant or are breastfeeding |
| NCT06589596 | Prior malignancy | Phase 1 | BeOne Medicines | Any malignancy ≤ 2 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively |
| NCT06589804 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. |
| NCT06589804 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x ULN OR direct bilirubin < ULN for participant with total bilirubin > 1.5 x institutional ULN. |
| NCT06589804 | HIV | Phase 3 | National Cancer Institute (NCI) | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial. |
| NCT06589804 | Performance status | Phase 3 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. |
| NCT06589804 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects. |
| NCT06589804 | Renal | Phase 3 | National Cancer Institute (NCI) | Creatinine ≤ 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault formula for participant with creatinine levels > 1.5 x institutional ULN. |
| NCT06597721 | Brain metastases | Phase 1 | Adcendo ApS | Central nervous system (CNS) metastasis. |
| NCT06597721 | Cardiac | Phase 1 | Adcendo ApS | Significant cardiac disease; recent myocardial infarction, acute coronary syndromes, congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias |
| NCT06597721 | Performance status | Phase 1 | Adcendo ApS | Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. |
| NCT06597721 | Prior malignancy | Phase 1 | Adcendo ApS | Prior second malignancy except for: |
| NCT06609473 | Age | Not given | Dana-Farber Cancer Institute | Child is ≤18 years of age at time of enrollment, or over 18 years of age but under medical guardianship; |
| NCT06615479 | Brain metastases | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM). |
| NCT06615479 | Performance status | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Participants must have an Eastern Cooperative Oncology group performance status 0 or 1. |
| NCT06616584 | Brain metastases | Phase 2/3 | SWOG Cancer Research Network | Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to randomization |
| NCT06616584 | Cardiac | Phase 2/3 | SWOG Cancer Research Network | Participants must not have any grade III/IV cardiac disease as defined by the New York Heart Association criteria (i.e., participants with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, and myocardial infarction within 6 months prior to randomization, or serious uncontrolled cardiac arrhythmia |
| NCT06616584 | Hepatic | Phase 2/3 | SWOG Cancer Research Network | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (within 28 days prior to randomization) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN |
| NCT06616584 | HIV | Phase 2/3 | SWOG Cancer Research Network | Participants with known human immunodeficiency virus (HIV) infection are eligible, provided they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to randomization |
| NCT06616584 | Performance status | Phase 2/3 | SWOG Cancer Research Network | Participants' most recent Zubrod/Eastern Cooperative Oncology Group (ECOG) performance status must be 0-1 and be documented within 28 days prior to randomization |
| NCT06616584 | Pregnancy | Phase 2/3 | SWOG Cancer Research Network | Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). |
| NCT06616584 | Prior malignancy | Phase 2/3 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT06616584 | Renal | Phase 2/3 | SWOG Cancer Research Network | Participants must have a creatinine ≤ the institutional (I)ULN or calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft-Gault formula. |
| NCT06619587 | Brain metastases | Phase 1 | Genentech, Inc. | Active brain metastases |
| NCT06619587 | Cardiac | Phase 1 | Genentech, Inc. | Clinically significant cardiovascular dysfunction or liver disease |
| NCT06619587 | Hepatic | Phase 1 | Genentech, Inc. | Clinically significant cardiovascular dysfunction or liver disease |
| NCT06623097 | Age | Not given | Dana-Farber Cancer Institute | Adult cancer survivors less than 65 years of age. |
| NCT06623097 | BMI | Not given | Dana-Farber Cancer Institute | Survivors with a BMI <25 kg/m2 and body fat <35% for people assigned female at birth and <25% for people assigned male at birth. |
| NCT06623097 | Pregnancy | Not given | Dana-Farber Cancer Institute | people who are pregnant, or plan to become pregnant during study duration will be excluded |
| NCT06623097 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Survivors receiving treatment for an active malignancy (exceptions are treatment for basal cell carcinoma. They may receive long term treatments for their diagnosed breast, lung, prostate or colorectal cancer including hormone therapy). This study is exclusively targeting survivors post-primary cancer treatment. |
| NCT06623422 | HIV | Phase 3 | Merck Sharp & Dohme LLC | Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART) |
| NCT06623422 | Performance status | Phase 3 | Merck Sharp & Dohme LLC | Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention |
| NCT06624644 | Performance status | Phase 2/3 | Linnaeus Therapeutics, Inc. | Eastern Cooperative Oncology Group Performance Status of 0 to 1. |
| NCT06625775 | Brain metastases | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Stable brain metastases |
| NCT06625775 | Performance status | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 |
| NCT06630234 | Brain metastases | Phase 1/2 | Deciphera Pharmaceuticals, LLC | Has known active central nervous system (CNS) metastases or an active primary CNS cancer |
| NCT06630234 | Performance status | Phase 1/2 | Deciphera Pharmaceuticals, LLC | Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 |
| NCT06630234 | Prior malignancy | Phase 1/2 | Deciphera Pharmaceuticals, LLC | Prior or concurrent malignancy that requires treatment or is expected to require treatment for active cancer |
| NCT06632977 | Prior malignancy | Phase 2 | Alliance for Clinical Trials in Oncology | Patients with variant histologies including neuroendocrine, small cell and sarcomatoid prostate cancer are allowed to enroll |
| NCT06635785 | Brain metastases | Phase 1/2 | OncoC4, Inc. | Patients who have brain metastases or leptomeningeal metastases. |
| NCT06635785 | Cardiac | Phase 1/2 | OncoC4, Inc. | Within past 6 months with history of significant cardiovascular acute myocardial infarction, acute coronary syndrome, ischemic or hemorrhagic stroke, revascularization procedures, acute pulmonary embolism or any disorders resulted in LVEF < 40% at the time of screening |
| NCT06635785 | Pregnancy | Phase 1/2 | OncoC4, Inc. | Patients who are pregnant or breastfeeding or plan pregnancy or fathering the child during the study or within 6 months after the last dosing of study drug |
| NCT06635785 | Prior malignancy | Phase 1/2 | OncoC4, Inc. | Patient with a different cancer other than the one treated under this protocol, which requires systemic treatments within 24 months prior to C1D1. |
| NCT06638307 | Brain metastases | Phase 1 | Stemline Therapeutics, Inc. | Active or newly diagnosed central nervous system metastases. |
| NCT06641908 | Brain metastases | Phase 1 | EMD Serono Research & Development Institute, Inc. | STS only: Participants with history of brain metastasis, leptomeningeal metastasis, or participants with spinal cord compression |
| NCT06641908 | Performance status | Phase 1 | EMD Serono Research & Development Institute, Inc. | Eastern Cooperative Oncology Group Performance Status (ECOG PS) below or equal to 1 |
| NCT06641908 | Prior malignancy | Phase 1 | EMD Serono Research & Development Institute, Inc. | Participant has a history of malignancy other than STS or glioblastoma (depending on the escalation/expansion cohort) within 3 years before the date of enrollment |
| NCT06643884 | Brain metastases | Phase 2 | Aura Biosciences | Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy where placement of the beam is likely to impact the study eye. |
| NCT06644183 | Age | Phase 1/2 | Jennifer R. Brown, MD, PhD | Patients who are < 75 years may have bilirubin of ≤ 3.0 × ULN |
| NCT06644183 | Brain metastases | Phase 1/2 | Jennifer R. Brown, MD, PhD | Patients with clinically inactive CNS disease or treated CNS disease that is no longer symptomatic, or who need corticosteroids or anticonvulsants may be enrolled in the study. |
| NCT06644183 | Cardiac | Phase 1/2 | Jennifer R. Brown, MD, PhD | Patients with a QTcF > 470 msec at screening. |
| NCT06644183 | Hepatic | Phase 1/2 | Jennifer R. Brown, MD, PhD | Total bilirubin ≤ 1.5 ×institutional upper limit of normal (ULN)* |
| NCT06644183 | HIV | Phase 1/2 | Jennifer R. Brown, MD, PhD | Known Human immunodeficiency virus (HIV) infection which is treated with agents that can interfere with venetoclax due to potential drug-drug interactions or increased risk of myelotoxicity. |
| NCT06644183 | Performance status | Phase 1/2 | Jennifer R. Brown, MD, PhD | Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. |
| NCT06644183 | Pregnancy | Phase 1/2 | Jennifer R. Brown, MD, PhD | Pregnant women are excluded from this study because venetoclax has the potential to cause embryo-fetal harm |
| NCT06644183 | Prior malignancy | Phase 1/2 | Jennifer R. Brown, MD, PhD | Patients with a history of other primary malignancy are excluded when they require therapy that will interfere with the investigational treatments. |
| NCT06644183 | Renal | Phase 1/2 | Jennifer R. Brown, MD, PhD | Creatinine clearance ≥ 60 mL/min** |
| NCT06644755 | Brain metastases | Phase 1 | Daiichi Sankyo | Has known symptomatic central nervous system (CNS) metastases, leptomeningeal disease, or cord compression. |
| NCT06644755 | Cardiac | Phase 1 | Daiichi Sankyo | Myocardial infarction within 6 months prior to screening |
| NCT06644755 | HIV | Phase 1 | Daiichi Sankyo | Has human immunodeficiency virus (HIV) infection. |
| NCT06644755 | Pregnancy | Phase 1 | Daiichi Sankyo | Participant does not breastfeed during the trial intervention period and for at least 120 days after last dose of trial intervention. |
| NCT06644755 | Prior malignancy | Phase 1 | Daiichi Sankyo | Has active other primary malignancies. |
| NCT06647953 | Age | Phase 3 | Children's Oncology Group | 21 years of age or younger |
| NCT06647953 | Cardiac | Phase 3 | Children's Oncology Group | Shortening fraction of ≥ 27% by echocardiogram, or ejection fraction of ≥ 50% by radionuclide angiogram |
| NCT06647953 | Hepatic | Phase 3 | Children's Oncology Group | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age |
| NCT06647953 | HIV | Phase 3 | Children's Oncology Group | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible as long as they are NOT receiving anti-retroviral agents that are strong inhibitors or inducers of CYP3A4 |
| NCT06647953 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT06647953 | Prior malignancy | Phase 3 | Children's Oncology Group | Administration of prior PPB-directed chemotherapy is an exclusion criterion. Prior treatment for another malignancy is not an exclusion criterion |
| NCT06647953 | Renal | Phase 3 | Children's Oncology Group | A glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 |
| NCT06649851 | Hepatic | Phase 2 | Massachusetts General Hospital | total bilirubin≤ institutional upper limit of normal (ULN) |
| NCT06649851 | HIV | Phase 2 | Massachusetts General Hospital | or known HIV (human immunodeficiency virus), since HIV/AIDS is an immunocompromising disease affecting lymphocyte counts |
| NCT06649851 | Language | Phase 2 | Massachusetts General Hospital | Presence of significant aphasia or any other language impairment at time of diagnosis with GBM is considered an exclusion criterion. |
| NCT06649851 | Performance status | Phase 2 | Massachusetts General Hospital | Karnofsky Performance Status (KPS) > 60, see Appendix A |
| NCT06649851 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study |
| NCT06649851 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (use of granulocyte colony stimulating factor (G-CSF)) are eligible for this trial. |
| NCT06649851 | Renal | Phase 2 | Massachusetts General Hospital | glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2. |
| NCT06651580 | Age | Not given | M.D. Anderson Cancer Center | All children must be under 18 years of age at the time of enrollment |
| NCT06655246 | Brain metastases | Phase 1 | Kura Oncology, Inc. | Active central nervous system metastases. |
| NCT06655246 | Cardiac | Phase 1 | Kura Oncology, Inc. | Mean corrected QT interval (QTcF) greater than 470ms. |
| NCT06655246 | Performance status | Phase 1 | Kura Oncology, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 at screening. |
| NCT06655246 | Pregnancy | Phase 1 | Kura Oncology, Inc. | Is pregnant or breastfeeding. |
| NCT06655246 | Prior malignancy | Phase 1 | Kura Oncology, Inc. | History of prior or current cancer that has potential to interfere with obtaining study results. |
| NCT06657222 | Brain metastases | Phase 1/2 | Gilead Sciences | For patients with known brain metastases, evidence of clinically stable disease post radiation therapy is required prior to enrollment. |
| NCT06657222 | Performance status | Phase 1/2 | Gilead Sciences | Eastern Cooperative Oncology Group (ECOG) 0-1. |
| NCT06661720 | Hepatic | Phase 3 | Alliance for Clinical Trials in Oncology | Total bilirubin =< 3 x upper limit of normal (ULN) |
| NCT06661720 | HIV | Phase 3 | Alliance for Clinical Trials in Oncology | HIV status: HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT06661720 | Performance status | Phase 3 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (or Karnofsky >= 60%) |
| NCT06661720 | Pregnancy | Phase 3 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. |
| NCT06661720 | Prior malignancy | Phase 3 | Alliance for Clinical Trials in Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT06661720 | Renal | Phase 3 | Alliance for Clinical Trials in Oncology | Calculated (calc.) creatinine clearance >= 30 mL/min (using Cockcroft Gault equation or the estimated glomerular filtration rate from the modification of diet in renal disease trial) |
| NCT06664151 | Cardiac | Early phase 1 | Dana-Farber Cancer Institute | uncontrolled cardiac disease (New York Heart Association Class III or IV heart failure, myocardial infarction in the 6 months prior to enrollment, unstable angina). |
| NCT06664151 | HIV | Early phase 1 | Dana-Farber Cancer Institute | For participants with a past medical history of Human immunodeficiency virus (HIV), they must be on effective anti-retroviral therapy with undetectable viral load measured within the 6 months prior to enrollment. |
| NCT06664151 | Performance status | Early phase 1 | Dana-Farber Cancer Institute | ECOG performance status ≤3 (Karnofsky ≥40%, see Appendix A). |
| NCT06664151 | Pregnancy | Early phase 1 | Dana-Farber Cancer Institute | Pregnant or nursing (breast-feeding) women are excluded from this study because there is an unknown but potential risk to multiple injections of flu vaccine in pregnant or nursing women. |
| NCT06664151 | Prior malignancy | Early phase 1 | Dana-Farber Cancer Institute | Participants with a past medical history of another malignancy whose natural history or treatment is likely to interfere with the safety or efficacy assessment of the investigational regimen, according to the treating investigator. |
| NCT06665100 | Pregnancy | Phase 2 | Pulmotect, Inc. | If female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. |
| NCT06667076 | Performance status | Phase 2 | Janssen Research & Development, LLC | Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 |
| NCT06667076 | Prior malignancy | Phase 2 | Janssen Research & Development, LLC | Has a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s) |
| NCT06667141 | Brain metastases | Phase 1/2 | Acrivon Therapeutics | Participants with known symptomatic brain metastases. |
| NCT06667141 | Performance status | Phase 1/2 | Acrivon Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry |
| NCT06667141 | Pregnancy | Phase 1/2 | Acrivon Therapeutics | Women who are pregnant or lactating. |
| NCT06667908 | Cardiac | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | Any of the following within 3 months prior to enrollment/randomization: severe or unstable angina, myocardial infarction, clinically significant ventricular arrhythmias or heart failure New York heart association functional classification class III to IV |
| NCT06667908 | Performance status | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 |
| NCT06667908 | Prior malignancy | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | Another concurrent or prior primary malignancy within the last 36 months at informed consent |
| NCT06672146 | Performance status | Phase 2 | National Cancer Institute (NCI) | Participants must have Zubrod Performance Status of 0-3 as determined by a history and physical (H&P) exam completed within 14 days prior to registration |
| NCT06676852 | Language | Not given | Massachusetts General Hospital | Inability to comprehend English as this is a preliminary/pilot study |
| NCT06677190 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participants with known brain metastases are eligible if they have completed primary CNS-directed therapy (such as surgical resection or radiotherapy) and if they have remained clinically stable, asymptomatic, radiologically stable without evidence of progression for at least 4 weeks by repeat imaging and have been off of steroids for at least 4 weeks prior to starting study treatment. |
| NCT06677190 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Participants with significant cardiovascular impairment, including uncontrolled hypertension, congestive heart failure of New York Heart Association Grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia within the past 6 months. |
| NCT06677190 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional upper limit of normal (ULN) (in the absence of liver metastases) or ≤ 5 x institutional ULN (in the presence of liver metastases) |
| NCT06677190 | HIV | Phase 2 | Dana-Farber Cancer Institute | Is known to be positive for Human Immunodeficiency Virus (HIV). |
| NCT06677190 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 (Karnofsky performance scale ≥70%, see Appendix A). |
| NCT06677190 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women are excluded from this study. |
| NCT06677190 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the Belzutifan, as determined after discussion with the Sponsor-Investigator, are eligible for this trial. |
| NCT06677190 | Renal | Phase 2 | Dana-Farber Cancer Institute | Creatinine ≤ 1.5 x institutional upper limit of normal (ULN) OR estimated creatinine clearance (CrCl) by the Cockcroft-Gault formula ≥51mL/min if creatinine > 1.5 x institutional ULN or institutional standard method |
| NCT06679101 | Cardiac | Phase 3 | GlaxoSmithKline | Recent history (within 3 months of screening) of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty or stenting, or bypass grafting. |
| NCT06679101 | Hepatic | Phase 3 | GlaxoSmithKline | Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the investigator's assessment). |
| NCT06679101 | HIV | Phase 3 | GlaxoSmithKline | Known human immunodeficiency virus (HIV) infection, unless the participant can meet all of the following criteria: |
| NCT06679101 | Performance status | Phase 3 | GlaxoSmithKline | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. |
| NCT06679101 | Pregnancy | Phase 3 | GlaxoSmithKline | A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies: |
| NCT06679101 | Prior malignancy | Phase 3 | GlaxoSmithKline | Participants with previous or concurrent malignancies other than multiple myeloma are excluded. |
| NCT06682988 | Performance status | Phase 2 | AbbVie | Participants with an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. |
| NCT06686394 | Brain metastases | Phase 1/2 | Merck Sharp & Dohme LLC | Part 2: Evidence of spinal cord compression or brain/CNS metastases. |
| NCT06686394 | HIV | Phase 1/2 | Merck Sharp & Dohme LLC | Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART) |
| NCT06686394 | Performance status | Phase 1/2 | Merck Sharp & Dohme LLC | Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention |
| NCT06686394 | Prior malignancy | Phase 1/2 | Merck Sharp & Dohme LLC | Known additional malignancy that is progressing or has required active treatment within the past 3 years |
| NCT06690775 | Brain metastases | Phase 2 | TORL Biotherapeutics, LLC | Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded. |
| NCT06690775 | Cardiac | Phase 2 | TORL Biotherapeutics, LLC | QTcF interval * 470 msec and without history of Torsades des Pointes or other symptomatic QTc abnormality. |
| NCT06690775 | Hepatic | Phase 2 | TORL Biotherapeutics, LLC | Serum total bilirubin: ≤1.5 X ULN (participants with known Gilbert disease or liver metastases who have serum bilirubin level ≤3×ULN may be enrolled |
| NCT06690775 | Performance status | Phase 2 | TORL Biotherapeutics, LLC | Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. |
| NCT06690775 | Pregnancy | Phase 2 | TORL Biotherapeutics, LLC | Participants must agree to not breastfeed from the first dose of study treatment through 90 days after the last dose of study treatment. |
| NCT06690775 | Prior malignancy | Phase 2 | TORL Biotherapeutics, LLC | History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. |
| NCT06690775 | Renal | Phase 2 | TORL Biotherapeutics, LLC | Measured or calculated creatinine clearance with a validated formula*: ≥30 mL/min |
| NCT06691217 | Hepatic | Phase 2 | Massachusetts General Hospital | known active or recurrent hepatic disease (including cirrhosis or ALT/AST levels >3 times the upper limit oof or total bilirubin >2 times the upper limits of normal) |
| NCT06691217 | Pregnancy | Phase 2 | Massachusetts General Hospital | pregnancy or breastfeeding |
| NCT06691217 | Renal | Phase 2 | Massachusetts General Hospital | estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73 m2 |
| NCT06697184 | HIV | Phase 1/2 | BeOne Medicines | Positive HIV serology (HIVAb) status unless certain conditions are met. |
| NCT06697184 | Performance status | Phase 1/2 | BeOne Medicines | Stable Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. |
| NCT06706076 | Performance status | Phase 1/2 | BlossomHill Therapeutics | Eastern Cooperative Oncology Group Performance Status ≤ 1. |
| NCT06706076 | Prior malignancy | Phase 1/2 | BlossomHill Therapeutics | History of any concurrent malignancy within the previous 2 years. |
| NCT06707493 | Age | Phase 2 | Massachusetts General Hospital | Between the ages of 18 and 75 years |
| NCT06707493 | Cardiac | Phase 2 | Massachusetts General Hospital | LVEF must be equal to or greater than 40%, as measured by MUGA scan or echocardiogram |
| NCT06707493 | Hepatic | Phase 2 | Massachusetts General Hospital | Direct bilirubin < 2.0 mg/dL |
| NCT06707493 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status ≤ 2 |
| NCT06707493 | Pregnancy | Phase 2 | Massachusetts General Hospital | Female patients of childbearing potential must have a negative pregnancy test |
| NCT06707493 | Prior malignancy | Phase 2 | Massachusetts General Hospital | History of other malignancy(ies) unless |
| NCT06707493 | Renal | Phase 2 | Massachusetts General Hospital | Calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula) |
| NCT06709495 | Age | Phase 1/2 | David S Shulman, MD | Age: ≥ 12 years and ≤ 49 years. |
| NCT06709495 | Brain metastases | Phase 1/2 | David S Shulman, MD | Patients with CNS metastatic disease will not be eligible for the phase 2 EWS and DSRCT cohorts. |
| NCT06709495 | Cardiac | Phase 1/2 | David S Shulman, MD | Adequate Cardiac Function: QTc < 480 msec |
| NCT06709495 | Hepatic | Phase 1/2 | David S Shulman, MD | Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age |
| NCT06709495 | Performance status | Phase 1/2 | David S Shulman, MD | Performance Status: Karnofsky ≥ 50% for patients >16 year of age and Lansky ≥ 50% for patients ≤ 16 years of age. |
| NCT06709495 | Pregnancy | Phase 1/2 | David S Shulman, MD | Pregnant participants, given that the effects of PEEL-224 on the developing human fetus are unknown. |
| NCT06709495 | Prior malignancy | Phase 1/2 | David S Shulman, MD | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06709495 | Renal | Phase 1/2 | David S Shulman, MD | Adequate Renal Function: Creatinine clearance or radioisotope GFR ≥70ml/min/1.73 m2 or A serum creatinine based on age/sex as follows: |
| NCT06710548 | Language | Not given | Dana-Farber Cancer Institute | English-speaking. |
| NCT06710548 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status of 0-2. |
| NCT06712355 | Brain metastases | Phase 3 | BioNTech SE | Participants with known leptomeningeal metastases. |
| NCT06712355 | Diabetes | Phase 3 | BioNTech SE | Have uncontrolled hypertension or poorly controlled diabetes prior to study treatment. |
| NCT06712355 | Performance status | Phase 3 | BioNTech SE | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06716580 | Age | Not given | Dana-Farber Cancer Institute | Group 1 (50 through 80 years of age) |
| NCT06716580 | Language | Not given | Dana-Farber Cancer Institute | Able to complete and understand the study's informed consent in English, Mandarin, Cantonese, Japanese, Korean, Vietnamese, Spanish, Portuguese, or Cape Verdean |
| NCT06716580 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant women |
| NCT06716580 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Personal diagnosis of lung cancer |
| NCT06716580 | Smoking | Not given | Dana-Farber Cancer Institute | Non-tobacco using (currently) |
| NCT06720987 | Brain metastases | Phase 1 | Kumquat Biosciences Inc. | Active primary central nervous system tumors |
| NCT06720987 | Cardiac | Phase 1 | Kumquat Biosciences Inc. | Cardiac abnormalities |
| NCT06721689 | Age | Phase 1/2 | Theodore Laetsch | Phase 2 Neuroblastoma (NBL) cohort: Age greater than or equal to 1 year and less than or equal to 30 years |
| NCT06721689 | Brain metastases | Phase 1/2 | Theodore Laetsch | Subjects with primary central nervous system (CNS) solid tumors or central nervous system (CNS) metastatic disease. |
| NCT06721689 | Cardiac | Phase 1/2 | Theodore Laetsch | Subjects with symptomatic congestive heart failure. |
| NCT06721689 | Hepatic | Phase 1/2 | Theodore Laetsch | Total bilirubin: less than or equal to 1.5 times the upper limit of normal with the exception of patients with Gilbert's syndrome who must have bilirubin less than 3X institutional upper limit of normal (ULN). |
| NCT06721689 | HIV | Phase 1/2 | Theodore Laetsch | Subjects with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening). |
| NCT06721689 | Performance status | Phase 1/2 | Theodore Laetsch | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 (age greater than 16 years) |
| NCT06721689 | Pregnancy | Phase 1/2 | Theodore Laetsch | Pregnant or lactating females. |
| NCT06721689 | Renal | Phase 1/2 | Theodore Laetsch | Adequate renal function as evidenced by creatinine clearance as calculated by the Schwartz equation (see below), radioisotope glomerular filtration rate (GFR) greater than or equal to 70 mL/min/1.73 m2, or maximum serum creatinine as below: |
| NCT06723236 | Brain metastases | Phase 1 | MacroGenics | Active brain metastases or leptomeningeal metastases. |
| NCT06723236 | Pregnancy | Phase 1 | MacroGenics | Participants must not be pregnant, planning to be pregnant, or breastfeeding. |
| NCT06723236 | Prior malignancy | Phase 1 | MacroGenics | Another malignancy that required treatment within the past 2 years, with the exception of those with a negligible risk of metastasis or death such as adequately treated non-melanomatous skin cancer, localized prostate cancer (Gleason Score < 6), or carcinoma in situ. |
| NCT06724016 | Brain metastases | Phase 1 | Hanmi Pharmaceutical Company Limited | Known active CNS metastases and/or carcinomatous meningitis. |
| NCT06724016 | Hepatic | Phase 1 | Hanmi Pharmaceutical Company Limited | History of chronic liver disease or evidence of hepatic cirrhosis. |
| NCT06724016 | HIV | Phase 1 | Hanmi Pharmaceutical Company Limited | Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients. |
| NCT06724016 | Performance status | Phase 1 | Hanmi Pharmaceutical Company Limited | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days before allocation or randomization. |
| NCT06726148 | Brain metastases | Phase 1/2 | Novartis Pharmaceuticals | Presence of symptomatic CNS metastases or CNS metastases that require local therapy or increasing doses of corticosteroids within 2 weeks prior to study entry. |
| NCT06726148 | Cardiac | Phase 1/2 | Novartis Pharmaceuticals | Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including MI, CABG, long QT syndrome, or risk factors for TdP. |
| NCT06726148 | Pregnancy | Phase 1/2 | Novartis Pharmaceuticals | WOCBP who are unwilling to use highly effective contraception methods, pregnant or nursing women. |
| NCT06736704 | Brain metastases | Phase 1/2 | Pikavation Therapeutics, Inc. | Active brain metastases or carcinomatous meningitis |
| NCT06736704 | Cardiac | Phase 1/2 | Pikavation Therapeutics, Inc. | Clinically significant ECG abnormalities, including QTcF ≥ 470 ms |
| NCT06736704 | Diabetes | Phase 1/2 | Pikavation Therapeutics, Inc. | Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus |
| NCT06742996 | Brain metastases | Phase 3 | BeOne Medicines | Known central nervous system involvement by lymphoma |
| NCT06742996 | Cardiac | Phase 3 | BeOne Medicines | Clinically significant cardiovascular disease |
| NCT06742996 | Performance status | Phase 3 | BeOne Medicines | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 |
| NCT06743126 | Brain metastases | Phase 3 | Immatics US, Inc. | Patients with active brain metastases or leptomeningeal metastases |
| NCT06743126 | Cardiac | Phase 3 | Immatics US, Inc. | History of cardiac conditions as per protocol |
| NCT06743126 | HIV | Phase 3 | Immatics US, Inc. | Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection. |
| NCT06743126 | Performance status | Phase 3 | Immatics US, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT06743126 | Pregnancy | Phase 3 | Immatics US, Inc. | Pregnant or breastfeeding |
| NCT06743126 | Prior malignancy | Phase 3 | Immatics US, Inc. | History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years |
| NCT06744296 | Age | Not given | Massachusetts Eye and Ear Infirmary | Patients <18 years of age |
| NCT06744296 | Pregnancy | Not given | Massachusetts Eye and Ear Infirmary | Active pregnancy during treatment. |
| NCT06744296 | Prior malignancy | Not given | Massachusetts Eye and Ear Infirmary | Active non-HNSCC malignancy. |
| NCT06747845 | Brain metastases | Phase 2 | Abramson Cancer Center at Penn Medicine | Patients must not have known, symptomatic brain or leptomeningeal metastases. |
| NCT06747845 | Hepatic | Phase 2 | Abramson Cancer Center at Penn Medicine | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper limit of normal (ULN); if liver metastases, then ≤5 x ULN |
| NCT06747845 | HIV | Phase 2 | Abramson Cancer Center at Penn Medicine | Patients with HIV may enroll, but must have an undetectable viral load at the time of enrollment and must be receiving a stable regimen of HAART. |
| NCT06747845 | Performance status | Phase 2 | Abramson Cancer Center at Penn Medicine | Eastern Cooperative Oncology (ECOG) performance status of 0 to 1. |
| NCT06747845 | Pregnancy | Phase 2 | Abramson Cancer Center at Penn Medicine | Female participant has a negative serum pregnancy test within 24 hours prior to taking study treatment if of childbearing potential |
| NCT06747845 | Prior malignancy | Phase 2 | Abramson Cancer Center at Penn Medicine | Patients must not be undergoing treatment for a second active cancer at the time of randomization. |
| NCT06747845 | Renal | Phase 2 | Abramson Cancer Center at Penn Medicine | Serum creatinine ≤1.5 x ULN or estimated glomerular filtration rate (GFR) ≥45 mL/min using Cockcroft Gault formula. |
| NCT06748222 | Age | Phase 3 | NRG Oncology | The participant must have been greater than or equal to 18 or less than or equal to 50 years of age at the time of breast cancer diagnosis. |
| NCT06748222 | Language | Phase 3 | NRG Oncology | Participant must be able to understand, speak, read, and write in English or Spanish. |
| NCT06748222 | Pregnancy | Phase 3 | NRG Oncology | Currently pregnant or planning to become pregnant in the near future. |
| NCT06748222 | Prior malignancy | Phase 3 | NRG Oncology | Current or past history of another cancer. Participants with a history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible. |
| NCT06758401 | Brain metastases | Phase 3 | Pfizer | Known active CNS lesions are excluded. |
| NCT06758401 | Diabetes | Phase 3 | Pfizer | Uncontrolled diabetes mellitus, defined as HbA1c ≥8.0% or HbA1c between 7.0% and 8.0% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. |
| NCT06758401 | HIV | Phase 3 | Pfizer | History of or current ongoing infection, including participants positive for active HIV, HBV, or HCV. |
| NCT06758401 | Prior malignancy | Phase 3 | Pfizer | Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. |
| NCT06759649 | Brain metastases | Phase 1 | Compugen Ltd | Have known active central nervous system (CNS) metastases and/or leptomeningeal disease (LMD). |
| NCT06759649 | HIV | Phase 1 | Compugen Ltd | Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or participants with human immunodeficiency virus (HIV). |
| NCT06759649 | Prior malignancy | Phase 1 | Compugen Ltd | History of another malignancy within 2 years prior to the first trial intervention administration (unless the malignancy was treated with curative intent with low risk of recurrence [e.g., nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar] which are allowed to enroll). |
| NCT06760819 | Brain metastases | Phase 2 | Bayer | Active brain metastases |
| NCT06763432 | Prior malignancy | Not given | Massachusetts General Hospital | Individuals with a personal history of colorectal cancer |
| NCT06765109 | Brain metastases | Phase 3 | Nuvalent Inc. | Brain metastases associated with progressive neurological symptoms or requiring increasing doses of corticosteroids to control CNS disease |
| NCT06765109 | Cardiac | Phase 3 | Nuvalent Inc. | QT corrected for heart rate by Fridericia's formula (QTcF) > 470 msec on repeated assessments |
| NCT06765109 | Prior malignancy | Phase 3 | Nuvalent Inc. | Active malignancy requiring therapy within 2 years prior to randomization |
| NCT06767514 | Brain metastases | Phase 3 | Summit Therapeutics | Symptomatic CNS metastases, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to randomization, potential need for CNS radiation within the first cycle, or leptomeningeal disease |
| NCT06767514 | Performance status | Phase 3 | Summit Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 |
| NCT06767514 | Prior malignancy | Phase 3 | Summit Therapeutics | Other prior malignancy (including previously treated NSCLC) unless the patient has undergone curative therapy with no evidence of recurrence of the disease for 3 years prior to randomization |
| NCT06769126 | Age | Phase 2 | SWOG Cancer Research Network | Participants must not have a history of limited stage small cell lung cancer |
| NCT06769126 | BMI | Phase 2 | SWOG Cancer Research Network | Participants must have body weight > 30 kg |
| NCT06769126 | Brain metastases | Phase 2 | SWOG Cancer Research Network | Participant must not have leptomeningeal disease, spinal cord compression, or symptomatic brain metastases unless: (1) metastases have been locally treated and have remained clinically controlled and asymptomatic for at least 14 days following treatment |
| NCT06769126 | Hepatic | Phase 2 | SWOG Cancer Research Network | Aspartate aminotransferase (AST)/alanine transaminase (ALT) ≤ 5 × institutional ULN (within 28 days prior to step 2) |
| NCT06769126 | HIV | Phase 2 | SWOG Cancer Research Network | Participants with a known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to step 2 registration |
| NCT06769126 | Performance status | Phase 2 | SWOG Cancer Research Network | Participants must have Zubrod performance status of 0-2 within 28 days prior to step 1 registration |
| NCT06769126 | Pregnancy | Phase 2 | SWOG Cancer Research Network | Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). |
| NCT06769126 | Prior malignancy | Phase 2 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT06769126 | Renal | Phase 2 | SWOG Cancer Research Network | Participants must have creatinine ≤ 1.5x the institutional upper limit of normal (IULN) OR measured OR calculated creatinine clearance ≥ 45 mL/min using the following Cockcroft-Gault Formula |
| NCT06770582 | Cardiac | Phase 2 | National Cancer Institute (NCI) | New York Heart Association Functional Classification II or better (New York Heart Association [NYHA] Functional Classification III/IV are not eligible) |
| NCT06770582 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin ≤ institutional upper limit of normal (ULN) (Not applicable to patients with known Gilbert's syndrome) |
| NCT06770582 | Performance status | Phase 2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 |
| NCT06770582 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Negative urine or serum pregnancy test (in persons of childbearing potential) within 14 days prior to registration. |
| NCT06770582 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT06770582 | Renal | Phase 2 | National Cancer Institute (NCI) | Adequate renal function defined as creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula |
| NCT06772623 | Brain metastases | Phase 1/2 | AbbVie | Known uncontrolled metastases to the central nervous system. |
| NCT06774963 | Brain metastases | Phase 1 | NextCure, Inc. | Has known active CNS metastases and/or carcinomatous meningitis |
| NCT06774963 | Cardiac | Phase 1 | NextCure, Inc. | Uncontrolled or significant cardiovascular disease |
| NCT06774963 | HIV | Phase 1 | NextCure, Inc. | Has a known history of human immunodeficiency virus (HIV) infection with an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within the last year, or a current CD4 count <350 cells/µl |
| NCT06774963 | Performance status | Phase 1 | NextCure, Inc. | Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 |
| NCT06774963 | Pregnancy | Phase 1 | NextCure, Inc. | A female participant is eligible to participate if she is not pregnant, not breastfeeding, not a woman of childbearing potential |
| NCT06774963 | Prior malignancy | Phase 1 | NextCure, Inc. | Has a known additional malignancy that is progressing or has required active treatment within the past 3 years |
| NCT06780137 | Brain metastases | Phase 1/2 | Merck Sharp & Dohme LLC | History of leptomeningeal disease |
| NCT06780137 | Cardiac | Phase 1/2 | Merck Sharp & Dohme LLC | clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF) (New York Heart Association > class II), and/or uncontrolled cardiac arrhythmia |
| NCT06780137 | Hepatic | Phase 1/2 | Merck Sharp & Dohme LLC | Active viral hepatitis, defined as hepatitis A (hepatitis A virus immunoglobulin M [IgM] positive in the setting of associated signs/symptoms), hepatitis B (hepatitis B virus surface antigen [HbsAg] positive and/or detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA]), or hepatitis C (hepatitis C virus [HCV] antibody positive and detectable HCV ribonucleic acid). Participants with HBV with undetectable viral load after treatment are eligible. Participants with HCV with undetectable virus after treatment are eligible. |
| NCT06780137 | HIV | Phase 1/2 | Merck Sharp & Dohme LLC | Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART) |
| NCT06780137 | Prior malignancy | Phase 1/2 | Merck Sharp & Dohme LLC | Known additional malignancy that is progressing or has required active treatment within the past 3 years |
| NCT06780670 | Cardiac | Phase 2/3 | Novartis Pharmaceuticals | History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease |
| NCT06780670 | Performance status | Phase 2/3 | Novartis Pharmaceuticals | ECOG performance status of 0 to 2. |
| NCT06780670 | Prior malignancy | Phase 2/3 | Novartis Pharmaceuticals | History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 2 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed). |
| NCT06780670 | Renal | Phase 2/3 | Novartis Pharmaceuticals | Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury) |
| NCT06784193 | Brain metastases | Phase 1 | Olema Pharmaceuticals, Inc. | Known active or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require CNS-specific treatment, or participants who did not demonstrate clinical and radiologic stability during the last 2 months prior to the first dose of study treatment or require or are currently on steroid therapy for CNS metastases. |
| NCT06784193 | Cardiac | Phase 1 | Olema Pharmaceuticals, Inc. | History of or ongoing impaired cardiac function or clinically significant cardiac disease within 6 months prior to the first dose of study treatment. |
| NCT06786104 | Language | Not given | Massachusetts General Hospital | Able to communicate in English or Spanish (the languages of the video decision aids). |
| NCT06787612 | Brain metastases | Phase 2 | Regeneron Pharmaceuticals | Untreated or active Central Nervous System (CNS) metastases, or carcinomatous meningitis, as described in the protocol |
| NCT06787612 | HIV | Phase 2 | Regeneron Pharmaceuticals | Uncontrolled infections including but not limited to human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency |
| NCT06787612 | Performance status | Phase 2 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT06787612 | Prior malignancy | Phase 2 | Regeneron Pharmaceuticals | Another malignancy that is progressing or requires active treatment, as described in the protocol |
| NCT06788990 | Brain metastases | Phase 2/3 | Bicara Therapeutics | Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded. |
| NCT06788990 | HIV | Phase 2/3 | Bicara Therapeutics | Known history of human immunodeficiency virus (HIV). |
| NCT06788990 | Performance status | Phase 2/3 | Bicara Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06788990 | Prior malignancy | Phase 2/3 | Bicara Therapeutics | Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer. |
| NCT06791057 | Language | Not given | Massachusetts General Hospital | Ability to read and respond to questions in English or Spanish |
| NCT06791057 | Performance status | Not given | Massachusetts General Hospital | Functioning independently per an Eastern Cooperative Oncology Group Performance Status ≤2 |
| NCT06793215 | Brain metastases | Phase 3 | Hoffmann-La Roche | History of leptomeningeal disease |
| NCT06793215 | Cardiac | Phase 3 | Hoffmann-La Roche | Significant cardiovascular disease within 3 months prior to screening |
| NCT06793215 | Performance status | Phase 3 | Hoffmann-La Roche | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT06793215 | Prior malignancy | Phase 3 | Hoffmann-La Roche | History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] rate >90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer |
| NCT06795529 | Language | Not given | Massachusetts General Hospital | able to complete questionnaires in English or Spanish |
| NCT06795529 | Performance status | Not given | Massachusetts General Hospital | functioning independently per an Eastern Cooperative Oncology Group performance status ≤2 |
| NCT06797336 | Brain metastases | Phase 1 | PAQ Therapeutics, Inc. | Active brain metastasis or carcinomatous meningitis. |
| NCT06797336 | HIV | Phase 1 | PAQ Therapeutics, Inc. | Known HIV infection with a cluster of differentiation 4+ (CD4+) T-cell count less than (<) 200 cells per microliter [/mcL] and/or a detectable viral load per parameters of assay and/or on an anti-retroviral regimen containing a strong or moderate cytochrome (CY)P3A4/5 inhibitor or inducer and/or on a new anti-retroviral regimen for less than 28 days prior to the initiation of study treatment. |
| NCT06797336 | Pregnancy | Phase 1 | PAQ Therapeutics, Inc. | Female participants who are pregnant or lactating/breast feeding or who plan to breastfeed while on study through 28 days after receiving the last dose of study drug. |
| NCT06797336 | Prior malignancy | Phase 1 | PAQ Therapeutics, Inc. | History of any other malignancy within the past 2 years, except: |
| NCT06799026 | Cardiac | Phase 1 | David Avigan | Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure |
| NCT06799026 | Hepatic | Phase 1 | David Avigan | Total bilirubin ≤1.5 x institutional upper limit of normal |
| NCT06799026 | HIV | Phase 1 | David Avigan | patients who have a known human immunodeficiency virus (HIV) |
| NCT06799026 | Performance status | Phase 1 | David Avigan | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 |
| NCT06799026 | Pregnancy | Phase 1 | David Avigan | Female patients who are pregnant (positive β-HCG) or breastfeeding |
| NCT06799026 | Prior malignancy | Phase 1 | David Avigan | Individuals with a history of a different malignancy are ineligible except for the following circumstances. |
| NCT06799026 | Renal | Phase 1 | David Avigan | Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal |
| NCT06800313 | Hepatic | Phase 1/2 | Janssen Research & Development, LLC | Adequate hematological, renal, and hepatic function. |
| NCT06800313 | Renal | Phase 1/2 | Janssen Research & Development, LLC | Adequate hematological, renal, and hepatic function. |
| NCT06801236 | Brain metastases | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | Spinal cord compression or known brain metastases or leptomeningeal carcinomatosis. |
| NCT06801236 | Diabetes | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | Poorly controlled diabetes mellitus. |
| NCT06801236 | HIV | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | Active infections, or a known history of HIV infection, or a known active hepatitis B or C, or a known active tuberculosis. |
| NCT06801236 | Performance status | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT06801236 | Prior malignancy | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | Other malignancies requiring treatment within 3 years prior to the first dose of study drug |
| NCT06802146 | Hepatic | Early phase 1 | Lachelle D. Weeks, MD, PhD | Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤3x upper limit of normal (ULN). |
| NCT06802146 | Performance status | Early phase 1 | Lachelle D. Weeks, MD, PhD | ECOG performance status 0-2 (see Appendix A). |
| NCT06802146 | Pregnancy | Early phase 1 | Lachelle D. Weeks, MD, PhD | Pregnant or lactating. |
| NCT06802146 | Prior malignancy | Early phase 1 | Lachelle D. Weeks, MD, PhD | Concurrent primary malignancy requiring active cytotoxic chemotherapy and/or ionizing radiation therapy. |
| NCT06802146 | Renal | Early phase 1 | Lachelle D. Weeks, MD, PhD | Creatinine clearance greater than 40 mL/min based on the Cockcroft-Gault glomerular filtration rate estimation. |
| NCT06803875 | Age | Phase 1/2 | Roberto Chiarle | Age ≥ 12 months and < 30 years at the time of consent |
| NCT06803875 | Brain metastases | Phase 1/2 | Roberto Chiarle | Uncontrolled CNS metastasis |
| NCT06803875 | HIV | Phase 1/2 | Roberto Chiarle | HIV/HBV/HCV infection |
| NCT06803875 | Pregnancy | Phase 1/2 | Roberto Chiarle | Pregnant or nursing (lactating) women |
| NCT06803875 | Prior malignancy | Phase 1/2 | Roberto Chiarle | Patients with a known additional malignancy other than non-melanomatous skin cancer or carcinoma in situ, unless not requiring active treatment and stable or disease-free for at least 3 years |
| NCT06805305 | Brain metastases | Phase 2 | Diakonos Oncology Corporation | Infratentorial, recurrent, leptomeningeal or extracranial disease. |
| NCT06805305 | Cardiac | Phase 2 | Diakonos Oncology Corporation | uncontrolled or severe cardiac disease |
| NCT06805305 | Hepatic | Phase 2 | Diakonos Oncology Corporation | Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) ≤ 3 times the ULN |
| NCT06805305 | HIV | Phase 2 | Diakonos Oncology Corporation | Known active HIV or hepatitis infection. Patients with HIV that is well-controlled and have undetectable viral titers remain eligible. |
| NCT06805305 | Performance status | Phase 2 | Diakonos Oncology Corporation | Karnofsky Performance Score ≥ 70 |
| NCT06805305 | Pregnancy | Phase 2 | Diakonos Oncology Corporation | Patients who are pregnant or breastfeeding. |
| NCT06805305 | Renal | Phase 2 | Diakonos Oncology Corporation | Calculated creatinine clearance (CrCl) > 30 mL/min using Cockcroft and Gault for-mula: |
| NCT06805617 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participant has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. |
| NCT06805617 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. |
| NCT06805617 | Performance status | Phase 2 | Dana-Farber Cancer Institute | Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. |
| NCT06805617 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant or lactating women as the effects of the investigational therapy (ivonescimab) on the developing human fetus are unknown. |
| NCT06805617 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or requires active treatment. |
| NCT06806033 | Brain metastases | Phase 2 | Hoffmann-La Roche | Primary or secondary CNS lymphoma at the time of recruitment. |
| NCT06806033 | Hepatic | Phase 2 | Hoffmann-La Roche | Clinically significant history of cirrhotic liver disease. |
| NCT06806033 | Performance status | Phase 2 | Hoffmann-La Roche | Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2. |
| NCT06806033 | Pregnancy | Phase 2 | Hoffmann-La Roche | Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 18 months after the final dose of study treatment. |
| NCT06806033 | Prior malignancy | Phase 2 | Hoffmann-La Roche | History of other primary malignancy, with exceptions defined by the protocol. |
| NCT06807086 | Language | Not given | Massachusetts General Hospital | Self-reported inability to speak and write in English |
| NCT06810544 | Performance status | Phase 1/2 | Tango Therapeutics, Inc. | Has an ECOG performance status score of 0 to 1 |
| NCT06810544 | Pregnancy | Phase 1/2 | Tango Therapeutics, Inc. | A female patient is who is pregnant or breastfeeding |
| NCT06819007 | Cardiac | Phase 3 | Daiichi Sankyo | Has a medical history of myocardial infarction within 6 months before randomization, symptomatic congestive heart failure (New York Heart Association Class II to IV). |
| NCT06819007 | Prior malignancy | Phase 3 | Daiichi Sankyo | Has ovarian, fallopian tube, or peritoneal cancer of non-epithelial origin. |
| NCT06820463 | Performance status | Phase 2 | AbbVie | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06820463 | Prior malignancy | Phase 2 | AbbVie | History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death. |
| NCT06827613 | Brain metastases | Phase 1/2 | Marengo Therapeutics, Inc. | No concurrent leptomeningeal disease or cord compression. |
| NCT06827613 | HIV | Phase 1/2 | Marengo Therapeutics, Inc. | Participants who are known to be human immunodeficiency virus positive or hepatitis B or C positive and have uncontrolled disease. |
| NCT06827613 | Pregnancy | Phase 1/2 | Marengo Therapeutics, Inc. | Pregnant, likely to become pregnant, or lactating women |
| NCT06827613 | Prior malignancy | Phase 1/2 | Marengo Therapeutics, Inc. | Second primary invasive malignancy not in remission for ≥ 1 year. |
| NCT06831552 | Age | Not given | Dana-Farber Cancer Institute | Patient aged 0-17 years at the time of consent |
| NCT06832865 | Cardiac | Phase 2 | Massachusetts General Hospital | Impaired cardiovascular function or clinically significant cardiovascular diseases, defined as any of the following within 6 months prior to enrollment: |
| NCT06832865 | Hepatic | Phase 2 | Massachusetts General Hospital | Serum bilirubin values < 2 mg/dL; and |
| NCT06832865 | HIV | Phase 2 | Massachusetts General Hospital | Participants with known active HBV, HCV, HIV, or any active, uncontrolled bacterial, fungal, or viral infection. |
| NCT06832865 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). |
| NCT06832865 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ and or other cancers treated with curative intent. |
| NCT06832865 | Renal | Phase 2 | Massachusetts General Hospital | Calculated creatinine clearance of ≥ 30 mL/min by Cockcroft-Gault equation. |
| NCT06835569 | Performance status | Phase 1 | Alterome Therapeutics, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06835803 | Age | Phase 2 | Brigham and Women's Hospital | Age ≥ 65 years old at time of glioblastoma diagnosis |
| NCT06835803 | Brain metastases | Phase 2 | Brigham and Women's Hospital | Participants with evidence of spinal, leptomeningeal, or more distant disease. |
| NCT06835803 | Hepatic | Phase 2 | Brigham and Women's Hospital | Total serum bilirubin ≤ 1.5 times the upper limit of normal |
| NCT06835803 | Performance status | Phase 2 | Brigham and Women's Hospital | Adequate functional status as measured by a ECOG Performance Status 0, 1 or 2, at time of enrollment. |
| NCT06835803 | Prior malignancy | Phase 2 | Brigham and Women's Hospital | Participants with a second invasive malignancy that is A) incompletely treated or requiring ongoing treatment, or B) reasonably anticipated to be associated with a median overall survival of less than 1 year based on population-level data for the specified disease site and stage. |
| NCT06835803 | Renal | Phase 2 | Brigham and Women's Hospital | Serum creatinine ≤ 1.5 times the upper limit of normal |
| NCT06840886 | Brain metastases | Phase 1 | Pheast Therapeutics | Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. |
| NCT06840886 | Performance status | Phase 1 | Pheast Therapeutics | Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale |
| NCT06840886 | Pregnancy | Phase 1 | Pheast Therapeutics | Pregnancy prevention requirements |
| NCT06840886 | Prior malignancy | Phase 1 | Pheast Therapeutics | History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. |
| NCT06843447 | Brain metastases | Phase 1/2 | Merck Sharp & Dohme LLC | Has known active CNS metastases and/or carcinomatous meningitis |
| NCT06843447 | HIV | Phase 1/2 | Merck Sharp & Dohme LLC | HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease |
| NCT06843447 | Performance status | Phase 1/2 | Merck Sharp & Dohme LLC | Has an Eastern Cooperative Oncology Group performance status of 0 to 1 |
| NCT06843447 | Prior malignancy | Phase 1/2 | Merck Sharp & Dohme LLC | Has known additional malignancy that is progressing or has required active treatment within the past 3 years |
| NCT06844383 | Brain metastases | Phase 2 | Prostate Cancer Clinical Trials Consortium | Untreated known or suspected brain metastases or spinal cord compression or clinically significant malignant epidural disease. |
| NCT06844383 | Cardiac | Phase 2 | Prostate Cancer Clinical Trials Consortium | cardiac disease that would preclude participation, as determined by the investigator |
| NCT06844383 | Diabetes | Phase 2 | Prostate Cancer Clinical Trials Consortium | uncontrolled diabetes mellitus |
| NCT06844383 | Hepatic | Phase 2 | Prostate Cancer Clinical Trials Consortium | Bilirubin ≤ 1.3 x ULN (unless documented Gilbert's disease) |
| NCT06844383 | Performance status | Phase 2 | Prostate Cancer Clinical Trials Consortium | Eastern Cooperative Oncology Group (ECOG) status of ≤2 (Appendix A: Performance Status Criteria). |
| NCT06844383 | Prior malignancy | Phase 2 | Prostate Cancer Clinical Trials Consortium | Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 2 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer or superficial bladder cancer. |
| NCT06844383 | Renal | Phase 2 | Prostate Cancer Clinical Trials Consortium | Creatinine ≤ 1.5 x the institutional upper limit of normal (ULN) |
| NCT06849713 | Brain metastases | Phase 2 | Massachusetts General Hospital | Known central nervous system involvement with CLL or SLL. |
| NCT06849713 | Cardiac | Phase 2 | Massachusetts General Hospital | Congestive heart failure, New York Heart Association III/IV. |
| NCT06849713 | HIV | Phase 2 | Massachusetts General Hospital | History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection. |
| NCT06849713 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status of 0, 1 or 2. |
| NCT06849713 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study given potential for teratogenic or abortifacient effects. |
| NCT06849713 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Other diagnosis of active malignancy or systemic therapy within 2 years of study treatment. |
| NCT06849713 | Renal | Phase 2 | Massachusetts General Hospital | CrCl or GFR ≥30 mL/min as estimated by the Cockcroft-Gault equation, the CKD-EPI equation, or as measured by 24-hour urine collection |
| NCT06852222 | Age | Phase 3 | Janssen Research & Development, LLC | >= 75 years of age and ineligible per physician's discretion |
| NCT06852222 | Cardiac | Phase 3 | Janssen Research & Development, LLC | ii) Severe cardiac disorder |
| NCT06852222 | Hepatic | Phase 3 | Janssen Research & Development, LLC | v) Moderate hepatic impairment |
| NCT06852222 | Performance status | Phase 3 | Janssen Research & Development, LLC | i) ECOG performance status of 2 |
| NCT06852222 | Pregnancy | Phase 3 | Janssen Research & Development, LLC | A female participant must agree not to be pregnant, breast-feed, plan to become pregnant and use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment |
| NCT06852222 | Renal | Phase 3 | Janssen Research & Development, LLC | iv) Renal impairment |
| NCT06854003 | Brain metastases | Phase 2 | Christine Ryan | Known central nervous system involvement. |
| NCT06854003 | Cardiac | Phase 2 | Christine Ryan | New York Heart Association Class III or IV heart failure. |
| NCT06854003 | Hepatic | Phase 2 | Christine Ryan | AST/ALT < 2.5 X institutional upper limit of normal (ULN), or < 5.0 X institutional ULN if documented liver involvement of lymphoma. |
| NCT06854003 | HIV | Phase 2 | Christine Ryan | Patients with known infection with human immunodeficiency virus (HIV) are eligible, provided all 3 of the following are true |
| NCT06854003 | Performance status | Phase 2 | Christine Ryan | Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. |
| NCT06854003 | Pregnancy | Phase 2 | Christine Ryan | Patients who are pregnant, breast-feeding, or intending to become pregnant during the study. |
| NCT06854003 | Prior malignancy | Phase 2 | Christine Ryan | Prior history of another malignancy unless treated with curative intent and disease-free for at least 3 years at time of screening with expected low risk of recurrence during expected timeframe of study participation. |
| NCT06854003 | Renal | Phase 2 | Christine Ryan | Estimated CrCl ≥ 30mL/min (by Cockcroft-Gault formula or by 24-hour urine collection). |
| NCT06854653 | Brain metastases | Phase 2 | Prescient Therapeutics, Ltd. | Patients with known central nervous system involvement. |
| NCT06854653 | Cardiac | Phase 2 | Prescient Therapeutics, Ltd. | Significant cardiovascular disease. |
| NCT06854653 | HIV | Phase 2 | Prescient Therapeutics, Ltd. | Patients with Human Immunodeficiency virus (HIV) must be on established and stable effective anti-retroviral therapy for at least 4 weeks and have an HIV viral load of less than 400 copies/mL. |
| NCT06854653 | Performance status | Phase 2 | Prescient Therapeutics, Ltd. | Has an ECOG PS of 0 to 2. |
| NCT06854653 | Pregnancy | Phase 2 | Prescient Therapeutics, Ltd. | Female patients are eligible to participate if they are not pregnant, not breastfeeding, and at least one of the following conditions applies: |
| NCT06854653 | Prior malignancy | Phase 2 | Prescient Therapeutics, Ltd. | Medical history of another malignant tumor within the past 5 years. Exceptions are patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ who have undergone curative therapy with no evidence of disease. |
| NCT06855277 | Performance status | Phase 3 | Novartis Pharmaceuticals | Participants must have an ECOG performance status of 0 to 2. |
| NCT06855771 | Brain metastases | Phase 2 | Bristol-Myers Squibb | Active brain metastases or carcinomatous meningitis. |
| NCT06855771 | Performance status | Phase 2 | Bristol-Myers Squibb | Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. |
| NCT06859424 | Age | Phase 2 | Center for International Blood and Marrow Transplant Research | Age 18 to < 66 years (chemotherapy-based conditioning) or < 61 years (TBI-based conditioning) at the time of signing informed consent |
| NCT06859424 | Cardiac | Phase 2 | Center for International Blood and Marrow Transplant Research | Cardiac function: Left ventricular ejection fraction ≥ 45% based on most recent echocardiogram or multi-gated acquisition scan (MUGA) results |
| NCT06859424 | HIV | Phase 2 | Center for International Blood and Marrow Transplant Research | Patients who are HIV-positive with persistently positive viral load. |
| NCT06859424 | Performance status | Phase 2 | Center for International Blood and Marrow Transplant Research | KPS of ≥ 70% (Appendix I - Performance Status) |
| NCT06859424 | Pregnancy | Phase 2 | Center for International Blood and Marrow Transplant Research | Subjects who are breastfeeding or pregnant |
| NCT06859424 | Prior malignancy | Phase 2 | Center for International Blood and Marrow Transplant Research | The presence of prior malignancy will not be used to calculate HCT-CI for this trial, to allow for the inclusion of patients with secondary or therapy-related AML or MDS. |
| NCT06859424 | Renal | Phase 2 | Center for International Blood and Marrow Transplant Research | Estimated creatinine clearance ≥ 45mL/min calculated by equation |
| NCT06861088 | Brain metastases | Phase 3 | Quercis Pharma AG | Participants with known brain metastases |
| NCT06861088 | Performance status | Phase 3 | Quercis Pharma AG | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. |
| NCT06861088 | Pregnancy | Phase 3 | Quercis Pharma AG | Females of child-bearing potential who are lactating, have a positive pregnancy test at Screening, or are unwilling to use acceptable contraception prior to study entry and for the duration of study participation until at least 4 weeks after study completion. |
| NCT06861088 | Renal | Phase 3 | Quercis Pharma AG | Estimated creatinine clearance (CrCl > 30 mL/min). |
| NCT06862856 | Prior malignancy | Not given | Massachusetts General Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06872346 | Age | Not given | Massachusetts General Hospital | have a cervix and are 21-70 years old |
| NCT06872346 | Language | Not given | Massachusetts General Hospital | are not English or Spanish-speaking. |
| NCT06875310 | Brain metastases | Phase 3 | Mirati Therapeutics Inc. | Participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter. |
| NCT06875310 | Cardiac | Phase 3 | Mirati Therapeutics Inc. | Uncontrolled or significant cardiovascular conditions within 6 months prior to enrollment that are ongoing or with risk of recurrence. |
| NCT06875310 | Hepatic | Phase 3 | Mirati Therapeutics Inc. | Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities. |
| NCT06879041 | Performance status | Phase 1 | AstraZeneca | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. |
| NCT06881992 | HIV | Phase 3 | Rezolute | Evidence of active infection including human immunodeficiency virus, hepatitis B, or hepatitis C (excluding immunization patterns). |
| NCT06886516 | Brain metastases | Early phase 1 | Rushad Patell | No known brain metastases. |
| NCT06886516 | Hepatic | Early phase 1 | Rushad Patell | Total bilirubin ≤ institutional upper limit of normal (ULN) |
| NCT06886516 | HIV | Early phase 1 | Rushad Patell | Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT06886516 | Performance status | Early phase 1 | Rushad Patell | ECOG performance status ≤2 |
| NCT06886516 | Pregnancy | Early phase 1 | Rushad Patell | Pregnant women are excluded from this study because apixaban has the potential for teratogenic or abortifacient effects. |
| NCT06886516 | Prior malignancy | Early phase 1 | Rushad Patell | Participants with luminal gastrointestinal malignancy or genitourinary cancer. |
| NCT06886516 | Renal | Early phase 1 | Rushad Patell | Glomerular filtration rate (GFR) ≥25 mL/min/1.73/m2 |
| NCT06890598 | Performance status | Phase 3 | Eli Lilly and Company | Must have an ECOG performance status of 0 or 1. |
| NCT06890598 | Pregnancy | Phase 3 | Eli Lilly and Company | Not be breastfeeding during treatment |
| NCT06890598 | Prior malignancy | Phase 3 | Eli Lilly and Company | Have another type of cancer that is progressing or required active treatment within the past 2 years before screening. |
| NCT06890884 | Brain metastases | Phase 2 | Merck Sharp & Dohme LLC | Known active central nervous system (CNS) lymphoma. |
| NCT06890884 | Cardiac | Phase 2 | Merck Sharp & Dohme LLC | Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication. |
| NCT06890884 | HIV | Phase 2 | Merck Sharp & Dohme LLC | HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease. |
| NCT06890884 | Prior malignancy | Phase 2 | Merck Sharp & Dohme LLC | Known additional malignancy that is progressing or has required active treatment within the past 2 years. |
| NCT06896474 | Age | Not given | Beth Israel Deaconess Medical Center | aged 70 or older |
| NCT06896474 | Language | Not given | Beth Israel Deaconess Medical Center | Non English or non-Spanish speaking: Women who do not speak English or Spanish will be excluded since these women are not eligible for the DA. |
| NCT06896474 | Prior malignancy | Not given | Beth Israel Deaconess Medical Center | History of invasive breast cancer |
| NCT06899126 | Cardiac | Phase 3 | Daiichi Sankyo | Has a QTc prolongation to >480 ms based on the average of the Screening triplicate 12- lead ECG. |
| NCT06900595 | Brain metastases | Phase 2 | National Cancer Institute (NCI) | No known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks after major surgery (e.g., removal or biopsy of brain metastasis) before registration. |
| NCT06900595 | Cardiac | Phase 2 | National Cancer Institute (NCI) | No myocardial infarction (MI) or unstable angina within 6 months of registration |
| NCT06900595 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) |
| NCT06900595 | HIV | Phase 2 | National Cancer Institute (NCI) | HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial |
| NCT06900595 | Performance status | Phase 2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance 0 - 2 (age 18 and above); or |
| NCT06900595 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects based on animal reproduction studies. |
| NCT06900595 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen will be eligible |
| NCT06900595 | Renal | Phase 2 | National Cancer Institute (NCI) | Calculated (Calc.) creatinine clearance ≥ 30 mL/min |
| NCT06901531 | Brain metastases | Phase 3 | Astellas Pharma Global Development, Inc. | Participant has history of central nervous system metastases and/or carcinomatous meningitis from gastric/GEJ cancer. |
| NCT06901531 | Cardiac | Phase 3 | Astellas Pharma Global Development, Inc. | Congestive heart failure (defined as New York Heart Association Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to randomization. |
| NCT06901531 | Diabetes | Phase 3 | Astellas Pharma Global Development, Inc. | Participant has type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy or skin disorders (e.g., vitiligo, psoriasis or alopecia) not requiring systemic treatment are allowed. |
| NCT06901531 | HIV | Phase 3 | Astellas Pharma Global Development, Inc. | Participant has a known history of a positive test for Human Immunodeficiency Virus (HIV) infection |
| NCT06901531 | Performance status | Phase 3 | Astellas Pharma Global Development, Inc. | Participant has Eastern Cooperative Oncology Group Performance Status (ECOG) performance status 0 to 1. |
| NCT06901531 | Pregnancy | Phase 3 | Astellas Pharma Global Development, Inc. | Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 5 half-lives (at least 9 months after the final oxaliplatin administration and 6 months after the final administration of all other study interventions). |
| NCT06901531 | Prior malignancy | Phase 3 | Astellas Pharma Global Development, Inc. | Participant has another malignancy for which treatment is required. |
| NCT06906562 | Brain metastases | Phase 2 | Sameek Roychowdhury | Patients with symptomatic central nervous system (CNS) metastases are excluded (because it is unclear how much CNS penetration the drug has). |
| NCT06906562 | Cardiac | Phase 2 | Sameek Roychowdhury | History of clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure, or arrhythmia requiring therapy. |
| NCT06906562 | Hepatic | Phase 2 | Sameek Roychowdhury | Total bilirubin ≥ 1.5x upper limit of normal (ULN) unless associated with patient's primary cancer and/or metastases and with principal investigator's approval |
| NCT06906562 | Performance status | Phase 2 | Sameek Roychowdhury | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (patients with ECOG performance status of 2 may be considered on a case-by-case basis after discussion with Incyte) |
| NCT06906562 | Pregnancy | Phase 2 | Sameek Roychowdhury | Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test |
| NCT06906562 | Prior malignancy | Phase 2 | Sameek Roychowdhury | History of another primary malignancy except adequately treated in situ carcinoma of the cervix or non-melanoma carcinoma of the skin or any other curatively treated malignancy that is not expected to require treatment for recurrence during the course of the study or affect survival |
| NCT06906562 | Renal | Phase 2 | Sameek Roychowdhury | Calculated or measured creatinine clearance of < 40 mL/min |
| NCT06907043 | Brain metastases | Phase 1/2 | Eikon Therapeutics | Known, symptomatic leptomeningeal disease. |
| NCT06907043 | Cardiac | Phase 1/2 | Eikon Therapeutics | Mean resting QTcF > 470 ms or QTcF < 340 ms |
| NCT06907797 | Language | Not given | Dana-Farber Cancer Institute | English speaking |
| NCT06910956 | Age | Not given | Massachusetts General Hospital | 50- to 77-year-old who currently or formerly smoked |
| NCT06910956 | Smoking | Not given | Massachusetts General Hospital | 50- to 77-year-old who currently or formerly smoked |
| NCT06910969 | Language | Not given | Massachusetts General Hospital | Have ability to participate in English or Spanish language group telehealth intervention. |
| NCT06914128 | Cardiac | Phase 1/2 | Bayer | A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). |
| NCT06914128 | Performance status | Phase 1/2 | Bayer | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06914128 | Prior malignancy | Phase 1/2 | Bayer | Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study. |
| NCT06915662 | Age | Phase 2 | Massachusetts General Hospital | Patients under 22 years old |
| NCT06915662 | Language | Phase 2 | Massachusetts General Hospital | English-speaking |
| NCT06915662 | Pregnancy | Phase 2 | Massachusetts General Hospital | Patients who are pregnant and/or breastfeeding |
| NCT06915753 | Brain metastases | Phase 1 | Tyra Biosciences, Inc | Active, symptomatic, or untreated brain metastases. |
| NCT06915753 | Cardiac | Phase 1 | Tyra Biosciences, Inc | History of or current uncontrolled cardiovascular disease. |
| NCT06915753 | Performance status | Phase 1 | Tyra Biosciences, Inc | Eastern Cooperative Oncology Group (ECOG) performance status of ≤1. |
| NCT06915753 | Pregnancy | Phase 1 | Tyra Biosciences, Inc | Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study. |
| NCT06917079 | Brain metastases | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Untreated brain metastases |
| NCT06917079 | Performance status | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 |
| NCT06917079 | Prior malignancy | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Malignancy within the last 2 years as specified in the protocol |
| NCT06917885 | Brain metastases | Phase 1 | David Reardon, MD | Presence of multifocal tumor, bi-hemispheric tumor (radiographic evidence of tumor extending from one hemisphere into the other through the corpus callosum), diffuse leptomeningeal or extracranial disease; |
| NCT06917885 | Cardiac | Phase 1 | David Reardon, MD | Has had clinically significant cardiovascular disease within 12 months of start of study drug, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent; |
| NCT06917885 | Hepatic | Phase 1 | David Reardon, MD | AST (SGOT) and ALT (SGPT) ≤ 3.0 X institutional ULN OR ≤ 5 X institutional ULN for participants with Gilberts syndrome |
| NCT06917885 | HIV | Phase 1 | David Reardon, MD | Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) and is receiving antiretroviral therapy. |
| NCT06917885 | Performance status | Phase 1 | David Reardon, MD | Have a Karnofsky performance status (KPS) ≥ 70 (Appendix A); |
| NCT06917885 | Pregnancy | Phase 1 | David Reardon, MD | Is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial |
| NCT06917885 | Prior malignancy | Phase 1 | David Reardon, MD | Has a known additional malignancy that is progressing or requires active treatment within 1 year of start of study drug |
| NCT06917885 | Renal | Phase 1 | David Reardon, MD | Measured or calculated creatinine clearance (CrCl) ≥45 mL/min for participant with creatinine levels > 1.5 X institutional ULN |
| NCT06919965 | Performance status | Phase 3 | Janssen Research & Development, LLC | Have an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1, or 2 |
| NCT06919965 | Prior malignancy | Phase 3 | Janssen Research & Development, LLC | Active malignancies (i.e., progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. |
| NCT06922591 | Brain metastases | Phase 1/2 | Tango Therapeutics, Inc. | Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms |
| NCT06922591 | Hepatic | Phase 1/2 | Tango Therapeutics, Inc. | Has current active liver disease from any cause |
| NCT06922591 | HIV | Phase 1/2 | Tango Therapeutics, Inc. | Is known to be HIV positive, unless all the following criteria are met: |
| NCT06922591 | Performance status | Phase 1/2 | Tango Therapeutics, Inc. | Has an ECOG PS of 0 or 1. |
| NCT06922591 | Pregnancy | Phase 1/2 | Tango Therapeutics, Inc. | Negative pregnancy test at screening |
| NCT06923397 | Language | Not given | Dana-Farber Cancer Institute | Speak English. |
| NCT06923397 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Patients receiving treatment for other active malignancies (except basal cell carcinoma). |
| NCT06923527 | Hepatic | Phase 2 | Yale University | ALT and AST <3 x ULN and total serum bilirubin <1.5 x ULN. |
| NCT06923527 | Performance status | Phase 2 | Yale University | ECOG performance status of 0 or 1. |
| NCT06923527 | Pregnancy | Phase 2 | Yale University | Participants who are pregnant. |
| NCT06923527 | Prior malignancy | Phase 2 | Yale University | Current or past invasive cancer other than breast cancer, except: |
| NCT06923527 | Renal | Phase 2 | Yale University | Cockcroft-Gault based creatinine clearance >50 mL/min. |
| NCT06925737 | Cardiac | Phase 3 | Merck Sharp & Dohme LLC | Has uncontrolled or significant cardiovascular disease |
| NCT06926868 | Brain metastases | Phase 2/3 | Bristol-Myers Squibb | Leptomeningeal metastases. |
| NCT06926868 | Cardiac | Phase 2/3 | Bristol-Myers Squibb | Myocardial infarction, uncontrolled angina, or stroke/transient ischemic attack within the past 6 months. |
| NCT06931626 | Brain metastases | Phase 1 | Nerviano Medical Sciences | Symptomatic, or untreated central nervous system (CNS) lesions except stable and well controlled with no neurological symptoms; |
| NCT06931626 | Cardiac | Phase 1 | Nerviano Medical Sciences | Patients with QT interval using Fridericia standard (QTcF) interval >450 milliseconds or with risk factors for torsade de pointes |
| NCT06931626 | HIV | Phase 1 | Nerviano Medical Sciences | viral including Human Immunodeficiency Virus [HIV] positivity or Hepatitis B Virus [HBV] or Hepatitis B Virus [HCV] infections) requiring systemic treatment; HIV or Acquired Immune Deficiency Syndrome (AIDS)-related illness are allowed as long as controlled more than 6 months to undetectable on anti-HIV medications. |
| NCT06931626 | Performance status | Phase 1 | Nerviano Medical Sciences | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. |
| NCT06931626 | Pregnancy | Phase 1 | Nerviano Medical Sciences | Breast-feeding women or women planning to breast feed during the study or within 3 months after study treatment. |
| NCT06931626 | Prior malignancy | Phase 1 | Nerviano Medical Sciences | Currently active second malignancy, except for adequately treated basal or squamous cell skin cancer and/or cone biopsied or post curative intention in situ carcinoma of the cervix uteri and/or superficial bladder cancer. |
| NCT06936878 | Language | Not given | Dana-Farber Cancer Institute | Able to speak and read English or Spanish (self-report) |
| NCT06940180 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Total bilirubin ≤institutional upper limit of normal (ULN) |
| NCT06940180 | HIV | Phase 2 | Dana-Farber Cancer Institute | Has a known history of human immunodeficiency virus (HIV) infection that is uncontrolled. |
| NCT06940180 | Performance status | Phase 2 | Dana-Farber Cancer Institute | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT06940180 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Women who are pregnant or breastfeeding. |
| NCT06940180 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. |
| NCT06940180 | Renal | Phase 2 | Dana-Farber Cancer Institute | Creatinine ≤institutional ULN or GFR of ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2 |
| NCT06941272 | Brain metastases | Phase 1/2 | Merck Sharp & Dohme LLC | Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis/leptomeningeal disease; participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks |
| NCT06941272 | Cardiac | Phase 1/2 | Merck Sharp & Dohme LLC | Has uncontrolled or significant cardiovascular disorder |
| NCT06941272 | HIV | Phase 1/2 | Merck Sharp & Dohme LLC | Has a history of human immunodeficiency virus (HIV) infection |
| NCT06941272 | Prior malignancy | Phase 1/2 | Merck Sharp & Dohme LLC | Has a known additional malignancy that is progressing or has required active treatment within the past 1 year |
| NCT06943872 | Brain metastases | Phase 3 | BeOne Medicines | Known central nervous system involvement by CLL/SLL |
| NCT06943872 | Cardiac | Phase 3 | BeOne Medicines | Clinically significant cardiovascular disease |
| NCT06943872 | Performance status | Phase 3 | BeOne Medicines | Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2 |
| NCT06945120 | Age | Not given | Dana-Farber Cancer Institute | Adults younger than 50 or older than 80 years |
| NCT06945120 | Language | Not given | Dana-Farber Cancer Institute | Speak either Korean, Mandarin, or English |
| NCT06945120 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant women |
| NCT06945120 | Smoking | Not given | Dana-Farber Cancer Institute | Are current smokers (i.e., have smoked at least 100 traditional cigarettes ever and have smoked at least one traditional cigarette within the prior 30 days) |
| NCT06946225 | Brain metastases | Phase 1 | Immatics US, Inc. | Participants with active brain metastases prior to lymphodepletion |
| NCT06946225 | Cardiac | Phase 1 | Immatics US, Inc. | History of cardiac conditions as per protocol |
| NCT06946225 | HIV | Phase 1 | Immatics US, Inc. | Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection |
| NCT06946225 | Performance status | Phase 1 | Immatics US, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status 0-1 |
| NCT06946225 | Pregnancy | Phase 1 | Immatics US, Inc. | Pregnant or breastfeeding |
| NCT06946225 | Prior malignancy | Phase 1 | Immatics US, Inc. | History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years |
| NCT06946225 | Renal | Phase 1 | Immatics US, Inc. | Participants with renal impairment AND reduced bone marrow reserve per protocol |
| NCT06947928 | Brain metastases | Phase 2/3 | TuHURA Biosciences, Inc. | Participants with known active brain metastases with the exception of treated brain metastases that have imaging proving stability at least 4 weeks prior to the start of study treatment, no new metastases, and not requiring steroids. |
| NCT06947928 | Cardiac | Phase 2/3 | TuHURA Biosciences, Inc. | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT06947928 | Performance status | Phase 2/3 | TuHURA Biosciences, Inc. | Eastern Cooperative Oncology Group (ECOG) Performance Status < 2. |
| NCT06947928 | Pregnancy | Phase 2/3 | TuHURA Biosciences, Inc. | Pregnant or breastfeeding females and females desiring to become pregnant or breastfeed within the timeframe of this study. |
| NCT06950034 | Cardiac | Phase 1 | Solu Therapeutics, Inc | QT interval corrected by Fridericia's formula (QTcF) >470 msec for both men and women on Screening electrocardiogram(s) (ECG). |
| NCT06950034 | HIV | Phase 1 | Solu Therapeutics, Inc | Known human immunodeficiency virus (HIV). |
| NCT06950034 | Performance status | Phase 1 | Solu Therapeutics, Inc | Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2. |
| NCT06950034 | Prior malignancy | Phase 1 | Solu Therapeutics, Inc | Other than AML or CMML, active malignancy and/or cancer history that requires active therapy. |
| NCT06950034 | Smoking | Phase 1 | Solu Therapeutics, Inc | Current active use of nicotine products including tobacco, nicotine patches or vaping products. |
| NCT06952010 | Brain metastases | Phase 1 | Exelixis | Primary brain tumors or known active brain metastases. |
| NCT06952010 | Performance status | Phase 1 | Exelixis | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. |
| NCT06952010 | Pregnancy | Phase 1 | Exelixis | A woman of childbearing potential has a positive serum pregnancy test within 7 days prior to study treatment. |
| NCT06952504 | Cardiac | Phase 3 | Merck Sharp & Dohme LLC | Has uncontrolled, significant cardiovascular disease or cerebrovascular disease |
| NCT06952504 | HIV | Phase 3 | Merck Sharp & Dohme LLC | Human Immunodeficiency Virus-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease |
| NCT06952803 | Cardiac | Phase 3 | AstraZeneca | Cardiac criteria, including history of arrhythmia and cardiovascular disease. |
| NCT06952803 | HIV | Phase 3 | AstraZeneca | Evidence of active and uncontrolled human immunodeficiency virus (HIV) infection. |
| NCT06952803 | Performance status | Phase 3 | AstraZeneca | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomization. |
| NCT06952803 | Prior malignancy | Phase 3 | AstraZeneca | History of another primary malignancy, with exceptions. |
| NCT06955169 | Cardiac | Phase 2 | RTOG Foundation, Inc. | congestive heart failure (≥ NYHA class II) |
| NCT06955169 | Hepatic | Phase 2 | RTOG Foundation, Inc. | AST (SGOT) and ALT (SGPT) ≤ 3 x the laboratory upper limit of normal (ULN) |
| NCT06955169 | Pregnancy | Phase 2 | RTOG Foundation, Inc. | Pregnant and/or breastfeeding patients who are unwilling to discontinue breast feeding. |
| NCT06955169 | Prior malignancy | Phase 2 | RTOG Foundation, Inc. | An active malignancy ≤ 3 years. |
| NCT06955169 | Renal | Phase 2 | RTOG Foundation, Inc. | Creatinine clearance (calculated by the Cockroft-Gault method) ≥40mL/min |
| NCT06957691 | Hepatic | Phase 2 | Shehzad Basaria, M.D. | Liver cirrhosis |
| NCT06957691 | Renal | Phase 2 | Shehzad Basaria, M.D. | Glomerular filtration rate < 30 mL/min |
| NCT06959706 | Brain metastases | Phase 1 | Tagworks Pharmaceuticals BV | Known symptomatic brain metastases. |
| NCT06959706 | Cardiac | Phase 1 | Tagworks Pharmaceuticals BV | Significant cardiovascular disease within 6 months prior to starting study drug. |
| NCT06959706 | Performance status | Phase 1 | Tagworks Pharmaceuticals BV | Eastern Cooperative Oncology Group Performance Status 0-1. |
| NCT06959706 | Pregnancy | Phase 1 | Tagworks Pharmaceuticals BV | Pregnant or a breastfeeding postpartum female. |
| NCT06959706 | Prior malignancy | Phase 1 | Tagworks Pharmaceuticals BV | Active second malignancy or history of another malignancy within the last 2 years |
| NCT06964009 | Brain metastases | Phase 1 | Elizabeth Stover, MD, PhD | Known active central nervous system involvement with metastatic cancer, including leptomeningeal disease. |
| NCT06964009 | Cardiac | Phase 1 | Elizabeth Stover, MD, PhD | Baseline prolongation of QTc interval (> 470 msec) using Bazett's formula or history of Long QT Syndrome. |
| NCT06964009 | HIV | Phase 1 | Elizabeth Stover, MD, PhD | Participants with known HIV infection should meet the following criteria: |
| NCT06964009 | Performance status | Phase 1 | Elizabeth Stover, MD, PhD | ECOG performance status 0-2. |
| NCT06964009 | Pregnancy | Phase 1 | Elizabeth Stover, MD, PhD | Pregnant females are excluded from this study because the effects of DT2216 on the developing fetus are unknown. |
| NCT06964009 | Prior malignancy | Phase 1 | Elizabeth Stover, MD, PhD | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT06964009 | Renal | Phase 1 | Elizabeth Stover, MD, PhD | eGFR (glomerular filtration rate) ≥50 mL/min**** |
| NCT06966024 | Cardiac | Phase 1 | Deciphera Pharmaceuticals, LLC | Impaired cardiac function |
| NCT06966024 | Pregnancy | Phase 1 | Deciphera Pharmaceuticals, LLC | If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements |
| NCT06966700 | Performance status | Phase 3 | Merck Sharp & Dohme LLC | Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 performed within 28 days before Cycle1 Day 1 (C1D1). |
| NCT06966700 | Prior malignancy | Phase 3 | Merck Sharp & Dohme LLC | Known additional malignancy that is progressing or has required active treatment within the past 5 years. |
| NCT06973187 | Brain metastases | Phase 3 | BeOne Medicines | Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by CLL/SLL |
| NCT06975293 | Brain metastases | Phase 1/2 | STORM Therapeutics LTD | Known active CNS metastases and/or leptomeningeal disease. |
| NCT06975293 | Cardiac | Phase 1/2 | STORM Therapeutics LTD | Clinically significant cardiovascular disease or condition. |
| NCT06975293 | Performance status | Phase 1/2 | STORM Therapeutics LTD | ECOG performance status 0 or 1. |
| NCT06975293 | Pregnancy | Phase 1/2 | STORM Therapeutics LTD | Pregnant and lactating women. |
| NCT06982521 | Brain metastases | Phase 3 | Relay Therapeutics, Inc. | Known active uncontrolled or symptomatic CNS metastases associated with progressive neurological symptoms or requiring ongoing corticosteroids or anticonvulsants for symptomatic control |
| NCT06982521 | Cardiac | Phase 3 | Relay Therapeutics, Inc. | Clinically significant, uncontrolled cardiovascular disease |
| NCT06982521 | Diabetes | Phase 3 | Relay Therapeutics, Inc. | Type 1 diabetes, or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or glycosylated hemoglobin (HbA1c) ≥7.0% (≥ 53 mmol/mol). |
| NCT06982521 | Performance status | Phase 3 | Relay Therapeutics, Inc. | Patient has ECOG performance status of 0-1 |
| NCT06983743 | Brain metastases | Phase 1 | Erasca, Inc. | Have primary central nervous system (CNS) tumors |
| NCT06983743 | Performance status | Phase 1 | Erasca, Inc. | Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 |
| NCT06983743 | Pregnancy | Phase 1 | Erasca, Inc. | Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial |
| NCT06986174 | Brain metastases | Phase 2 | Shayna Sarosiek, MD | Current CNS involvement by WM |
| NCT06986174 | Cardiac | Phase 2 | Shayna Sarosiek, MD | History of myocardial infarction within 6 months prior to planned start |
| NCT06986174 | Hepatic | Phase 2 | Shayna Sarosiek, MD | total bilirubin ≤1.5 times the upper limit of normal or ≤3 times the upper limit of normal with documented liver involvement, hemolysis or Gilbert's disease |
| NCT06986174 | HIV | Phase 2 | Shayna Sarosiek, MD | Current history of uncontrolled HIV |
| NCT06986174 | Performance status | Phase 2 | Shayna Sarosiek, MD | ECOG performance status ≤2 |
| NCT06986174 | Pregnancy | Phase 2 | Shayna Sarosiek, MD | Participants who are pregnant, breast feeding, or planning to become pregnant while enrolled in this study or within 3 month after last study dose (2 weeks for breastfeeding) |
| NCT06986174 | Prior malignancy | Phase 2 | Shayna Sarosiek, MD | History of another malignancy, except adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer, or other adequately treated cancer currently in complete remission |
| NCT06986174 | Renal | Phase 2 | Shayna Sarosiek, MD | Creatinine clearance ≥30 ml/min using Cockcroft/Gault equation |
| NCT06989112 | Brain metastases | Phase 3 | AstraZeneca | Spinal cord compression or clinically active central nervous system metastases. |
| NCT06989112 | Cardiac | Phase 3 | AstraZeneca | Left ventricular ejection fraction ≥ 50% within 28 days before randomization. |
| NCT06989112 | HIV | Phase 3 | AstraZeneca | HIV infection that is not well controlled. |
| NCT06989112 | Performance status | Phase 3 | AstraZeneca | ECOG 0-1. |
| NCT06993844 | Brain metastases | Phase 1/2 | Ensem Therapeutics | Has symptomatic brain or spinal metastases or a known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement. |
| NCT06993844 | Diabetes | Phase 1/2 | Ensem Therapeutics | Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2. |
| NCT06993844 | Performance status | Phase 1/2 | Ensem Therapeutics | An ECOG performance status score of 0 or 1. |
| NCT06993844 | Prior malignancy | Phase 1/2 | Ensem Therapeutics | Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancers being studied. |
| NCT06994676 | Brain metastases | Phase 1 | Crossbow Therapeutics, Inc. | Active central nervous system (CNS) disease. |
| NCT06994676 | Cardiac | Phase 1 | Crossbow Therapeutics, Inc. | QTc using Fridericia's correction (QTcF) >480 msec |
| NCT06994676 | Hepatic | Phase 1 | Crossbow Therapeutics, Inc. | Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 × ULN (unless attributed to leukemic involvement with discussion with the Study Responsible Physician). |
| NCT06994676 | HIV | Phase 1 | Crossbow Therapeutics, Inc. | Known HIV infection. |
| NCT06994676 | Performance status | Phase 1 | Crossbow Therapeutics, Inc. | ECOG PS score 0-1 (if aged ≥18 years) |
| NCT06994676 | Pregnancy | Phase 1 | Crossbow Therapeutics, Inc. | Pregnant or nursing women |
| NCT06994676 | Prior malignancy | Phase 1 | Crossbow Therapeutics, Inc. | Concurrent malignancy in the previous 2 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ, melanoma in situ) treated with potentially curative therapy. |
| NCT06994676 | Renal | Phase 1 | Crossbow Therapeutics, Inc. | Estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2 based on local institutional practice for age-appropriate determination |
| NCT06995677 | Cardiac | Phase 2 | Tyra Biosciences, Inc | History of prolonged QT syndrome or baseline heart rate-corrected QT interval using Fridericia formula (QTcF) interval >470 ms |
| NCT06995677 | Diabetes | Phase 2 | Tyra Biosciences, Inc | i.e., uncontrolled diabetes |
| NCT06995677 | Hepatic | Phase 2 | Tyra Biosciences, Inc | Total bilirubin < or = ULN |
| NCT06995677 | HIV | Phase 2 | Tyra Biosciences, Inc | Participants who are positive for human immunodeficiency virus (HIV) must have a viral load below the limits of detection and on stable antiretroviral therapy for at least 3 months prior to C1D1. |
| NCT06995677 | Performance status | Phase 2 | Tyra Biosciences, Inc | Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 |
| NCT06995677 | Pregnancy | Phase 2 | Tyra Biosciences, Inc | Females who are pregnant, breastfeeding or planning to become pregnant within 6 months after the last dose of TYRA-300 |
| NCT06995677 | Prior malignancy | Phase 2 | Tyra Biosciences, Inc | Other malignancy within 3 years of signing ICF, except for skin cancer |
| NCT06995677 | Renal | Phase 2 | Tyra Biosciences, Inc | estimated glomerular filtration rate >30 mL/min calculated using the modification of diet in renal disease equation or CKD-EPI formula |
| NCT06997185 | Language | Not given | London School of Economics and Political Science | Adults fluent in English |
| NCT06998407 | Brain metastases | Phase 1/2 | Avenzo Therapeutics, Inc. | Has known active brain metastasis (have either previously untreated intracranial CNS metastasis or previously treated intracranial central nervous system (CNS) metastasis with radiologically documented new or progressing CNS lesions) or leptomeningeal disease |
| NCT06998407 | Cardiac | Phase 1/2 | Avenzo Therapeutics, Inc. | History of serious cardiovascular conditions within 6 months prior to first dose on study |
| NCT06998407 | Performance status | Phase 1/2 | Avenzo Therapeutics, Inc. | Eastern Cooperative Oncology Group (ECOG) 0-1 |
| NCT06998407 | Prior malignancy | Phase 1/2 | Avenzo Therapeutics, Inc. | Other concurrent invasive malignancy or a prior invasive malignancy for which treatment was completed within 3 years before the first dose on study except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ, or colorectal adenomatous polyps |
| NCT07000084 | Pregnancy | Phase 3 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. |
| NCT07000084 | Prior malignancy | Phase 3 | Alliance for Clinical Trials in Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT07002034 | Brain metastases | Phase 2 | Reunion Neuroscience Inc | Has active or a history of central nervous system malignancy |
| NCT07002034 | Pregnancy | Phase 2 | Reunion Neuroscience Inc | If female is not pregnant or planning to become pregnant. |
| NCT07007312 | Age | Phase 3 | Kura Oncology, Inc. | Age ≥75, OR |
| NCT07007312 | Brain metastases | Phase 3 | Kura Oncology, Inc. | Active central nervous system (CNS) involvement by AML. |
| NCT07007312 | Cardiac | Phase 3 | Kura Oncology, Inc. | Uncontrolled intercurrent illness including but not limited to, cardiac illness as defined in the protocol. |
| NCT07007312 | HIV | Phase 3 | Kura Oncology, Inc. | Known uncontrolled HIV infection or known active hepatitis B virus, hepatitis C virus infection, or other uncontrolled infection. |
| NCT07007312 | Performance status | Phase 3 | Kura Oncology, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. |
| NCT07007312 | Pregnancy | Phase 3 | Kura Oncology, Inc. | Women who are pregnant or lactating. |
| NCT07007312 | Prior malignancy | Phase 3 | Kura Oncology, Inc. | History of other active concurrent malignancies prior to study entry except: |
| NCT07011719 | Brain metastases | Phase 3 | Arcus Biosciences, Inc. | History of leptomeningeal disease or spinal cord compression. |
| NCT07011719 | Performance status | Phase 3 | Arcus Biosciences, Inc. | A Karnofsky Performance Status (KPS) score ≥ 80% |
| NCT07011719 | Prior malignancy | Phase 3 | Arcus Biosciences, Inc. | Other prior malignancy active within the previous year except for locally curable cancers that have been apparently cured. |
| NCT07013435 | Language | Not given | Massachusetts General Hospital | English or Spanish speaking adults (18+ at time of enrollment) |
| NCT07014293 | Language | Not given | Massachusetts General Hospital | English speaking adult (18 years or older at enrollment) |
| NCT07015242 | HIV | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | History of or active human immunodeficiency virus (HIV). |
| NCT07015242 | Performance status | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. |
| NCT07015242 | Pregnancy | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Individuals of childbearing potential (IOCBP) must have a negative highly sensitive pregnancy test within 24 hours prior to the start of study intervention. |
| NCT07015242 | Prior malignancy | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | History of another primary malignancy that has not been in remission for ≥2 years. |
| NCT07020221 | Brain metastases | Phase 1/2 | Verastem, Inc. | Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases. |
| NCT07020221 | Cardiac | Phase 1/2 | Verastem, Inc. | Adequate cardiac function |
| NCT07020221 | Performance status | Phase 1/2 | Verastem, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 |
| NCT07020221 | Pregnancy | Phase 1/2 | Verastem, Inc. | Individuals who are pregnant or breastfeeding. |
| NCT07020533 | Age | Phase 1 | City of Hope Medical Center | DONORS: Age: 18 - 75. |
| NCT07020533 | Cardiac | Phase 1 | City of Hope Medical Center | RECIPIENTS: Left ventricular ejection fraction (LVEF) ≥ 50%. |
| NCT07020533 | Hepatic | Phase 1 | City of Hope Medical Center | RECIPIENTS: Total bilirubin ≤ 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease) (to be performed within 45 days prior to day 1 of protocol therapy). |
| NCT07020533 | HIV | Phase 1 | City of Hope Medical Center | RECIPIENTS: Seronegative for HIV antigen (Ag)/antibody (Ab) combination (combo), hepatitis c virus (HCV)*, active hepatitis b virus (HBV) (surface antigen negative) and syphilis (RPR) within 2 months of registration and no history of disseminated cutaneous human papillomavirus (HPV) related disease. |
| NCT07020533 | Pregnancy | Phase 1 | City of Hope Medical Center | DONORS: Females only: Pregnant or breastfeeding. |
| NCT07020533 | Renal | Phase 1 | City of Hope Medical Center | RECIPIENTS: Estimated creatinine clearance acceptable per institutional guidelines (to be performed within 45 days prior to day 1 of protocol therapy). |
| NCT07023627 | Brain metastases | Phase 2 | Incyte Corporation | Known active CNS metastases and/or carcinomatous meningitis. |
| NCT07023627 | Cardiac | Phase 2 | Incyte Corporation | Clinically significant or uncontrolled cardiac disease within 6 months before the first dose of study drug. |
| NCT07023627 | Prior malignancy | Phase 2 | Incyte Corporation | Known additional malignancy that is progressing or requires active treatment. |
| NCT07024615 | Cardiac | Phase 1 | Astellas Pharma Global Development, Inc. | Participant has a corrected QT interval by Fridericia (QTcF) ≤ 470 msec. |
| NCT07024615 | HIV | Phase 1 | Astellas Pharma Global Development, Inc. | Participant is known to have human immunodeficiency virus (HIV) infection. However, participants with cluster of differentiation (CD) 4+ T cell counts ≥ 350 cells/µL and no history of acquired immunodeficiency syndrome (AIDS) defining opportunistic infections within the past 6 months are eligible. |
| NCT07024615 | Performance status | Phase 1 | Astellas Pharma Global Development, Inc. | Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07024615 | Pregnancy | Phase 1 | Astellas Pharma Global Development, Inc. | Female participant must not be breastfeeding or lactating starting at screening and throughout the investigational period and for 5 half-lives (6 months) after final ASP2138 intervention administration |
| NCT07024615 | Prior malignancy | Phase 1 | Astellas Pharma Global Development, Inc. | Participant has another malignancy for which treatment is required. |
| NCT07024706 | HIV | Phase 2 | AstraZeneca | HIV positive |
| NCT07024706 | Performance status | Phase 2 | AstraZeneca | ECOG performance status 0, 1 or 2 |
| NCT07024706 | Prior malignancy | Phase 2 | AstraZeneca | History of prior or current malignancy. |
| NCT07027748 | Age | Phase 1 | Steven DuBois, MD | Patients 1 - 30 years of age at the time of enrollment are eligible for this study. |
| NCT07027748 | Brain metastases | Phase 1 | Steven DuBois, MD | Untreated central nervous system (CNS) metastatic disease |
| NCT07027748 | Cardiac | Phase 1 | Steven DuBois, MD | Ejection fraction of ≥ 50% |
| NCT07027748 | Hepatic | Phase 1 | Steven DuBois, MD | Total bilirubin ≤ 1.5 x ULN for age* |
| NCT07027748 | Performance status | Phase 1 | Steven DuBois, MD | Patients must demonstrate adequate performance level as measured by Karnofsky ≥ 70% for patients aged 16 years or older, OR Lansky ≥ 70% for patients younger than 16 years. |
| NCT07027748 | Pregnancy | Phase 1 | Steven DuBois, MD | Pregnant or currently breast feeding: Pregnant participants are excluded from this study because protocol therapy has the potential for teratogenic or abortifacient effects. |
| NCT07027748 | Renal | Phase 1 | Steven DuBois, MD | Radioisotope GFR ≥ 70ml/min/1.73 m2 |
| NCT07029399 | Brain metastases | Phase 1 | NiKang Therapeutics, Inc. | Known active CNS metastases and/or carcinomatous meningitis |
| NCT07029399 | Cardiac | Phase 1 | NiKang Therapeutics, Inc. | Clinically significant cardiovascular event, including myocardial infarction, arterial thromboembolism, or cerebrovascular thromboembolism, within 6 months |
| NCT07029399 | Hepatic | Phase 1 | NiKang Therapeutics, Inc. | Significant liver disease (Child Pugh class B or C) |
| NCT07029399 | Performance status | Phase 1 | NiKang Therapeutics, Inc. | ECOG status of 0 or 1 |
| NCT07029399 | Prior malignancy | Phase 1 | NiKang Therapeutics, Inc. | History of another malignancy except for the following |
| NCT07032714 | Hepatic | Phase 1 | Massachusetts General Hospital | Serum bilirubin values < 1.5 x ULN. Isolated bilirubin x 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%. Patients with elevated bilirubin due to Gilbert's syndrome may be permitted with PI approval (e.g. total bilirubin <3 mg/dL and normal direct bilirubin); and |
| NCT07032714 | Performance status | Phase 1 | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix). |
| NCT07032714 | Renal | Phase 1 | Massachusetts General Hospital | Calculated creatinine clearance of ≥ 30 mL/min by Modified Diet in Renal Disease (MDRD) formula or Cockcroft-Gault formula |
| NCT07037758 | Brain metastases | Phase 1 | Amgen | Symptomatic central nervous system (CNS) metastases. |
| NCT07038343 | Age | Phase 1/2 | Avenzo Therapeutics, Inc. | between 18 and 75 years of age |
| NCT07038343 | Brain metastases | Phase 1/2 | Avenzo Therapeutics, Inc. | Patients with suspected or confirmed leptomeningeal disease are not eligible, even if treated. |
| NCT07038343 | Performance status | Phase 1/2 | Avenzo Therapeutics, Inc. | with an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 |
| NCT07039916 | Prior malignancy | Phase 3 | Immunovant Sciences GmbH | Have any active or untreated malignant thymoma |
| NCT07046923 | Brain metastases | Phase 1 | Eli Lilly and Company | Individual with known or suspected history of uncontrolled central nervous system (CNS) metastases. |
| NCT07046923 | Cardiac | Phase 1 | Eli Lilly and Company | Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 milliseconds (ms) |
| NCT07046923 | Performance status | Phase 1 | Eli Lilly and Company | Eastern Cooperative Oncology Group (ECOG) performance status of greater than or equal to (≤) 1. |
| NCT07046923 | Pregnancy | Phase 1 | Eli Lilly and Company | Individuals who are pregnant, breastfeeding, or plan to breastfeed during the trial or within 30 days of the last dose of trial intervention. |
| NCT07052695 | Brain metastases | Phase 1/2 | Inhye Ahn | known CNS involvement of CLL |
| NCT07052695 | Cardiac | Phase 1/2 | Inhye Ahn | Significant cardiovascular disease such as uncontrolled arrhythmi, class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, ejection fraction < 40% by any methods in the 12 months of enrollment, unstable angina or acute coronary syndrome including myocardial infarction within 6 months of enrollment. |
| NCT07052695 | Hepatic | Phase 1/2 | Inhye Ahn | Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis |
| NCT07052695 | HIV | Phase 1/2 | Inhye Ahn | Patients who have tested positive for HIV are excluded due to potential drug-drug interactions between anti-retroviral medications and pirtobrutinib and risk of opportunistic infections with both HIV and irreversible BTK inhibitors. |
| NCT07052695 | Performance status | Phase 1/2 | Inhye Ahn | ECOG performance status ≤ 2 |
| NCT07052695 | Pregnancy | Phase 1/2 | Inhye Ahn | Pregnancy, lactation or plan to breastfeed during the study or within 6 months of the last dose of study treatment. |
| NCT07052695 | Prior malignancy | Phase 1/2 | Inhye Ahn | For patients with history of other malignancies with life expectancy of < 2 years. |
| NCT07059845 | Performance status | Phase 2 | AbbVie | Participants must have an Eastern Cooperative Oncology Group performance status of 0 or 1. |
| NCT07059884 | Age | Not given | Alliance for Clinical Trials in Oncology | Age 18-64 years |
| NCT07059884 | Language | Not given | Alliance for Clinical Trials in Oncology | Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions |
| NCT07059884 | Pregnancy | Not given | Alliance for Clinical Trials in Oncology | Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated |
| NCT07061951 | Cardiac | Phase 2 | National Cancer Institute (NCI) | Patients with corrected QT (QTc) > 470 ms |
| NCT07061951 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome, autoimmune hemolytic anemia,(AIHA), or of non-hepatic origin |
| NCT07061951 | Performance status | Phase 2 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%) |
| NCT07061951 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Pregnant women are excluded from this study because mirdametinib is MEK inhibitor agent with the potential for teratogenic or abortifacient effects. |
| NCT07061951 | Renal | Phase 2 | National Cancer Institute (NCI) | Glomerular filtration rate (GFR) 50 ml/min estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (Levey et al., 2009) |
| NCT07061964 | Hepatic | Phase 2 | National Cancer Institute (NCI) | Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x institutional ULN (within 28 days prior to registration) |
| NCT07061964 | HIV | Phase 2 | National Cancer Institute (NCI) | Participants with a history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration |
| NCT07061964 | Performance status | Phase 2 | National Cancer Institute (NCI) | Participants must have Zubrod performance status of 0-2 |
| NCT07061964 | Pregnancy | Phase 2 | National Cancer Institute (NCI) | Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). |
| NCT07061964 | Prior malignancy | Phase 2 | National Cancer Institute (NCI) | Participants must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder within 24 months prior to registration except Ta/T1/carcinoma in situ (CIS) of the upper urinary tract, including renal pelvis or ureter if the participant underwent complete nephroureterectomy |
| NCT07061964 | Renal | Phase 2 | National Cancer Institute (NCI) | Participants must have a creatinine ≤ the institutional (I)ULN OR measured OR calculated creatinine clearance ≥ 40 mL/min using the following Cockcroft-Gault Formula. |
| NCT07061977 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled) |
| NCT07061977 | Performance status | Phase 3 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 |
| NCT07061977 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Not pregnant and not nursing |
| NCT07061977 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | No prior definitive surgical, radiation, or systemic therapy for cervical cancer |
| NCT07061977 | Renal | Phase 3 | National Cancer Institute (NCI) | Creatinine clearance (CrCL) of ≥ 50 mL/min by the Cockcroft-Gault formula |
| NCT07062965 | Hepatic | Phase 3 | Pfizer | Renal impairment, hepatic dysfunction, or hematologic abnormalities. |
| NCT07062965 | Performance status | Phase 3 | Pfizer | Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. |
| NCT07062965 | Renal | Phase 3 | Pfizer | Renal impairment, hepatic dysfunction, or hematologic abnormalities. |
| NCT07063745 | Brain metastases | Phase 2/3 | Bristol-Myers Squibb | Participants must not have symptomatic brain metastases or spinal cord compression. |
| NCT07063745 | Performance status | Phase 2/3 | Bristol-Myers Squibb | Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. |
| NCT07070232 | Cardiac | Phase 1/2 | BioNTech SE | Have LVEF <50% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment. |
| NCT07070232 | Performance status | Phase 1/2 | BioNTech SE | Have ECOG performance status of 0 or 1. |
| NCT07070232 | Pregnancy | Phase 1/2 | BioNTech SE | Are a participant of child-bearing potential who are pregnant or breastfeeding or are planning pregnancy within 225 days (~7.5 months) after receiving last dose of BNT326 and within 6 months after last dose of pumitamig, whichever is longer. |
| NCT07070466 | Brain metastases | Phase 2 | Massachusetts General Hospital | Participants with brain metastases (active brain metastases) or leptomeningeal disease are not eligible. |
| NCT07070466 | Cardiac | Phase 2 | Massachusetts General Hospital | congestive heart failure (New York Heart Association [NYHA] classification ≥ grade 2) |
| NCT07070466 | Hepatic | Phase 2 | Massachusetts General Hospital | total bilirubin ≤ 1.5x institutional upper limit of normal (ULN). |
| NCT07070466 | HIV | Phase 2 | Massachusetts General Hospital | Participants with a known history of Human Immunodeficiency Virus (HIV) infection are excluded unless they meet all of the following criteria: |
| NCT07070466 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG Performance status of 0-2 |
| NCT07070466 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued if the mother is treated with ivonescimab. |
| NCT07070466 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT07070466 | Renal | Phase 2 | Massachusetts General Hospital | Creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥50 mL/min. |
| NCT07075185 | Brain metastases | Phase 1 | Kelonia Therapeutics, Inc. | Participants must not have known central nervous system (CNS) involvement with myeloma |
| NCT07075185 | Performance status | Phase 1 | Kelonia Therapeutics, Inc. | Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1 |
| NCT07081646 | Cardiac | Phase 1/2 | Alexion Pharmaceuticals, Inc. | NYHA class III or IV |
| NCT07081646 | Performance status | Phase 1/2 | Alexion Pharmaceuticals, Inc. | ECOG performance status of 0 to 2 |
| NCT07085767 | Brain metastases | Phase 3 | Olema Pharmaceuticals, Inc. | Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment. |
| NCT07085767 | Performance status | Phase 3 | Olema Pharmaceuticals, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07090499 | Performance status | Phase 1 | Pfizer | ECOG Performance status 0-1 |
| NCT07091032 | Language | Not given | Massachusetts General Hospital | speaking a language other than English or Spanish |
| NCT07091032 | Pregnancy | Not given | Massachusetts General Hospital | those with current pregnancy |
| NCT07094113 | Brain metastases | Phase 1 | Amgen | Untreated symptomatic central nervous system or leptomeningeal metastases. |
| NCT07094113 | HIV | Phase 1 | Amgen | Presence or history of any of the following viral infections: HIV, Hepatitis C, Hepatitis B, and active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). |
| NCT07094113 | Performance status | Phase 1 | Amgen | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. |
| NCT07094113 | Prior malignancy | Phase 1 | Amgen | History of other malignancy within the past 5 years. |
| NCT07095517 | Age | Phase 1 | Massachusetts General Hospital | Age 18-50 years |
| NCT07095517 | BMI | Phase 1 | Massachusetts General Hospital | BMI between 27 and 40 kg/m2 |
| NCT07095517 | Diabetes | Phase 1 | Massachusetts General Hospital | Participants with a history of diabetes mellitus |
| NCT07095517 | Pregnancy | Phase 1 | Massachusetts General Hospital | Participants who are pregnant. |
| NCT07095517 | Prior malignancy | Phase 1 | Massachusetts General Hospital | Participants with a history of cancer (excluding non-melanoma skin) within the last three years |
| NCT07097142 | Cardiac | Phase 3 | NRG Oncology | New York Heart Association Functional Classification II or better (NYHA Functional Classification III/IV are not eligible) |
| NCT07097142 | Hepatic | Phase 3 | NRG Oncology | Total bilirubin ≤ 2 x institutional upper limit of normal (ULN) |
| NCT07097142 | Performance status | Phase 3 | NRG Oncology | Zubrod performance status of ≤ 2 |
| NCT07097142 | Pregnancy | Phase 3 | NRG Oncology | Not pregnant and not nursing |
| NCT07097142 | Prior malignancy | Phase 3 | NRG Oncology | Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder within 24 months prior to registration |
| NCT07097142 | Renal | Phase 3 | NRG Oncology | Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula |
| NCT07100080 | Brain metastases | Phase 2/3 | Bristol-Myers Squibb | Leptomeningeal metastases or spinal cord compression. |
| NCT07100106 | Performance status | Phase 1/2 | Genentech, Inc. | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. |
| NCT07100106 | Prior malignancy | Phase 1/2 | Genentech, Inc. | History of malignancy within 3 years prior to screening, except for cancer under investigation in this study and malignancies with a negligible risk of metastasis or death. |
| NCT07100990 | Pregnancy | Phase 3 | Mayo Clinic | Pregnancy |
| NCT07101328 | Brain metastases | Phase 1 | Eli Lilly and Company | Known or suspected central nervous system (CNS) involvement by systemic lymphoma. |
| NCT07101328 | Cardiac | Phase 1 | Eli Lilly and Company | Significant cardiovascular disease |
| NCT07101328 | Performance status | Phase 1 | Eli Lilly and Company | Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07101328 | Pregnancy | Phase 1 | Eli Lilly and Company | Pregnant and/or planning to breastfeed during the trial or within 90 days of the last dose of study intervention. |
| NCT07101328 | Prior malignancy | Phase 1 | Eli Lilly and Company | Active second malignancies, unless in remission, with life expectancy greater than 2 years with Sponsor approval. |
| NCT07102797 | Age | Not given | Massachusetts General Hospital | ages 8-12 years old at time of enrollment |
| NCT07102797 | BMI | Not given | Massachusetts General Hospital | BMI >/= 85th percentile |
| NCT07102797 | Cardiac | Not given | Massachusetts General Hospital | Significant cardiac, hepatic, oncologic, inflammatory, or psychiatric disease. |
| NCT07102797 | Diabetes | Not given | Massachusetts General Hospital | Insulin dynamics: Type 1 diabetes, Type 2 diabetes, Congenital Hyperinsulinism |
| NCT07102797 | Hepatic | Not given | Massachusetts General Hospital | Significant cardiac, hepatic, oncologic, inflammatory, or psychiatric disease. |
| NCT07102797 | Language | Not given | Massachusetts General Hospital | Caregiver of child (ie mother, father, or other legal guardian), English-speaking, Access to a device where they are able to receive study e-mails or texts |
| NCT07104331 | Brain metastases | Phase 2 | Sarcoma Alliance for Research through Collaboration | Active central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity. |
| NCT07104331 | Cardiac | Phase 2 | Sarcoma Alliance for Research through Collaboration | Myocardial infarction within 12 months of screening |
| NCT07104331 | Hepatic | Phase 2 | Sarcoma Alliance for Research through Collaboration | Total bilirubin <2 x ULN |
| NCT07104331 | HIV | Phase 2 | Sarcoma Alliance for Research through Collaboration | HIV+ patients are allowed provided the patient has a CD4 count greater than 200 and is HIV undetectable on antiviral medications, and there are no AIDS-defining illnesses within 12 months. |
| NCT07104331 | Performance status | Phase 2 | Sarcoma Alliance for Research through Collaboration | ECOG performance status ≤2 |
| NCT07104331 | Pregnancy | Phase 2 | Sarcoma Alliance for Research through Collaboration | Pregnant women are excluded from this study |
| NCT07104331 | Prior malignancy | Phase 2 | Sarcoma Alliance for Research through Collaboration | Co-existing malignancies or use of any other concurrent investigational agents or anticancer agents, excluding adjuvant hormonal therapy for breast or prostate cancer. |
| NCT07104331 | Renal | Phase 2 | Sarcoma Alliance for Research through Collaboration | Creatinine <1.5 x ULN or measured CrCl of >30ml/m2/1.73 m2 |
| NCT07109726 | Brain metastases | Phase 1/2 | Terremoto Biosciences Inc. | Active brain metastases or carcinomatous meningitis. |
| NCT07109726 | Diabetes | Phase 1/2 | Terremoto Biosciences Inc. | Clinically significant abnormalities of glucose metabolism |
| NCT07109726 | Performance status | Phase 1/2 | Terremoto Biosciences Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT07111520 | Brain metastases | Phase 1/2 | BioNTech SE | Have clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. |
| NCT07111520 | Cardiac | Phase 1/2 | BioNTech SE | Have left ventricular ejection fraction <50% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment. |
| NCT07111520 | Hepatic | Phase 1/2 | BioNTech SE | Child-Pugh class B or C cirrhosis |
| NCT07111520 | Performance status | Phase 1/2 | BioNTech SE | Have Eastern Cooperative Oncology Group performance status of 0 or 1. |
| NCT07111520 | Pregnancy | Phase 1/2 | BioNTech SE | Are participants of childbearing potential who are pregnant or breastfeeding or are planning pregnancy within the time specified in the protocol or are potentially fertile males, who are planning to father children during the study or within the time specified in the protocol. |
| NCT07112287 | Language | Not given | Christopher Reilly | Ability to understand and provide a signed and completed consent document in English. |
| NCT07114601 | Performance status | Phase 1 | Eli Lilly and Company | Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1. |
| NCT07116616 | Brain metastases | Phase 1/2 | ModernaTX, Inc. | Known central nervous system (CNS) myeloma or clinical signs and symptoms of CNS involvement of myeloma. |
| NCT07121972 | Age | Not given | University of California, San Francisco | ages 40-89 years old |
| NCT07121972 | Diabetes | Not given | University of California, San Francisco | Diabetes treated with insulin or other prescribed medications. |
| NCT07121972 | Hepatic | Not given | University of California, San Francisco | History of severe hepatic disease/liver transplant/pending liver transplant. |
| NCT07121972 | Pregnancy | Not given | University of California, San Francisco | Pregnant women. |
| NCT07121972 | Renal | Not given | University of California, San Francisco | participants with severely impaired renal function (GFR < 30 mL/min) will be excluded. |
| NCT07123090 | Brain metastases | Phase 2 | Stephanie Berg | Participants with untreated brain metastases. |
| NCT07123090 | Cardiac | Phase 2 | Stephanie Berg | Has had any major cardiovascular event within 6 months prior to treatment start, including but not limited to: myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic event or New York Heart Association Class III or IV heart failure. |
| NCT07123090 | Hepatic | Phase 2 | Stephanie Berg | Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) with the following exception: patients with known Gilbert disease should have a total serum bilirubin ≤ 3 x ULN |
| NCT07123090 | HIV | Phase 2 | Stephanie Berg | Patients with known viral infection (such as HIV) are excluded given the potential for interactions between antiretroviral agents and palbociclib and axitinib |
| NCT07123090 | Performance status | Phase 2 | Stephanie Berg | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). |
| NCT07123090 | Pregnancy | Phase 2 | Stephanie Berg | Females that are pregnant or breastfeeding. |
| NCT07123090 | Prior malignancy | Phase 2 | Stephanie Berg | Other malignancy diagnosed within 2 years of treatment start unless negligible risk of metastases or death according to the investigator |
| NCT07123090 | Renal | Phase 2 | Stephanie Berg | Creatinine clearance ≥30 mL/min according to the CKD-EPI equation. (APPENDIX C) |
| NCT07123090 | Smoking | Phase 2 | Stephanie Berg | Current or past tobacco users with a history of cigarette smoking greater than 30 pack-yrs (i.e., # of packs of cigarettes smoked per day × # of years patient has smoked > 30). |
| NCT07123649 | Age | Phase 2 | Dana-Farber Cancer Institute | Women aged ≥ 80 years at the time of registration |
| NCT07123649 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Pregnant women, young patients, and those in prison will not be eligible for enrollment given the study design and aims supporting study in a different population focused on older adults |
| NCT07123649 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | History of stage 0-III breast cancer (Of note: ductal carcinoma in situ [DCIS], pleomorphic lobular carcinoma in situ [because it is typically treated like DCIS], or invasive breast cancer of any subtype are all eligible) |
| NCT07127874 | Brain metastases | Phase 1 | Pheon Therapeutics | Has unstable central nervous system metastasis. |
| NCT07127874 | Performance status | Phase 1 | Pheon Therapeutics | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07128303 | HIV | Phase 1 | Gilead Sciences | Active human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) infection |
| NCT07128303 | Performance status | Phase 1 | Gilead Sciences | Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1. |
| NCT07128303 | Pregnancy | Phase 1 | Gilead Sciences | Positive serum pregnancy test or participant who is breastfeeding. |
| NCT07128303 | Prior malignancy | Phase 1 | Gilead Sciences | Active second malignancy. Participants with a history of malignancy who have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or participants with surgically cured tumors with low risk of recurrence may be enrolled. |
| NCT07128355 | Brain metastases | Early phase 1 | Massachusetts General Hospital | Uncontrolled brain metastases. |
| NCT07128355 | Cardiac | Early phase 1 | Massachusetts General Hospital | symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia |
| NCT07128355 | Hepatic | Early phase 1 | Massachusetts General Hospital | AST and ALT ≤ 2.5 x ULN |
| NCT07128355 | HIV | Early phase 1 | Massachusetts General Hospital | Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). |
| NCT07128355 | Performance status | Early phase 1 | Massachusetts General Hospital | ECOG performance status ≤ 1 |
| NCT07128355 | Pregnancy | Early phase 1 | Massachusetts General Hospital | WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG). |
| NCT07128355 | Prior malignancy | Early phase 1 | Massachusetts General Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT07128355 | Renal | Early phase 1 | Massachusetts General Hospital | Creatinine Clearance ≥ 40 mL/min if calculated using Cockcroft-Gault formula |
| NCT07128641 | Brain metastases | Phase 2 | Gottfried von Keudell, MD PhD | Patients with known or suspected CNS involvement or leptomeningeal disease are excluded |
| NCT07128641 | Cardiac | Phase 2 | Gottfried von Keudell, MD PhD | Cardiac ejection fraction >40% by echocardiogram or multi-gated acquisition (MUGA) scan |
| NCT07128641 | Hepatic | Phase 2 | Gottfried von Keudell, MD PhD | Total bilirubin ≤1.5 × upper limit of normal (ULN) (≤3 × ULN if attributed to lymphoma infiltration of liver) |
| NCT07128641 | HIV | Phase 2 | Gottfried von Keudell, MD PhD | Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) NOTE: Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 cells/μL either spontaneously or on a stable antiviral regimen) are permitted |
| NCT07128641 | Performance status | Phase 2 | Gottfried von Keudell, MD PhD | ECOG performance status > 2 |
| NCT07128641 | Pregnancy | Phase 2 | Gottfried von Keudell, MD PhD | Pregnant women or participants unwilling to adhere to institutional guidelines for highly effective contraception during odronextamab treatment and for 12 months after the last dose are excluded |
| NCT07128641 | Prior malignancy | Phase 2 | Gottfried von Keudell, MD PhD | Another active malignancy (aside from B-cell NHL) in the past 2 years, with the following exceptions |
| NCT07128641 | Renal | Phase 2 | Gottfried von Keudell, MD PhD | Calculated creatinine clearance by Cockcroft Gault formula ≥40 mL/min |
| NCT07130786 | Brain metastases | Phase 2 | Ayal A. Aizer, MD | Participants with widespread, definitive leptomeningeal disease given that leptomeningeal disease and brain metastases are different entities |
| NCT07130786 | Performance status | Phase 2 | Ayal A. Aizer, MD | Karnofsky performance status of at least 60 |
| NCT07130786 | Pregnancy | Phase 2 | Ayal A. Aizer, MD | Pregnant women are excluded from this study because levetiracetam crosses the placenta. |
| NCT07130786 | Renal | Phase 2 | Ayal A. Aizer, MD | Participants with end stage renal disease due to risk of nephrogenic systemic fibrosis in this patient population after exposure to gadolinium-based contrast agents |
| NCT07132190 | Brain metastases | Phase 2 | Ayal A. Aizer, MD | Participants with widespread, definitive leptomeningeal disease |
| NCT07132190 | Performance status | Phase 2 | Ayal A. Aizer, MD | Karnofsky performance status of at least 60 |
| NCT07132190 | Pregnancy | Phase 2 | Ayal A. Aizer, MD | Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. |
| NCT07132190 | Renal | Phase 2 | Ayal A. Aizer, MD | Participants with end stage renal disease |
| NCT07137416 | Brain metastases | Phase 1 | National Cancer Institute (NCI) | Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy |
| NCT07137416 | Cardiac | Phase 1 | National Cancer Institute (NCI) | Patients must have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within 28 days before randomization/enrollment |
| NCT07137416 | Hepatic | Phase 1 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) (or ≤ 2 × institutional ULN in patients with documented Gilbert's syndrome) |
| NCT07137416 | HIV | Phase 1 | National Cancer Institute (NCI) | Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT07137416 | Performance status | Phase 1 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%) |
| NCT07137416 | Pregnancy | Phase 1 | National Cancer Institute (NCI) | Pregnant women are excluded from this study because CX-5461 (pidnarulex) and T-DXd are agents with the potential for teratogenic or abortifacient effects. |
| NCT07137416 | Prior malignancy | Phase 1 | National Cancer Institute (NCI) | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT07137416 | Renal | Phase 1 | National Cancer Institute (NCI) | Glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 (using the Cockcroft-Gault equation for participants with creatinine levels above institutional ULN) |
| NCT07139769 | Language | Not given | Zeba Ahmad, Ph.D. | English-speaking |
| NCT07140900 | Brain metastases | Phase 1 | Amgen | Prior history of central nervous system (CNS) metastases. |
| NCT07144280 | Brain metastases | Phase 3 | Pfizer | Participants with a history of leptomeningeal metastasis are excluded. |
| NCT07144280 | Prior malignancy | Phase 3 | Pfizer | History of another malignancy within 3 years before the first dose of PF-08046054, or any evidence of residual disease from a previously diagnosed malignancy. |
| NCT07148180 | Brain metastases | Phase 1/2 | Jacqueline Garcia, MD | Subjects with known active/symptomatic CNS involvement. CNS prophylaxis allowed |
| NCT07148180 | Cardiac | Phase 1/2 | Jacqueline Garcia, MD | Left ventricular ejection fraction ≥ institutional lower limit of normal by MUGA or echocardiogram within 30 days of first protocol treatment. |
| NCT07148180 | Hepatic | Phase 1/2 | Jacqueline Garcia, MD | AST(SGOT) and ALT(SGPT) ≤ 3.0 × institutional upper limit of normal |
| NCT07148180 | HIV | Phase 1/2 | Jacqueline Garcia, MD | Subjects with known HIV positivity are permitted provided they have undetectable viral load at the time of screening (HIV testing is not required). |
| NCT07148180 | Performance status | Phase 1/2 | Jacqueline Garcia, MD | ECOG performance status ≤2 (see Appendix A). |
| NCT07148180 | Pregnancy | Phase 1/2 | Jacqueline Garcia, MD | Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects. |
| NCT07148180 | Prior malignancy | Phase 1/2 | Jacqueline Garcia, MD | Subject has a concurrent malignancy or prior malignancy within the 6-month period before screening. |
| NCT07148180 | Renal | Phase 1/2 | Jacqueline Garcia, MD | Creatinine clearance ≥ 45 ml/min GFR by MDRD |
| NCT07149363 | Performance status | Phase 2 | Alliance Foundation Trials, LLC. | ECOG performance status 0-1. |
| NCT07149363 | Prior malignancy | Phase 2 | Alliance Foundation Trials, LLC. | History of another primary malignancy except for: |
| NCT07154706 | Cardiac | Phase 3 | Nuvation Bio Inc. | Have clinically significant cardiovascular disease within 3 months prior to Randomization. |
| NCT07154706 | HIV | Phase 3 | Nuvation Bio Inc. | or known human immunodeficiency virus (HIV)- or acquired immunodeficiency syndrome-related illness. |
| NCT07154706 | Performance status | Phase 3 | Nuvation Bio Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07154706 | Prior malignancy | Phase 3 | Nuvation Bio Inc. | History of other malignancies except adequately treated non-melanoma skin cancer, curatively treated in situ cancer, or other tumors curatively treated with no evidence of disease for >3 years after the end of treatment |
| NCT07155174 | Brain metastases | Phase 2 | AbbVie | Known active/symptomatic central nervous system (CNS) metastases should be excluded. |
| NCT07155174 | Performance status | Phase 2 | AbbVie | Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment. |
| NCT07162337 | Age | Not given | Massachusetts General Hospital | Age 18-80 years. |
| NCT07162337 | BMI | Not given | Massachusetts General Hospital | BMI of at least 18.5 kg/m2 but less than 35 kg/m2 |
| NCT07162337 | Cardiac | Not given | Massachusetts General Hospital | Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. |
| NCT07162337 | Hepatic | Not given | Massachusetts General Hospital | Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis. |
| NCT07162337 | HIV | Not given | Massachusetts General Hospital | Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection. |
| NCT07162337 | Pregnancy | Not given | Massachusetts General Hospital | Pregnant or breastfeeding. |
| NCT07162337 | Prior malignancy | Not given | Massachusetts General Hospital | Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of nonmelanoma skin) in which there has been any active treatment within the last three years. |
| NCT07162337 | Renal | Not given | Massachusetts General Hospital | Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis. |
| NCT07164443 | Cardiac | Phase 3 | Janssen Research & Development, LLC | Congestive heart failure (New York Heart Association class II to IV) |
| NCT07164443 | Hepatic | Phase 3 | Janssen Research & Development, LLC | Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) less than or equal to (≤) 3 times the Upper Limit of Normal (ULN) |
| NCT07164443 | Performance status | Phase 3 | Janssen Research & Development, LLC | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 |
| NCT07164443 | Prior malignancy | Phase 3 | Janssen Research & Development, LLC | Prior or concurrent second malignancy (other than the disease under study) for which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s) |
| NCT07164443 | Renal | Phase 3 | Janssen Research & Development, LLC | A) eGFR ≥ 40 milliliters per minute (mL/min) |
| NCT07166094 | Brain metastases | Phase 3 | Genmab | Known active central nervous system metastases or carcinomatous meningitis. |
| NCT07166094 | Prior malignancy | Phase 3 | Genmab | Has a past or current malignancy other than the inclusion diagnosis before the planned first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. |
| NCT07168629 | Age | Not given | Baystate Medical Center | Adults between the age of 50 and 80. |
| NCT07168629 | Smoking | Not given | Baystate Medical Center | smoking history (has not smoked more than 20 pack-years of tobacco cigarettes or quit more than 15 years ago) |
| NCT07173751 | Performance status | Phase 3 | BioNTech SE | Eastern cooperative oncology group (ECOG) performance status of 0 or 1. |
| NCT07173751 | Pregnancy | Phase 3 | BioNTech SE | Are pregnant or breastfeeding or are planning pregnancy or planning to father children during the trial or within 6 months after the last dose of pumitamig or placebo. |
| NCT07181161 | Brain metastases | Phase 1/2 | AstraZeneca | Cancer related spinal cord compression, or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to study enrolment. |
| NCT07181161 | Cardiac | Phase 1/2 | AstraZeneca | Cardiovascular disorder (History of arrhythmia, uncontrolled hypertension, symptomatic hypotension, history of brain perfusion problems, symptomatic heart failure, prior or current cardiomyopathy, severe valvular heart disease) |
| NCT07181161 | HIV | Phase 1/2 | AstraZeneca | Active infection exclusions, including tuberculosis and infections with Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV). |
| NCT07181161 | Performance status | Phase 1/2 | AstraZeneca | Eastern cooperative oncology group (ECOG) performance status of 0 or 1. |
| NCT07181161 | Prior malignancy | Phase 1/2 | AstraZeneca | History of malignancy |
| NCT07182149 | Performance status | Phase 1 | Normunity AccelCo, Inc. | Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. |
| NCT07193511 | Brain metastases | Phase 1/2 | Avenzo Therapeutics, Inc. | Patients with active central nervous system (CNS) metastases are not eligible. |
| NCT07193511 | Cardiac | Phase 1/2 | Avenzo Therapeutics, Inc. | History of any serious cardiovascular condition. |
| NCT07193511 | Performance status | Phase 1/2 | Avenzo Therapeutics, Inc. | Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1 |
| NCT07195682 | Performance status | Phase 1 | Bristol-Myers Squibb | Eastern Cooperative Oncology Group performance status of 0 to 1. |
| NCT07197554 | Brain metastases | Phase 1 | SEED Therapeutics, Inc. | Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable |
| NCT07197554 | Performance status | Phase 1 | SEED Therapeutics, Inc. | Has an ECOG performance status ≤ 2 at screening. |
| NCT07198074 | Cardiac | Phase 3 | National Cancer Institute (NCI) | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better |
| NCT07198074 | Hepatic | Phase 3 | National Cancer Institute (NCI) | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled) |
| NCT07198074 | Performance status | Phase 3 | National Cancer Institute (NCI) | Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 |
| NCT07198074 | Pregnancy | Phase 3 | National Cancer Institute (NCI) | Not pregnant and not nursing |
| NCT07198074 | Prior malignancy | Phase 3 | National Cancer Institute (NCI) | Patients may have received: * NO prior chemotherapy for treatment of endometrial cancer OR |
| NCT07198074 | Renal | Phase 3 | National Cancer Institute (NCI) | Creatinine clearance (CrCl) of ≥ 30 mL/min by the Cockcroft-Gault formula |
| NCT07198724 | Brain metastases | Phase 1/2 | Kristina A. Fanucci | Participants with a history of central nervous system (CNS) metastases are eligible if: Stable or untreated, asymptomatic brain metastases not needing immediate local therapy. |
| NCT07198724 | Cardiac | Phase 1/2 | Kristina A. Fanucci | Baseline LVEF ≥ 50% prior to registration, as measured by echocardiogram |
| NCT07198724 | Diabetes | Phase 1/2 | Kristina A. Fanucci | uncontrolled diabetes mellitus |
| NCT07198724 | Hepatic | Phase 1/2 | Kristina A. Fanucci | Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (or ≤ 2 x ULN in patients with documented Gilbert's syndrome) |
| NCT07198724 | Performance status | Phase 1/2 | Kristina A. Fanucci | ECOG performance status ≤ 2. |
| NCT07198724 | Pregnancy | Phase 1/2 | Kristina A. Fanucci | Patients who are pregnant or breastfeeding, or who expect to become pregnant within the projected duration of the study. |
| NCT07198724 | Prior malignancy | Phase 1/2 | Kristina A. Fanucci | Patients with a history of different malignancy are ineligible, except for those who have been disease-free for at least three years and are deemed by the investigator to be at low risk for recurrence of the prior malignancy. |
| NCT07198724 | Renal | Phase 1/2 | Kristina A. Fanucci | Creatinine ≤ 1.5 x institutional ULN OR |
| NCT07204340 | Brain metastases | Phase 1 | Treeline Biosciences, Inc. | Patients must not have active brain metastases. |
| NCT07204340 | Cardiac | Phase 1 | Treeline Biosciences, Inc. | Patients must not have clinically significant cardiovascular disease. |
| NCT07204340 | Performance status | Phase 1 | Treeline Biosciences, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07204340 | Pregnancy | Phase 1 | Treeline Biosciences, Inc. | Pregnant or lactating. |
| NCT07206056 | Brain metastases | Phase 1/2 | Novartis Pharmaceuticals | Participants with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purpose of maintaining neurologic integrity. |
| NCT07209436 | BMI | Not given | Amy Colwell | Morbid obesity as defined as a BMI greater than 40 kg/m2 |
| NCT07209436 | Renal | Not given | Amy Colwell | Renal insufficiency |
| NCT07213791 | Brain metastases | Phase 1 | Eli Lilly and Company | Have known active central nervous system (CNS) metastases or carcinomatous meningitis. |
| NCT07213791 | Cardiac | Phase 1 | Eli Lilly and Company | Have prolongation of the corrected QTcF >470 milliseconds (msec) during screening. |
| NCT07213791 | Performance status | Phase 1 | Eli Lilly and Company | Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1. |
| NCT07213791 | Renal | Phase 1 | Eli Lilly and Company | Measured creatinine clearance ≥60 milliliters per minute (mL/min) |
| NCT07214987 | Hepatic | Phase 2 | Massachusetts General Hospital | total bilirubin ≤ 2 institutional upper limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤ 2 × institutional ULN |
| NCT07214987 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status ≤ 1 |
| NCT07214987 | Pregnancy | Phase 2 | Massachusetts General Hospital | Pregnant women are excluded from this study because toripalimab, cisplatin and docetaxel have the potential for teratogenic or abortifacient effects. |
| NCT07214987 | Prior malignancy | Phase 2 | Massachusetts General Hospital | Presence of a second malignancy that is considered active by the investigator. |
| NCT07214987 | Renal | Phase 2 | Massachusetts General Hospital | creatinine ≤ 2 x institutional ULN OR glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m2 |
| NCT07215910 | Brain metastases | Phase 3 | Alliance for Clinical Trials in Oncology | No evidence of spinal or leptomeningeal disease |
| NCT07215910 | Cardiac | Phase 3 | Alliance for Clinical Trials in Oncology | No significant active cardiac disease within 6 months prior to registration, including New York Heart Association Functional Classification class III or IV congestive heart failure, myocardial infarction, unstable angina, and/or stroke. To be eligible for this trial, patients should be class 2B or better |
| NCT07215910 | Hepatic | Phase 3 | Alliance for Clinical Trials in Oncology | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) |
| NCT07215910 | HIV | Phase 3 | Alliance for Clinical Trials in Oncology | Patients with known HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial |
| NCT07215910 | Performance status | Phase 3 | Alliance for Clinical Trials in Oncology | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (or Karnofsky performance status [KPS] ≥ 60%) |
| NCT07215910 | Pregnancy | Phase 3 | Alliance for Clinical Trials in Oncology | Not pregnant and not nursing, because this study involves agents whose genotoxic, mutagenic, and teratogenic effects on the developing fetus and newborn are unknown |
| NCT07215910 | Prior malignancy | Phase 3 | Alliance for Clinical Trials in Oncology | Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial |
| NCT07215910 | Renal | Phase 3 | Alliance for Clinical Trials in Oncology | Creatinine ≤ 2.0 x ULN or calculated (calc.) creatinine clearance > 40 mL/min |
| NCT07216560 | Brain metastases | Phase 1/2 | Mabwell (Shanghai) Bioscience Co., Ltd. | Active, untreated or symptomatic CNS metastasis |
| NCT07216560 | Diabetes | Phase 1/2 | Mabwell (Shanghai) Bioscience Co., Ltd. | Poorly controlled blood glucose with fasting blood glucose above 10mmol/L |
| NCT07216560 | HIV | Phase 1/2 | Mabwell (Shanghai) Bioscience Co., Ltd. | Active HIV or hepatitis B/C infection. |
| NCT07216560 | Performance status | Phase 1/2 | Mabwell (Shanghai) Bioscience Co., Ltd. | ECOG 0-1 |
| NCT07216560 | Pregnancy | Phase 1/2 | Mabwell (Shanghai) Bioscience Co., Ltd. | Pregnant or breastfeeding women |
| NCT07216560 | Prior malignancy | Phase 1/2 | Mabwell (Shanghai) Bioscience Co., Ltd. | Other concurrent malignancy in the recent 3 years except for adequately treated carcinoma in situ. |
| NCT07217587 | Prior malignancy | Phase 3 | Janssen Research & Development, LLC | Currently has a malignancy or has a history of malignancy within 3 years before baseline |
| NCT07217704 | Hepatic | Phase 3 | SOFIE | Hepatic function: T. bili >1.5X ULN or alk phos, ALT, or AST >5X ULN |
| NCT07217704 | Performance status | Phase 3 | SOFIE | Eastern Cooperative Oncology Group (ECOG) performance status ≤2. |
| NCT07217704 | Pregnancy | Phase 3 | SOFIE | Pregnant or currently breast feeding (a negative pregnancy test is required in women of childbearing potential). |
| NCT07217704 | Prior malignancy | Phase 3 | SOFIE | Previous cancer (except basal cell carcinoma of the skin or in situ carcinoma of the cervix/uterus (participants treated with curative intent and disease free for more than 5 years are permitted). |
| NCT07217704 | Renal | Phase 3 | SOFIE | Renal function: GFR < 30 mL/min |
| NCT07218809 | Prior malignancy | Phase 3 | AstraZeneca | Participants with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed tumours containing any of the above histologies, or low-grade or borderline ovarian tumour. |
| NCT07218926 | Brain metastases | Phase 3 | GlaxoSmithKline | Known untreated or active central nervous system metastases. |
| NCT07218926 | Prior malignancy | Phase 3 | GlaxoSmithKline | Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease. |
| NCT07219212 | Performance status | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 |
| NCT07219459 | Brain metastases | Phase 2 | CatalYm GmbH | Known or detected clinically active central nervous system (CNS) involvement by HCC or other tumors. |
| NCT07219459 | Cardiac | Phase 2 | CatalYm GmbH | Have one of the following cardiovascular risk factors: myocardial infarction, peri/myocarditis, or history of ischemic stroke in the past 3 months before planned treatment start, uncontrolled heart failure, uncontrolled ventricular arrhythmia, QT interval corrected for heart rate using Fridericia's formula interval ≥ 470 ms regardless of sex. |
| NCT07219459 | Diabetes | Phase 2 | CatalYm GmbH | Comedication with metformin or metformin-containing antidiabetics in participants with type II diabetes. |
| NCT07219459 | Hepatic | Phase 2 | CatalYm GmbH | Child-Pugh score of A6 or better. |
| NCT07219459 | Performance status | Phase 2 | CatalYm GmbH | ECOG performance status ≤1. |
| NCT07219459 | Prior malignancy | Phase 2 | CatalYm GmbH | Known history of other prior malignancy unless participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy. |
| NCT07219537 | Age | Not given | Massachusetts General Hospital | Who are over 75 years of age or older |
| NCT07219537 | Pregnancy | Not given | Massachusetts General Hospital | Who are pregnant |
| NCT07219537 | Prior malignancy | Not given | Massachusetts General Hospital | With a history or current diagnosis of colorectal cancer |
| NCT07220239 | Pregnancy | Not given | Jessica D. St. Laurent, MD | Current pregnancy |
| NCT07220239 | Prior malignancy | Not given | Jessica D. St. Laurent, MD | Prior history of endometrial cancer |
| NCT07222215 | Age | Phase 2 | Kristina A. Fanucci | Because no dosing or adverse event data are currently available on the use of capecitabine in combination with elacestrant participants <18 years of age are excluded from this study |
| NCT07222215 | Brain metastases | Phase 2 | Kristina A. Fanucci | Participants with active brain metastases. |
| NCT07222215 | Cardiac | Phase 2 | Kristina A. Fanucci | congestive heart failure (≥ New York Heart Association Classification Class II) |
| NCT07222215 | Diabetes | Phase 2 | Kristina A. Fanucci | uncontrolled diabetes mellitus |
| NCT07222215 | HIV | Phase 2 | Kristina A. Fanucci | HIV-infected participants must have well-controlled HIV on ART, defined as: |
| NCT07222215 | Performance status | Phase 2 | Kristina A. Fanucci | ECOG PS 0-1 |
| NCT07222215 | Pregnancy | Phase 2 | Kristina A. Fanucci | Female participants lactating or nursing. |
| NCT07222215 | Prior malignancy | Phase 2 | Kristina A. Fanucci | Individuals with a history of a different malignancy are ineligible except for the following circumstances: |
| NCT07222215 | Renal | Phase 2 | Kristina A. Fanucci | Creatinine clearance > 50 mL/min/1.73 m2 |
| NCT07222800 | Brain metastases | Phase 3 | Pfizer | Participants with known active symptomatic CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression |
| NCT07222800 | Performance status | Phase 3 | Pfizer | Eastern Cooperative Oncology Group performance status (ECOG) 0-1 |
| NCT07224776 | Cardiac | Phase 1 | Brigham and Women's Hospital | History of congestive heart failure (New York Heart Association Class II-IV) |
| NCT07224776 | Hepatic | Phase 1 | Brigham and Women's Hospital | Jaundice, hepatitis, or known hepatobiliary disease (excluding asymptomatic cholelithiasis), or alanine aminotransferase and/or aspartate aminotransferase >2 times the upper limit of the normal at screening. |
| NCT07224776 | Pregnancy | Phase 1 | Brigham and Women's Hospital | Pregnant or breastfeeding |
| NCT07224776 | Renal | Phase 1 | Brigham and Women's Hospital | Estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 |
| NCT07225621 | Age | Phase 2 | Alpheus Medical, Inc. | ≥ 18 and ≤ 80 years of age |
| NCT07225621 | Brain metastases | Phase 2 | Alpheus Medical, Inc. | Leptomeningeal disease |
| NCT07225621 | Hepatic | Phase 2 | Alpheus Medical, Inc. | Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x upper limit of normal (ULN) |
| NCT07225621 | HIV | Phase 2 | Alpheus Medical, Inc. | Known human immunodeficiency virus (HIV) infection (Note: testing is not required). |
| NCT07225621 | Performance status | Phase 2 | Alpheus Medical, Inc. | WHO performance status of ≤ 2 at screening |
| NCT07225621 | Pregnancy | Phase 2 | Alpheus Medical, Inc. | Non-pregnant, non-lactating females who are postmenopausal, surgically sterile |
| NCT07225621 | Prior malignancy | Phase 2 | Alpheus Medical, Inc. | Has any history of glioma, a concurrent malignancy, or malignancy within 3 years of randomization, unless definitive therapy is completed |
| NCT07225621 | Renal | Phase 2 | Alpheus Medical, Inc. | Creatinine clearance (CrCl) as estimated by Cockcroft-Gault equation of ≥ 50 ml/min |
| NCT07225946 | Brain metastases | Phase 3 | Janssen Research & Development, LLC | Known history of either brain or leptomeningeal prostate cancer metastases |
| NCT07225946 | Performance status | Phase 3 | Janssen Research & Development, LLC | Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 |
| NCT07225946 | Prior malignancy | Phase 3 | Janssen Research & Development, LLC | Prior or concurrent second malignancy (other than the disease under study) |
| NCT07226349 | Brain metastases | Phase 1 | BeOne Medicines | Participants with active leptomeningeal disease or uncontrolled, untreated brain metastasis. |
| NCT07226349 | Performance status | Phase 1 | BeOne Medicines | Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. |
| NCT07226843 | Brain metastases | Phase 1 | Eli Lilly and Company | Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval. |
| NCT07226843 | Cardiac | Phase 1 | Eli Lilly and Company | Has known significant heart disease |
| NCT07226843 | HIV | Phase 1 | Eli Lilly and Company | Has known hepatitis B or C infection or uncontrolled HIV |
| NCT07226843 | Prior malignancy | Phase 1 | Eli Lilly and Company | Has an active second cancer |
| NCT07227168 | Brain metastases | Phase 1 | Sutro Biopharma, Inc. | Untreated brain metastases |
| NCT07227168 | Performance status | Phase 1 | Sutro Biopharma, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 |
| NCT07227415 | Brain metastases | Phase 1/2 | Pfizer | Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression. |
| NCT07227415 | Performance status | Phase 1/2 | Pfizer | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. |
| NCT07227415 | Prior malignancy | Phase 1/2 | Pfizer | History of another malignancy within 3 years |
| NCT07227584 | Age | Phase 2 | Dana-Farber Cancer Institute | 3.1.3 Age 18.00 - 50.99 years |
| NCT07227584 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | 3.1.4 Direct bilirubin <1.4 mg/dL (total bilirubin < 1.4 mg/dL is acceptable). |
| NCT07227584 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | 3.2.7 Pregnant women are excluded from this study because many of the agents used on this protocol have potential for teratogenic or abortifacient effects. |
| NCT07227623 | Language | Not given | Massachusetts General Hospital | Ability to use a digital health intervention that includes verbal and written information in English |
| NCT07227623 | Performance status | Not given | Massachusetts General Hospital | Eastern Cooperative Oncology Group Performance Status = 0-2 (i.e., fully active to at least ambulatory and up and about more than 50% of waking hours) |
| NCT07228832 | Performance status | Phase 3 | Summit Therapeutics | ECOG performance status score of 0 or 1 |
| NCT07231952 | Brain metastases | Phase 2 | Memorial Sloan Kettering Cancer Center | History of stroke or intracranial hemorrhage within 6 months of start of treatment |
| NCT07231952 | Cardiac | Phase 2 | Memorial Sloan Kettering Cancer Center | Prolongation of the QT interval corrected for heart rate (QTcF) > 470 msec. |
| NCT07231952 | Hepatic | Phase 2 | Memorial Sloan Kettering Cancer Center | Total bilirubin < 1.5 x upper normal institutional limits. In patients with Gilbert's disease total bilirubin up to 3x ULN will be allowed |
| NCT07231952 | HIV | Phase 2 | Memorial Sloan Kettering Cancer Center | Patients who have tested positive for Human Immunodeficiency Virus (HIV) are excluded |
| NCT07231952 | Performance status | Phase 2 | Memorial Sloan Kettering Cancer Center | ECOG performance status ≤2 |
| NCT07231952 | Pregnancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Pregnancy or plan to become pregnant during the study or within 1 month of the last dose of study treatment. |
| NCT07231952 | Prior malignancy | Phase 2 | Memorial Sloan Kettering Cancer Center | Active second malignancy unless in remission and with life expectancy > 2 years. |
| NCT07231952 | Renal | Phase 2 | Memorial Sloan Kettering Cancer Center | Creatinine within normal institutional limits OR Creatinine clearance >40 mL/min for patients with creatinine levels above institutional normal (by Cockcroft-Gault estimate or 12-24h creatinine clearance measurements) |
| NCT07232043 | Pregnancy | Not given | Dana-Farber Cancer Institute | We will not have any mechanism for identifying, targeting, or excluding pregnant women or prisoners. |
| NCT07233408 | Language | Not given | Massachusetts General Hospital | Speaks English |
| NCT07244341 | Brain metastases | Phase 1 | Daiichi Sankyo | Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. |
| NCT07244341 | Cardiac | Phase 1 | Daiichi Sankyo | Uncontrolled or significant cardiovascular disease, |
| NCT07244341 | HIV | Phase 1 | Daiichi Sankyo | Has active or uncontrolled HIV infection. |
| NCT07244341 | Prior malignancy | Phase 1 | Daiichi Sankyo | Prior malignancy, active within the previous 3 years except for locally curable cancers that have been apparently cured or successfully resected, such as basal or squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the stomach, or carcinoma in situ of the breast. |
| NCT07249346 | Brain metastases | Phase 2 | Hannah Choe, MD | Active CNS (central nervous system) involvement by malignant cells |
| NCT07249346 | Cardiac | Phase 2 | Hannah Choe, MD | Cardiac function: Left ventricular ejection fraction at least 45% |
| NCT07249346 | Hepatic | Phase 2 | Hannah Choe, MD | Liver function: AST(Aspartate aminotransferase)/ALT(Alanine aminotransferase) <3x Upper Limit of Normal (ULN); Total bilirubin <2 mg/dL excluding Gilbert's syndrome or hemolysis |
| NCT07249346 | HIV | Phase 2 | Hannah Choe, MD | Patients seropositive for human immunodeficiency virus (HIV) with detectable viral load. HIV+ patients with an undetectable viral load on antiviral therapy are eligible. |
| NCT07249346 | Performance status | Phase 2 | Hannah Choe, MD | Karnofsky Performance Score at least 70%. |
| NCT07249346 | Pregnancy | Phase 2 | Hannah Choe, MD | Female patients who are pregnant or lactating |
| NCT07249346 | Prior malignancy | Phase 2 | Hannah Choe, MD | Patients with prior malignancies except resected non-melanoma skin cancer or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. |
| NCT07249346 | Renal | Phase 2 | Hannah Choe, MD | Estimated creatinine clearance greater than 60 ml/min (C-G formula) |
| NCT07249840 | Hepatic | Phase 1 | Brigham and Women's Hospital | ALT (SGPT) and AST (SGOT) ≤ 2.5x upper limit of normal (ULN), |
| NCT07249840 | HIV | Phase 1 | Brigham and Women's Hospital | Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months of C1D1 are eligible for this trial. |
| NCT07249840 | Performance status | Phase 1 | Brigham and Women's Hospital | ECOG performance status (PS) ≤ 3 |
| NCT07249840 | Pregnancy | Phase 1 | Brigham and Women's Hospital | Pregnant or lactating. |
| NCT07249840 | Prior malignancy | Phase 1 | Brigham and Women's Hospital | Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. |
| NCT07249840 | Renal | Phase 1 | Brigham and Women's Hospital | eGFR >60 mL/min |
| NCT07252232 | Performance status | Phase 3 | Revolution Medicines, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07258511 | Brain metastases | Phase 3 | Janssen Research & Development, LLC | Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM |
| NCT07258511 | Performance status | Phase 3 | Janssen Research & Development, LLC | Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the start of study treatment administration |
| NCT07266428 | Performance status | Phase 1/2 | Ottimo Pharma Limited | ECOG performance status 0-1. |
| NCT07276399 | Brain metastases | Phase 3 | Janssen Research & Development, LLC | Have untreated brain metastases or history of known presence of leptomeningeal disease |
| NCT07276399 | Cardiac | Phase 3 | Janssen Research & Development, LLC | Have a history of clinically significant cardiovascular disease |
| NCT07276399 | Performance status | Phase 3 | Janssen Research & Development, LLC | Have an ECOG performance status of 0 or 1 |
| NCT07277231 | Performance status | Phase 3 | BeOne Medicines | Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 |
| NCT07284186 | Brain metastases | Phase 1 | Plexium, Inc. | Symptomatic CNS disease |
| NCT07284186 | Cardiac | Phase 1 | Plexium, Inc. | Prolongation of QT interval |
| NCT07284186 | Performance status | Phase 1 | Plexium, Inc. | ECOG PS of 0 or 1 |
| NCT07284186 | Prior malignancy | Phase 1 | Plexium, Inc. | History of other malignancies |
| NCT07288073 | Brain metastases | Phase 2 | Karam Khaddour, MD, MS | Have symptomatic untreated brain metastases. |
| NCT07288073 | Cardiac | Phase 2 | Karam Khaddour, MD, MS | Patients must have a left ventricular ejection fraction (LVEF) ≥ 45% and be New York Heart Association (NYHA) Class 1 or 2. |
| NCT07288073 | Hepatic | Phase 2 | Karam Khaddour, MD, MS | Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN); and for patients with liver metastases ≤ to 5 times ULN. |
| NCT07288073 | HIV | Phase 2 | Karam Khaddour, MD, MS | Have any form of primary immunodeficiency (e.g., severe combined immunodeficiency disease [SCID] or acquired immune deficiency syndrome [AIDS]). |
| NCT07288073 | Performance status | Phase 2 | Karam Khaddour, MD, MS | Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 in the investigator's opinion (Appendix B). |
| NCT07288073 | Pregnancy | Phase 2 | Karam Khaddour, MD, MS | Are pregnant or breastfeeding. |
| NCT07288073 | Prior malignancy | Phase 2 | Karam Khaddour, MD, MS | Have had another primary malignancy within the previous 1 year (except for malignancies that do not require treatment or have been curatively treated, and do not pose a significant risk of recurrence including, but not limited to in situ carcinoma of the cervix, early stage skin cancer, including non-melanoma skin cancer; ductal carcinoma in situ (DCIS) or lobular carcinoma in the situ (LCIS) of the breast; intraductal carcinoma of the breast that has been treated with curative intent including patients who are on adjuvant hormonal treatment, prostate cancer with Gleason score ≤ to 6; or superficial bladder cancer). |
| NCT07288073 | Renal | Phase 2 | Karam Khaddour, MD, MS | Estimated creatinine clearance (eCrCl) ≥ 40 mL/min using the Cockcroft-Gault formula at Screening. |
| NCT07288073 | Smoking | Phase 2 | Karam Khaddour, MD, MS | History of cigarette smoking of ≥ 20 pack-years |
| NCT07288112 | Brain metastases | Phase 1/2 | Diakonos Oncology Corporation | Brain metastases allowed if stable after prior treatment |
| NCT07288112 | Cardiac | Phase 1/2 | Diakonos Oncology Corporation | uncontrolled or severe cardiac dis-ease |
| NCT07288112 | Hepatic | Phase 1/2 | Diakonos Oncology Corporation | Total bilirubin ≤ 1.5 times upper limit of normal (ULN) except in patients with Gilbert's disease for which total bilirubin must be ≤ 3 times ULN |
| NCT07288112 | HIV | Phase 1/2 | Diakonos Oncology Corporation | Known active HIV or hepatitis infection. Patients with HIV that is well-controlled and have undetectable viral titers remain eligible. |
| NCT07288112 | Performance status | Phase 1/2 | Diakonos Oncology Corporation | Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1 |
| NCT07288112 | Pregnancy | Phase 1/2 | Diakonos Oncology Corporation | Patients who are pregnant or breastfeeding. |
| NCT07288112 | Renal | Phase 1/2 | Diakonos Oncology Corporation | Calculated creatinine clearance (CrCl) > 30 mL/min using Cockcroft and Gault formula: |
| NCT07291037 | Brain metastases | Phase 3 | AstraZeneca | Spinal cord compression or brain metastases, unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 7 days prior to randomisation. |
| NCT07291037 | HIV | Phase 3 | AstraZeneca | Known human immunodeficiency virus (HIV) infection that is not well controlled. |
| NCT07291037 | Performance status | Phase 3 | AstraZeneca | Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. |
| NCT07291037 | Prior malignancy | Phase 3 | AstraZeneca | History of another primary malignancy other than NSCLC, except for malignancy treated with curative intent with no known active disease within 3 years before randomisation and of low potential risk for recurrence. |
| NCT07296484 | Diabetes | Phase 2 | Sparrow Pharmaceuticals | Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY); |
| NCT07296484 | Hepatic | Phase 2 | Sparrow Pharmaceuticals | Significant hepatic impairment (e.g., Child-Pugh Class B or C); |
| NCT07296484 | Pregnancy | Phase 2 | Sparrow Pharmaceuticals | Pregnancy (including a positive urine test) or current breast feeding. |
| NCT07296484 | Renal | Phase 2 | Sparrow Pharmaceuticals | Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m². |
| NCT07300150 | Brain metastases | Phase 1 | PAQ Therapeutics, Inc. | Active brain metastasis or carcinomatous meningitis. |
| NCT07300150 | Cardiac | Phase 1 | PAQ Therapeutics, Inc. | Baseline QT interval corrected for heart rate using Fridericia's formula (QTcF) >=470 msec |
| NCT07300150 | Hepatic | Phase 1 | PAQ Therapeutics, Inc. | Known history of drug-induced liver injury; primary biliary cirrhosis; or ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver, or portal hypertension |
| NCT07300150 | HIV | Phase 1 | PAQ Therapeutics, Inc. | Known HIV infection with a CD4+ T-cell count <200 cells/mcL and/or a detectable viral load per parameters of assay and/or on an anti-retroviral regimen containing a strong or moderate CYP3A4/5 inhibitor or inducer and/or on a new anti-retroviral regimen for less than 28 days prior to the initiation of study treatment |
| NCT07300150 | Performance status | Phase 1 | PAQ Therapeutics, Inc. | ECOG Performance Status 0 or 1 |
| NCT07300150 | Pregnancy | Phase 1 | PAQ Therapeutics, Inc. | Women who are lactating/breast feeding or who plan to breastfeed while on study through 28 days after receiving the last dose of study drug |
| NCT07300150 | Prior malignancy | Phase 1 | PAQ Therapeutics, Inc. | History of any other malignancy within the past 2 years, except: |
| NCT07300150 | Renal | Phase 1 | PAQ Therapeutics, Inc. | Participants with laboratory values indicating inadequate hematology, hepatic, or renal function |
| NCT07303816 | Brain metastases | Phase 4 | Brigham and Women's Hospital | primary brain tumors, primary CNS lymphoma |
| NCT07303816 | Hepatic | Phase 4 | Brigham and Women's Hospital | Child Pugh Class B or C liver disease |
| NCT07303816 | HIV | Phase 4 | Brigham and Women's Hospital | Known hepatitis C or HIV disease |
| NCT07303816 | Performance status | Phase 4 | Brigham and Women's Hospital | ECOG performance status 0-2 |
| NCT07303816 | Renal | Phase 4 | Brigham and Women's Hospital | eGFR < 30 ml/min/1.73m2 |
| NCT07305740 | Language | Not given | Dana-Farber Cancer Institute | Ability to read and write in English. |
| NCT07305740 | Prior malignancy | Not given | Dana-Farber Cancer Institute | A diagnosis of cancer (except non-melanoma skin cancer) ≥ 12 months prior. |
| NCT07321652 | Age | Phase 3 | Alliance for Clinical Trials in Oncology | STEP 0: Age ≥ 65 years |
| NCT07321652 | Brain metastases | Phase 3 | Alliance for Clinical Trials in Oncology | No patients with known active progressive central nervous system (CNS) disease |
| NCT07321652 | Cardiac | Phase 3 | Alliance for Clinical Trials in Oncology | Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better. |
| NCT07321652 | Hepatic | Phase 3 | Alliance for Clinical Trials in Oncology | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless due to liver involvement, hemolysis or Gilbert's disease) |
| NCT07321652 | HIV | Phase 3 | Alliance for Clinical Trials in Oncology | STEP 0: Patients with known HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial |
| NCT07321652 | Performance status | Phase 3 | Alliance for Clinical Trials in Oncology | STEP 0: ECOG performance status ≤ 2 |
| NCT07321652 | Renal | Phase 3 | Alliance for Clinical Trials in Oncology | Calculated (calc.) creatinine clearance by Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) ≥ 30 mL/min |
| NCT07326566 | Brain metastases | Phase 2 | Black Diamond Therapeutics, Inc. | Recurrent multifocal disease, metastatic, leptomeningeal, or extracranial GBM, or gliomatosis cerebri. |
| NCT07326566 | Prior malignancy | Phase 2 | Black Diamond Therapeutics, Inc. | Significant other uncontrolled health conditions or other malignancies. |
| NCT07349537 | Performance status | Phase 1 | Revolution Medicines, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07355335 | Age | Phase 1 | Massachusetts General Hospital | Age ≥16 years during dose escalation portion of study, patients must weigh ≥40 kg. |
| NCT07355335 | Brain metastases | Phase 1 | Massachusetts General Hospital | Active central nervous system (CNS) involvement by AML (i.e., CNS-2 or CNS-3 disease). Previously treated CNS disease or those receiving prophylactic intrathecal chemotherapy per institutional standard is allowed. |
| NCT07355335 | Cardiac | Phase 1 | Massachusetts General Hospital | Cardiac LVEF of ≥40%, as measured by echocardiogram or MUGA scan |
| NCT07355335 | Hepatic | Phase 1 | Massachusetts General Hospital | AST(SGOT)/ALT(SGPT) ≤5 × institutional ULN and total bilirubin ≤ 2x institutional ULN unless related to leukemic involvement or known Gilbert's syndrome (for bilirubin). |
| NCT07355335 | HIV | Phase 1 | Massachusetts General Hospital | Clinically active HIV disease. |
| NCT07355335 | Performance status | Phase 1 | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) performance status must be 0, 1, or 2; Karnofsky ≥50 for patients ≥16 years of age; and Lansky ≥50 for patients ≥12 to 16 years of age. |
| NCT07355335 | Pregnancy | Phase 1 | Massachusetts General Hospital | Patients of childbearing potential are eligible for the study but must comply with the pregnancy prevention plan for study drugs. |
| NCT07355335 | Prior malignancy | Phase 1 | Massachusetts General Hospital | Patients with concurrent malignancy who are receiving chemotherapy or whose disease is uncontrolled or progressing are not eligible. |
| NCT07355335 | Renal | Phase 1 | Massachusetts General Hospital | Glomerular filtration rate (GFR)≥30 mL/min/1.73 m2 |
| NCT07357519 | Cardiac | Phase 1/2 | Lantheus Medical Imaging | Clinically relevant cardiovascular disease |
| NCT07357519 | Hepatic | Phase 1/2 | Lantheus Medical Imaging | Known active liver disease from any cause, Hepatitis A Virus |
| NCT07357519 | HIV | Phase 1/2 | Lantheus Medical Imaging | Known to be human immunodeficiency virus (HIV) positive |
| NCT07357519 | Performance status | Phase 1/2 | Lantheus Medical Imaging | Eastern Cooperative Oncology Group (ECOG) Performance Score (PS): 0 - 2 |
| NCT07357519 | Pregnancy | Phase 1/2 | Lantheus Medical Imaging | A female participant who is pregnant or breastfeeding |
| NCT07357519 | Prior malignancy | Phase 1/2 | Lantheus Medical Imaging | Active prior or concurrent malignancy: immunoglobulin), |
| NCT07358195 | Age | Early phase 1 | Massachusetts General Hospital | Patient ages 18-70 |
| NCT07358195 | Cardiac | Early phase 1 | Massachusetts General Hospital | LVEF > 40% as measured by echocardiography or MUGA |
| NCT07358195 | Hepatic | Early phase 1 | Massachusetts General Hospital | Total bilirubin < 2.0 (unless diagnosis of Gilbert's or hemolysis is made) |
| NCT07358195 | HIV | Early phase 1 | Massachusetts General Hospital | Positivity for active infection with HIV, HCV, or HBV |
| NCT07358195 | Performance status | Early phase 1 | Massachusetts General Hospital | ECOG performance status 0 or 1 |
| NCT07358195 | Renal | Early phase 1 | Massachusetts General Hospital | Participants should be on dialysis or have a CrCl ≤ 35 ml/min |
| NCT07358260 | Age | Phase 1 | Robbie Majzner | Age >=9 months and <30 years. |
| NCT07358260 | Brain metastases | Phase 1 | Robbie Majzner | Participants with known current brain metastases or leptomeningeal disease. |
| NCT07358260 | Cardiac | Phase 1 | Robbie Majzner | Ejection fraction ≥50% or fractional shortening ≥28%, measured by echocardiography |
| NCT07358260 | Hepatic | Phase 1 | Robbie Majzner | Serum ALT/AST <3.0X ULN |
| NCT07358260 | HIV | Phase 1 | Robbie Majzner | HIV/HBV/HCV infection: Participants are required to be negative for HIV Antibody or HIV viral load |
| NCT07358260 | Performance status | Phase 1 | Robbie Majzner | Lansky/Karnofsky performance status ≥50% (see Appendix A) |
| NCT07358260 | Pregnancy | Phase 1 | Robbie Majzner | Pregnant women are excluded from this study because the effects of B7-H3.CD28Z.CART cells on the developing fetus are unknown |
| NCT07358260 | Prior malignancy | Phase 1 | Robbie Majzner | Participants with a known additional malignancy other than non-melanomatous skin cancer or carcinoma in situ, unless not requiring active treatment and stable or disease-free for at least 3 years. |
| NCT07358260 | Renal | Phase 1 | Robbie Majzner | Adequate renal function defined as creatinine below normal limits for age OR creatinine clearance (as estimated by Cockcroft Gault Equation for participants ≥ 18yo and Bedside Schwartz for participants <18yo) ≥70mL/min/1.73m2 |
| NCT07359820 | Brain metastases | Phase 2 | Elevar Therapeutics | CNS metastases or primary CNS tumor that is associated with progressive neurologic symptoms. |
| NCT07359820 | Cardiac | Phase 2 | Elevar Therapeutics | QT interval corrected using Fridericia's formula (QTcF) > 480 msec or history of prolonged QT syndrome, Torsades de pointes or familial history of prolonged QT syndrome. |
| NCT07359820 | HIV | Phase 2 | Elevar Therapeutics | Patient has active infection, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and/or hepatitis C virus (HCV) (defined in protocol). |
| NCT07359820 | Performance status | Phase 2 | Elevar Therapeutics | Patient has ECOG performance status of 0-1. |
| NCT07364474 | Hepatic | Not given | Massachusetts General Hospital | Alanine aminotransferase (ALT) / Aspartate aminotransferase (AST) < 5 x ULN |
| NCT07364474 | Language | Not given | Massachusetts General Hospital | in a language understood by the subject |
| NCT07364474 | Performance status | Not given | Massachusetts General Hospital | Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 |
| NCT07364474 | Pregnancy | Not given | Massachusetts General Hospital | Pregnant or lactating |
| NCT07364474 | Renal | Not given | Massachusetts General Hospital | Glomerular filtration rate (GFR) >30 ml/min |
| NCT07365241 | Brain metastases | Phase 3 | AbbVie | Participants with known active/symptomatic central nervous system metastases. |
| NCT07365241 | Performance status | Phase 3 | AbbVie | Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment. |
| NCT07374029 | Cardiac | Phase 1 | David Avigan | Patients must not have active significant cardiac disease characterized by symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia. |
| NCT07374029 | Hepatic | Phase 1 | David Avigan | total bilirubin≤ 2.0 mg/dL |
| NCT07374029 | HIV | Phase 1 | David Avigan | Because of compromised cellular immunity, patients who have active human immunodeficiency virus (HIV), untreated hepatitis C virus (HCV) or evidence of active hepatitis B virus (HBV). |
| NCT07374029 | Performance status | Phase 1 | David Avigan | ECOG performance status ≤ 2 (Appendix A) |
| NCT07374029 | Pregnancy | Phase 1 | David Avigan | Patients must not be pregnant. |
| NCT07374029 | Renal | Phase 1 | David Avigan | creatinine ≤ 2.0 mg/dl |
| NCT07377435 | Cardiac | Phase 1 | David Avigan | Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias. |
| NCT07377435 | Hepatic | Phase 1 | David Avigan | Total bilirubin ≤ 1.5 x institutional upper limit of normal |
| NCT07377435 | HIV | Phase 1 | David Avigan | Patients who have known active uncontrolled infections with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV) |
| NCT07377435 | Performance status | Phase 1 | David Avigan | Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 |
| NCT07377435 | Pregnancy | Phase 1 | David Avigan | Female patients who are pregnant (positive β-HCG) or breastfeeding. |
| NCT07377435 | Renal | Phase 1 | David Avigan | Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal |
| NCT07383441 | Brain metastases | Phase 3 | SWOG Cancer Research Network | Participants with new or progressive brain metastases (active brain metastases) or leptomeningeal disease must not require immediate central nervous system (CNS) specific treatment at the time of study registration or anticipated treatment during the first cycle of therapy |
| NCT07383441 | Hepatic | Phase 3 | SWOG Cancer Research Network | Total bilirubin ≤ institutional upper limit of normal (ULN) unless history of Gilbert's disease (within 28 days prior to registration) Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN |
| NCT07383441 | HIV | Phase 3 | SWOG Cancer Research Network | Participants with a history human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load on the most recent test results obtained within 6 months prior to registration |
| NCT07383441 | Language | Phase 3 | SWOG Cancer Research Network | Participants who have the ability to complete questionnaires in English or Spanish must be offered the opportunity to participate in the patient-reported outcome study |
| NCT07383441 | Performance status | Phase 3 | SWOG Cancer Research Network | Participants must have a Zubrod performance status 0-2 within 28 days of registration |
| NCT07383441 | Pregnancy | Phase 3 | SWOG Cancer Research Network | Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). |
| NCT07383441 | Prior malignancy | Phase 3 | SWOG Cancer Research Network | Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen |
| NCT07383441 | Renal | Phase 3 | SWOG Cancer Research Network | Participants must have serum creatinine ≤ 2 x ULN (upper limit of normal). This specimen must have been drawn and processed within 28 days prior to registration |
| NCT07383506 | Cardiac | Phase 1 | Cogent Biosciences, Inc. | Have an ejection fraction ≥50% |
| NCT07383506 | Diabetes | Phase 1 | Cogent Biosciences, Inc. | Diagnosis of diabetes mellitus type 1 or uncontrolled diabetes mellitus type 2 (defined as fasting glucose ≥140 mg/dL and HbA1c ≥7.0%; antihyperglycemic medical management permitted with the exception of insulin) |
| NCT07383506 | Performance status | Phase 1 | Cogent Biosciences, Inc. | Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 |
| NCT07390539 | Age | Phase 1 | Robbie Majzner | Age: greater than or equal to two (2) years of age and less than or equal to 21 years of age. |
| NCT07390539 | Cardiac | Phase 1 | Robbie Majzner | Ejection fraction ≥50% or fractional shortening ≥28%, measured by echocardiography |
| NCT07390539 | Hepatic | Phase 1 | Robbie Majzner | Serum ALT/AST ≤3.0 upper limit of normal (ULN) |
| NCT07390539 | HIV | Phase 1 | Robbie Majzner | Ongoing infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). |
| NCT07390539 | Performance status | Phase 1 | Robbie Majzner | Performance status: Karnofsky performance status ≥60% for participants ≥16 years of age and Lansky performance status ≥60% for participants <16 years of age |
| NCT07390539 | Pregnancy | Phase 1 | Robbie Majzner | Females of childbearing potential must have a negative serum or urine pregnancy test |
| NCT07390539 | Renal | Phase 1 | Robbie Majzner | Adequate renal function defined as creatinine within normal limits for age OR creatinine clearance (as estimated by Cockcroft Gault Equation for participants ≥ 18yo and Bedside Schwartz for participants <18yo) ≥70mL/min |
| NCT07393282 | Performance status | Phase 3 | Regeneron Pharmaceuticals | Eastern Cooperative Oncology Group performance status score ≤1 |
| NCT07393867 | Performance status | Phase 2 | Martin T. King, MD, PhD | Eastern Oncology Group Status 0 to 1. |
| NCT07397611 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Screening echocardiogram or MUGA scan must demonstrate a left ventricular ejection fraction (LVEF) greater than the institutional lower limit of normal (LLN). |
| NCT07397611 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Aspartate transaminase (AST) ≤ 2.5 × upper limit of normal (ULN) |
| NCT07397611 | HIV | Phase 2 | Dana-Farber Cancer Institute | human immunodeficiency virus (HIV) infection with detectable viral load or acquired immunodeficiency syndrome (AIDS)-related illness. |
| NCT07397611 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status of 0-1. |
| NCT07397611 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Negative serum pregnancy test at screening for women of childbearing potential. |
| NCT07397611 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Other prior malignancy active within the previous year except for locally curable cancers (>90%) that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or Gleason 6 prostate cancer. |
| NCT07397611 | Renal | Phase 2 | Dana-Farber Cancer Institute | Calculated creatinine clearance ≥ 40 mL/min (≥ 0.67 mL/sec) using the Cockcroft-Gault equation: |
| NCT07403812 | Pregnancy | Not given | Beth Israel Deaconess Medical Center | pregnant women |
| NCT07405190 | Brain metastases | Phase 2 | Massachusetts General Hospital | Clinically asymptomatic treated or untreated brain metastases are allowed if they have not required increasing doses of steroids within 2 weeks prior to study entry for CNS symptoms. |
| NCT07405190 | Cardiac | Phase 2 | Massachusetts General Hospital | Unstable angina, myocardial infarction, congestive heart failure (New York Heart Association [NYHA] classification ≥ grade 2) |
| NCT07405190 | Hepatic | Phase 2 | Massachusetts General Hospital | Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); for patients with liver metastases or confirmed/suspected Gilbert syndrome, TBIL ≤3 × ULN |
| NCT07405190 | HIV | Phase 2 | Massachusetts General Hospital | Known history of human immunodeficiency virus (HIV) whose viral load is not controlled. |
| NCT07405190 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status of 0 or 1. |
| NCT07405190 | Pregnancy | Phase 2 | Massachusetts General Hospital | Patient is breastfeeding or plans to breastfeed during the study |
| NCT07405190 | Renal | Phase 2 | Massachusetts General Hospital | Creatinine clearance (CrCl) ≥ 50 mL/min using the Cockcroft-Gault formula (Cohorts 1 and 2) or estimated glomerular filtration rate (eGFR) value ≥ 60 mL/min (for Cohort 1) or ≥30 mL/min (for Cohort 2) |
| NCT07406633 | Prior malignancy | Phase 2 | Kumquat Biosciences Inc. | Other active malignancies within the last 2 years. |
| NCT07412041 | BMI | Not given | Dana-Farber Cancer Institute | Patients who are morbidly obese (BMI>40 kg/m2) or Anorexic (BMI<17 kg/m2). |
| NCT07412041 | Pregnancy | Not given | Dana-Farber Cancer Institute | Patients who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses. |
| NCT07414836 | Brain metastases | Phase 1 | BeOne Medicines | Active leptomeningeal disease or uncontrolled, untreated brain metastasis. |
| NCT07419295 | Brain metastases | Phase 3 | Merck Sharp & Dohme LLC | Has a current or past history of central nervous system (CNS) metastases and/or carcinomatous meningitis |
| NCT07419295 | Cardiac | Phase 3 | Merck Sharp & Dohme LLC | Has uncontrolled, significant cardiovascular disease or cerebrovascular disease |
| NCT07419295 | HIV | Phase 3 | Merck Sharp & Dohme LLC | If human immunodeficiency virus (HIV) positive, has well-controlled HIV on antiretroviral therapy (ART) |
| NCT07419295 | Performance status | Phase 3 | Merck Sharp & Dohme LLC | Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization |
| NCT07419295 | Prior malignancy | Phase 3 | Merck Sharp & Dohme LLC | Has a known additional malignancy that is progressing or has required active treatment within the past 3 years |
| NCT07426484 | Brain metastases | Phase 4 | Dana-Farber Cancer Institute | Participants with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy. |
| NCT07426484 | Cardiac | Phase 4 | Dana-Farber Cancer Institute | Uncontrolled or significant cardiovascular disease. |
| NCT07426484 | Hepatic | Phase 4 | Dana-Farber Cancer Institute | AST(SGOT) ≤ 2.5 × institutional ULN |
| NCT07426484 | Performance status | Phase 4 | Dana-Farber Cancer Institute | ECOG performance status 0-2 (see Appendix A for definitions of this and Karnofsky Performance Status). |
| NCT07426484 | Pregnancy | Phase 4 | Dana-Farber Cancer Institute | Pregnant and breastfeeding women are excluded from this study |
| NCT07426484 | Prior malignancy | Phase 4 | Dana-Farber Cancer Institute | Participants with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the study drug are excluded. |
| NCT07426484 | Renal | Phase 4 | Dana-Farber Cancer Institute | Adequate renal function, defined as defined as estimated glomerular filtration rate (eGFR) ≥ 30 mL/min |
| NCT07427043 | Renal | Phase 3 | Brigham and Women's Hospital | Chronic kidney disease (baseline Cr >1.3) |
| NCT07428616 | Performance status | Phase 2 | Exelixis | Karnofsky performance status (KPS) ≥ 60%. |
| NCT07432295 | Brain metastases | Phase 2 | I-Mab Biopharma US Limited | Active CNS metastases or carcinomatous meningitis (previously treated brain metastases allowed if stable). |
| NCT07432295 | Cardiac | Phase 2 | I-Mab Biopharma US Limited | Significant cardiovascular disease (NYHA Class 3-4 CHF, recent MI, unstable angina, TIA/stroke, or major cardiac procedures within 6 months). |
| NCT07432295 | Hepatic | Phase 2 | I-Mab Biopharma US Limited | AST/ALT ≤3×ULN (≤5×ULN if liver metastases); bilirubin ≤1.5×ULN (≤3×ULN if Gilbert's) |
| NCT07432295 | HIV | Phase 2 | I-Mab Biopharma US Limited | Active or uncontrolled HIV, hepatitis B, or hepatitis C infection, or immunodeficiency (controlled infection allowed). |
| NCT07432295 | Performance status | Phase 2 | I-Mab Biopharma US Limited | ECOG performance status 0 or 1. |
| NCT07432295 | Prior malignancy | Phase 2 | I-Mab Biopharma US Limited | Second malignancy within 3 years, except certain skin or cervical cancers. |
| NCT07432295 | Renal | Phase 2 | I-Mab Biopharma US Limited | Creatinine ≤1.5×ULN or eGFR ≥50 mL/min/1.73 m² |
| NCT07434843 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. |
| NCT07434843 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Participants must have a QTc interval length of below 450 msec. QTc will be calculated via the Fridericia's formula. |
| NCT07434843 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | total bilirubin ≤1.5 × institutional upper limit of normal (ULN) |
| NCT07434843 | HIV | Phase 2 | Dana-Farber Cancer Institute | Human immunodeficiency virus (HIV)-infected participants on effective non-CYP3A4 interacting (see Section 3.2.3) anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT07434843 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status ≤2 |
| NCT07434843 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days of initial dose of pemigatinib (INCB054828), and again within 7 days prior to treatment on day 1. |
| NCT07434843 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Participants must be disease-free of prior invasive malignancies for > 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. |
| NCT07434843 | Renal | Phase 2 | Dana-Farber Cancer Institute | glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 (using the CDK-EPI formula see Appendix B) |
| NCT07439211 | Age | Phase 1 | Jacqueline Garcia, MD | Age 18-90 years. |
| NCT07439211 | Hepatic | Phase 1 | Jacqueline Garcia, MD | total serum bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) or |
| NCT07439211 | Performance status | Phase 1 | Jacqueline Garcia, MD | Eastern Cooperative Oncology Group performance status ≤ 3 if 18 to 74 years of age or ECOG 0-2 if ≥ 75 years of age. |
| NCT07439211 | Pregnancy | Phase 1 | Jacqueline Garcia, MD | Pregnant women are excluded from this study because eganelisib is an agent without known fertility and developmental toxicity studies. |
| NCT07439211 | Prior malignancy | Phase 1 | Jacqueline Garcia, MD | Prior systemic cancer therapy is allowed as long as >14 days prior to study treatment start. |
| NCT07439211 | Renal | Phase 1 | Jacqueline Garcia, MD | Creatinine clearance (CrCl) ≥ 30 L/min (Cockcroft-Gault formula) |
| NCT07441694 | Cardiac | Phase 1 | Incyte Corporation | Clinically significant or uncontrolled cardiac disease. |
| NCT07441694 | HIV | Phase 1 | Incyte Corporation | Acute or chronic HBV, Active HCV or known HIV or tuberculosis infection. |
| NCT07441694 | Prior malignancy | Phase 1 | Incyte Corporation | Malignancy within the last 3 years prior to enrollment. |
| NCT07458347 | Brain metastases | Phase 1 | Kestrel Therapeutics, Inc. | Central nervous system (CNS) tumors or untreated or unstable metastases. |
| NCT07458347 | Performance status | Phase 1 | Kestrel Therapeutics, Inc. | Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. |
| NCT07458347 | Pregnancy | Phase 1 | Kestrel Therapeutics, Inc. | Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial. |
| NCT07465276 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | total serum bilirubin ≤1.5X upper limit of normal (ULN) (except for subjects with documented Gilbert syndrome) and AST (SGOT) and ALT (SGPT) ≤2.5X ULN |
| NCT07465276 | HIV | Phase 2 | Dana-Farber Cancer Institute | Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). |
| NCT07465276 | Performance status | Phase 2 | Dana-Farber Cancer Institute | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07465276 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Active pregnancy or breastfeeding. |
| NCT07465276 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to registration with the exception of the following: |
| NCT07465276 | Renal | Phase 2 | Dana-Farber Cancer Institute | Creatinine ≤institutional ULN or GFR of ≥30 mL/min/1.73 m2 |
| NCT07466316 | Age | Phase 3 | Children's Oncology Group | Patient must be ≤ 50 years of age at the time of enrollment |
| NCT07466316 | Brain metastases | Phase 3 | Children's Oncology Group | Patients with central nervous system involvement of RMS as defined below: |
| NCT07466316 | Hepatic | Phase 3 | Children's Oncology Group | Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age |
| NCT07466316 | HIV | Phase 3 | Children's Oncology Group | Known HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial |
| NCT07466316 | Performance status | Phase 3 | Children's Oncology Group | Patients must have a performance status of Lansky performance status score ≥ 50 for patients ≤ 16 years of age or Karnofsky performance status score ≥ 50 for patients > 16 years of age |
| NCT07466316 | Pregnancy | Phase 3 | Children's Oncology Group | Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. |
| NCT07466316 | Prior malignancy | Phase 3 | Children's Oncology Group | Previous or concurrent cancer(s) that is/was being treated with chemotherapy and/or radiation. |
| NCT07466316 | Renal | Phase 3 | Children's Oncology Group | OR a glomerular filtration rate (GFR) ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard). |
| NCT07467772 | Brain metastases | Phase 2 | Dana-Farber Cancer Institute | Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. |
| NCT07467772 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | Participants must have a QTc interval length of below 450 msec. QTc will be calculated via the Fridericia's formula. |
| NCT07467772 | Diabetes | Phase 2 | Dana-Farber Cancer Institute | uncontrolled diabetes |
| NCT07467772 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | total bilirubin ≤1.5 × institutional upper limit of normal (ULN) |
| NCT07467772 | HIV | Phase 2 | Dana-Farber Cancer Institute | Human immunodeficiency virus (HIV)-infected participants on effective non-CYP3A4 interacting (see Section 3.2.3) anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. |
| NCT07467772 | Performance status | Phase 2 | Dana-Farber Cancer Institute | ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). |
| NCT07467772 | Pregnancy | Phase 2 | Dana-Farber Cancer Institute | Female participants who are pregnant or nursing. |
| NCT07467772 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Participants must be disease-free of prior invasive malignancies for > 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. |
| NCT07467772 | Renal | Phase 2 | Dana-Farber Cancer Institute | glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2 |
| NCT07478185 | Cardiac | Not given | University of Massachusetts, Worcester | Contraindications to physical activity, including unstable cardiac disease, severe pulmonary disease, or recent myocardial infarction |
| NCT07478185 | Language | Not given | University of Massachusetts, Worcester | Ability to read, write and understand English |
| NCT07478185 | Pregnancy | Not given | University of Massachusetts, Worcester | Pregnant |
| NCT07482384 | Age | Not given | Dana-Farber Cancer Institute | Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer |
| NCT07482384 | Language | Not given | Dana-Farber Cancer Institute | Able to speak, understand and read English |
| NCT07482384 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant patients |
| NCT07489495 | Cardiac | Phase 3 | Merck Sharp & Dohme LLC | Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram |
| NCT07489495 | HIV | Phase 3 | Merck Sharp & Dohme LLC | Has a history of human immunodeficiency virus infection |
| NCT07489495 | Prior malignancy | Phase 3 | Merck Sharp & Dohme LLC | Has a known additional malignancy that is progressing or has required active treatment within the past 3 years |
| NCT07491497 | Brain metastases | Phase 1/2 | TRIANA Biomedicines, Inc. | For participants with central nervous system (CNS) metastases or spinal cord compression, they must not be associated with progressive neurological symptoms or require increasing doses of corticosteroids to control the CNS disease |
| NCT07513311 | Language | Not given | Massachusetts General Hospital | Ability to read and respond in English or Spanish |
| NCT07518186 | Brain metastases | Phase 3 | Janssen Research & Development, LLC | Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required |
| NCT07518186 | Performance status | Phase 3 | Janssen Research & Development, LLC | Have an eastern cooperative oncology group (ECOG) performance status of 0 to 2 at screening and immediately before the first dose of study medication |
| NCT07518186 | Prior malignancy | Phase 3 | Janssen Research & Development, LLC | Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy |
| NCT07522073 | Brain metastases | Phase 3 | Incyte Corporation | Known active CNS metastases |
| NCT07522073 | Performance status | Phase 3 | Incyte Corporation | ECOG Performance status 0-1 |
| NCT07524855 | Brain metastases | Phase 1 | Janssen Research & Development, LLC | Participants with Inflammatory breast cancer or leptomeningeal disease or brain metastases, with the exception of patients with definitively treated brain metastases that are clinically stable and asymptomatic for >2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment. |
| NCT07524855 | HIV | Phase 1 | Janssen Research & Development, LLC | Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed) |
| NCT07524855 | Performance status | Phase 1 | Janssen Research & Development, LLC | Eastern cooperative oncology group (ECOG) performance status 0-1 and life expectancy of at least 3 months |
| NCT07524855 | Pregnancy | Phase 1 | Janssen Research & Development, LLC | Pregnancy or breastfeeding |
| NCT07524855 | Prior malignancy | Phase 1 | Janssen Research & Development, LLC | Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers) |
| NCT07527858 | Performance status | Phase 2 | Gilead Sciences | Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1. |
| NCT07544589 | Brain metastases | Phase 1 | Dispatch Biotherapeutics | Known active central nervous system (CNS) metastases |
| NCT07544589 | HIV | Phase 1 | Dispatch Biotherapeutics | Known history of hepatitis B or HIV infection |
| NCT07544589 | Performance status | Phase 1 | Dispatch Biotherapeutics | Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 |
| NCT07544589 | Prior malignancy | Phase 1 | Dispatch Biotherapeutics | Previous or concurrent malignancy except if curatively treated more than 3 years prior to enrollment |
| NCT07548476 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant women |
| NCT07553572 | Language | Not given | Patrick C. Johnson, MD | Ability to understand English |
| NCT07570979 | HIV | Phase 1 | Novartis Pharmaceuticals | Patients who are HIV+ or immune compromised. |
| NCT07570979 | Performance status | Phase 1 | Novartis Pharmaceuticals | An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤2. |
| NCT07578571 | Brain metastases | Phase 1 | Immunome, Inc. | Known active central nervous system (CNS) metastases and/or carcinomatous meningitis |
| NCT07578571 | Performance status | Phase 1 | Immunome, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 |
| NCT07578571 | Prior malignancy | Phase 1 | Immunome, Inc. | Known history of another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of recurrence for at least 2 years and approved by the Medical Monitor |
| NCT07581184 | Brain metastases | Phase 1 | Aktis Oncology, Inc. | Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids |
| NCT07581184 | Cardiac | Phase 1 | Aktis Oncology, Inc. | Impaired cardiac function or clinically significant cardiac disease |
| NCT07581184 | Performance status | Phase 1 | Aktis Oncology, Inc. | ECOG Performance Status of 0 or 1 |
| NCT07584226 | Brain metastases | Phase 1 | Relay Therapeutics, Inc. | Central nervous system (CNS) metastases that are associated with progressive neurologic symptoms or require ongoing corticosteroids to control the CNS disease. |
| NCT07584226 | Performance status | Phase 1 | Relay Therapeutics, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. |
| NCT07601243 | Performance status | Phase 1 | Gilead Sciences | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 |
| NCT07601243 | Pregnancy | Phase 1 | Gilead Sciences | Participants with plans to breastfeed during the study period or within 7 days following the last dose of study intervention. |
| NCT07601243 | Prior malignancy | Phase 1 | Gilead Sciences | Active second malignancy. Individuals with a history of malignancy who have been completely treated with no evidence of active cancer for 5 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence may be enrolled. |
| NCT07621718 | Brain metastases | Phase 3 | Revolution Medicines, Inc. | Active or known history of untreated central nervous system metastatic disease. |
| NCT07621718 | Performance status | Phase 3 | Revolution Medicines, Inc. | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07624513 | Age | Phase 3 | Dana-Farber Cancer Institute | Age 18 - 75 years. |
| NCT07624513 | Brain metastases | Phase 3 | Dana-Farber Cancer Institute | Central nervous system (CNS) involvement of MM |
| NCT07624513 | Cardiac | Phase 3 | Dana-Farber Cancer Institute | Concurrent uncontrolled cardiovascular conditions (uncontrolled hypertension [HTN], uncontrolled arrhythmias, congestive heart failure [CHF], unstable angina, grade 3 thromboembolic event or myocardial infarction in the past 6 months) |
| NCT07624513 | Hepatic | Phase 3 | Dana-Farber Cancer Institute | Total Bilirubin ≤ 2 X upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) |
| NCT07624513 | HIV | Phase 3 | Dana-Farber Cancer Institute | Seropositive for human immunodeficiency virus (HIV-1) |
| NCT07624513 | Performance status | Phase 3 | Dana-Farber Cancer Institute | Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix A) |
| NCT07624513 | Pregnancy | Phase 3 | Dana-Farber Cancer Institute | Pregnant or breast feeding female or female who intends to become pregnant during the study |
| NCT07624513 | Prior malignancy | Phase 3 | Dana-Farber Cancer Institute | Prior history of malignancies, other than MM, will be excluded unless the participant has been free of the disease for ≥ 3 years, except for the following non-invasive malignancies: basal or squamous cell skin carcinoma, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histological findings of prostate cancer (T1a or T1b using the TNM clinical staging system), or prostate cancer that is curative |
| NCT07624513 | Renal | Phase 3 | Dana-Farber Cancer Institute | Calculated creatinine clearance ≥30 mL/min (See Appendix B) |
| NCT07630974 | Age | Phase 1/2 | Merck Sharp & Dohme LLC | ≥1 month to <12 years of age for Part 1 and ≥1 month to <18 years for Part 2 |
| NCT07630974 | Brain metastases | Phase 1/2 | Merck Sharp & Dohme LLC | Has known active CNS metastases and/or carcinomatous meningitis/leptomeningeal disease/spinal cord compression. Participants with untreated and asymptomatic brain metastases or previously treated brain metastases may participate provided they are radiologically stable, (i.e, without evidence of progression) for at least 4 weeks |
| NCT07630974 | Cardiac | Phase 1/2 | Merck Sharp & Dohme LLC | Has uncontrolled or significant cardiovascular disease, including conduction abnormalities, hypertension, ischemic heart disease, heart failure, and peripheral vascular disease |
| NCT07630974 | HIV | Phase 1/2 | Merck Sharp & Dohme LLC | Has history of human immunodeficiency virus (HIV) infection. |
| NCT07630974 | Prior malignancy | Phase 1/2 | Merck Sharp & Dohme LLC | Has known additional malignancy that is progressing or has required active treatment within the past 1 year. |
| NCT07637734 | Pregnancy | Phase 3 | Verrica Pharmaceuticals Inc. | Are pregnant or breastfeeding. |
| NCT07637734 | Prior malignancy | Phase 3 | Verrica Pharmaceuticals Inc. | Have an active malignancy or are undergoing treatment for any malignancy other than basal cell carcinoma. |
| NCT07644559 | Brain metastases | Phase 2 | Verastem, Inc. | Untreated or symptomatic CNS metastasis |
| NCT07644559 | Performance status | Phase 2 | Verastem, Inc. | ECOG PS=0 or 1 |
| NCT07654426 | Brain metastases | Phase 2 | Beth Israel Deaconess Medical Center | Presence of central nervous system involvement |
| NCT07654426 | Cardiac | Phase 2 | Beth Israel Deaconess Medical Center | New York Heart Association (NYHA) Class III or IV exertional dyspnea. |
| NCT07654426 | Hepatic | Phase 2 | Beth Israel Deaconess Medical Center | Ineligible for R-CHOP or pola-R-CHP because of liver disease per institutional policies |
| NCT07654426 | HIV | Phase 2 | Beth Israel Deaconess Medical Center | Patients with HIV can be enrolled if they have anti-retroviral therapy options without drug-drug interactions with the cancer treatment, agree to take anti-retroviral therapy and do not have uncontrolled opportunistic infections. |
| NCT07654426 | Pregnancy | Phase 2 | Beth Israel Deaconess Medical Center | Pregnant women are excluded from this study because dexrazoxane and liposomal doxorubicin are agents with the potential for teratogenic or abortifacient effects. |
| NCT07662239 | Age | Not given | Dana-Farber Cancer Institute | Age 15-39 at time of diagnosis |
| NCT07662239 | Cardiac | Not given | Dana-Farber Cancer Institute | Unstable cardiovascular disease in the last 6 months |
| NCT07662239 | Language | Not given | Dana-Farber Cancer Institute | Able to read and understand English (to complete required questionnaires and participate in training/coaching) |
| NCT07662239 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant |
| NCT07671209 | Language | Not given | Massachusetts General Hospital | Ability to complete surveys in English, Spanish, or with assistance of an interpreter. |
| NCT07675967 | Prior malignancy | Not given | Dana-Farber Cancer Institute | Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). |
| NCT07711483 | Brain metastases | Phase 2 | Massachusetts General Hospital | Patients with primary CNS lymphoma are not eligible. |
| NCT07711483 | Hepatic | Phase 2 | Massachusetts General Hospital | Serum Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3 times the ULN |
| NCT07711483 | HIV | Phase 2 | Massachusetts General Hospital | HIV infection with positive viral titer by PCR. HIV with negative viral titer by PCR is not an exclusion as long as CD4 count is ≥200 and patient is taking combination antiretroviral therapy. |
| NCT07711483 | Performance status | Phase 2 | Massachusetts General Hospital | ECOG performance status 0-2 |
| NCT07711483 | Pregnancy | Phase 2 | Massachusetts General Hospital | Breastfeeding or pregnant: Pregnant women are excluded from this study because glofitamab, gemcitabine, oxaliplatin, fludarabine, and cyclophosphamide are agents with the potential for teratogenic or abortifacient effects. |
| NCT07711483 | Prior malignancy | Phase 2 | Massachusetts General Hospital | History of prior malignancy that could affect compliance with the protocol or interpretation of results, except for the following: Non-melanoma skin cancers, in situ malignancies, prostate cancer followed with watchful waiting, indolent lymphoma, any previously treated malignancy felt at low risk for recurrence. |
| NCT07711483 | Renal | Phase 2 | Massachusetts General Hospital | Estimated creatinine clearance of ≥30 mL/min, calculated using the Cockcroft and Gault equation (if male: [140 - Age] x Mass [kg] / [72 x creatinine g/dL]; multiply by 0.85 if female) |
| NCT07718854 | Brain metastases | Phase 2 | Tufts Medical Center | Participants with known brain metastases are excluded from this clinical trial |
| NCT07718854 | Cardiac | Phase 2 | Tufts Medical Center | New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to >480 ms |
| NCT07718854 | HIV | Phase 2 | Tufts Medical Center | HIV-infected participants must have well-controlled HIV on ART, defined as: |
| NCT07718854 | Performance status | Phase 2 | Tufts Medical Center | ECOG performance status 0-1 |
| NCT07718854 | Pregnancy | Phase 2 | Tufts Medical Center | Participant is not pregnant or breastfeeding, and at least one of the following conditions applies: |
| NCT07718854 | Prior malignancy | Phase 2 | Tufts Medical Center | Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. |
| NCT07729150 | Performance status | Not given | Dana-Farber Cancer Institute | ECOG performance status ≤ 2 |
| NCT07729150 | Pregnancy | Not given | Dana-Farber Cancer Institute | Pregnant and nursing women are excluded as prostate cancer is a disease of men. |
| NCT07735624 | Cardiac | Phase 2 | Dana-Farber Cancer Institute | congestive heart failure (New York Heart Association class ≥ III) |
| NCT07735624 | Hepatic | Phase 2 | Dana-Farber Cancer Institute | Aspartate aminotransferase/alanine aminotransferase ≤ 1.5 × upper limit of normal (ULN). |
| NCT07735624 | HIV | Phase 2 | Dana-Farber Cancer Institute | Uncontrolled infection with HIV and/or active infection with opportunistic pathogens. |
| NCT07735624 | Performance status | Phase 2 | Dana-Farber Cancer Institute | Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07735624 | Prior malignancy | Phase 2 | Dana-Farber Cancer Institute | Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment |
| NCT07735624 | Renal | Phase 2 | Dana-Farber Cancer Institute | Creatinine clearance ≥ 30 mL/min as measured or calculated per local institutional standards. |
| NCT07755436 | Brain metastases | Phase 1 | ArriVent BioPharma, Inc. | Symptomatic Central nervous system and/or meninges metastasis. |
| NCT07755436 | Cardiac | Phase 1 | ArriVent BioPharma, Inc. | History of severe cardiovascular diseases. |
| NCT07755436 | Diabetes | Phase 1 | ArriVent BioPharma, Inc. | History of uncontrolled diabetes mellitus or diabetic neuropathy within 3 months before the first dose of study treatment. |
| NCT07755436 | HIV | Phase 1 | ArriVent BioPharma, Inc. | Infection of active hepatitis B, active hepatitis C, or HIV. |
| NCT07755436 | Performance status | Phase 1 | ArriVent BioPharma, Inc. | The score of Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. |
| NCT07755436 | Prior malignancy | Phase 1 | ArriVent BioPharma, Inc. | Patients with more than one cancer. |
| NCT07787156 | Language | Not given | Brigham and Women's Hospital | Language other than English |
| NCT07787156 | Pregnancy | Not given | Brigham and Women's Hospital | Currently pregnant |
| NCT07787156 | Prior malignancy | Not given | Brigham and Women's Hospital | Cancer diagnosis in the last 3 years (excluding non-melanoma skin cancers) |
| NCT07832292 | Hepatic | Phase 2 | Janssen Research & Development, LLC | Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment) |
| NCT07832292 | Renal | Phase 2 | Janssen Research & Development, LLC | Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease (with exception of patients with Gilbert's Syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment) |
| NCT07883720 | Language | Not given | Brigham and Women's Hospital | Non-english speaking individuals |
| NCT07883720 | Pregnancy | Not given | Brigham and Women's Hospital | magnetic resonance imaging (MRI) contraindications (e.g., electrical implants, ferromagnetic implants or objects, pregnancy) |